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Abstract 
 
Vaccination coverage in adults remains suboptimal. Health organisations have only recently begun 
to recognise the role of socio-psychological factors in vaccination decisions. These factors are 
particularly important, given that they are inherently amenable to policy and behaviour change. This 
thesis employs a mixed-methods approach to investigate the determinants of adult seasonal 
influenza and tetanus vaccination in the UK general adult population. It focuses on socio-
psychological factors and draws upon health behaviour models, heuristics and biases and customer 
journey mapping theoretical approaches to guide research and elucidate findings. 
A narrative and a systematic review and meta-analysis reveal there are a number of socio-
psychological factors frequently associated with vaccination, particularly influenza and influenza 
vaccine risk perception, perceived vaccine effectiveness and reported physician recommendation, 
and show that most of the evidence in this area is produced in the US. They also highlight the 
importance of some vaccine risk perceptions, such as influenza-like symptoms and unspecific side-
effects, and demonstrate that the existing evidence is highly heterogeneous and often lacking in 
quality, further supporting a case for robust empirical research on this topic. 
Two qualitative studies show that vaccine uptake is largely driven by people’s risk perception of 
influenza and tetanus, and that the tetanus vaccine is perceived as safe, unlike the influenza vaccine. 
They also reveal how specific healthcare ‘touchpoints’ across the immunisation journey can facilitate 
or hinder uptake. A novel finding is that certain childhood experiences can influence adult 
vaccination decisions. 
Two cross-sectional survey studies show that a compact set of variables can predict 91% of influenza 
and 75% of tetanus vaccination behaviour. They also demonstrate that socio-psychological factors 
are the most important determinants of vaccination behaviour. 
This thesis shows that incorporating socio-psychological dimensions in all aspect of immunisation 
policy, from surveillance systems to policy evaluation, is critical to improve vaccination rates. 
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1 Introduction 
1.1   Background 
Vaccination, a preventive measure aimed at protecting individuals and communities from infectious 
diseases through passive or active immunity, is widely recognised as one of the most effective and 
cost-effective public health interventions (WHO, 2008; WHO, UNICEF et al., 2009). Efforts to reduce 
global inequalities in childhood vaccination have been fruitful. By the end of 2010, 85% of infants 
worldwide had received the vaccination schedule recommended by the World Health Organisation 
(WHO) (WHO and UNICEF, 2005). In contrast, routine vaccination coverage in adults is often 
suboptimal (WHO and UNICEF, 2005; Zhang, While et al., 2011). US mortality rates due to vaccine-
preventable diseases illustrate this trend: while approximately 200 children die every year of these 
type of diseases, annual adult deaths can reach 70,000 (Poland, Jacobson et al., 2009). This gap has 
widened by the failure of vaccine development efforts to keep pace with rapid demographic 
changes; whilst current vaccines were well suited to address the needs of a relatively young 20th 
century society, they are not designed to meet the health requirements of a population that is 
expected to live almost twice as long (Rappuoli, Mandl et al., 2011).  
In high-income countries, adult immunisation schedules comprise a number of vaccines usually 
designed for specific populations (e.g. older adults, those at risk of certain sexually transmitted 
diseases, etc.). Two vaccines are widely administered to different age groups: the seasonal influenza 
vaccine (hereinafter referred to as “influenza vaccine”) and tetanus-containing boosters (hereinafter 
referred to as “tetanus boosters” or “tetanus vaccines”). A brief overview of the challenges posed by 
influenza and tetanus, and current efforts to prevent their occurrence, is provided next. 
Upper respiratory tract infections are a leading cause of vaccine-preventable mortality and 
morbidity among adults living in developed economies, and influenza is a major contributor to this 
burden of disease (GBD 2013 Mortality and Causes of Death Collaborators, 2013). Estimates show 
that influenza epidemics can cause up to 49,000 deaths every year in the US and 40,000 in the 
European Union (CDC (1), 2010; ECDC (1), 2015), and can cost billions in medical visits, 
hospitalisation and loss of productivity (Ryan, Zoellner et al., 2006; WHO (1), 2014). In most 
developed countries, a vaccine is recommended every year to those at higher risk of developing 
complications, that is people 65 years and older (≥65s), people with certain chronic health 
conditions, pregnant women and those in close contact with vulnerable individuals (56th World 
Health Assembly, 2003; Council of the European Union, 2009; CDC (2), 2010). Despite continuous 
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efforts to improve influenza vaccination rates, uptake among high-risk groups remains below the 
minimum 75% coverage recommended by the WHO and the Council of the European Union (56th 
World Health Assembly, 2003; Council of the European Union, 2009). For example, during the 
2013/2014 influenza season 65% of ≥65s and 46% of younger adults with eligible health conditions 
were vaccinated against influenza in the US (CDC, 2014). In the same season, influenza vaccination 
rates in the UK, one of the highest in Europe, were 73% in ≥65s and 53% in eligible younger adults 
(PHE, 2014). Importantly, excess mortality and morbidity due to influenza can be partly attributed to 
inadequate vaccination coverage, but also to partial vaccine efficacy (CDC (3), 2014).  
In contrast, only 10-30 cases of tetanus are reported on average every year in high-income 
countries, mostly among inadequately immunised older people and injecting drug users (VENICE II 
and ECDC, 2010; CDC, 2012), yet tetanus mortality rate can reach 50% (ECDC (2), 2015). Low tetanus 
incidence is attributed to safer healthcare practices, efficacious and longer-lasting vaccines, and 
effective childhood vaccination programmes (CDC, 2011). However, uptake of adult tetanus 
boosters, which are recommended for all adults or certain at-risk individuals every 5-20 years 
(depending on the country), remains substandard (CDC, 2011; ECDC (3), 2015). In the US, for 
example, where a booster is routinely recommended every 10 years, 55-64% of adults received one 
in the past 10 years (Williams WW, Lu P-J et al., 2014). Uptake is also insufficient in Germany and 
France (both 73%) (Guthmann, Fonteneau, 2012; Böhmer, Walter, 2011), albeit higher than in the 
US.  To my knowledge, there are no publically available coverage data for adult tetanus boosters in 
the UK.  
The existing evidence on the determinants of influenza vaccination and, to a lesser extent, tetanus 
vaccination indicates that uptake is largely determined by healthcare system factors, demographic, 
socio-economic and health-related factors, and socio-psychological factors (Chapman and Coups, 
1999; Brewer and Hallman, 2006; Kohlhammer, 2007; Johnson, 2008; Böhmer, Walter et al., 2011; 
Silva, Perrier et al., 2015). While these categories of determinants are often interrelated, they 
encompass distinct sets of barriers and drivers to vaccination.  
Healthcare system factors known to influence vaccination uptake, as might be expected, include 
vaccine availability and provision. Although these barriers are commonly associated with developing 
countries, they can also affect vaccination coverage in developed economies, particularly during 
vaccine shortages (Brewer and Hallman, 2006). Demographic, socio-economic and health-related 
factors that have predicted vaccination include age, health status, income and health insurance 
(Chapman and Coups, 1999; Xakellis, 2005; Kohlhammer, 2007; Ward and Draper, 2008). Socio-
psychological factors play a significant role in vaccination decisions and are increasingly recognised 
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as the ‘Achilles heel’ of immunisation (Chapman and Coups, 1999; Kohlhammer, 2007; Brewer, 
Chapman et al., 2007). For example, the perceived likelihood of acquiring a specific disease and the 
perceived benefits of vaccinating against it have been significantly associated with higher uptake, 
whereas perceived harm from vaccinations has been found to have the opposite effect (Chapman 
and Coups, 1999; CDC, 2004; Tabbarah, Zimmerman et al., 2005; Kohlhammer, 2007).  
Identifying and addressing the constellation of factors that drive and hinder vaccination uptake is 
critical to maintain both individual and herd immunity. Yet, socio-psychological factors are of 
particular interest, given that they are inherently amenable to policy and behaviour change. Recent 
vaccine-related controversies, which have resulted in widespread vaccination refusal, illustrate the 
importance of monitoring public sentiment toward vaccination and responding rapidly and 
effectively when trust is compromised. In France, for example, errors of official risk communications 
about the effectiveness and safety of the A(H1N1)pdm09 vaccine against pandemic influenza in 
2009/2010, resulted in long lasting unfavourable attitudes toward vaccination in general, and a 
significant drop in seasonal influenza vaccination rates (Bone, Guthmann et al., 2010). In the UK, a 
scare sparked by extensive media coverage of an article reporting a purported link between the 
MMR vaccine and autism (Wakefield, Murch et al., 1998), which was later retracted, is still causing 
ripples and was partly blamed for a measles outbreak in Wales in 2013 (National Assembly for 
Wales, 2013). In Japan, the Health Ministry recently issued a nationwide notice that HPV vaccination 
should no longer be recommended due to safety concerns after a string of alleged adverse events 
(The Japan Times, 2013). The full effect of this decision on women’s health and overall vaccination 
rates remains to be evaluated. 
A decline in public confidence in vaccines is an ongoing challenge which has been recognised by 
national and supranational health organisations. As a result, the WHO established the Strategic 
Advisory Group of Experts (SAGE) on Immunization to provide advice on how to address vaccine 
hesitancy and its determinants (WHO (2), 2014). Similarly, the US National Vaccination Advisory 
Committee has recently formed the Vaccine Hesitancy Working Group to identify factors that drive 
confidence in vaccines to inform and evaluate future interventions (NVAC, 2013). Public Health 
England, in conjunction with the London School of Hygiene and Tropical Medicine (LSHTM), has 
recently formed the NIHR Health Protection Research Unit in Immunisation at LSHTM, a 5-year 
initiative aiming to undertake research to extend the implementation and coverage of existing 
vaccine policy, including work on communications, implementation and vaccine acceptability 
(LSHTM, 2014). Vaccine manufacturers are also taking action against decreasing vaccine confidence, 
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through targeted advocacy and communication initiatives (Vaccines Europe, 2014), and research 
funding such as the grant supporting my work. 
Worryingly, the evidence likely to inform multilateral efforts to systematise existing knowledge and 
explore better ways to measure and improve confidence in vaccines has several gaps. First, the 
existing body of knowledge is methodologically disparate and often lacking in quality (e.g. small 
convenience samples and non-validated measures). Secondly, most studies assess a limited number 
of constructs, which does not allow a robust assessment of their relative importance in predicting 
vaccination behaviour. Furthermore, socio-psychological predictors of vaccination are generally 
evaluated separately from demographic, socio-economic and health-related determinants; thus, the 
extent to which vaccination behaviour is predicted by socio-psychological factors over and above the 
population characteristics routinely collected in national health surveys, has not been systematically 
explored. Thirdly, the majority of studies are country and vaccine-specific, thus the validity of 
employed measures across different countries and vaccines remains largely untested. Fourthly, key 
socio-psychological constructs that are likely to influence vaccination behaviour such as trust (in 
vaccines, manufacturers, commissioners and providers), fear (of both diseases and vaccines), and 
personality variables and coping styles, such as overconfidence, information-seeking, avoidance and 
denial, remain largely unexplored (Miller, Brody et al., 1988; Weinstein, Kwitel et al., 2007). Lastly, 
most of the evidence on adult vaccination focuses on influenza vaccination, particularly pandemic 
influenza, and studies evaluating socio-psychological factors influencing tetanus vaccination among 
the general population are scarce (Johnson, 2008; Böhmer, Walter et al., 2011). Importantly, 
comparative analyses across different vaccines have not been undertaken to any great extent.  
Although the target populations of influenza and tetanus vaccines overlap, their schedule, 
composition and the diseases they are designed to prevent differ greatly. An in-depth exploration of 
the factors underlying the uptake of such different products can provide valuable insights into 
vaccination decisions and, in turn, result in a more meaningful contribution to science, policy and 
practice. The focus of this thesis is, therefore, on the determinants of adult seasonal influenza and 
tetanus vaccination uptake in the UK general adult population, as well as on key areas of 
convergence and divergence. This work forms part of a large scale multinational project aiming to 
identify the determinants of adult vaccination and to predict uptake in both developing and 
developed countries.  
I pay particular attention to socio-psychological factors and seek to address the identified gaps 
drawing upon health behaviour models such as the Health Belief Model (Rosenstock, 1966) and the 
Protection Motivation Theory (Rogers, 1975), and two theoretical approaches: heuristics and biases 
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(Meehl, 1954; Simon, 1957; Kahneman and Tversky, 1973; Tversky and Kahneman, 1974) and 
Customer journey mapping (Tseng MM, Qinhai M et al., 1999; Dunn and Davis, 2002).Pandemic 
influenza is beyond the remit of this research because perceptions around novel viruses and 
vaccines have been found to differ in nature and intensity from those associated with seasonal 
influenza and routine vaccination (Poland, Jacobson et al., 2009; Maurer, Uscher-Pines et al., 2010). 
This introductory chapter is split into three main parts. First, I provide an overview of adult 
vaccination in the UK, influenza and tetanus, and the corresponding vaccines and vaccination 
programmes. Secondly, I summarise the relevant models of health behaviour and other theoretical 
approaches used in this thesis, and their application to seasonal influenza and tetanus vaccination.  I 
conclude this chapter with an explication of the aims of my thesis and the rationale behind each of 
the ensuing chapters. 
1.2 Adult vaccination in the UK 
Although vaccines have been available for use since the 1700s, most recommended adult 
vaccinations were introduced in the last few decades, as illustrated in Figure 1.1. (PHE (1), 2013). 
Over the years, the development of new and safer vaccines has led to variations in the schedule. 
These include the introduction of new vaccines (e.g. shingles), new routes of administration (e.g. 
intranasal), new targeted population groups (e.g. pregnant women) and improved products [e.g. 
multivalent (more than one virus strand), conjugated (more than one antigen/disease) and 
adjuvenated vaccines (contain an agent that enhances their efficacy)].  
 
 
 
 
Note: adapted from the Historical vaccine development and introduction of vaccines in the UK (PHE (1), 2013).  
Armed forces1; people with tetanus-prone wounds2; at risk groups3; temporary pandemic flu4; pregnant women5 
 
Figure 1.1 Timeline of introduction of key adult vaccines in the UK 
Currently, adults in the UK are recommended to receive a series of vaccinations when they reach a 
certain age (usually ≥65s) or if they belong to a specific risk group. For the first time in 2013, a 
comprehensive vaccination schedule was published by the National Health Service (NHS), which 
comprises all the recommended vaccines across an individual’s lifespan (NHS (1), 2013). The adult 
vaccination section of the schedule is summarised in Table 1.1. 
1930s 1950s 1960s 1970s 1980s 1990s 2000s 2010s 
Pneumococcal 
conjugate3 
Chickenpox3 
Influenza4  
 
Shingles3 
Pertussis5 
Influenza5  
 
Hepatitis B3 
MMR3 BCG
3 
 
 
Tetanus1 
 
 
Influenza3 Tetanus2 
 
Hepatitis A3 
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In addition to the routinely recommended vaccines, selected vaccinations are offered free of charge 
to those who are in contact with vulnerable individuals, or who are exposed to particular risks due to 
their occupation, incomplete or unknown vaccination history or life-style choices. These are: 
chickenpox vaccine, BCG (tuberculosis) vaccine, hepatitis B vaccine and MMR (Measles, Mumps and 
Rubella) for non-immune adults. Vaccines against some travel-related infections are also freely 
available, including diphtheria, polio and tetanus (tetanus-containing booster), typhoid, hepatitis A 
(including when combined with typhoid or hepatitis B) and cholera. Other travel vaccines privately 
provided at a cost are: hepatitis B (when not combined with hepatitis A), Japanese encephalitis, tick-
borne encephalitis, meningococcal meningitis, rabies, tuberculosis (TB) and yellow fever. Individuals 
who do not meet the NHS eligibility criteria described above can obtain influenza vaccines at a cost.  
Table 1.1 The complete UK routine vaccination schedule 2013/14 – adult vaccination 
When to immunise Diseases protected 
against 
Vaccine given Vaccination site 
18 to 64 years at clinical 
risk1 
Influenza 
Inactivated influenza 
vaccine (annual) 
Upper arm 
From 28 weeks of  
Pregnancy 
Pertussis dTaP/IPV (Repevax) Upper arm 
65 years old Pneumococcal disease 
PPV Pneumococcal 
polysaccharide vaccine  
(Pneumovax II) 
Upper arm 
≥65 years old Influenza 
Influenza injection 
(annual) 
Upper arm 
70 years old Shingles  Shingles (Zostavax) 
Upper arm  
(subcutaneous) 
1Eligible medical conditions are: chronic (long-term) respiratory disease, such as asthma, chronic obstructive pulmonary 
disease (COPD) or bronchitis, chronic heart disease, such as heart failure, chronic kidney disease, chronic liver disease, such 
as hepatitis, chronic neurological conditions, such as Parkinson's disease or motor neurone disease, diabetes, problems 
with spleen (e.g. sickle cell disease), weakened immune system (e.g. HIV, chemotherapy, etc.). Other eligible people 
include: pregnant women, those living in a long-stay residential care home or other long-stay care facility, carers of an 
elderly or disabled person whose welfare may be at risk, healthcare professionals or social care workers with direct patient 
contact (NHS (2), 2014). 
 
 
The vaccination policy and schedule in the UK is decided by the Department of Health, with the 
advice of the Joint Committee on Vaccination and Immunisation (JCVI). The JCVI is an independent 
committee and statutory body constituted by expert and lay members. Its mission is to review the 
existing evidence on the burden of disease, on vaccine safety and efficacy and on the impact and 
cost effectiveness of vaccination strategies in order to make objective recommendations to UK 
health departments (JCVI, 2013). As shown in Figure 1.2, the successful implementation of 
vaccination programmes in the UK depends upon a number of interrelated aspects, from vaccine 
development and delivery to vaccine acceptance. 
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Adult vaccinations are commonly recommended and administered by a general practitioner (GP) or 
nurse within the primary care setting. Whilst most adult vaccines are delivered free of charge in 
primary care settings to those who are eligible, some vaccines are also in secondary care facilities 
such Accidents & Emergency Departments (A&E), or at a cost in pharmacies and other commercial 
outlets.  
 
Note: adapted from The aims of vaccination: national policy and schedules (HPA, 2011). 
Figure 1.2 Components of vaccination programmes 
Depending on the vaccination programme, official communication strategies range from mass media 
national campaigns and internet-based information, to leaflets provided in GP practices and 
personalised invitations. Unofficial sources of information, particularly internet-based, are prevalent 
and widely accessed (Bish, Yardley et al., 2011). While some of these sources, such as university-
based websites, pharmacy websites, and websites sponsored by pharmaceutical companies provide 
evidence which largely coincide with the information provided by the NHS, others, such as personal 
blogs and websites sponsored by purported “natural” products such as vitamin and nutritional 
supplements, often provide a distorted account of vaccination safety and effectiveness (Natural 
News, 2015).   
Policy 
development
Vaccine 
development
Communication
Monitoring 
attitudes to 
vaccination
Surveillance of 
adverse events
Predicting the 
future -
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Although immunisation programmes have some commonalities, they are generally vaccine-specific. 
This is partly because adult vaccines have different schedules and most are only recommended for 
specific populations such as people in their late teens and early twenties (e.g. human papilloma 
virus), the elderly (e.g. herpes zoster and pneumococcal) and those who are travelling to particular 
countries (hepatitis A, yellow fever).  
1.3 Influenza 
1.3.1 Influenza and the influenza vaccine 
Influenza is an acute and highly contagious respiratory viral infection. In the northern hemisphere, 
influenza commonly occurs during the winter season. There are three types of influenza viruses: A, B 
and C. Influenza A viruses are the most common and the cause of most epidemics, and in some cases 
pandemics. Influenza B viruses are generally milder and the cause of smaller outbreaks. Influenza is 
usually transmitted by becoming in contact with respiratory secretions of an infected individual with 
an incubation period ranging from 1-3 days (PHE, 2015). The most common symptoms of influenza 
are fever, chills, headache, myalgia, fatigue, dry cough,sore throat and congested nose (PHE, 2015). 
In healthy people, influenza symptoms are usually mild to moderate and can last between 2-7 days 
(PHE, 2015). Influenza, however, can lead to complications such as bronchitis and secondary 
bacterial pneumonia, and can be particularly serious among older people, those with chronic health 
conditions such as chronic respiratory, heart, kidney, liver and neurological diseases, diabetes, 
immunosuppression and asplenia, and pregnant women (PHE, 2015). 
Influenza viruses suffer small changes overtime commonly known as “antigenic drift” and “antigenic 
shift” (CDC (3), 2010).  Antigenic drift results in new virus strands that may not be recognised by the 
body's immune system. Antigenic shift is a sudden, major change in the influenza A viruses that 
produces a new influenza A subtype to which the population may have little or no immunity. This 
novel virus can lead to widespread epidemics or pandemics such as the one caused by the new N1H1 
virus in 2009 (CDC (3), 2010). 
Most hospitalisations and influenza-related deaths are among those in clinical high-risk groups, 
particularly the elderly (PHE (3), 2013). The excess winter deaths potentially attributable to influenza 
fluctuate significantly depending on different factors, notably, the type of circulating viruses, the 
match between these and the strands contained in the vaccine and vaccine coverage (PHE, 2015; 
CDC (1), 2015).  
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Due to the changing nature of influenza viruses, different vaccines are produced every year. These 
vaccines contain the predominant virus strands which are expected to circulate in the forthcoming 
winter for both the northern and southern hemispheres, according to WHO recommendations 
(WHO (3), 2014).  The effectiveness of influenza vaccines depends upon two main factors: 1) 
individuals’ characteristics (e.g. age and health) and 2) the match between the vaccine and 
circulating viruses (CDC (3), 2014). Most influenza vaccines are trivalent and contain two subtypes of 
influenza A and one B virus. Quadrivalent vaccines, which include an additional B virus, were 
available in the UK for the first time in 2013 and are expected to decrease influenza morbidity and 
mortality, as it matches a wider spectrum of circulating strands (PHE, 2015). The partial effectiveness 
of influenza vaccines, however, continues to challenge health systems, particularly when the 
circulating and vaccine strands are mismatched. A recent comprehensive systematic review and 
meta-analysis found that current influenza vaccines are overall moderately effective against 
infection and illness, yet in some seasons and age groups (e.g. over 65s) the level of protection was 
low or non-existent (Osterholm, Kelley et al., 2012). Therefore, promising results in developing a 
universal long-lasting influenza vaccine would most likely improve its efficacy and significantly 
reduce the burden of influenza-associated illness (Pica and Palese, 2013).   
1.3.2 Influenza vaccination in the UK 
An annual influenza vaccine is offered free of charge through GP surgeries to those at higher risk of 
morbidity and mortality, usually between October and January.  This includes people ≥65 years of 
age and under 65s with certain medical conditions such as asthma, heart disease and diabetes, and 
also those who are in close contact with at risk-individuals, such as healthcare professionals and 
healthy family members (NHS (2), 2014). The aim of the current influenza vaccination programme is 
to protect people at higher risk of influenza-related complications, but also to reduce transmission.  
WHO guidance recommends a minimum coverage of 75% in older people living in high-income 
countries (56th World Health Assembly, 2003). Similarly, the European Union Council has 
encouraged its members to vaccinate at least 75% of high-risk populations (Council of the European 
Union, 2009). This proposed coverage, however, is insufficient to establish herd immunity (80% of 
healthy people and 90% of high-risk individuals) (Plans-Rubió, 2012). 
Despite widely available influenza vaccination, influenza and pneumonia are the 4th highest cause of 
death in women and the 6th in men the UK (ONS (2), 2013).  In some winters, as many as 25,000 
deaths can be attributed to this disease in the UK (HPA, 2012). This is due to both partial vaccine 
effectiveness and insufficient vaccination coverage. As shown in Figure 1.3, in 2013/2014, although a 
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relatively high percentage of people aged 65 and older received an influenza vaccine (73%), uptake 
among under 65s with chronic medical conditions was inadequate (53%)(PHE (1), 2014). Similar 
coverage was observed during the previous influenza season (2012/2013), which resulted in over 
10,000 deaths due to influenza-related illness (PHE (4), 2013). 
 
Data from Seasonal Influenza Vaccine Uptake amongst GP Patient Groups in England (PHE (2), 2014) 
Figure 1.3 Seasonal influenza vaccination uptake estimates by year in England 
 
1.4 Tetanus 
1.4.1 Tetanus and the tetanus vaccine 
Tetanus is a serious infection caused when the bacteria clostridium tetani, which is present in soil or 
manure, becomes in contact with a puncture wound, burn or scratch (PHE (5), 2013). The tetanus 
bacteria then release a neurotoxin which affects nerve function. Tetanus has an incubation period of 
between four and 21 days and its symptoms include muscle stiffness usually involving the jaw 
(lockjaw) and neck.  Mortality ranges from 10 to 90% and it is highest in infants and the elderly (PHE 
(5), 2013).  
The tetanus vaccine contains tetanus toxoid, a cell-free purified toxin extracted from a strand of 
clostridium tetani, and in high-income countries, it is only available as a combined vaccine such as 
the tetanus, diphtheria and inactivated polio vaccine (Td/IPV), the diphtheria, tetanus, acellular 
pertussis and inactivated polio vaccine (DTaP/IPV or dTaP/IPV) or the diphtheria, tetanus, acellular 
pertussis, inactivated polio and haemophilus influenzae type b vaccine (DTaP/IPV/Hib) (CDC (2), 
2015; NHS (3), 2014). Common side-effects include pain, swelling or redness at the injection site and 
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may occur more frequently following subsequent doses (Miller, 1999). Confirmed post-vaccination 
anaphylaxis occurs extremely rarely (PHE (5), 2013). 
Tetanus-prone wounds in unprotected individuals are normally treated with intravenous or 
intramuscular tetanus immunoglobulin. Post-injury tetanus vaccination is not recommended as 
treatment since it may not boost immunity early enough to provide the required protection within 
the incubation period of the disease (Porter, Perkin et al., 1992). 
1.4.2 Tetanus vaccination in the UK 
Tetanus vaccination was first introduced in the UK Armed Forces in 1938, and nationally in 1961 
(PHE (1), 2013). Tetanus primary vaccination is a five-dose course starting in childhood, which 
according to the NHS, should provide life-long vaccination (NHS (3), 2014). The first three doses are 
given in the DTaP/IPV/Hib vaccine for babies at two, three and four months of age, followed by a 
booster of the DTaP/IPV vaccine administered at around four years of age, and a final Td/IPV booster 
given to children between 13 and 18 years. A full five-dose course is also recommended for 
immunosuppressed patients, for individuals whose vaccination status is uncertain and those born 
before 1961 who may not have been immunised in infancy (NHS (3), 2014).  
A tetanus, diphtheria and polio booster (Td/IPV) is currently only recommended as a travel vaccine 
for adults who have not been vaccinated before or have not been fully vaccinated,  those who are 
travelling to a country with limited medical facilities, and those whose last dose of the tetanus 
vaccine was more than 10 years ago (NHS (3), 2014). In 2012, a tetanus, diphtheria, pertussis and 
polio (DTaP/IPV) booster was introduced for pregnant women as a response to increased neonatal 
mortality due to pertussis (NHS (2), 2014).  
Although tetanus cases in the UK are rare (83 reported infections in last 10 years in England and 
Wales, mostly among people over 65s) (HPA, 2014), evidence suggests that people born before 
1961, the year in which tetanus vaccination was introduced to the national routine childhood 
programme, are disproportionally affected due to inadequate vaccination (Department of Health, 
Scottish Executive Health Department et al., 2006). Therefore, experts have recommended a dual 
vaccination policy: one for those who were born before 1961 (full primary course of vaccinations or 
boosters as required) and other for those who were born after that year (a booster every 20 years) 
(Bracebridge, Crowcroft et al., 2004).  
Worryingly, a recent study concluded that low tetanus rates in the UK may be partly due to the 
misalignment between current tetanus vaccination guidelines and A&E departments’ approach to 
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tetanus prevention – when in doubt err on the side of vaccination (Savage, Nash et al., 2007). This 
mismatch between policy and practice may also be occurring in primary care settings. 
1.5 Understanding adult vaccination behaviour 
As noted at the beginning of this chapter, previous research on influenza vaccination and emerging 
evidence on tetanus vaccination have shown that their uptake is significantly influenced by socio-
psychological factors (Chapman and Coups, 1999; Kohlhammer, 2007; Brewer, Chapman et al., 2007; 
Johnson, 2008; Böhmer, Walter et al., 2011). Research focusing upon the socio-psychological aspects 
of influenza vaccination often uses health behaviour models to understand and predict vaccination 
uptake, albeit with varying degrees of success (Montano, 1986; Nexøe, Kragstrup et al., 1999; 
Brewer, Chapman et al., 2007). The premise of these models is that social cognitions, the processes 
through which people make sense of other people and themselves (Fiske and Taylor, 2013), are 
proximal determinants of behaviour and that these cognitions are modifiable, thus they constitute a 
powerful mechanism to triggering behaviour change. Importantly, health behaviour models 
acknowledge that individuals’ decision-making processes are influenced by their social context, 
beliefs and attitudes, and often driven by intuition rather than rational thought (Kahneman, Slovic et 
al., 1982). An outline of the main models of health behaviour and their relevance to influenza 
vaccination is provided below.  
1.5.1 Health behaviour models and influenza vaccination 
Four models have been frequently used to explain influenza vaccination behaviour: The Health Belief 
Model (HBM) (Rosenstock, 1966), the Theory of Reasoned Action (TRA) (Fishbein and Ajzen, 1975; 
Ajzen and Fishbein, 1977), which evolved into the Theory of Planned Behaviour (TPB) (Ajzen, 1985; 
Ajzen, 1991), and the Theory of Interpersonal Behaviour (TIB) (Triandis, 1977). An important 
limitation of health behaviour theories is that they focus on individual beliefs and perceptions as 
determinants of behaviour, and overlook policy and social context factors which can significantly 
influence preventive behaviours such as vaccination (Brewer & Rimer, 2008).  Another shortfall is the 
notion that intention causes behaviour, a relationship that has been disproved in a number of 
studies (Webb & Sheeran, 2006). Further, most studies testing these  theories use correlational 
rather than experimental designs, thus the proposed causal links between predictors and behaviour 
have often been erroneously inferred (Weinstein, 2007). Moreover, research employing these 
models use measures of varying quality, thus their findings may not be comparable. Despite these 
shortcomings, health behaviour models, particularly when used in combination (Brewer & Rimer, 
2008), offer a useful set of well-defined constructs to study the social-cognitive processes that might 
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underlie individuals’ vaccination choices (Ogden, 2003), some of which are highly predictive of 
vaccination behaviour (Brewer, Chapman et al., 2007).   
The HBM postulates that health behaviour depends upon three categories of factors occurring 
simultaneously: sufficient motivation or health concern (perceived susceptibility to and severity of 
the disease) and the perceived benefits (e.g. effectiveness) and costs (e.g. side-effects) of the 
response or intervention, in this case, vaccination (Rosenstock, 1966). Later modifications of the 
model incorporated cue to action (internal or external stimuli which trigger a health behaviour), self-
efficacy (confidence in own ability to carry out a health behaviour) and modifying variables such as 
demographic (e.g. age and sex) and socio-psychological factors (e.g. social influences and personality 
traits) (Rosenstock, Strecher et al., 1988). A frequent criticism of the HBM is that it a simple 
catalogue of variables which predict behaviour (Prentice-Dunn and Rogers, 1986), rather than an 
explanatory model. Furthermore, the HBM omits emotional factors such as fear, which may 
significantly influence behaviour. Although the HBM explains influenza vaccination only modestly 
(Montano, 1986), it provides a relevant set of constructs, most of which have been found to be 
associated with vaccination acceptance, particularly perceived disease and vaccine risks, as well as 
vaccine effectiveness (Larson, Olsen et al., 1979; Chapman and Coups, 1999; Nexøe, Kragstrup et al., 
1999).  
The TRA  postulates that intention is the best predictor of behaviour, and that intention is, in turn, 
determined by individuals’ attitudes toward the specific behaviour (belief toward an outcome and 
evaluation of the outcome) and their subjective norms (what experts think and motivation to comply 
with others) (Fishbein and Ajzen, 1975). The TPB, the successor of TRA, suggests that the 
achievement of a health behaviour depends upon motivation (intention), which is influenced by 
beliefs and attitudes (behavioural beliefs and attitudes toward the behaviour), social norms 
(normative beliefs and subjective norms) and ability (control beliefs and perceived behavioural 
control) (Ajzen, 1985; Ajzen, 1991). These models, however, also overlook emotional aspects such as 
fear, regret or past experience, and assume that individuals have the opportunities and resources to 
achieve the behaviour. Although attitudes and social norms are significantly associated with 
influenza vaccination uptake, perceived behavioural control does not appear to be linked to 
influenza vaccination behaviour (Montano, 1986; Gallagher and Povey, 2006).   
Similarly, the TIB theorises that behaviour is a function of intention, habit and facilitating (or 
constraining) conditions, and that intention is shaped by attitudes (beliefs about outcomes and 
rational evaluation of outcomes), social factors (norms, roles and self-concept) and affective factors 
(emotions) (Triandis, 1977). Importantly, the TIB conceives habit as a heuristic or shortcut, which 
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minimises the cognitive effort required to make periodic decisions, and postulates that the repeated 
experience of a behaviour leads to an increased influence of habit and a decline of the importance of 
intention (Triandis, 1977). Studies using TIB to explain influenza vaccination behaviour have shown 
that the model’s constructs, particularly habit, are good predictors of intention to vaccinate and, to a 
lesser extent, of vaccination uptake (Montano, 1986; Zimmerman, Nowalk et al., 2003; Zimmerman, 
Santibanez et al., 2003; Nowalk, Zimmerman et al., 2004).  
Other relevant approaches with a focus on affect, which have successfully predicted health 
behaviours but are yet to be used in the context of vaccination, are the Protection Motivation 
Theory (PMT) (Rogers, 1975; Maddux and Rogers, 1983) and the Risk-as-Feelings hypothesis. The 
PMT originated from research on fear appeals (communications about a threat) and postulates that 
information sources (verbal persuasion, observational learning, personality variables, prior 
experience, etc.) initiate cognitive activity (cognitive mediating processes), which lead to protection 
motivation and later to health protective behaviour. A process of threat appraisal (perceived severity 
of and vulnerability to the threat, and fear) and a process of coping appraisal (perceived self-efficacy, 
perceived response effectiveness and perceived response cost), in which the options of minimising a 
threat are evaluated, can lead to either adaptive coping (protection motivation) or maladaptive 
coping (response that may lead to health risk – e.g. avoidance). The Risk-as-Feelings hypothesis 
(Slovic, Finucane et al., 2004) proposes that immediate visceral reactions to risky situations, such as 
fear and anxiety, often drive behaviour, and are sometimes strikingly divergent from the cognitive 
assessment of those risks. Consistently, recent studies have found that feelings about influenza can 
be better predictors of vaccination uptake than cognitive evaluations (Weinstein, Kwitel et al., 2007; 
Liao, Wong et al., 2013).  
In sum, the evidence shows that these models are comprised of a number of often overlapping 
constructs, some of which have consistently predicted influenza vaccination uptake. This thesis 
intends to further investigate the relevance of these constructs, alongside other individual and 
contextual barriers and drivers, to influenza and tetanus vaccination behaviour through a broader 
narrative review of the literature and a more focused systematic review and meta-analysis (Chapters 
2 and 3), an in-depth exploration of the factors underpinning vaccination decisions (Chapters 4 and 
5) and a quantitative assessment of the ability of said constructs to predict vaccination uptake when 
evaluated simultaneously (Chapter 6 and 7). 
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1.5.2 Heuristics and biases 
A significant body of research has demonstrated that when people are unable to assess risk using 
statistical reasoning they often rely on heuristics, an experience-based and intuitive approach used 
to facilitate decision-making (Meehl, 1954; Simon, 1957; Kahneman and Tversky, 1973). Heuristics 
represent what psychologists have termed “cognitive shortcuts”, in other words, they allow an 
inference to be made regarding risk without going through numerous analytical calculations.  
A frequently used heuristic is availability, the tendency to make judgements about the frequency or 
probability of an event based on the ease with which a similar episode can be recalled (Tversky and 
Kahneman, 1974). The use of this heuristic could yield accurate actions but it could also lead to 
erroneous decisions. For example, a high-risk individual may be prompted to have an influenza 
vaccine after being exposed to extensive media coverage about one single influenza-related death. 
The following season, he may decide not to have the influenza vaccine due to a friend experiencing 
side-effects (e.g. influenza-like symptoms) after receiving an influenza vaccine. In both cases, his 
decision-making is determined by the ease with which the risks associated with influenza or the 
influenza vaccine spring to mind (which vary between the two seasons), as opposed to the statistical 
probability of experiencing either adverse effect (which may be constant across the two seasons). 
The first decision, however, is aligned with current vaccination recommendations, whereas the 
second is not. 
Additionally, it has been established that people’s evaluation of the logical strength of an argument 
is often biased by their pre-existent belief in the truth or falsity of the conclusion (Evans and Curtis-
Holmes, 2005). For example, if the same high-risk individual distrusts the medical establishment and 
the pharmaceutical industry and prefers alternative medicine instead, it is likely that the news about 
an influenza-related death will have a lesser impact on his vaccination decision than his friend’s 
reported side-effects – due to mentally over-weighting the vaccine adverse effects, which are 
consistent with his pre-existing beliefs. Importantly, belief-based decision-making need not be 
conscious (Haidt, 2001; Wilson, 2009). Thus, a decision based on intuition may be later post-
rationalised and explained using analytical-sounding arguments, when in reality cost-benefit analysis 
was not employed.    
Consequently, this thesis seeks to go beyond explicit enquiry to elicit actual drivers of vaccination – 
as opposed to readily available information or post-decisional rationalisations – by developing and 
testing a new qualitative approach and undertaking an in-depth exploration of psychological and 
contextual factors that may provide a broader picture of what motivates or deters people from 
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vaccinating (Chapters 4 and 5). Additionally, my work attempts to minimise common research biases 
such as social desirability bias, by carefully considering the order and phrasing of questions and 
statements of qualitative and quantitative empirical studies.  
1.5.3 Customer journey mapping 
The customer journey mapping approach is commonly used in service design to capture and 
evaluate people’s experience of different services (Shostack, 1984; Bitner, 1992; Kingman-Brundage, 
1992; Tseng MM, Qinhai M et al., 1999). Although some elements may be more important than 
others, this approach considers the overall experience of the service user as the result of every 
element in a journey through a service. Although the customer journey mapping approach has been 
mainly used by the transport and tourism industries, it has also enabled health providers to improve 
their service provision by uncovering key areas which deserve attention and focus improvement 
efforts on such areas (Westbrook, Coiera et al., 2007). Of particular note is “the brand touchpoint 
wheel” developed a decade ago by Dunn and Davies (Dunn and Davis, 2002). This conceives the 
customer journey as a wheel comprised of three main stages (pre-purchase, purchase and post-
purchase experience) and a number of “touchpoints”, which are key points at which the consumer 
interacts with a particular product or service (see Figure 1.4). 
                                    
 
Source: (Dunn and Davis, 2002) – see permission to republish in Appendix 1. 
Figure 1.4 The brand touchpoint wheel 
Website 
Advertising 
Collateral 
Product  
assortment 
Point of 
purchase 
displays 
Parts 
delivery 
Customer 
service 
Billing 
Loyalty 
programs 
Product 
quality 
  
  
  
Product 
performance 
Pre - 
purchase 
experience 
Purchase 
experience 
Post - 
purchase 
experience 
Brand 
touchpoint 
wheel 
35 
 
Further investigation into the applicability of this approach to adult vaccination behaviour will be 
undertaken as part of this this thesis (Chapter 5). The aim is to explore how people’s experience of 
health services and immunisation communications impacts uptake, and which areas require 
improvement. 
1.6 Thesis aims and rationale 
A growing body of empirical literature has demonstrated that social and psychological factors 
significantly influence adult vaccination decisions. However, in the UK and elsewhere, efforts to 
robustly investigate, monitor and incorporate these factors into immunisation policies and 
communication strategies have been insufficient. This, in turn, may partly explain the limited success 
of some adult vaccination programmes. At a time when national and international health 
organisations are beginning to recognise the importance of understanding and addressing vaccine 
hesitancy and its determinants, it is critical that we take stock of the existing evidence, evaluate its 
gaps and methodological weaknesses, and develop better tools to measure vaccination behaviour.  
As illustrated in Figure 1.5, drawing upon the theoretical perspectives presented in the previous 
section, this thesis focuses on gaining in-depth understanding of adult influenza and tetanus 
vaccination behaviour in the UK, and developing evidence-based survey tools to better explain and 
predict uptake. My overall hypothesis is that socio-psychological factors are better predictors of 
vaccination behaviour than commonly monitored population characteristics. As stated at the 
beginning of this chapter, this programme of research is part of a larger multinational project 
undertaken in collaboration with Sanofi Pasteur (a pharmaceutical company), Ipsos MORI and 
Double Helix (market research companies). This work will be made available to industry and 
policymakers seeking to track vaccination sentiment and to inform and evaluate interventions.  
A narrative review will aim to provide an overview of the empirical evidence on aspects associated 
with influenza vaccination behaviour among adults in high-income countries and to identify the most 
salient socio-psychological factors underpinning vaccination uptake. The latter factors will be 
systematically reviewed and meta-analysed to estimate the strength and variability of the 
associations between such factors and influenza vaccination, and to identify moderators of these 
relationships (e.g. sample size, study design, measure quality, etc.). Qualitative studies will then 
investigate in depth the socio-psychological factors influencing the uptake of influenza and tetanus 
vaccines in the UK, by exploring how people’s context and experiences shape their beliefs, attitudes 
and behaviour toward these vaccines. These studies will also evaluate whether the identified factors 
are comparable between vaccines or vaccine-specific. Lastly, findings from the literature reviews and 
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the qualitative studies will inform the development and testing of two survey tools aiming to identify 
the determinants of influenza and tetanus vaccination and to predict vaccination behaviour, as well 
as to examine whether vaccination determinants are comparable across vaccines and to ascertain 
the importance of socio-psychological factors in relation to population characteristics and practical 
barriers. This research was approved by the Imperial College Research Ethics Committee (see 
Appendices 2 and 3). 
 
                         
 
Figure 1.5 PhD research design overview 
The specific objectives of this thesis are: 
i. To review and evaluate the existing evidence on the socio-psychological factors influencing the 
uptake of adult influenza and tetanus vaccines (Chapters 2 and 3). 
ii. To identify the drivers and barriers of adult vaccination in the UK, specifically influenza and 
tetanus, and to assess whether they are comparable or vaccine-specific (Chapter 4). 
iii. To explore in depth the wider constellation of factors likely to influence adult influenza and 
tetanus vaccination decisions in the UK over time, and to ascertain differences and 
commonalities between vaccines (Chapter 5). 
iv. To develop and test survey tools to identify the determinants of adult influenza and tetanus 
vaccination in the UK and to assess whether they are comparable across vaccines, to examine 
whether socio-psychological factors are better predictors of vaccination than population 
characteristics and practical barriers, and to predict vaccination behaviour (Chapters 6 and 7). 
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2 Socio-psychological factors underlying adult 
influenza vaccination behaviour in high-income 
countries: a narrative review 
2.1   Introduction 
As discussed in Chapter 1, influenza vaccination in high-income countries remains suboptimal, 
particularly among younger at-risk individuals, resulting in increased morbidity, mortality and steep 
healthcare costs (Ryan, Zoellner et al., 2006; CDC (1), 2010; WHO (1), 2014; ECDC (1), 2015).  
Research investigating the causes of low seasonal influenza vaccination rates has demonstrated the 
importance of socio-psychological factors on vaccination uptake, as synthesised by three reviews of 
the literature (Chapman and Coups, 1999; Kohlhammer, 2007; Ward and Draper, 2008). Chapman 
and Coups identified vaccine effectiveness and perceived likelihood of side-effects, perceived risks 
associated with influenza, previous vaccination and a physician recommendation as the most 
relevant predictors of vaccination (Chapman and Coups, 1999). Similarly, Kohlhammer showed that a 
physician recommendation, perceived vaccine effectiveness and side-effects, and perceived 
influenza risks were the most frequently reported factors influencing vaccination (Kohlhammer, 
2007). Lastly, Ward and Draper found that previous vaccination, concerns about the vaccine, 
perceived risks of contracting influenza and advice and information regarding the vaccine were 
associated with uptake (Ward and Draper, 2008).  
The two most recent reviews, however, include a relatively small number of studies (10-14) and 
focus on the elderly (Kohlhammer, 2007; Ward and Draper, 2008). Furthermore, they were 
published before the A(H1N1) pandemic influenza in 2009/2010 and the controversies around the 
vaccine that ensued, which had a negative impact on people’s attitudes toward seasonal influenza 
vaccination (Poland, Jacobson et al., 2009; Maurer, Uscher-Pines et al., 2010; Bone, Guthmann et al., 
2010). Given that people’s views about vaccines are shaped by continually changing contextual 
factors (Larson, Cooper et al., 2011), an up-to date review of the empirical evidence is needed to 
identify the social and psychological aspects underpinning influenza vaccination decisions among 
adults.  
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2.1.1 Study aims 
This study has three aims: i) to synthesise the available evidence and provide an up-to-date overview 
of the socio-psychological factors associated with seasonal influenza vaccination uptake among 
adults in the high-income countries; ii) to identify the most salient socio-psychological factors 
underpinning vaccination behaviour; iii) to evaluate areas that require attention and identify 
directions for further research.  
2.2 Methods: search, selection criteria and synthesis strategy 
I conducted searches in MEDLINE, PsycINFO and EMBASE using the OVID interface and reviewed 
references from seminal articles. I included English-language articles reporting qualitative and 
quantitative data on socio-psychological factors of influenza vaccination in adults, published from 
the date databases started until December 2012. The main search terms were vaccine(s), 
immunisation(s), influenza, flu, elderly, older, chronic disease, factor, determinant, social, 
psychological, attitude, behavio(u)r, belief and decision-making.  Preliminary searches yielded only 
two articles on tetanus vaccination behaviour, thus this review focuses only on influenza vaccination 
for consistency. 
The outcome measure was vaccination uptake. I excluded reviews, articles with no primary data (e.g. 
editorials or commentaries), articles that conflated multiple constructs and those focusing on 
healthcare professionals and pregnant women, as their vaccination decision-making processes are 
significantly influenced by those they care for and/or regulated by healthcare authorities and 
professional bodies, thus some of their motivations and concerns may differ (Tong, Biringer et al., 
2008; Riphagen Dalhuisen, 2012; Meharry, Colson et al., 2013). No study was excluded based on 
quality, as I sought to capture all potential determinants reported in the literature. Psychological 
factors included thoughts, feelings, emotions, subjective perceptions and understanding, and social 
factors encompassed social networks, community, family and environment (Hewstone, Stroebe et 
al., 2012). Although healthcare system barriers were not the focus of this review, I included 
perceptions relating to such barriers (e.g. perceived lack of vaccine availability in subsequent 
seasons after a shortage).  
The retrieved articles (both quantitative and qualitative) were qualitatively analysed by two coders –
one coder analysed 100% of the articles (myself) and the second analysed 50% (Dr Stephanie Russ). 
The reported data were synthesised into relevant themes using an inductive thematic analysis 
approach, in which codes are derived from the extracted data and refined as the analysis progresses 
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(Brown, Long et al., 2012). There were no significant disagreements between coders. Based on this 
approach, relevant socio-psychological factors were identified and synthesised into broad themes 
(see themes definition in Appendix 4). 
2.3 Results 
Forty-five articles met the inclusion criteria. Twenty-six articles reported data from the US (Carter, 
1986; Ganguly and Cameron, 1989; Ganguly, Webster et al., 1990; Fiebach and Viscoli, 1991; Nichol, 
Mac Donald et al., 1996; Chapman and Coups, 1999; Armstrong, Berlin et al., 2001; Abel, McGaha et 
al., 2003; Madhavan, Rosenbluth et al., 2003; Zimmerman, Nowalk et al., 2003; Zimmerman, 
Santibanez et al., 2003; CDC, 2004; Mayo and Cobler, 2004; Nowalk, Zimmerman et al., 2004; 
Tabbarah, Zimmerman et al., 2005; Brewer and Hallman, 2006; Chapman and Coups, 2006; Winston, 
Wortley et al., 2006; Weinstein, Kwitel et al., 2007; Wray, 2007; Johnson, 2008; Benin, Learsy-Cahill 
et al., 2009; Harris, Maurer et al., 2009; Althoff, Anastos et al., 2010; Frew, Painter et al., 2012; Shim, 
Chapman et al., 2012), nine from the UK (Honkanen, Keistinen et al., 1996; Lewis-Parmar and 
McCann, 2002; Bekker, Gough et al., 2003; Telford and Rogers, 2003; Gallagher and Povey, 2006; 
Mangtani, Breeze et al., 2006; Evans, Prout et al., 2007; Keenan, Campbell et al., 2007; Colley, 2008), 
three from the Netherlands (van Essen, Kuyvenhoven et al. (1), 1997; van Essen, Kuyvenhoven et al. 
(2), 1997; Opstelten, Hak et al., 2001; ), two from Spain (Gene, Espinola et al., 1992; Rodriguez-
Rodriguez, Gaton del Amo et al., 2006), and one from Italy (Pregliasco, Sodano et al., 1999), Canada 
(Roy, Fradet et al., 1996), Israel (Shahrabani and Benzion, 2010), Singapore (Tan, Lim et al., 2010) 
and Hong Kong (Lau, Yang et al., 2006). Three articles reported qualitative data (Telford and Rogers, 
2003; Evans, Prout et al., 2007; Wray, 2007).  
To analyse a fairly complex evidence base, a simple coding scheme was developed: for all the 
identified themes, I first counted the times the factor had been studied and whether it had been 
linked to vaccination uptake or refusal. I then rank-ordered the factors from those most researched 
to those least researched. The results are presented in Figure 2.3.     
In the following sections, I summarise the existing evidence around eight themes: social influence, 
disease related factors, vaccine related factors, habit, general beliefs and perceptions toward health 
and vaccines, awareness, practical barriers and motivators, and altruism. Demographic, socio-
economic and health-related factors that emerged from the review as associated with uptake are 
only briefly summarised, as these were outside the scope of this study. 
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                 Factor reported by unvaccinated participants                                                Factor reported by vaccinated participants 
 
Note: themes are in descending order from most recurrent factor. The grey and orange bars illustrate the number of papers addressing each 
factor reported by unvaccinated and vaccinated participants, respectively.  
 
Figure 2.3 Socio-psychological factors underlying influenza vaccination 
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2.3.1   Social influence 
Healthcare professionals, close relatives and friends can play a major role in adult vaccination 
uptake. A recommendation from a healthcare professional was the most mentioned motivator for 
vaccination (Carter, 1986; Ganguly, Webster et al., 1990; Roy, Fradet et al., 1996; van Essen, 
Kuyvenhoven et al. (1), 1997; Pregliasco, Sodano et al., 1999; Armstrong, Berlin et al., 2001; Lewis-
Parmar and McCann, 2002; Mangtani, Breeze et al., 2006; Abel, McGaha et al., 2003; Bekker, Gough 
et al., 2003; Zimmerman, Nowalk et al., 2003; Zimmerman, Santibanez et al., 2003; Mayo and 
Cobler, 2004; Nowalk, Zimmerman et al., 2004; Tabbarah, Zimmerman et al., 2005; Brewer and 
Hallman, 2006; Gallagher and Povey, 2006; Rodriguez-Rodriguez, Gaton del Amo et al., 2006; 
Winston, Wortley et al., 2006; Evans, Prout et al., 2007; Keenan, Campbell et al., 2007; Colley, 2008; 
Shahrabani and Benzion, 2010; Frew, Painter et al., 2012). Doctors not recommending vaccination 
was also reported as a reason for not receiving the influenza vaccination (Ganguly, Webster et al., 
1990; Fiebach and Viscoli, 1991; Lewis-Parmar and McCann, 2002; CDC, 2004; Mayo and Cobler, 
2004; Johnson, 2008).  
Similarly, there was some evidence that a recommendation or bad experience from family members 
or friends persuaded or dissuaded people from vaccinating against influenza, respectively (Gene, 
Espinola et al., 1992; van Essen, Kuyvenhoven et al. (1), 1997; Pregliasco, Sodano et al., 1999; 
Bekker, Gough et al., 2003; Telford and Rogers, 2003; Zimmerman, Nowalk et al., 2003; Zimmerman, 
Santibanez et al., 2003; Nowalk, Zimmerman et al., 2004; Gallagher and Povey, 2006; Mangtani, 
Breeze et al., 2006).   
2.3.2 Disease related factors         
Perceived susceptibility to, or likelihood of, catching influenza was an important incentive to 
vaccinate (Ganguly, Webster et al., 1990; Gene, Espinola et al., 1992; van Essen, Kuyvenhoven et al. 
(1), 1997; Abel, McGaha et al., 2003; Madhavan, Rosenbluth et al., 2003; Telford and Rogers, 2003; 
Zimmerman, Nowalk et al., 2003; Zimmerman, Santibanez et al., 2003; Brewer and Hallman, 2006; 
Mangtani, Breeze et al., 2006; Rodriguez-Rodriguez, Gaton del Amo et al., 2006; Evans, Prout et al., 
2007; Keenan, Campbell et al., 2007; Weinstein, Kwitel et al., 2007; Shahrabani and Benzion, 2010; 
Tan, Lim et al., 2010; Shim, Chapman et al., 2012), as was anticipated regret or worry that people 
associated with contracting influenza in the future if they did not get vaccinated (Chapman and 
Coups, 2006; Gallagher and Povey, 2006; Weinstein, Kwitel et al., 2007). Misperceptions about own 
risk of contracting influenza were also common among unvaccinated participants, even those at 
higher risk of infection (Ganguly, Webster et al., 1990; Lewis-Parmar and McCann, 2002; Abel, 
42 
 
McGaha et al., 2003; Telford and Rogers, 2003; Zimmerman, Santibanez et al., 2003; CDC, 2004; 
Tabbarah, Zimmerman et al., 2005; Mangtani, Breeze et al., 2006; Wray, 2007; Colley, 2008; 
Johnson, 2008; Harris, Maurer et al., 2009; Shahrabani and Benzion, 2010).  
Similarly, vaccination was more frequent among those who believed influenza was a serious disease 
(Carter, 1986; Ganguly, Webster et al., 1990; Gene, Espinola et al., 1992; Roy, Fradet et al., 1996; van 
Essen, Kuyvenhoven et al. (1), 1997; van Essen, Kuyvenhoven et al. (2), 1997; Armstrong, Berlin et 
al., 2001; Bekker, Gough et al., 2003; Brewer and Hallman, 2006; Lau, Yang et al., 2006; Rodriguez-
Rodriguez, Gaton del Amo et al., 2006; Keenan, Campbell et al., 2007), while there is some indication 
that those who were not vaccinated may underestimate the severity of influenza (Carter, 1986; 
Opstelten, Hak et al., 2001; Evans, Prout et al., 2007; Wray, 2007).   
2.3.3 Vaccine related factors          
Perceived vaccine protectiveness was often reported as a vaccination driver (Carter, 1986; Gene, 
Espinola et al., 1992; Honkanen, Keistinen et al., 1996; Nichol, Mac Donald et al., 1996; Roy, Fradet 
et al., 1996; van Essen, Kuyvenhoven et al. (1), 1997; van Essen, Kuyvenhoven et al. (2), 1997; 
Chapman and Coups, 1999; Lewis-Parmar and McCann, 2002; Abel, McGaha et al., 2003; Telford and 
Rogers, 2003; Zimmerman, Nowalk et al., 2003; Zimmerman, Santibanez et al., 2003; Nowalk, 
Zimmerman et al., 2004; Brewer and Hallman, 2006; Gallagher and Povey, 2006; Lau, Yang et al., 
2006; Keenan, Campbell et al., 2007; Weinstein, Kwitel et al., 2007; Althoff, Anastos et al., 2010), 
while unvaccinated participants mentioned the limited effectiveness of the vaccine as one of the 
reasons behind their decision to abstain from vaccinating (Fiebach and Viscoli, 1991; Pregliasco, 
Sodano et al., 1999; Telford and Rogers, 2003; CDC, 2004; Mangtani, Breeze et al., 2006; Evans, 
Prout et al., 2007; Wray, 2007; Johnson, 2008). I also found some evidence that people who believe 
that influenza vaccination ameliorates the symptoms of influenza were more prone to receive it 
(Bekker, Gough et al., 2003) and vice-versa (Harris, Maurer et al., 2009). 
The most salient concern among both of these groups of unvaccinated people was perceived or 
previously experienced side-effects of the influenza vaccine, yet these were seldom specified 
(Carter, 1986; Ganguly and Cameron, 1989; Ganguly, Webster et al., 1990; Fiebach and Viscoli, 1991; 
Gene, Espinola et al., 1992; Wrenn, Zeldin et al., 1994; Pregliasco, Sodano et al., 1999; Bekker, 
Gough et al., 2003; Telford and Rogers, 2003; Zimmerman, Nowalk et al., 2003; Zimmerman, 
Santibanez et al., 2003; CDC, 2004; Mayo and Cobler, 2004; Tabbarah, Zimmerman et al., 2005; Lau, 
Yang et al., 2006; Rodriguez-Rodriguez, Gaton del Amo et al., 2006; Evans, Prout et al., 2007; 
Keenan, Campbell et al., 2007; Wray, 2007; Johnson, 2008; Harris, Maurer et al., 2009; Shahrabani 
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and Benzion, 2010). In contrast, those who reported not worrying about the vaccine side-effects 
were more likely to vaccinate (Chapman and Coups, 1999; Lewis-Parmar and McCann, 2002; Frew, 
Painter et al., 2012).  
Safety issues around influenza vaccination, such as causing influenza or worsening pre-existing 
health conditions, were also commonly raised by those who refused vaccination (Carter, 1986; 
Ganguly, Webster et al., 1990; Roy, Fradet et al., 1996; van Essen, Kuyvenhoven et al. (1), 1997; van 
Essen, Kuyvenhoven et al. (2), 1997; Armstrong, Berlin et al., 2001; Lewis-Parmar and McCann, 2002; 
Abel, McGaha et al., 2003; Bekker, Gough et al., 2003; Madhavan, Rosenbluth et al., 2003; 
Zimmerman, Nowalk et al., 2003; Zimmerman, Santibanez et al., 2003; CDC, 2004; Mayo and Cobler, 
2004; Mangtani, Breeze et al., 2006; Winston, Wortley et al., 2006; Wray, 2007; Johnson, 2008; 
Shahrabani and Benzion, 2010). As with side-effects, people who vaccinated were not concerned 
about the safety of the vaccine (Lewis-Parmar and McCann, 2002; Brewer and Hallman, 2006). 
Lastly, the available evidence suggests that some people did not vaccinate due to fear of pain caused 
by injections (Ganguly and Cameron, 1989; Gene, Espinola et al., 1992; Armstrong, Berlin et al., 
2001; Madhavan, Rosenbluth et al., 2003; CDC, 2004; Mangtani, Breeze et al., 2006; Johnson, 2008; 
Shahrabani and Benzion, 2010).  
2.3.4 Habit            
Having been previously vaccinated against influenza was an important predictor of future 
vaccination (Carter, 1986; Chapman and Coups, 1999; Armstrong, Berlin et al., 2001; Lewis-Parmar 
and McCann, 2002; Zimmerman, Santibanez et al., 2003; Mayo and Cobler, 2004; Brewer and 
Hallman, 2006; Gallagher and Povey, 2006; Rodriguez-Rodriguez, Gaton del Amo et al., 2006; Althoff, 
Anastos et al., 2010; Shahrabani and Benzion, 2010; Frew, Painter et al., 2012). However, it cannot 
be inferred from the reported data whether this repeated behaviour occurred unconsciously or was 
prompted by others (e.g. a GP). 
2.3.5 General beliefs and perceptions toward prevention and vaccination 
A number of studies linked attitudes and beliefs toward prevention and vaccination with influenza 
vaccination uptake (Ganguly, Webster et al., 1990; Opstelten, Hak et al., 2001; Madhavan, 
Rosenbluth et al., 2003; Telford and Rogers, 2003; Zimmerman, Nowalk et al., 2003; Zimmerman, 
Santibanez et al., 2003; Nowalk, Zimmerman et al., 2004; Tabbarah, Zimmerman et al., 2005; 
Mangtani, Breeze et al., 2006; Rodriguez-Rodriguez, Gaton del Amo et al., 2006; Harris, Maurer et 
al., 2009; Shahrabani and Benzion, 2010; Frew, Painter et al., 2012). These ranged from feeling that 
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vaccination against influenza was a wise thing to do (Zimmerman, Nowalk et al., 2003; Zimmerman, 
Santibanez et al., 2003; Nowalk, Zimmerman et al., 2004; Tabbarah, Zimmerman et al., 2005; 
Rodriguez-Rodriguez, Gaton del Amo et al., 2006) or reporting a positive attitude toward prevention 
in general (Mangtani, Breeze et al., 2006), to not trusting vaccines or believing that vaccination 
weakens the immune system (Opstelten, Hak et al., 2001; Telford and Rogers, 2003; Rodriguez-
Rodriguez, Gaton del Amo et al., 2006; Shahrabani and Benzion, 2010).  
2.3.6 Awareness and lack of consideration 
An important proportion of unvaccinated people expressed lack of awareness of the need or when 
to vaccinate against influenza, including high risk individuals (Ganguly and Cameron, 1989; Ganguly, 
Webster et al., 1990; Wrenn, Zeldin et al., 1994; Madhavan, Rosenbluth et al., 2003; Zimmerman, 
Nowalk et al., 2003; CDC, 2004; Johnson, 2008), whereas most of those who vaccinated knew they 
were at higher risk of influenza-related complications (Carter, 1986; Zimmerman, Santibanez et al., 
2003; Bekker, Gough et al., 2003; Madhavan, Rosenbluth et al., 2003). However, few reported that 
public health communication campaigns had encouraged them to vaccinate (Pregliasco, Sodano et 
al., 1999; Bekker, Gough et al., 2003; Zimmerman, Santibanez et al., 2003). Lack of consideration or 
forgetfulness were also reported as reasons for not vaccinating against influenza (Carter, 1986; 
Ganguly and Cameron, 1989; Ganguly, Webster et al., 1990; Wrenn, Zeldin et al., 1994; van Essen, 
Kuyvenhoven et al. (1), 1997; Pregliasco, Sodano et al., 1999; Abel, McGaha et al., 2003; CDC, 2004; 
Mangtani, Breeze et al., 2006; Rodriguez-Rodriguez, Gaton del Amo et al., 2006; Harris, Maurer et 
al., 2009).  
2.3.7 Practical barriers and motivators 
In the US, heightened urgency to vaccinate was reported during influenza vaccination shortages 
(Brewer and Hallman, 2006; Benin, Learsy-Cahill et al., 2009). Lack of availability of influenza 
vaccination was also associated with a decrease in uptake in the same country, even in subsequent 
seasons when supply had been normalised (Abel, McGaha et al., 2003; CDC, 2004; Brewer and 
Hallman, 2006; Johnson, 2008). Some studies reported that having health insurance or not needing 
to pay for a vaccine (Madhavan, Rosenbluth et al., 2003; Zimmerman, Santibanez et al., 2003; Mayo 
and Cobler, 2004; Shahrabani and Benzion, 2010), vaccinating in the work place and wishing to 
minimise time off work (Shahrabani and Benzion, 2010) stimulated vaccination.  
In contrast, lack of time and issues around access, cost and transportation were raised as barriers to 
vaccination (Carter, 1986; Ganguly and Cameron, 1989; Pregliasco, Sodano et al., 1999; Lewis-
Parmar and McCann, 2002; Madhavan, Rosenbluth et al., 2003; CDC, 2004; Harris, Maurer et al., 
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2009; Shahrabani and Benzion, 2010; Tan, Lim et al., 2010), yet it is not clear the extent to which 
these were perceived or actual barriers. 
2.3.8 Altruism           
There was some evidence that altruism (e.g. vaccinating oneself to help maintain herd immunity) 
may be both facilitating and hindering influenza vaccination uptake. While some individuals reported 
that protecting others motivated them to vaccinate (Carter, 1986; Shahrabani and Benzion, 2010; 
Shim, Chapman et al., 2012), others, particularly in the presence of vaccine shortages, decided not to 
vaccinate so that those at higher risk of complications were able to do so (Johnson, 2008; Benin, 
Learsy-Cahill et al., 2009). 
2.3.9 Population characteristics 
The demographic, socio-economic and health-related predictors of influenza vaccination have been 
extensively examined (Nagata, Hernandez-Ramos et al., 2013) and I do not intend to address them 
fully in this chapter. However, there are a number of characteristics that have been frequently 
associated with vaccination uptake, which deserve consideration; notably, age, chronic health 
conditions and insurance cover (Chapman and Coups, 1999; Xakellis, 2005; Winston, Wortley et al., 
2006; Kohlhammer, 2007; Ward and Draper, 2008). Although there is no consensus regarding the 
impact of gender, marital status, education and income on vaccination rates, there is some evidence 
that these characteristics may be correlated with vaccination (Chapman and Coups, 1999; Evans and 
Watson, 2003; Kohlhammer, 2007; Ward and Draper, 2008; Nagata, Hernandez-Ramos et al., 2013). 
Ethnicity has been linked to vaccination uptake, particularly in the US, where influenza vaccination 
rates in African American and Hispanic populations are lower than among white populations (Abel, 
McGaha et al., 2003; Winston, Wortley et al., 2006; Frew, Painter et al., 2012). This health disparity 
may be explained by community-specific attitudes toward vaccines, inadequate access to care, 
marginalisation and lack of trust in the health system (Abel, McGaha et al., 2003; Winston, Wortley 
et al., 2006; Frew, Painter et al., 2012).  
2.4 Discussion 
This study focuses on the social and psychological factors associated with seasonal influenza 
vaccination uptake among adults in high-income countries. It has updated and expanded previous 
reviews by providing a more detailed account of the factors likely to influence the behaviour of both 
vaccinated and unvaccinated people. Out of the 45 studies that were included in this review, the 
majority were conducted in the US (58%) and only 9 studies were UK-based – the most recent was 
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published in 2008, before the 2009/2010 A(H1N1) pandemic influenza. This highlights the 
importance of further research in this area, particularly outside the US.  
I identified eight broad themes and 22 factors within which the evidence base can be categorised. 
Social influence, perceived disease and vaccine characteristics, habit and general beliefs and 
perceptions toward health and vaccines, awareness and knowledge, and to a lesser extent, practical 
barriers and motivators, and altruism all play an important role in the uptake of influenza 
vaccination in developed economies. Consistent with previous literature reviews, the most reported 
socio-psychological factors associated with influenza vaccination uptake are a recommendation from 
a healthcare professional, perceived susceptibility to influenza or likelihood of acquiring it, vaccine 
effectiveness, side effects and safety, and having had an influenza vaccination in the past (Chapman 
and Coups, 1999; Kohlhammer, 2007; Ward and Draper, 2008). These findings suggest that people’s 
perceptions about influenza and the influenza vaccine remain largely unscathed and that improved 
approaches to modify erroneous beliefs are much needed.  Newly identified factors include 
anticipated regret of contracting influenza, generally valuing (or nor valuing) prevention or influenza 
vaccination, not considering or forgetting to vaccinate, and being unaware of the need to vaccinate.  
The reviewed evidence confirms the importance of the role of healthcare professionals in 
vaccination acceptance. However, the reported lack awareness of the need to vaccinate indicates 
that healthcare professionals may not be reaching many of those who are eligible for vaccination. 
Widespread influenza-related misperceptions (e.g. lack of susceptibility) and concerns around 
influenza vaccination (e.g. side-effects and safety) further support the need for better strategies to 
engage with under-vaccinated populations, both through mass and targeted communications. These 
may range from expanding the use of effective communication mechanisms such as personalised 
letters or phone calls (Thomas, Russell et al., 2010), to improving the quality of the information 
exchanged during consultations in order to adequately address people’s anxieties. Seasonal 
fluctuations in vaccine effectiveness, however, undoubtedly erode trust in influenza vaccination, 
thus better and more reliable products are certainly needed to increase vaccination confidence.  
Importantly, effective communication strategies should be informed by public opinion, which in turn 
requires periodic and sound monitoring.  
Interestingly, general perceptions around prevention or vaccination are associated with both 
influenza vaccination and non-vaccination. This indicates that there may be important synergies 
across different preventive practices and vaccines. For example, those who believe that vaccines are 
untrustworthy may be not only be unwilling to vaccinate against influenza but also against other 
diseases. Future research exploring these links is needed. 
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My findings revealed important gaps in the evidence-base. Given that most of the existing evidence 
is from the US, the importance of general perceptions (e.g. trust in vaccines), psychological 
constructs (e.g. altruism) and population characteristics (e.g. ethnicity) on vaccination uptake should 
be further investigated in other settings. Similarly, practical barriers such as limited access to 
vaccines and lack of time were mainly reported in the US, which may be explained by its largely 
privatised healthcare system and long working hours. Yet, the presence of these barriers in other 
high-income countries deserves further investigation. One important issue in the reviewed evidence 
is the varying quality of the employed methods of enquiry and survey measures. Consequently, key 
questions remain unanswered. For instance, do people who vaccinate successively do it out of habit 
or because they are prompted by external stimuli such as annual reminders from physicians? Is there 
overlap between perceived vaccine side-effects and perceived vaccine safety? Is lack of awareness of 
the need to vaccinate due to poor patient-physician communication, inadequate access to 
healthcare, lack of trust in the healthcare system or all of the above? I believe that better 
understanding these associations, which means concurrent assessment of them within a single 
study, will facilitate the development of more effective public health strategies.  
 
Lastly, there is a need to examine how socio-psychological factors affect other adult vaccines. 
Although there is some evidence on pneumococcal vaccines (Kohlhammer, Schnoor et al., 2007), 
other routine vaccinations such as tetanus containing vaccines, are largely unexplored. Comparative 
research across populations and vaccines using barometer-type instruments could enhance our 
understanding of the effect of these factors on vaccination rates, and enable the design of more 
effective and synergistic policies to increase vaccination coverage in adults.  
2.4.1 Limitations  
This review is limited by its methodology and the quality and quantity of the evidence I was able to 
retrieve. Due to the limitations of the reviewed studies, research focusing on specific populations 
and within particular settings may have limited generalisability. For example, the attitudes of 
diabetic patients may not be shared by elderly people who do not have the condition. There are also 
limitations associated with interpreting results from qualitative studies, which by nature are not 
representative of the investigated population. Such studies aim to obtain detailed understanding of 
an issue and to develop further hypotheses rather than to extrapolate their findings to a larger 
population. Further, some quantitative studies included in this review had relatively small sample 
sizes and samples were generally not representative of the population of interest, which may have 
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led to selection bias. Finally, a number of studies provided insufficient information about the 
measures employed, thus their validity may be questionable. 
More broadly, it should be noted that the review was not systematic, thus some articles may have 
been omitted. Furthermore, the reviewed data is methodologically disparate, thus my qualitative 
synthesis may represent some of these studies more accurately than others. Future reviews could 
address some of these limitations by selecting a narrower subset of studies and more comparable 
methodologies.  
2.4.2 Summary and implications for further research 
Since its inception, influenza vaccination coverage in high-income countries has dramatically 
improved, particularly among over 65s. However, compliance among at risk populations is still 
suboptimal. This study confirmed that socio-psychological factors significantly affect influenza 
vaccination uptake among adults in high-income settings, and identified the most reported reasons 
for accepting or refraining from influenza vaccination. These will be explored further in the following 
chapters. 
An important finding is that the existing evidence in this area is mostly from the US. Better 
understanding of how socio-psychological factors influence vaccination decisions in different 
contexts and across vaccines remains a priority. Further, routinely collecting socio-psychological data 
using standardised methodologies and quality measures will help address the identified knowledge 
gaps and focus resources where they are most needed.  
As an initial step, in the next chapter I undertake a systematic review of the literature and meta-
analysis, honing in on the most salient socio-psychological factors associated with vaccination 
identified in this study. I aim to gauge the importance of these factors on vaccination uptake and to 
better understand the influence of methodological aspects such as measure quality on effect 
magnitude. 
  
49 
 
3 Socio-psychological predictors of seasonal 
influenza vaccination in the general population: a 
systematic review and meta-analysis 
3.1   Introduction 
As established in Chapter 2, socio-psychological factors have an important role in influenza 
vaccination behaviour. This finding is supported by four previous literature reviews exploring the 
factors associated with influenza vaccination. Three non-systematic reviews of the literature 
(Chapman and Coups, 1999; Ward and Draper, 2008; Wheelock, Thomson et al., 2013) and one 
systematic review focusing on elderly people (Kohlhammer, 2007) indicated that influenza risk 
perception (e.g. perceived likelihood of catching influenza), vaccine side-effects (e.g. post-
vaccination flu-like symptoms), vaccine effectiveness, and a physician recommendation were the 
most salient aspects associated with influenza vaccination decisions (Kohlhammer, 2007; Ward and 
Draper, 2008; Wheelock, Thomson et al., 2013). However, these reviews also showed that the 
existing evidence is disparate and often methodologically limited, thus conclusions drawn from 
qualitative syntheses may be inaccurate or at best incomplete.  
There is little research on the factors influencing tetanus vaccination and, to my knowledge, reviews 
of the literature evaluating socio-psychological factors associated with the uptake of tetanus 
boosters are not presently available. As described in the previous chapter, research assessing 
barriers to tetanus vaccination found that as with the influenza vaccine, people are concerned about 
the side-effects and effectiveness of tetanus boosters, and uptake is influenced by a physician 
recommendation. Yet, the importance of tetanus risk perceptions in tetanus vaccination decisions 
remains largely unexplored.  
Thus far, the only attempt to quantitatively synthesize the existing evidence regarding the link 
between perceptions and adult vaccination is a meta-analysis published in 2007 (Brewer, Chapman 
et al., 2007). It explored the association between three dimensions of risk perception (perceived 
disease likelihood, susceptibility and severity) and the uptake of a number of vaccines, including 
influenza. This study found small to moderate associations between influenza vaccination and 
influenza risk perception. Given that people’s attitudes are sensitive to contextual factors such as 
vaccine scares and poor risk communications (Bone, Guthmann et al., 2010; Larson, Cooper et al., 
2011), a meta-analysis of the ever increasing evidence-base on important socio-psychological 
50 
 
predictors of influenza vaccination behaviour, particularly those which have not been previously 
meta-analysed, is warranted. 
The present study follows a rigorous systematic approach to provide a transparent representation of 
the existing evidence and to quantitatively estimate the importance of these factors on vaccination 
uptake. Building upon the work of Brewer et al. (Brewer, Chapman et al., 2007), this study seeks to 
systematically review and meta-analyse studies assessing the association between adult influenza 
and tetanus vaccination uptake (actual or self-reported) and the four dimensions that have been 
most frequently linked to vaccination behaviour: disease risk perception, vaccine risk perception, 
perceived vaccine effectiveness and reported physician recommendation.  
3.1.1 Study aims 
The aims of this study are: (i) to gauge the importance of the aforementioned dimensions on 
vaccination uptake by focusing on studies using comparable measures, whenever possible; (ii) to 
assess methodological factors that might modify the strength of the associations between the 
evaluated perceptions and vaccination, including sample composition, vaccination rate and measure 
quality; and (iii) to measure the consistency of findings across studies. The ultimate aim is to inform 
the development of the survey-tools reported in Chapters 6 and 7.  
3.2 Methods 
3.2.1 Study research 
On 18 February 2014, the following databases were accessed using the OVID interface from the 
beginning of their collection, to search for literature relevant to the aims of this literature review: 
MEDLINE (from 1946), Embase Classic + Embase (from 1947) and PsycINFO (from 1967). The Centers 
for Disease Control and World Health Organisation publication databases were also reviewed. 
Searches were not restricted by time of publication, as, to my knowledge, no other systematic 
review of the literature has achieved the above aims. Database searching was complemented with 
scoping searches using Google Scholar and hand-searching bibliographies of retrieved reports which 
were eligible for inclusion.  
A search strategy was developed using an iterative process. The search comprised three facets 
dictated by the aims of this study: vaccine (e.g. influenza), population (e.g. adult) and social or 
psychological factors (e.g. perceptions, decisions, etc.). Each facet included search terms and 
Medical Subject Headings (MeSH®) terms relevant to each database. MeSH terms were “exploded” 
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to ensure their sub-headings were included in the search. To maximise the specificity and sensitivity 
of the search, different combinations of terms were tested. The search was only restricted to human 
studies. The detailed search strategy can be found in Appendix 5. Initially, I aimed to assess the 
social and psychological determinants of both influenza and tetanus vaccination. However, I was not 
able to retrieve tetanus studies which met the eligibility criteria. Hence, this chapter focuses on 
influenza only. 
3.2.2 Screening and data extraction 
After removing duplicate references, titles and abstracts were screened independently by two 
researchers: I reviewed 100% of the titles and a second investigator (Dr Stephanie Russ) reviewed 
50% of the titles. If either reviewer considered a title relevant or potentially relevant, the abstract 
was reviewed. Disagreements were resolved by consensus. When studies seemed to meet the 
eligibility criteria, the full text articles were retrieved. Reasons for exclusion were coded. Data were 
extracted with a standardised form comprised of a number of criteria, which I describe in the 
following section. 
3.2.3 Selection criteria 
3.2.3.1 Type of reports included 
I included all published articles reporting original data which provided sufficient information to 
calculate bivariate effect sizes (e.g. frequencies, means and standard errors). I excluded studies 
reporting only multivariate associations, as these analyses may understate the true relation between 
vaccination behaviour and the assessed measures. However, attempts were made to contact the 
authors of such studies to request the additional information needed (Honkanen P, Keistinen, et al., 
1996; Nexøe J, Kragstrup J, et al., 1999; Tsutsui Y, Benzion U, et al., 2012). I also excluded reports 
which aggregated “I do not know” and yes or no responses because this strategy can bias results, 
and studies assessing the acceptability of new routes of administration (e.g. dermal), since novel 
products fall outside the remit of this thesis. If multiple published reports used the same sample, I 
included only the one which provided the most detailed information on the assessed measures. 
3.2.3.2 Type of participants included 
I included relevant articles reporting on adult influenza vaccination uptake. Yet, for the same reasons 
described in Chapter 2, I excluded studies which focused or included pregnant women or healthcare 
professionals. 
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3.2.3.3 Type of outcome measures included 
The outcome measure was vaccination uptake. Although actual vaccination (e.g. extracted from 
medical records) is recognised as the most accurate measure of vaccination, for practical reasons, 
the vast majority of studies in this area use self-reported vaccination as the outcome measure. Since 
actual and self-reported influenza vaccination are strongly correlated (Irving, Donahue et al., 2009), 
the latter was acceptable as a reliable outcome measure. 
3.2.3.4 Type of survey measures included 
3.2.3.4.1 Influenza risk perception  
I included three distinct sub-dimensions of risk: perceived likelihood of getting influenza, perceived 
susceptibility to influenza and perceived severity of influenza, as defined by Brewer et al. (Brewer, 
Chapman et al., 2007). Perceived likelihood is the perceived probability of harm conditioned on not 
taking action to prevent it (i.e. not getting the influenza vaccine). It is illustrated by the question “If 
you do not get the influenza vaccine, what is the likelihood that you will get the influenza this year?” 
Although it is often used as a synonym of likelihood, perceived susceptibility, is hereby understood as 
perceived constitutional vulnerability to harm. It is represented by the question “if you got influenza, 
would you feel sicker than people your age?” The third construct, perceived severity, refers to the 
extent of harm a disease could cause. This construct can be captured with the question “If you were 
to get influenza, how severe would it be?”  
Influenza risk measures were acceptable if they captured the individual’s own perceived risk (e.g. 
“Influenza could make me severely ill”) rather than general risk (e.g. “Influenza is a serious disease”), 
as the latter may be interpreted as knowledge and misrepresent actual perceived risk. Likelihood 
measures were required to condition the perception on not having received the influenza vaccine 
(e.g. “Without the influenza vaccine, I would get influenza this winter”). Susceptibility measures 
were included only if they specifically addressed the individual’s intrinsic vulnerability (e.g. “If I got 
influenza, I would feel sicker than other people my age”).  
3.2.3.4.2 Vaccine risk perception: perceived side-effects 
The perceived harm of influenza vaccines is commonly addressed in the literature as side-effects and 
regarded as one of the most important barriers to vaccination. However, there is important variance 
in the measures used to assess perceived side-effects. Some measures capture general attitudes 
toward side-effects (e.g. “Are you concerned about the side-effects from the influenza vaccine?”), 
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whilst others focus on specific types of side-effect or perceived safety issues (e.g. “People can get 
influenza from the influenza vaccine”). I believe it is important to unpack this construct to uncover 
which aspects generate the most anxiety. 
Due to the characteristics of the available evidence, the inclusion criteria for side-effects measures 
were less strict than for influenza risk perception measures (e.g. they did not have to concern the 
individual). Included measures were categorised as follows: perceived general side-effects (e.g. “I am 
concerned about influenza vaccine’s side-effects”), perceived post-vaccination illness (e.g. “The 
influenza vaccine makes you ill”), perceived likelihood of side-effects (e.g. “It is common to 
experience side-effects after having the influenza vaccine”), previous side-effects (“I have 
experienced side-effects after having the influenza vaccine), perceived severity of side-effects (e.g. 
“Side-effects from the influenza vaccine can be serious”), perceived vaccine safety (e.g. “Some of the 
contents from the influenza vaccine could be harmful” or “The influenza vaccine gives you 
influenza”) and perceived pain (e.g. “The influenza vaccine can be painful”). 
3.2.3.4.3 Perceived vaccine effectiveness 
Perceived vaccine effectiveness is understood as the perceived ability of a vaccine to prevent one or 
more diseases. Since the effectiveness of the influenza vaccine is partial and varies depending on 
individuals characteristics such as age and health, and how well the influenza virus strains match the 
vaccine’s in any given year, this construct is particularly relevant when assessing the perceived utility 
of the vaccine. As with side-effects, the criteria applied to perceived effectiveness measures were 
more relaxed. For example, the terms efficacy (how well a treatment works in clinical trials) and 
effectiveness (how well a treatment works in practice) were often used interchangeably. Thus, I 
included studies which addressed both perceived vaccine effectiveness (e.g. “The influenza vaccine 
protects people from catching influenza”) and efficacy (e.g. “The influenza vaccine is very 
efficacious”), regardless of the specificity of the measure. Measures which assessed the vaccine’s 
ability to ameliorate influenza symptoms were excluded, as this is a different construct. 
3.2.3.4.4 Physician recommendation 
Influenza vaccination is usually prompted by the recommendation of a physician.  The existing 
evidence suggests that a physician recommendation is the single most important predictor of 
influenza vaccination uptake. Most studies assessing physician recommendation use straightforward 
measures (e.g. “My doctor recommended the influenza vaccine”). However, some studies use 
ambiguous statements such as “I discussed the influenza vaccine with my doctor”. I excluded such 
54 
 
measures because discussing the pros and cons of the influenza vaccine with a doctor does not 
necessarily result in it being recommended. 
3.2.4 Data Analyses 
Computed effect sizes (rs) per study ranged from 1-6, depending on the number of eligible measures 
reported. The effect sizes were then converted to Fisher’s zs for meta-analytical synthesis as this 
corrects for the skew in the r value distribution as population value deviates from zero (Rosenthal, 
1984). For each assessed dimension, a pooled z score was generated and converted back into r for 
reporting (Rosenthal, 1994; Brewer, Chapman et al., 2007). If the same study reported multiple 
eligible measures of the same construct (e.g. two or more likelihood measures), I averaged the rs. If 
the same study reported multiple measures of different constructs (e.g. perceived general side-
effects, side-effects likelihood and influenza severity), these were included separately in the meta-
analysis under the corresponding construct. I tested the pooled r score of each of the assessed 
dimensions for its difference from zero using t-test. Determination of heterogeneity was undertaken 
using the 2 test (Cochran’s Q) and I2 value; with I 2  50% taken to denote a high degree of 
heterogeneity.  When I 2 was  50%, I assessed four possible factors which have been shown to 
moderate the relationship between the studied dimensions and vaccination behaviour: study design, 
vaccination rate, population and measure quality (Brewer, Chapman et al., 2007). Moderators were 
calculated using t-test only if there were three studies or more in each moderator’s dichotomous 
sub-category (e.g. ≥3 high vaccination rate vs.  ≥3 low vaccination rate). When possible, associations 
between moderators were computed using chi-square tests. However, due to the size of the sub-
samples, these analyses should be considered indicative of a possible association rather than a 
statistically robust one. Reporting biases and other biases were assessed using visual inspection of 
funnel plots along with Egger’s and Begg and Mazumdar’s tests for small-study effects (Borenstein, 
2009). Inter-rater reliability was calculated using Cohen’s kappa statistic. Analyses were conducted 
by a meta-analysis expert (Dr Hutan Ashrafian), a fellow researcher (Ms Leanne Harling) and myself 
using Stata® 12 (version 12.1; StataCorp LP, College Station, TX, USA) and IBM SPSS Statistics 22. 
3.2.5 Study coding 
For each study, the following data was extracted: country of origin, study design (i.e., retrospective 
or prospective), vaccination rate (i.e., high or low, based on the average rate), population (i.e., 
healthy or high-risk participants – ≥65s or with an eligible chronic health condition) and sample size. 
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Additionally, each measure received a quality score based on the quality assessment criteria 
proposed by Brewer et al. (Brewer, Chapman et al., 2007). Scoring was performed separately by 
myself (100%) and Dr Stephanie Russ (50%) with no disagreements. All measures received one point 
if they concerned the individual and an additional point if the categories of the response scale were 
not dichotomised for analysis, which would reduce the variability of the independent variable 
(minimum score = 0; Maximum score = 2). Perceived side-effects measures received an extra point if 
they specified the assessed adverse effect, for example “the influenza vaccine could give me 
influenza” rather than “the influenza vaccine is unsafe” (minimum score = 0; Maximum score = 3). 
An additional point was given to perceived influenza likelihood measures that specified time frame, 
for example this winter (minimum score = 0; maximum score = 3). 
3.3 Results 
The PRISMA diagram in Figure 3.1 illustrates the number of articles identified, their sources and 
reasons for exclusion. Database searches produced 4,891 publications and three articles were 
retrieved through hand-searching. Of these, after removing duplicates, 2,542 were excluded based 
on the information provided in the title, and a further 359 using the information in the abstract. The 
agreement between reviewers was excellent (K = 0.891, p<0.001). Out of the 213 papers eligible for 
full text screening, 43 met the eligibility criteria and were included in the meta-analysis.  
Details of the included studies and measures are presented in Table 3.1.  Most studies were 
conducted in the US (23) (Buchner, Carter et al., 1985; Carter, 1986; Fiebach and Viscoli, 1991; 
Nichol, Lofgren et al., 1992; Pearson and Thompson, 1994; Nichol, Mac Donald et al., 1996; Chapman 
and Coups, 1999; Armstrong, Berlin et al., 2001; Evans and Watson, 2003; Zimmerman, Nowalk et 
al., 2003; Zimmerman, Santibanez et al., 2003; Mayo and Cobler, 2004; Nowalk, Zimmerman et al., 
2004; Tabbarah, Zimmerman et al., 2005; Brewer and Hallman, 2006; Winston, Wortley et al., 2006; 
Weinstein, Kwitel et al., 2007; Althoff, Anastos et al., 2010; Wooten, Wortley et al., 2012; Lorenz, 
Norris et al., 2013), followed by the UK (5) (Lewis-Parmar and McCann, 2002; Bekker, Gough et al., 
2003; Evans and Watson, 2003; Burns, Ring et al., 2005; Keenan, Campbell et al., 2007), The 
Netherlands (3) (Meynaar, van't Wout et al., 1991; van Essen, Kuyvenhoven et al., (1) 1997; van 
Essen, Kuyvenhoven et al. (2), 1997), Hong Kong (Lau, Yang et al., 2006; Liao, Wong et al., 2013), 
Israel (Abramson and Cohen-Naor, 2000; Shahrabani and Benzion, 2010) and Spain (Gené, Espínola 
et al., 1992; Rodríguez-Rodríguez, Gatón et al., 2006) (2 each), and Brazil (Avelino-Silva, Avelino-Silva 
et al., 2011), Canada (Roy, Fradet et al., 1995), Denmark (Nexøe, Kragstrup et al., 1999), Italy 
(Pregliasco, Sodano et al., 1999) and Singapore (Tan, Lim et al., 2010) (1 each).  
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The total number of participants across studies was 26,235 (median=610; range 78-4,496). There 
were 36 retrospective and 7 prospective studies.  Thirty-four studies focused on high-risk groups and 
nine assessed healthy populations. The median vaccination rate was 58% (range 11-83%). A total of 
120 measures were included, 38% of which used samples ≤ 200 participants and 62% used samples ≥ 
200 participants. Twenty-nine measures were of low quality (minimum score) and only 14 were of 
high quality (maximum score).  
 
                
 
Figure 3.1 PRISMA flow diagram 
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Table 3.1 Characteristics of included studies and measures 
Study Country Design Vaccination 
rate (%) 
Population r N Quality 
score 
Perceived influenza likelihood 
Brewer et al., 2006 USA p 25 healthy 0.35 300 3 
Liao et al., 2013 Hong Kong p 11 healthy 0.27 505 3 
Shahrabani & Benzion, 2010 Israel r 24 healthy 0.27 583 1 
Weinstein et al., 2007 USA p 28 healthy 0.26 423 3 
Wooten et al., 2012 USA r 74 high risk+ 0.42 3821 2 
Perceived influenza susceptibility 
Althoff et al., 2010 USA r 57 high risk 0.09 1158 1 
Brewer et al., 2006 USA p 25 healthy 0.61 300 1 
Gene et al., 1992 Spain r 57 high risk 0.10 137 1 
Liao et al., 2013 Hong Kong p 11 healthy 0.02 505 2 
Mayo & Cobler, 2004 USA r 83 high risk 0.55 90 1 
Weinstein et al., 2007 USA p 28 healthy 0.03 423 2 
Perceived influenza severity 
Althoff et al., 2010 USA r 57 high risk 0.09 1158 1 
Gene et al., 1992 Spain r 59 high risk 0.03 145 1 
Keenan et al., 2007 UK r 49 high risk 0.09 136 1 
Lau et al., 2006 Hong Kong r 44 high risk+ 0.10 539 2 
Lewis-Parmar & McCann, 2002a* UK r 70 high risk+ 0.19 275 2 
Opstelten et al., 2001 Netherlands r 68 high risk+ 0.38 634 1 
van Essen et al. (1), 1997a Netherlands r 66 high risk 0.32 553 1 
van Essen et al. (2), 1997b Netherlands r 66 high risk+ 0.19 152 1 
Weinstein et al., 2007 USA p 28 healthy -0.01 423 2 
Perceived general side-effects 
Gene et al., 1992 Spain r 61 high risk -0.28 139 1 
Lewis-Parmar & McCann, 2002a* UK r 70 high risk+ -0.60 275 1 
Lewis-Parmar & McCann, 2002a** UK r 68 high risk -0.22 102 1 
Pregliasco et al., 1999 Italy r 26 high risk+ -0.21 150 0 
Roy et al., 1995 Canada r 58 high risk -0.35 116 0 
Perceived post-vaccination illness 
Keenan et al., 2007 UK r 40 high risk -0.15 136 1 
Nichol et al., 1992 USA r 62 high risk -0.42 480 0 
Nichol et al., 1996 USA r 74 high risk -0.28 364 0 
van Essen et al. (1), 1997a Netherlands r 67 high risk -0.54 550 1 
van Essen et al. (2), 1997b Netherlands r 70 high risk+ -0.62 164 1 
Perceived side-effects likelihood 
Bekker et al., 2003 UK r 77 high risk+ -0.24 168 2 
Chapman & Coups, 1999a USA r 44 healthy -0.32 78 1 
Chapman & Coups, 1999b USA r 40 healthy -0.31 398 1 
Previous side-effects 
Althoff et al., 2010 USA r 54 high risk 0.17 1167 1 
Armstrong et al., 2001 USA r 63 high risk+ 0.27 486 1 
Buchner et al., 1985 USA p 72 high risk 0.50 196 1 
Carter et al., 1986 USA p 74 high risk+ 0.17 325 1 
Evans et al., 2003 USA r 75 high risk+ 0.38 325 1 
Fiebach et al., 1991 USA p 78 high risk 0.14 599 1 
Nichol et al., 1992 USA r 62 high risk 0.39 480 1 
Nichol et al., 1996 USA r 74 high risk 0.42 364 1 
Perceived side-effects severity 
Armstrong et al., 2001 USA r 63 high risk+ 0.11 486 0 
Bekker et al., 2003 UK r 77 high risk+ 0.21 168 1 
Brewer et al., 2006 USA p 25 healthy 0.25 300 1 
Carter et al., 1986 USA p 74 high risk 0.02 325 1 
Lau et al., 2006 Hong Kong r 56 high risk+ 0.27 257 0 
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Study Country Design Vaccination 
rate (%) 
Population r N Quality 
score 
Lewis-Parmar & McCann, 2002a* UK r 70 high risk+ 0.22 275 1 
Pearson & Thompson, 1994a* USA r 62 high risk 0.44 105 0 
Pearson & Thompson, 1994a** USA r 58 high risk 0.21 122 0 
Zimmerman et al., 2003a USA r 47 healthy 0.22 182 0 
Zimmerman et al., 2003a* USA r 66 high risk+ 0.09 189 0 
Perceived safety 
Abramson et al., 2000 Israel r 68 high risk+ -0.26 626 1 
Armstrong et al., 2001 USA r 63 high risk+ -0.17 486 1 
Bekker et al., 2003 UK r 77 high risk+ -0.12 168 3 
Brewer et al., 2006 USA p 23 healthy -0.24 277 1 
Evans & Watson, 2003 UK r 60 high risk+ -0.31 1031 0 
Lorenz et al., 2013 USA r 37 healthy -0.26 293 3 
Weinstein et al., 2007 USA r 28 healthy -0.23 423 3 
Zimmerman et al., 2003a USA r 47 healthy -0.32 182 1 
Zimmerman et al., 2003a* USA r 66 high risk+ -0.17 189 1 
Zimmerman et al., 2003b USA r 79 high risk -0.41 998 2 
Perceived pain 
Althoff et al., 2010 USA r 57 high risk -0.01 1158 2 
Armstrong et al., 2001 USA r 63 high risk+ -0.19 486 1 
Gene et al., 1992 Spain r 61 high risk -0.19 134 2 
Zimmerman et al., 2003a USA r 47 healthy -0.03 182 1 
Zimmerman et al., 2003a* USA r 66 high risk+ -0.02 189 1 
Perceived vaccine effectiveness 
Abramson et al., 2000 Israel r 68 high risk+ 0.63 626 0 
Althoff et al., 2010 USA r 57 high risk 0.17 1158 1 
Armstrong et al., 2001 USA r 63 high risk+ 0.17 486 0 
Brewer et al., 2006 USA p 25 healthy 0.41 300 1 
Evans & Watson, 2003 UK r 63 high risk+ 0.34 990 1 
Fiebach et al., 1991 USA p 78 high risk 0.24 599 0 
Gene et al., 1992 Spain r 57 high risk 0.38 146 1 
Keenan et al., 2007 UK r 49 high risk 0.17 136 1 
Lau et al., 2006 Hong Kong r 39 high risk+ 0.09 439 0 
Lewis-Parmar & McCann, 2002a* UK r 70 high risk+ 0.49 275 1 
Lewis-Parmar & McCann, 2002a** UK r 68 high risk 0.33 102 1 
Lorenz et al., 2013 USA r 37 healthy 0.20 293 1 
Nichol et al., 1992 USA r 62 High risk 0.16 480 0 
Nichol et al., 1996 USA r 74 High risk 0.25 364 0 
Norwalk et al., 2004 USA r 76 high risk+ 0.21 554 0 
Pearson & Thompson, 1994a* USA r 62 high risk+ 0.41 105 0 
Pearson & Thompson, 1994a** USA r 58 high risk 0.29 122 0 
Pregliasco et al., 1999 Italy r 26 high risk+ 0.32 150 0 
Rodriguez-Rodriguez et al., 2006 Spain r 71 high risk+ 0.26 326 0 
Roy et al., 1995 Canada r 57 high risk+ 0.34 127 0 
Tan et al 2010 Singapore r 31 high risk 0.31 307 0 
van Essen et al. (1), 1997a Netherlands r 67 high risk 0.53 556 0 
van Essen et al. (2), 1997b Netherlands r 70 high risk+ 0.50 169 0 
Weinstein et al., 2007 USA r 28 healthy 0.23 423 1 
Wooten et al., 2012 USA r 74 high risk+ 0.42 3821 1 
Zimmerman et al., 2003a USA r 47 healthy 0.17 182 0 
Zimmerman et al., 2003a* USA r 66 high risk+ 0.31 189 0 
Zimmerman et al., 2003b USA r 79 high risk 0.25 998 0 
Physician recommendation 
Abramson et al., 2000 Israel r 68 high risk+ 0.21 626 1 
Armstrong et al., 2001 USA r 63 high risk+ 0.31 486 1 
Avelino-Silva et al., 2011 Brazil r 67 high risk+ 0.23 134 1 
Bekker et al., 2003 UK r 77 high risk+ 0.28 168 2 
Brewer et al., 2006 USA p 25 healthy 0.51 299 1 
Burns et al., 2005 UK r 82 high risk+ 0.30 444 1 
CDC, 1988 USA r 58 high risk+ 0.60 596 1 
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Study Country Design Vaccination 
rate (%) 
Population r N Quality 
score 
Evans & Watson, 2003 UK r 51 high risk+ 0.33 1468 1 
Keenan et al., 2007 UK r 49 high risk 0.05 136 1 
Lewis-Parmar & McCann, 2002a* UK r 70 high risk+ 0.22 275 2 
Lewis-Parmar & McCann, 2002a** UK r 68 high risk 0.41 102 2 
Lorenz et al., 2013 USA r 39 healthy 0.35 262 1 
Mayo & Cobler, 2004 USA r 76 high risk 0.09 108 1 
Meynaar et al., 1991 Netherlands r 75 high risk 0.72 595 1 
Nexoe et al., 1999 Denmark p 37 high risk+ 0.54 1167 1 
Nichol et al., 1992 USA r 62 high risk 0.22 480 1 
Nichol et al., 1996 USA r 74 high risk 0.44 364 1 
Norwalk et al., 2004 USA r 76 high risk+ 0.42 554 1 
Pearson & Thompson, 1994a* USA r 62 high risk 0.64 105 1 
Pearson & Thompson, 1994a** USA r 58 high risk 0.44 122 1 
Roy et al., 1995 Canada r 52 high risk+ 0.51 164 1 
Tabbarah et al., 2005 USA r 71 high risk+ 0.20 248 1 
Winston et al., 2006 USA r 54 high risk+ 0.41 4496 1 
Zimmerman et al., 2003a USA r 47 healthy 0.40 182 1 
Zimmerman et al., 2003a* USA r 66 high risk+ 0.40 189 1 
Zimmerman et al., 2003b USA r 79 high risk 0.50 998 1 
 
A population was classified as healthy when the majority of participants fitted that category but may include at-risk 
participants. Study design categories are p = prospective and r = retrospective. a = same study; b = different study; *sample 
of ≥65s; **sample of ≤65s with eligible chronic health condition; + = All participants are ≥65s. 
3.3.1 Influenza risk perception (Figure 3.2) 
3.3.1.1 Perceived likelihood  
Data on 5,632 participants from five reports were included. Effect sizes ranged from 0.26 to 0.42. 
The positive pooled effect of perceived likelihood on influenza vaccination was significant (t = 6.66, 
p<0.001) and moderate in size (r = 0.32). Variation attributable to heterogeneity was high (I2 = 
88.2%), which indicated the presence of moderators.  These could not be assessed as only five 
reports measured likelihood. 
3.3.1.2 Perceived susceptibility  
Data on 2,613 participants from six reports were included. Effect sizes ranged from 0.02 to 0.61. The 
positive pooled effect of perceived susceptibility on influenza vaccination was significant (t = 2.34, 
p<0.02) and small to moderate in size (r = 0.25). Variation attributable to heterogeneity was high (I2 = 
96.2%). The assessed moderators (study design, vaccination rate and population) were not 
statistically significant (Table 3.2). 
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3.3.1.3 Perceived severity 
Data on 4,015 participants from six reports were included. Effect sizes ranged from 0.03 to 0.37. The 
positive pooled effect of perceived severity on influenza vaccination was significant (t = 3.19, 
p<0.001) and small in size (r = 0.16). Variation attributable to heterogeneity was high (I2 = 89.1%). 
Reports with high vaccination rate and lower quality measures yielded significantly larger pooled 
effect sizes (Table 3.2).  
Perceived likelihood of influenza     ES (95% CI) % Weight 
Brewer et al., 2006     0.36 (0.25, 0.48) 17.82 
Liao et al., 2013    0.27 (0.19, 0.36) 19.79 
Shahrabani & Benzion, 2010    0.26 (0.17, 0.36) 19.19 
Weinstein et al., 2007    0.28 (0.20, 0.36) 20.22 
Wooten et al., 2012    0.45 (0.42, 0.48) 22.99 
Overall (I-squared=88.2%, p<0.001)    0.33 (0.23, 0.43) 100.00 
Perceived susceptibility of influenza       
Althoff et al., 2010     0.09 (0.04, 0.15) 17.53 
Brewer et al., 2006    0.71 (0.60, 0.83) 16.91 
Gene et al., 1992    0.10 (-0.07, 0.27) 15.99 
Liao et al., 2013    0.02 (-0.06, 0.11) 17.25 
Mayo & Cobler, 2004    0.62 (0.41, 0.83) 15.17 
Weinstein et al., 2007    0.03 (-0.06, 0.13) 17.15 
Overall (I-squared=96.2%, p<0.001)    0.26 (0.04, 0.47) 100.00 
Perceived severity of influenza       
Althoff et al., 2010     0.09 (0.03, 0.15) 12.52 
Gene et al., 1992     0.03 (-0.13, 0.20) 9.62 
Keenan et al., 2007     0.09 (-0.08, 0.25) 9.46 
Lau et al., 2006     0.10 (0.02, 0.19) 11.94 
Lewis-Parmar & McCann, 2002a*     0.19 (0.07, 0.31) 11.01 
Opstelten et al., 2001     0.39 (0.32, 0.47) 12.09 
van Essen et al. (1), 1997a     0.33 (0.25, 0.42) 11.96 
van Essen et al. (2), 1997b     0.20 (0.04, 0.36) 9.74 
Weinstein et al., 2007     -0.01 (-0.11, 0.09) 11.66 
Overall (I-squared=89.1%, p<0.001)     0.16 (0.06, 0.26) 100.00 
        -1             -0.5             0              0.5             1 
    Less vaccination      More vaccination   
 
Note: weights are derived from random effects analysis; ES = effect size; CI = confidence interval; a = same study; b = different 
study; *sample of ≥65s; **sample of ≤65s with eligible chronic health condition. 
Figure 3.2 Forrest plot of the association between vaccination and influenza risk perceptions 
3.3.2 Influenza vaccine risk perception (Figure 3.3) 
3.3.2.1 Perceived general side-effects 
Data on 782 participants from five reports were included. Effect sizes ranged from 0.21 to 0.60. The 
negative pooled effect of perceived general side-effects on influenza vaccination was significant (t = 
3.41, p<0.001) and moderate in size (r = -0.35). Variation attributable to heterogeneity was high (I2 = 
87.9%), but moderators could not be computed as only five reports measured general side-effects. 
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3.3.2.2 Perceived post-vaccination illness 
Data on 1694 participants from five reports were included. Effect sizes ranged from -0.15 to -0.62. 
The negative pooled effect of perceived post-vaccination illness on influenza vaccination was 
significant (t = 5.20, p<0.000) and moderate to high in size (r = -0.42). Variation attributable to 
heterogeneity was high (I2 = 91.1%), but moderators could not be computed as only five reports 
measured post-vaccination illness. 
3.3.2.3 Perceived side-effects likelihood 
Data on 644 participants from three reports were included. Effect sizes ranged from -0.24 to -0.32. 
The negative pooled effect of perceived side-effects likelihood on influenza vaccination was 
significant (t = 7.61, p<0.000) and small to moderate in size (r = -0.29). There was no heterogeneity 
in this sub-sample. 
3.3.2.4 Previously experienced side-effects 
Data on 3,942 participants from eight reports were included. Effect sizes ranged from -0.14 to -0.50. 
The negative pooled effect of previously experienced side-effects on influenza vaccination was 
significant (t = 6.23, p<0.000) and moderate in size (r = -0.31). Variation attributable to 
heterogeneity was high (I2 = 89.3%). Reports with a retrospective design had a larger negative pooled 
effect (Table 3.2).  
3.3.2.5 Perceived side-effects severity 
Data on 2,409 participants from 10 reports were included. Effect sizes ranged from -0.021 to -0.44. 
The negative pooled effect of perceived side-effects severity on influenza vaccination was significant 
(t = 5.56, p<0.000) and small to moderate in size (r = -0.20). Variation attributable to heterogeneity 
was also moderate (I2 = 64.9%). Reports with low vaccination rate and low quality measures had a 
larger negative pooled effect size (Table 3.2). 
3.3.2.6 Perceived vaccine safety 
Data on 4,673 participants from 10 reports were included. Effect sizes ranged from -0.14 to -0.50. 
The negative pooled effect of perceived vaccine safety on influenza vaccination was significant (t = 
5.20, p<0.000) and small to moderate in size (r = -0.26). Variation attributable to heterogeneity was 
high (I2 = 91.1%). The assessed moderators (vaccination rate and population) were not statistically 
significant (Table 3.2).  
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Perceived general side-effects     ES (95% CI) % Weight 
Gene et al., 1992     -0.29 (-0.46, -0.12)  19.97 
Lewis-Parmar & McCann, 2002a*    -0.23 (-0.42, -0.03) 19.05 
Lewis-Parmar & McCann, 2002a**    -0.69 (-0.81, -0.57) 21.36 
Pregliasco et al., 1999    -0.21 (-0.37, -0.05) 20.17 
Roy et al., 1995    -0.37 (-0.55, -0.18) 19.46 
Overall (I-squared=87.9%, p<0.001)    -0.36 (-0.57, -0.15) 100.00 
Perceived post-vaccination illness       
Keenan et al., 2007     -0.15 (-0.32, -0.02) 17.53 
Nichol et al., 1992    -0.44 (-0.53, -0.35) 16.91 
Nichol et al., 1996    -0.29 (-0.39, -0.19) 15.99 
van Essen et al., 1997a    -0.60 (-0.69, -0.52) 17.25 
van Essen et al., 1997b    -0.72 (-0.87, -0.56) 15.17 
Overall (I-squared=91.1%, p<0.001)    -0.44 (-0.61, -0.28) 17.15 
Perceived side-effects likelihood       
Bekker et al., 2003     -0.24 (-0.40, -0.09) 25.98 
Chapman & Coups, 1999a     -0.33 (-0.56, -0.11) 11.81 
Chapman & Coups, 1999b     -0.32 (-0.42, -0.22) 62.20 
Overall (I-squared=0.0%, p=0.689)     -0.30 (-0.38, -0.22) 100.00 
Previously experienced side-effects 
Althoff et al., 2010     -0.17 (-0.23, -0.11) 13.62 
Armstrong et al., 2001     -0.28 (-0.37, -0.19) 12.79 
Buchner et al., 1985     -0.55 (-0.69, -0.41) 11.07 
Carter et al., 1986     -0.17 (-0.28, -0.06) 12.16 
Evans et al., 2003     -0.40 (-0.51, -0.29) 12.16 
Fiebach et al., 1991     -0.14 (-0.22, -0.06) 13.05 
Nichol et al., 1992     -0.41 (-0.50, -0.32) 9.39 
Nichol et al., 1996     -0.45 (-0.55, -0.34) 9.54 
Overall (I-squared=89.3%, p<0.001)     -0.31 (-0.41, -0.22) 100.00 
Perceived side-effects severity       
Armstrong et al., 2001     -0.11 (-0.20, -0.02) 12.69 
Bekker et al., 2003     -0.21 (-0.36, -0.06) 9.07 
Brewer et al., 2006     -0.25 (-0.37, -0.14) 11.24 
Carter et al., 1986     -0.02 (-0.13, -0.09) 11.50 
Lau et al., 2006     -0.28 (-0.40, -0.16) 10.70 
Lewis-Parmar & McCann, 2002a*     -0.22 (-0.34, -0.10) 10.94 
Pearson & Thompson, 1994a*     -0.47 (-0.67, -0.28) 7.16 
Pearson & Thompson, 1994a**     -0.21 (-0.39, -0.03) 7.77 
Zimmerman et al., 2003a     -0.22 (-0.37, -0.07) 9.39 
Zimmerman et al., 2003a*     -0.09 (-0.24, -0.05) 9.54 
Overall (I-squared=64.9%, p=0.002)     -0.20 (-0.27, -0.13) 100.00 
Perceived safety       
Abramson et al., 2000     -0.27 (-0.35, -0.19) 11.52 
Armstrong et al., 2001     -0.17 (-0.26, -0.09) 10.92 
Bekker et al., 2003     -0.12 (-0.28, 0.03) 7.57 
Brewer et al., 2006     -0.25 (-0.36, -0.13) 9.29 
Evans & Watson, 2003     -0.32 (-0.38, -0.26) 12.44 
Lorenz et al., 2013     -0.26 (-0.38, -0.15) 9.47 
Weinstein et al., 2007     -0.23 (-0.33, -0.14) 10.56 
Zimmerman et al., 2003a     -0.33 (-0.47, -0.18) 7.85 
Zimmerman et al., 2003a*     -0.17 (-0.31, -0.02) 7.99 
Zimmerman et al., 2003b     -0.43 (-0.49, -0.37) 12.39 
Overall (I-squared=75.4%, p<0.001)     -0.26 (-0.33, -0.20) 100.00 
Perceived pain       
Althoff et al., 2010     -0.01 (-0.07, 0.04) 27.50 
Armstrong et al., 2001     -0.19 (-0.28, -0.10) 23.74 
Gene et al., 1992     -0.20 (-0.37, -0.02) 14.55 
Zimmerman et al., 2003a     -0.03 (-0.17, 0.12) 16.96 
Zimmerman et al., 2003a*     -0.02 (-0.16, 0.13) 17.26 
Overall (I-squared=69.6%, p=0.01)     -0.08 (-0.17, 0.01) 100.00 
       -1             -0.5             0              0.5             1 
    Less vaccination      More vaccination   
 
Note: weights are derived from random effects analysis; ES = effect size; CI = confidence interval; a = same study; b = different 
study; *sample of ≥65s; **sample of ≤65s with eligible chronic health condition. 
 
 Figure 3.3             Forrest plot of the association between vaccination and vaccine risk perceptions 
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3.3.2.7 Perceived pain 
Data on 2,149 participants from five reports were included. Effect sizes ranged from -0.014 to -0.19. 
The pooled effect of perceived pain on influenza vaccination was not significant (r = -0.08, t = 1.85, 
p<0.065). Variation attributable to heterogeneity was moderate (I2 = 69.6%), but moderators could 
not be computed as only three reports measured perceived pain. 
3.3.3 Perceived vaccine effectiveness (Figure 3.4) 
Data on 14,083 participants from 28 reports were included. Effect sizes ranged from 0.09 to 0.63. 
The positive pooled effect of perceived vaccine effectiveness on influenza vaccination was significant 
(t = 11.33, p<0.001) and moderate in size (r = 0.31). Variation attributable to heterogeneity was high 
(I2 = 89.4%). Reports with high vaccination rate and at-risk populations yielded a larger pooled effect 
size. Reports with high and low quality measures had similar pooled effect sizes (Table 3.2).  
 
Perceived vaccine effectiveness     ES (95% CI) % Weight 
Abramson et al., 2000     0.74 (0.58, 0.91) 3.13 
Althoff et al., 2010    0.18 (0.12, 0.23) 4.14 
Armstrong et al., 2001    0.17 (0.09, 0.25) 3.98 
Brewer et al., 2006    0.43 (0.32, 0.55) 3.66 
Evans & Watson, 2003    0.36 (0.29, 0.42) 4.10 
Fiebach et al., 1991    0.25 (0.17, 0.33) 3.97 
Gene et al., 1992    0.40 (0.24, 0.57) 3.13 
Keenan et al., 2007    0.17 (0.00, 0.34) 3.07 
Lau et al., 2006    0.09 (-0.01, 0.18) 3.85 
Lewis-Parmar & McCann, 2002a*    0.34 (0.14, 0.54) 2.79 
Lewis-Parmar & McCann, 2002a**    0.54 (0.42, 0.65) 3.60 
Lorenz et al., 2013    0.20 (0.09, 0.32) 3.64 
Nichol et al., 1992    0.16 (0.07, 0.25) 3.88 
Nichol et al., 1996    0.25 (0.15, 0.36) 3.76 
Norwalk et al., 2004    0.21 (0.12, 0.29) 3.94 
Pearson & Thompson, 1994a*    0.43 (0.24, 0.63) 2.82 
Pearson & Thompson, 1994a**    0.30 (0.12, 0.48) 2.96 
Pregliasco et al., 1999    0.33 (0.17, 0.49) 3.15 
Rodriguez-Rodriguez et al., 2006    0.27 (0.16, 0.38) 3.70 
Roy et al., 1995    0.36 (0.18, 0.53) 3.00 
Tan et al 2010    0.32 (0.20, 0.43) 3.67 
van Essen et al. (1), 1997a    0.59 (0.50, 0.67) 3.94 
van Essen et al. (2), 1997b    0.54 (0.39, 0.69) 3.25 
Weinstein et al., 2007    0.23 (0.14, 0.33) 3.83 
Wooten et al., 2012    0.44 (0.41, 0.47) 4.27 
Zimmerman et al., 2003a    0.17 (0.03, 0.32) 3.31 
Zimmerman et al., 2003a*    0.31 (0.17, 0.46) 3.34 
Zimmerman et al., 2003b    0.25 (0.19, 0.31) 4.11 
Overall (I-squared=89.4%, p<0.001)    0.32 (0.26, 0.37) 100.00 
       -1             -0.5             0              0.5             1 
   Less vaccination      More vaccination   
 
Note: weights are derived from random effects analysis; ES = effect size; CI = confidence interval; a = same study; b = different 
study; *sample of ≥65s; **sample of ≤65s with eligible chronic health condition. 
Figure 3.4  Forrest plot of the association between vaccination and perceived vaccine effectiveness 
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3.3.4 Physician recommendation  
Data on 15,286 participants from 26 reports were included. Effect sizes ranged from 0.05 to 0.72. 
The positive pooled effect of a recommendation from a physician on influenza vaccination was 
significant (t = 11.29, p<0.001) and moderate to high in size (r = 0.39). Variation attributable to 
heterogeneity was high (I2 = 94.2%). Reports with low vaccination rate, healthy people and low 
quality measures yielded larger pooled effect sizes (Table 3.2).  
 
Physician recommendation     ES (95% CI) % Weight 
Abramson et al., 2000     0.22 (0.14, 0.30) 4.10 
Armstrong et al., 2001    0.32 (0.23, 0.41) 4.04 
Avelino-Silva et al., 2011    0.24 (0.07, 0.41) 3.45 
Bekker et al., 2003    0.29 (0.14, 0.45) 3.59 
Brewer et al., 2006    0.56 (0.45, 0.68) 3.88 
Burns et al., 2005    0.31 (0.22, 0.41) 4.01 
CDC, 1988    0.34 (0.29, 0.40) 4.22 
Evans & Watson, 2003    0.05 (-0.12, 0.22) 3.46 
Keenan et al., 2007    0.43 (0.24, 0.63) 3.23 
Lewis-Parmar & McCann, 2002a*    0.22 (0.10, 0.34) 3.85 
Lewis-Parmar & McCann, 2002a**    0.36 (0.24, 0.48) 3.87 
Lorenz et al., 2013    0.09 (0.01, 0.17) 4.09 
Mayo & Cobler, 2004    0.90 (0.82, 0.98) 4.09 
Meynaar et al., 1991    0.69 (0.61, 0.77) 4.09 
Nexoe et al., 1999    0.60 (0.54, 0.66) 4.20 
Nichol et al., 1992    0.22 (0.13, 0.31) 4.04 
Nichol et al., 1996    0.47 (0.37, 0.57) 3.95 
Norwalk et al., 2004    0.45 (0.37, 0.53) 4.07 
Pearson & Thompson, 1994a*    0.75 (0.56, 0.94) 3.26 
Pearson & Thompson, 1994a**    0.47 (0.30, 0.65) 3.38 
Roy et al., 1995    0.56 (0.40, 0.71) 3.58 
Tabbarah et al., 2005    0.21 (0.08, 0.33) 3.80 
Winston et al., 2006    0.44 (0.41, 0.47) 4.28 
Zimmerman et al., 2003a    0.42 (0.28, 0.57) 3.64 
Zimmerman et al., 2003a*    0.42 (0.28, 0.56) 3.66 
Zimmerman et al., 2003b    0.55 (0.49, 0.61) 4.18 
Overall (I-squared=94.2%, p<0.001)    0.41 (0.34, 0.48) 4.10 
       -1             -0.5             0              0.5             1 
   Less vaccination      More vaccination   
 
Note: weights are derived from random effects analysis; ES = effect size; CI = confidence interval; a = same study; b = different 
study; *sample of ≥65s; **sample of ≤65s with eligible chronic health condition. 
Figure 3.5          Forrest plot of the association between vaccination and physician recommendation 
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3.3.5 Funnel plots 
Funnel plot asymmetry was examined in sub-dimensions comprised of 10 or more studies (Figure 
3.6) (Sterne, Sutton et al., 2011). Asymmetry was identified for “perceived safety”. Additional 
analyses performed using both Egger’s and Begg and Mazumdar’s tests again revealed the presence 
of significant small study effects for this sub-dimension (-3.97; SE 1.62; 95% CI [-7.71, -0.24]; 
p=0.040). No statistically significant small study effects were identified for any other outcome.  
 
 
 
 
 
 
       
               (a) Perceived side-effects severity                                                      (b) Perceived safety 
  
 
 
 
 
 
 
               (c) Perceived vaccine effectiveness                                    (d) Physician recommendation 
    Figure 3.6 Funnel plots 
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3.3.6 Associations between moderator variables 
Associations between moderators were calculated for studies with two or more significant 
moderator variables. In the studies that assessed severity, no association was found between 
moderators. In the studies that examined perceived susceptibility, however, vaccination rate was 
correlated with study design and population (2 =6.0, p<0.05) – all the studies in healthy populations 
were prospective and had low vaccination rates. In studies assessing perceived vaccine safety, 
vaccination rate was correlated with population (2 =11.00, p<0.01) – all the studies in healthy 
populations had low vaccination rates. In the studies that examined effectiveness, vaccination rate 
was correlated with population (2 =7.99, p<0.05) – all the studies in healthy populations had low 
vaccination rates. In the studies evaluating physician recommendation, vaccination rate was also 
correlated with population (2 =5.42, p<0.05) – all the studies in healthy populations had low 
vaccination rates. The associations between moderators warrant cautious interpretation of their 
effect on the relationship between the assessed dimensions and vaccination uptake. 
Table 3.2 Moderator analyses 
Measures Design 
(retrospective / 
prospective) 
Vaccination rate 
(high / low) 
Population 
(high-risk / healthy) 
Quality score 
(high / low) 
Perceived likelihood         
Perceived susceptibility 
r=0.25 vs. r=0.25 
(t=0.00, p=1.00) 
r=0.25 vs. r=0.25 
(t=0.00, p=1.00) 
r=0.25 vs. r=0.25 
(t=0.00, p=1.00) 
  
Perceived severity   
r=0.21 vs. r=0.06 
(t=9.74, p<0.001) 
  
r=0.09 vs. r=0.19 
(t=6.37, p<0.001) 
General side-effects         
Post-vaccination illness         
Side-effects likelihood         
Previous side-effects 
r=-0.34 vs. r=-0.28 
(t=3.58, p<0.001)  
      
Side-effects severity   
r=-0.17 vs. r=-0.25 
(t=3.69, p<0.001)  
  
r=-0.17 vs. r=-0.22 
(t=2.16, p=0.03) 
Safety   
r=-0.26 vs. r=-0.26 
(t=0.07, p=0.95) 
r=-0.26 vs. r=-0.26 
(t=0.07, p=0.95) 
  
Pain         
Vaccine effectiveness   
r=0.34 vs. r=0.25 
(t=10.72, p<0.001) 
 r=0.32 vs. r=0.26 
(t=7.13, p<0.001)  
r=0.32 vs. r=0.30 
(t=2.37, p=0.01) 
Physician recommendation   
r=0.36 vs. r=0.43 
(t=8.68, p<0.001) 
r=0.38 vs. r=0.42 
(t=4.95, p<0.001) 
r=0.24 vs. r=0.41 
(t=21.33, p<0.001) 
 
Grey cells = No moderators were examined due to insufficient number of reports. 
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3.4 Discussion 
This study has shown that the perceived risks of influenza and the influenza vaccine, the perceived 
effectiveness of the vaccine and a recommendation from a physician are significantly associated with 
vaccination uptake. It has also revealed that the existing evidence is highly heterogeneous and 
overly representative of developed countries, particularly the US (54% of studies). Thus, further 
research is required to ascertain the relevance of these factors in other contexts. 
Specifically, from the evaluated influenza risk perceptions, perceived likelihood of catching influenza 
yielded the strongest association with vaccination uptake (r=0.32), followed by perceived 
susceptibility (r=0.25) and severity (r=0.16). These results are consistent with findings from Brewer 
et al. (Brewer, Chapman et al., 2007) and confirm that the perceived severity of influenza may be 
less indicative of vaccine uptake than the perceived probability of becoming infected or feeling 
vulnerable to the disease. A plausible explanation is that most people recognise that influenza can 
be a serious disease that can sometimes be fatal, but only for those who are older and frail (Nowak 
GJ, Sheedy, et al., 2015). Hence, risk communications may benefit from shifting their focus from the 
severity of influenza to likelihood of infection and constitutional vulnerability to harm (CDC, 2013; 
NHS, 2013). 
In contrast, those who expressed concerns about post-vaccination illness were the least likely to 
vaccinate (r = -0.42). Individuals who were worried about general side-effects (r=-0.35), had 
experienced side-effects (r=-0.31), perceived side-effects to be more likely (r=-0.29), had concerns 
about the vaccine safety (r=-0.26) or the severity of side-effects (r=-0.20) were also less likely to 
vaccinate. Perceived pain (r=-0.08), however, was not associated with vaccination uptake. These 
findings indicate that, although important, concerns around the vaccine safety or the severity of its 
side-effects may be less influential than the commonly experienced post-vaccination influenza-like 
symptoms. Furthermore, it is possible that general measures assessing vaccine risk perceptions (e.g. 
perceived general side-effects, side-effects likelihood and experienced side-effects) may have also 
captured participants’ anxieties about post-vaccination symptoms. Fear of acquiring viruses from 
vaccines is often reported in the literature and dates back to smallpox inoculation – the unsafe 
practice of deliberately introducing material from smallpox pustules into the skin of healthy 
individuals to produce a milder infection (Gross and Sepkowitz, 1998). Understandably, if the 
influenza vaccine is perceived to cause the same symptoms as the disease it is supposed to prevent, 
vaccination may be perceived as futile. Thus, improved strategies to address misconceptions about 
the severity of post-vaccination influenza-like symptoms are warranted. 
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Consistent with the above results, participants who believed the influenza vaccine was effective 
were more likely to receive it (r = 0.31).  This association can be largely explained by the changing 
nature of influenza viruses and the decreased effectiveness of vaccines in seasons when circulating 
and vaccine strains are mismatched (CDC (3), 2014). The introduction of products which offer better 
protection against influenza, such as the quadrivalent vaccine, may have a positive impact on 
perceived vaccine effectiveness (Grohskopf LA, Olsen SJ, et al., 2014; PHE (3), 2014). Further 
research examining whether this holds true is needed.    
Unsurprisingly, I found that a recommendation from a physician was moderately associated with 
vaccination uptake (r = 0.39). This confirms that healthcare professionals are an important influence 
in vaccination acceptance and supports the need for continuous efforts to develop more effective 
interventions and communication strategies within primary health. 
Where possible, I also evaluated the factors moderating the relationship between the assessed 
dimensions and vaccination. It has been postulated that prospective studies are preferable, because 
retrospective designs may lead to confirmation bias (e.g. I vaccinated, therefore, I must be 
susceptible to influenza), which could in turn result in inflated effect sizes (Weinstein, 2007). I found, 
however, that prospective studies yielded similar results to retrospective studies for perceived 
susceptibility, consistent with findings from Brewer et al. (Brewer, Chapman et al., 2007). This may 
be because confirmation bias from previous seasons can influence the responses of recurrent 
vaccinators. Retrospective designs yielded a larger negative effect size for previous side-effects. A 
possible explanation is that a recent memory of an unpleasant side-effect is likely to be more intense 
and available than one experienced in previous seasons.  
The moderators “vaccination rate” and “population” had similar effects on the assessed measures as 
they often overlapped: studies with high-risk populations had higher vaccination rates. Studies with 
high vaccination rates and high-risk participants yielded similar results to those with low vaccination 
rates and healthy participants for perceived susceptibility and perceived vaccine safety. The former 
finding may be due to the inclusion of younger high-risk participants in all of the studies assessing 
susceptibility, who tend to underestimate their risk (Brewer, Chapman et al., 2007; Wheelock, 
Thomson et al., 2013), and of high-risk participants in studies with a majority of healthy individuals, 
both of which may have biased results. Concerns around vaccine safety appear to be ubiquitous and 
not dependent on belonging to a risk group, which may explain why vaccination rate was not a 
significant moderator for this sub-dimension. In studies with high vaccination rates, however, the 
perceived severity of influenza was significantly higher than in those with lower vaccination rates. 
This finding confirms the relevance of this dimension in vaccination decisions, particularly among 
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those at higher risk of complications. Finally, a higher vaccination rate yielded a lower effect for 
physician recommendation, an indication that such a recommendation is more prevalent among 
high-risk individuals; hence, other factors (e.g. susceptibility) may play a more significant role in the 
decision to vaccinate. 
Unlike results from Brewer et al. (Brewer, Chapman et al., 2007), my analyses showed that studies 
assessing perceived influenza severity, vaccine side-effects severity and physician recommendation 
with low quality measures yielded higher pooled effect sizes than those with high quality measures. 
This unexpected finding may be because studies with high quality measures only differed from those 
with low quality measures as to whether the categories of the used scales were not combined for 
analysis, a criterion which may have not made much difference on its own. Conversely, high-quality 
measures of perceived vaccine effectiveness comprised either of the two employed quality criteria 
(non-dichotomized scales and scales concerning the individual) and yielded a higher effect than low-
quality measures.  
Importantly, although the heterogeneity of findings across studies may be partly explained by 
differences in study characteristics, it could also be attributed to seasonal fluctuations in vaccine 
effectiveness – which could affect people’s perceived need to vaccinate – and epidemiological and 
contextual factors such as the emergence of influenza pandemics and the impact of ensuing policies 
and risk communications on vaccination behaviour (Bone, Guthmann et al., 2010). 
3.4.1 Limitations 
There were a number of limitations related to the quality and quantity of the reviewed evidence; 
thus, the results of this study should be interpreted with caution. First, and perhaps the most 
important limitation is the methodological variability of the existing evidence, reflected by high 
between-study heterogeneity. Funnel plot asymmetry identified in one of the four assessed sub-
dimensions provides further evidence of methodological differences across studies – although 
reporting biases and other contextual factors cannot be excluded. Secondly, due to the small 
number of studies in some of the assessed categories, I was not always able to perform moderator 
analyses (or assess funnel plot asymmetry), which limited the possibility of drawing meaningful 
conclusions. Therefore, this study does not provide robust evidence about the influence of the 
assessed moderators on the effect sizes of the included dimensions, and there is a chance that other 
factors, which I was not able to evaluate, also moderated the relationship between these 
dimensions and vaccination behaviour. Thirdly, studies using objective outcome measures (i.e. 
actual vaccine uptake) were rare, thus this important characteristic could not be assessed as a 
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potential moderator. Fourthly, due to the disparate nature of the included studies, the extent to 
which the studied dimensions predict uptake when assessed concurrently, and over and above other 
factors such as socio-demographic characteristics, could not be explored. Finally, since most of the 
evidence is from a few developed countries, the results may not be generalisable to other 
geographies. 
3.4.2 Summary and implications for further research 
My systematic review and meta-analysis showed that influenza and vaccine risk perceptions, 
perceived vaccine effectiveness and a recommendation from a physician were, individually, 
significantly associated with influenza vaccination. Perceived likelihood of catching influenza was the 
most important influenza risk perception sub-dimension, whereas perceived severity was the least 
important.  Interestingly, concerns about post-vaccination illness and general side-effects were more 
important than those related to safety issues and the severity of side-effects.  
This study also revealed that the existing evidence is highly heterogeneous and should be 
interpreted with caution. Moreover, most of the research in this field continues to arise from the US, 
consistent with the government’s efforts to better understand and monitor the public’s perceptions 
about the influenza vaccine (NVAC, 2013; CDC (1), 2014). Therefore, the findings presented here 
may not be generalisable to other countries, including the UK. 
Reflecting on these findings, there are a number of implications for further research that are 
particularly relevant to Chapters 6 and 7. First, in order to predict influenza, but also tetanus 
vaccination, and to uncover the relative importance of the determinants of vaccination behaviour, 
both well-known predictors and potentially relevant variables ought to be tested concurrently.  
Second, when possible, studies should aim to employ measures which are continuous to improve 
the statistical power of the study, they should also be disease or vaccine-specific to avoid 
misinterpretation, capture individuals’ own perceived risk, and condition risk perceptions on not 
having received the vaccine.  
In the following two chapters, I examine in depth perceptual and contextual drivers and barriers to 
influenza and tetanus vaccination, in order to determine whether: i) the factors identified in this and 
the previous chapter are relevant to the UK population; ii) these factors are comparable between 
vaccines or vaccine-specific; and iii) there are country-specific aspects which have yet to be 
uncovered.    
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4 Socio-psychological drivers and barriers of 
influenza and tetanus vaccination in adults: a 
qualitative study 
4.1   Introduction 
As highlighted in Chapters 2 and 3, a large body of work has found that individuals’ perceptions of 
influenza and the influenza vaccine, and the influence of others are consistently associated with 
influenza vaccination uptake. In countries with good vaccination coverage, where structural barriers 
to access are limited, these perceptions are particularly relevant in shaping vaccination decisions 
(Honkanen, Keistinen et al., 1996; Bekker, Gough et al., 2003; Telford and Rogers, 2003; Mangtani, 
Breeze et al., 2006; Keenan, Campbell et al., 2007). 
One important gap is that the vast majority of the evidence in this field is quantitative (i.e. survey-
based). Whilst quantitative data enable researchers to extrapolate their findings to entire 
populations, qualitative research provides an opportunity to better understand a topic and to 
unearth new issues by delving in depth into individuals’ views and experiences. 
The UK is no exception; to date, few studies have explored influenza vaccination decision-making 
qualitatively and most have focused on the elderly (Telford and Rogers, 2003; Evans, Prout et al., 
2007; Kwong, Pang et al., 2010). Research evaluating drivers and barriers to tetanus vaccination 
uptake from the perspective of the vaccinee is non-existent in the UK. 
4.1.1 Study aims 
This study had two aims: i) to explore in depth adults’ perceptions of vaccination and the factors that 
drive them to have themselves vaccinated (or not) against seasonal influenza and tetanus; and ii) to 
evaluate whether these factors are comparable between vaccines or vaccine-specific.  
4.2 Methods  
This study was approved by the Imperial College Research Ethics Committee (See Appendix 2). 
4.2.1 Sampling and recruitment 
Interviews were carried out in three regions in the UK: London, South East and West Midlands. 
Although representative samples are not required in qualitative research, I sought to attain relevant 
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perspectives by recruiting participants from areas where the majority of the UK population reside. I 
used a purposive sampling strategy to select 20 adult participants who were both vaccinated or not 
vaccinated against influenza and tetanus, and represented a range of population characteristics 
associated with vaccination uptake, particularly age and health status (see Table 4.1). In line with 
sampling criteria used in the previous chapters, this study also excluded pregnant women and 
healthcare professionals. To reduce recall bias, only those who had been vaccinated in the past 12 
months at the time of recruitment were eligible as vaccinated participants (Coughlin, 1990). A 
screening question was used to exclude participants who were fundamentally opposed to 
vaccination, as this stance represents only a small minority of the non-vaccinated population and 
hence, could confound the results (Leask, Kinnersley et al., 2012). Participants were recruited via 
telephone using random dialing, sourced from telephone directories, by Ipsos MORI, an 
international market research company.  
Table 4.1 Purposive sampling strategy 
Key participant characteristics Minimum participant quota per country  
Eligible chronic condition* 7 = with, 7 = without 
Gender 8 = female, 8 = male 
Parent/Guardian of child/children under 18 4 = mothers, 4 = fathers 
Age 8 = 18-49, 4 = 50-64, 6 = ≥65 
Socio-economic group (social grade)** 7 = ABC1, 7 = C2DE 
Adults who have had ONE of the vaccines 4 = influenza, 3 = tetanus 
Have had both tetanus and influenza vaccines 6 
Have not had either vaccination 6 
*Asthma, obstructive pulmonary disease (COPD) or bronchitis, heart disease, kidney disease, liver disease, neurological 
conditions, weakened immune system due to conditions such as HIV and AIDS, or as a result of medication such as 
steroid tablets or chemotherapy, among others. **A = higher socio-economic group and E = lower socioeconomic group. 
Occupation and income data was used to determine participants’ social grade.  
The interview schedule was designed through expert consultations and a review of the relevant 
literature (Chapters 2 and 3). The schedule was then tested with two researchers from Imperial 
College and two researchers from Ipsos MORI who were not involved in the present study. The 
duration and flow of the interview were discussed and the schedule was finessed as a result. The 
refinements to the schedule were related to wording (e.g. using ‘flu’ instead of ‘influenza’ for 
simplicity) and reordering and/or deletion of redundant probes. These interviews were not included 
in the final sample.  
Piloting was subsequently carried out for the first three interviews, whereby the research team 
observed each interview conducted by an Ipsos MORI trained interviewer behind a one-way mirror 
and evaluated its quality in real-time (see Figure 4.1). At the end of the session, minor improvements 
were made to the interviewers’ instructions included in the schedule. 
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Figure 4.1 Indicative image of interviewing facilities used for piloting phase  
4.2.2 Procedure 
Participants were presented with a research information sheet and briefed on 
confidentiality/anonymity of their data before they were asked to sign a consent form (See 
Appendices 6 and 7). Participants were interviewed face-to-face in their homes or at a central 
interviewing facility for approximately 60 minutes. Each participant received £70 in return for their 
time. In order to minimise interviewer bias, half of the interviews were conducted by myself and half 
by a trained interviewer from Ipsos MORI. Two versions of the interview schedule were used: one 
for vaccinated and one for non-vaccinated participants (see summary in Table 4.2 and full interview 
schedules in Appendices 8 and 9).  
The interview schedule comprised six sections. Section 1 obtained an overview of participants’ life 
and values, to build rapport with the interviewee and to identify important issues to assist with 
probing throughout the interview. Section 2 elicited participants’ general information-seeking 
behaviours and influences. Section 3 examined participants’ views toward health, healthcare 
professionals and adult vaccines. Section 4 evaluated participants’ decision-making “journeys to 
vaccination or non-vaccination”. Section 5 examined participants’ attitudes toward paediatric 
influenza and tetanus vaccines. The aim was to understand whether or not people’s views about 
adult vaccines correspond with their views about childhood vaccines. Finally, in section 6 I explored 
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participants’ knowledge of the two diseases and vaccines (i.e. influenza and tetanus) to understand 
to what extent their decision-making was influenced by factual information. 
Table 4.2 Interview schedule 
Interview topic (sections 1-6) Key interview questions 
1. Overview of life and values 
 Tell me about yourself and your life, for example, what you spend your 
time doing and how you enjoy yourself. 
 What sorts of things do you worry about? 
2. Information seeking behaviours 
and influences 
 Can you tell me how you find out what is happening generally in the 
world? 
 And who are the people whose opinion you value or with whom you 
discuss important issues with? And why is that? 
3. Views about health and 
vaccinations 
 Can I ask how you feel your own health is?  
 When you think about your health, what are all the things that come to 
mind? Do you do anything to keep healthy? What sorts of things? 
 Which doctors or nurses do you particularly trust and listen to, if any? 
And why is that? Why is that important to you? 
 Thinking now about vaccinations, what are all the things that come to 
mind when you think about vaccinations? 
 Looking at these cards, which are all adult vaccinations, please can you 
sort them into groups? 
4. Journey to vaccination (or non-
vaccination) 
 How would you describe to a friend how you came to have (or not to 
have) the vaccination? What things happened that meant you ended up 
getting (or not getting) vaccinated? 
 What would you say happened at that point that triggered that change 
(or decision)? And why was that important? 
 How did you know where to go for the vaccination? How did you book an 
appointment and fit it into your plans? What other things were 
competing for your time? 
 Before you were vaccinated, do you remember any times when you 
thought about or started the process toward being vaccinated but didn’t 
end up getting vaccinated? (vaccinated) 
 Of all of those things, which would you say was the most important thing 
that led to you not getting vaccinated? And why is that? And the second 
most important thing? And the third? (non-vaccinated) 
5. Children’s vaccinations 
 In general, do you think people should vaccinate their children against 
tetanus? Why/why not? 
 And do you think people should vaccinate their children against 
influenza? Why/why not? 
6. Factual knowledge on influenza 
and tetanus and related vaccines 
 How much would you say you know about influenza/tetanus? How 
serious or life-threatening do you think the disease is? In general, how 
likely do you think you are to catch the disease?  
 How much would you say you know about the vaccine for 
influenza/tetanus? Do you happen to know how often it is recommended 
that you have it, or who it is recommended for? 
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I explored the set of circumstances and emotional factors that drove participants to accept or refuse 
vaccination, aided by qualitative interviewing approaches aimed at obtaining information which 
explicit enquiry (i.e. a direct question) may fail to capture – as follows. First, throughout the 
interview I used an elicitation technique called ‘laddering’, which provides a simple and systematic 
way of establishing people’s core values and beliefs, and the linkages between these and key 
behaviours, in this case, vaccination (Reynolds and Olson, 2001). In section 3, general views on adult 
vaccines were evaluated by asking participants to spontaneously arrange and rank, using a category 
of their choice, cards depicting five adult vaccines (influenza, tetanus, pneumonia, hepatitis and 
measles, mumps and rubella (MMR)) into one or more groups. By identifying how people group 
vaccines, and the reasons for their groupings, I aimed to contextualise and gain deeper 
understanding of their views on influenza vaccines and tetanus boosters.  
In section 4, I employed the “journey to vaccination” approach (Wheelock, Miraldo et al., 2014), a 
visual exercise in which the interviewer and the participant jointly draw a timeline that captures 
salient events that led the participant to get or not to get vaccinated. These results will be presented 
in the following chapter, as they require different analysis. Briefly, a journey to vaccination for 
influenza and other for tetanus is drawn for each participant. Differences and commonalities 
emerging from these data are identified and synthesised, and typical journeys proposed. 
4.2.3 Data Analysis 
The recorded interviews were professionally transcribed verbatim and checked for accuracy by Ipsos 
MORI. To ensure reliability of coding and interpretation, I analysed all the transcripts and 50% of the 
transcripts were double-coded independently by Dr Anam Parand, an experienced qualitative 
researcher (Pope, Ziebland et al., 2000). Differences were resolved through discussion and review 
until consensus was reached. Using thematic analysis, an initial categorising system was developed 
based on the study objectives and the topics explored (Silverman, 2001; Flick, 2009). New themes 
and sub-themes emerging from the data analysis were identified and included when deemed 
relevant by the coders. Two identical thematic indexes, one for influenza and one for tetanus, were 
produced to code the majority of the data. This coding strategy enabled me to evaluate whether the 
assessed factors were comparable between vaccines or were vaccine-specific. I also examined 
whether participants’ views varied depending upon their vaccination status. Additionally, a separate 
matrix was developed to code and analyse the categories and rankings proposed by participants 
during the card exercise in section 3 of the interview schedule.  
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4.3 Results 
4.3.1 Participant characteristics 
Twenty members of the UK public were interviewed in May 2013. The sample was equally split by 
gender. Eight participants were 18-49 years, seven were 50-64 years and five were 65+. The majority 
were white British (N=16) and half were educated to university level. Just under half of the sample 
were retired or had a chronic health condition. Participants’ characteristics are fully described in 
Table 4.3. Distinctive vaccination behaviour patterns emerged from the data. Thus, the dichotomous 
vaccination status (i.e. vaccinated/not vaccinated) initially employed was fine-tuned; participants 
were classified as regular (vaccinated most or all the time; N=8), intermittent (had vaccinated only 
for a period of time; N=5) and unvaccinated (never had vaccinated; N=7) for influenza; and 
preventive (vaccinated before an injury; N=4), injury-led (vaccinated after an injury; n=9), mixed 
(both preventive and injury-led) (N=3) and unvaccinated (never had vaccinated; N=4) for tetanus. In 
the sections that follow, I use this classification to report my findings.  
4.3.2 Context of vaccine perceptions 
Participants widely agreed on the importance of vaccination in general and childhood vaccination in 
particular. When asked to rank influenza, tetanus, pneumococcal, hepatitis and MMR for adults 
(cards exercise), participants employed three main categories: disease severity, vaccine importance 
and vaccination age. Most found it difficult to categorise MMR and generally regarded it as a 
childhood vaccine, despite interviewers stressing that it was also an adult vaccine.  
Severity of the disease emerged as a key classification category. Regular vaccinators classified 
influenza as the most or one of the most severe diseases, followed by tetanus, pneumonia and 
hepatitis, although some stressed that their knowledge of the latter was limited. Overall, those who 
had not vaccinated against influenza did not perceive this disease to be as severe as hepatitis or 
pneumonia, and ranked tetanus as being more severe than influenza.  
“How do vaccinations help? Well, in my opinion, they help to keep a lot of infection away. 
You could be infected by something and it could take your life, it could kill you if you never 
had that vaccination” (P20) 
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N City Influenza 
vaccination 
Tetanus 
vaccination 
Age Gender Chronic 
illness 
Marital 
status 
Children 
under 18 
Socioec.  
grade 
Private 
insurance 
Employment 
status 
Type of 
employment 
Education 
(completed) 
Religion Ethnicity 
1 London Unvaccinated Unvaccinated 18-49 Male No Married Two ABC1 No Employed 
part-time 
Supervisor High school or 
equivalent 
Sikh Other ethnic 
group 
2 London Regular Mixed 18-49 Female Yes Single None C2DE No Prefer not to 
say 
Shop owner, 
artisan, other  
Post-graduate 
degree 
Non White 
British 
3 London Intermittent Injury-led 50-64 Male No Cohabiting One ABC1 No Employed full-
time 
Middle 
management 
Secondary 
school 
Not 
stated 
White 
British 
4 South 
East 
Unvaccinated Injury-led 50-64 Male No Married One ABC1 No Self-employed Business owner (full 
or partner) 
Post-graduate 
degree 
Hindu White 
British 
5 London Regular Preventive 18-49 Male Yes Single None ABC1 No Self-employed Shop owner, 
artisan, other 
Post-graduate 
degree 
Non White 
British 
6 London Regular Injury-led 65+ Female No Widowed None C2DE No Retired Employed position, 
not at a desk 
Primary 
school 
Christian White 
British 
7 London Intermittent Injury-led 50-64 Male No Cohabiting One ABC1 No Self-employed Business owner (full 
or partner) 
University 
 degree 
Christian White 
British 
8 London Regular Preventive 50-64 Female No Married None ABC1 Yes Retired Employed position 
at a desk 
Secondary 
school 
Muslim White 
British 
9 South 
East 
Unvaccinated Injury-led 65+ Female No Divorced None ABC1 No Retired Top management High school or 
equivalent 
Muslim White 
British 
10 London Unvaccinated Injury-led 18-49 Female No Single None ABC1 No Self-employed Shop owner, 
artisan, other 
University 
 degree 
Non White 
British 
11 West 
Midlands 
Regular Mixed 18-49 Male Yes Married Two ABC1 No Looking for 
work 
Skilled manual 
worker 
Primary 
school 
Non White 
British 
12 West 
Midlands 
Unvaccinated Unvaccinated 50-64 Female Yes Single None ABC1 No Retired Employed position 
at a desk 
University 
 degree 
Buddhist Black 
background 
13 West 
Midlands 
Intermittent Injury-led 50-64 Male Yes Married None ABC1 No Retired Middle 
management 
University 
 degree 
Christian White 
British 
14 West 
Midlands 
Unvaccinated Preventive 65+ Female No Divorced None C2DE No Retired Business owner (full 
or partner) 
High school or 
equivalent 
Non White 
British 
15 London Intermittent Injury-led 18-49 Male No Single None C2DE No Self-employed Skilled manual 
worker 
University 
 degree 
Christian Other white 
background 
16 West 
Midlands 
Regular Unvaccinated 18-49 Male Yes Cohabiting None ABC1 No Student Employed position 
at a desk 
Primary 
school 
Non Other white 
background 
17 West 
Midlands 
Regular Mixed 50-64 Male Yes Married None C2DE No Retired Professional (e.g. 
lawyer, architect) 
University 
 degree 
Christian White 
British 
18 West 
Midlands 
Intermittent Unvaccinated 65+ Female No Divorced One C2DE Yes Retired Middle 
management 
Post-graduate 
degree 
Christian White 
British 
19 West 
Midlands 
Unvaccinated Preventive 18-49 Female Yes Married None ABC1 No Self-employed Other (unskilled 
manual worker) 
High school or 
equivalent 
Christian White 
British 
20 West 
Midlands 
Regular Injury-led 65+ Female Yes Widowed None C2DE No Retired Employed position 
not at a desk 
Secondary 
school 
Other White 
British 
4.3 Participant characteristics 
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Some of those who had previously vaccinated against influenza also chose vaccine importance to 
categorise vaccines. Perceived vaccine importance was associated with both perceived severity and 
likelihood of the disease it protected against, and, consequently, the importance of “being 
protected”. The influenza vaccine was ranked among the two most important vaccines, followed by 
tetanus, pneumonia, hepatitis and MMR.  
“…I think so many very elderly people die of flu in the winter; I think [the flu jab] is important. 
Yes, that one [tetanus boosters] because as we grow up, certainly teenagers and everybody 
onwards needs one of those… The same with that one [pneumococcal vaccine] but I think 
there's more flu. I'm assuming there are more flus than pneumonia around” (P14) 
Some participants used vaccination age as a ranking category and associated the influenza and 
pneumonia vaccines with adults, particularly the elderly. Hepatitis was also linked to adulthood. In 
contrast, tetanus was associated with teenagers and adults and MMR with children. 
4.3.3 Drivers and barriers to vaccination: Findings of the thematic analysis 
Thematic saturation was reached at 14 interviews (i.e. no new themes appeared in the last 6 
interviews that were carried out). Five overarching themes emerged from the analysis: i) perceived 
health and health behaviours; ii) knowledge; iii) vaccination influences (salient previous experiences, 
healthcare professionals and media); iv) disease appraisal (perceived susceptibility, severity and 
likelihood); and v) vaccination appraisal (perceived benefits and costs). These are reported in detail 
below. 
4.3.3.1 Perceived health and health behaviours 
Exercise, a balanced diet, not smoking and moderate alcohol consumption were perceived by most 
participants as desirable healthy behaviours, yet vaccination was generally not associated with the 
‘healthy living’ paradigm.  
“…I'm not 20 years old you know? I get tired so quickly. By keeping fit, going to the gym, and 
eating healthy you know, you're putting more life into your body” (P1) 
Those with chronic conditions were generally aware of their health status and the recommended 
health behaviours for preventing complications, including influenza vaccination. Accordingly, two 
thirds of participants who reported having a chronic health condition regularly vaccinated against 
influenza and had had a preventive tetanus booster. However, they were the least likely to engage in 
other healthy behaviours. 
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4.3.3.2 Knowledge 
Several participants felt they did not know enough about influenza and tetanus, or the associated 
vaccines. Most mentioned that influenza was a potentially severe illness, yet those who had 
vaccinated in the past were more likely to stress it was a life-threatening disease. 
“Well I know that people die from [flu], so it's quite serious [laughs], it can be quite serious. I 
don't think that I've ever had proper flu” (P10) 
Participants were widely aware about high-risk groups but were less specific about the influenza 
symptoms, which were commonly referred to as a “very bad cold”. Most knew the influenza vaccine 
was offered once a year and that it could cause side-effects. A third of the sample accurately 
mentioned that the vaccine did not protect against all circulating virus strands. 
“I think like the surgery where I am, I think it's diabetes, chest complaints and old age 
pensioners that get [the flu jab]… I believe that it is the flu virus but it's not live. And is it 
grown in eggs is it? Because I know my mother-in-law can't have it because she's allergic to 
eggs and that's where it starts. I believe that to be right. Which is why I think when people 
say, 'Oh it gave me the flu', I don't know if it does or if it doesn't, because it's never given it to 
me” (P11) 
Tetanus was generally referred as “lockjaw” and perceived to be a very serious disease; yet 
additional symptoms were seldom identified. Cuts, rust and animal bites were mentioned as main 
sources of infection. Some believed tetanus did not exist in the UK any more.  
“…tetanus? Only that I believe it can lead to lockjaw, which is quite nasty, and I also believe 
that it can flow through, the actual localised injury can sort of lead to, say you have it in your 
foot, it could lead to amputation, this is my belief” (P7) 
Just under half of participants mentioned that a tetanus booster was recommended every 10 years 
and several noted they would get it if they had an injury, but they did not see the need to have it 
preventively. 
“…I was under the awareness that it was every 10 years that you have to be vaccinated 
against tetanus… the influenza one in my mind is a preventative and the tetanus is also a 
preventative, but it can be taken after the incident” (P10) 
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4.3.3.3 Vaccination influences 
4.3.3.3.1 Salient previous experiences 
Most participants reported experiencing influenza-like symptoms once or more times over the 
course of their lives and several stressed, unprompted, that they knew the difference between a 
cold and influenza. None of the participants had contracted tetanus.  
“…'No, no, I'm not having it', and then one year, I was, again, I was so ill here. It was just 
after Christmas, I can't remember what year it was, it was after I retired and I was so ill and I 
thought, 'Oh dear, maybe I should have had that flu jab'. The following year I did have it and 
I've had it ever since and I have no problems at all” (P6) 
Some participants reported they had considered having the influenza vaccine or had decided to get 
vaccinated after relatives or friends had either suffered a bout of the disease or had recommended 
the influenza vaccine.  
“I don’t know that many people that have had really bad flu but I know the ones that have 
had it, when they’ve said how rotten they felt, I can't imagine feeling like that for three or 
four weeks in bed aching or whatever. So, for me, again, yes, the outcome is that I'd rather 
not have it than have it.” (P2) 
All influenza unvaccinated participants, except one young healthy participant, mentioned that a 
relative, a friend or both had had a bad experience with the vaccine, and some recalled that 
although in certain seasons they had heard or read media reports about influenza-related deaths, no 
one they knew had been severely affected.  
“I suppose, I can't remember, but I would seem to remember things, well, on the telly of 
people getting the flu, that people had died from getting the flu. That nobody I knew, I knew 
lots of people I knew got the flu, but nobody died from it and I suppose from a sort of 
childhood perspective, I just thought flu is just like a cold, but a bit worse.” (P4) 
Some tetanus vaccinators also mentioned that advice from a relative had influenced their decision to 
seek medical help after an injury. 
“Yes, well, I was frightened. Well, it's not so much me that’s frightened, my daughter, she 
kind of hits the roof, she's worried all the time, you see, 'You’ve got to have [the tetanus 
booster], Mum. Mum, you don’t know, you don’t know where the dog's been” (P6) 
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4.3.3.3.2 Healthcare professionals 
Many participants had discussed vaccinations, particularly influenza, with their GP. Several 
unvaccinated or intermittent vaccinators expressed negative feelings toward healthcare 
professionals, which revolved around GP’s lack of empathy, NHS perverse incentives (e.g. GPs 
receiving payments for each administered vaccine) and general distrust of the medical profession. In 
contrast, all regular influenza vaccinators reported that their GPs had recommended and routinely 
reminded them to get vaccinated during regular consultations, through GP surgery adverts and 
letters. Some participants mentioned they had either got vaccinated against influenza or were 
reminded to do so at a pharmacy.  
“My doctor, my GP, yes, he's the one who started the ball rolling with the flu vaccine… I know 
when they'll start because it's on the surgery wall, you know, 'Get your flu vaccine here', 
whatever… I'm almost living in these people's pockets, you know. I bring them all panettone 
at Christmas” (P5) 
Receiving a tetanus booster preventively or after an injury was generally triggered by a 
recommendation from a GP or an A&E doctor.  
“Yes, I fell and cut the jeans open and had a big gash and elbow gash as well, but nothing 
serious I thought. But I went to the doctor… she said, 'Just when was the last time you had 
your tetanus jab?' I sort of looked and thought, 'No, I can't remember. I know I have had 
tetanus jabs, but...' She said, 'Well if you can't remember, you'll have to have a tetanus jab', 
so that was that” (P7) 
Some participants, however, reported that healthcare professionals seemed somewhat unsure as to 
what the course of action was, particularly when the request for a booster was patient-led.  
“Does tetanus exist in the UK or not? Don't go round to the surgery and they go, 'You don't 
really need that.' What sort of message does that give out? Yes? Do I or don't I?... Where is 
the provision of this information? Is it schools? Who's doing it? Is it the GP? Is it from birth? 
This is the thing I think they've got to worry about here…” (P5) 
Others mentioned they hoped their GPs would know from their electronic medical records when 
they were due for a tetanus booster. Two participants, one intermittent and one unvaccinated, 
raised specific concerns regarding the pharmaceutical industry’s lack of trustworthiness. 
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“…pharmaceutical companies are out to make a buck… I'm not an advocate of conspiracy 
theories but these people have got enormous power and a lot of money and they wouldn’t be 
above publishing a lot of information and research that scares the hell out of us, so we all go 
and get a vaccine” (P8) 
4.3.3.3.3 Media 
Some participants mentioned finding out the risks of catching influenza through the news (accessed 
through different media), whilst others had read about influenza vaccines’ risks mainly through user-
generated web-based sources such as personal blogs and social media. 
“I'm friends with a professor on Facebook, and he just constantly puts things about the 
poison that's going into your body with the flu jab and everything, and he is very switched-
on… I know he's extreme so I don't totally think, 'Everything he says is absolutely right', but I 
do think sometimes there's no smoke without fire” (19) 
4.3.3.4 Disease appraisal 
4.3.3.4.1 Perceived susceptibility 
As mentioned in Chapter 3, susceptibility denotes constitutional vulnerability to a particular hazard, 
rather than the likelihood of exposure to it. All regular and some intermittent influenza vaccinators 
reported feeling susceptible to the disease.  
“…I know that I can't afford to get the flu because it's very, I've never had it, I know some 
people are in bed for a couple of weeks. If I had it, I'd probably be off for a month and it 
would be really bad for me. But some people don’t have that attitude because maybe the risk 
of getting something isn’t such a big deal. But I don’t” (P2) 
In contrast, although some unvaccinated participants said they would consider having the vaccine 
when they were older and therefore more vulnerable to influenza, most felt that the risks influenza 
currently posed to their health did not warrant vaccination. Furthermore, some intermittent and 
unvaccinated participants, felt they were able to prevent influenza by “improving the immune 
system” or “keeping healthy”. 
“[If] I get the flu now, I'm pretty unlikely to die from it because I'm quite healthy and I had it 
a couple of years ago and I was all right. So [I] think, 'Well, it's not worth taking it now but if 
the danger arises, so to speak, so like as I get older, then I probably would'” (P4) 
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A minority of preventive vaccinators reported feeling particularly vulnerable to tetanus. Having a 
“good immune system” was raised by only one injury-led vaccinator as a reason why they did not 
feel the need to have a preventive tetanus booster. 
4.3.3.4.2 Perceived severity 
Most participants acknowledged that influenza could be life-threatening for high-risk groups, but 
only a few were concerned about having a severe bout of the disease. The majority, particularly 
those who had not vaccinated, perceived themselves as being able to “cope” with influenza.  
“So, I've never, never thought of [the flu] as being a kind of dangerous thing to have… I'd 
seen things on the telly of people dying, that people did die from it, although mostly kind of 
elderly and weak people” (P4) 
In contrast, just under half of participants, most of whom had had a preventive booster, stated that 
they had a tetanus booster for fear of contracting a life-threatening disease. 
“I suppose [I am] generally aware that [tetanus] was a dangerous thing to get and could kill 
you if you weren't looked after properly. Lockjaw it used to be called, didn't it?... and that 
was always a scary thought, a scary way to die” (P17) 
4.3.3.4.3 Perceived likelihood 
Most regular influenza vaccinators felt they were likely to catch influenza, whereas some 
intermittent and unvaccinated participants felt it was unlikely they would catch it. Participants 
generally interchanged susceptibility to influenza and likelihood of getting it throughout their 
interviews. 
“I'd say 20 plus and it becomes more difficult to catch, but under that then obviously a lot of 
germs are being spread about. The same with older people as well, because your immune 
system gets a lot weaker when you're older, so it'll be easier to catch if you're old” (P16) 
Almost half of the sample mentioned they were likely to contract tetanus, commonly due to lifestyle 
choices (e.g. gardening or travelling abroad), risky work environment (e.g. construction) or injuries. 
The other half, however, felt the likelihood of contracting tetanus was very low. 
“A flu jab or the MMR or something, these were things that you might possibly get; you 
might or you might not. The tetanus, I might possibly get infected but there's more of a 
chance of me getting it now because I've got an injury there that's swollen” (P3) 
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4.3.3.5 Vaccination appraisal 
4.3.3.5.1 Perceived benefits 
Although many were aware that the influenza vaccine was not 100% effective, those who vaccinated 
regularly were more likely to acknowledge the benefits of being protected or protecting a vulnerable 
family member against influenza, albeit partially. Remaining productive at work or at home was 
raised as one of the benefits of influenza vaccination.  
“So, for me, [influenza vaccination] is one of these things that I fit into time… I was freelance 
working, so I got paid when I actually worked, so if you had flu, it's three or four weeks… you 
not want to be ill really because four weeks off work, not many people can afford to not be 
paid for four weeks” (P2) 
Most participants, however, were unsupportive of the paediatric influenza vaccine. Many stated that 
“children’s immune system should be built naturally” whereas others questioned the need for an 
influenza vaccine for children due to perceived low prevalence of the disease among this group. 
“I used to work in a school and I'm not aware of children getting influenza” (P8) 
Being immunised against tetanus was considered important, yet many thought a booster was only 
needed after an injury and not as a preventive measure.  
“I thought because we travel a lot, I thought that's important to having [the tetanus 
boosters] up-to-date and it's not good to get…I think it's called lockjaw, isn't it, if you're not 
up-to-date with tetanus? That I think is very important” (P8) 
In contrast, the majority of participants felt that vaccinating children against tetanus preventively 
was necessary, as they were more prone to falls and injuries. 
4.3.3.5.2 Perceived costs 
4.3.3.5.2.1 Vaccine side-effects and safety 
Some intermittent and most unvaccinated participants mentioned the influenza vaccine’s side-
effects as a main concern. The most commonly mentioned adverse effects were influenza-like 
symptoms and pain in the arm. Compared to other vaccines, such as tetanus, the influenza vaccine 
was generally perceived as unreliable, particularly by those who had not vaccinated in the past, and 
some participants thought the vaccine caused influenza. 
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“A lot of people I've heard say, 'Had my blooming flu jab and I still had flu, I was really poorly 
with it afterwards'. So I've heard that it's not totally effective. Whereas, as far as I'm aware, 
something like the measles jab, it's very, very rare to then go on to get measles after you've 
had your jab; with tetanus as well and so on, as long as you have it every time that you're 
meant to.” (P19) 
Others mentioned side-effects could change yearly, depending of the composition of the vaccine, 
and others believed the vaccine was unsafe.  
“…if it's not broke, then you don’t fix it, sort of thing and, okay, you can take a [flu] vaccine 
but I don’t know what's in the vaccine. It might be fine and one would hope that it's been 
thoroughly researched and thoroughly tested but then I also know that there have been 
things in the past that have supposedly been thoroughly tested that then turn out to have 
something, side effect or something wrong with them. So, I won't, I don’t want to take that 
risk unless the risk equates against the danger” (P4) 
No important concerns regarding the side-effects or safety of tetanus boosters were raised. Several 
participants noted that the vaccine had been sufficiently tested and that they had not heard 
anything negative about it. 
4.3.3.5.2.2 Needle-related pain 
Some participants, including regular influenza vaccinators, were apprehensive about needles. 
Feelings of fear generally stemmed from their previous experiences or those of others.  
“…it was either my second or third [flu jab]… She literally just stabbed me with a needle and 
took me completely by surprise, so that worried me” (P16)  
Fear of needles, however, generally waned when confronted with the decision of vaccinating against 
a disease which was perceived as a serious threat to their health: tetanus in most cases and 
influenza in the case of those who reported feeling particularly vulnerable to it. 
4.3.3.5.2.3 Practical barriers 
Competing priorities or lack of time was raised by some as the main practical barrier to influenza 
vaccination.  
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“It's just kind of seeing myself at risk, having the time… Just the same as having any 
inoculation, having to book an appointment, the accessibility to it. I don’t really like needles” 
(P15) 
Although affordability was not an issue, two participants who were not eligible to have a free 
vaccine through the NHS had difficulties getting it elsewhere. One reported lack of vaccine 
availability at the local pharmacy and the other was denied the vaccine at a supermarket due to high 
blood pressure. Just under a third of participants mentioned that keeping up-to-date with tetanus 
boosters was challenging due to their recommended time interval (10 years). 
4.4 Discussion 
This study explored in depth the socio-psychological factors influencing adult vaccination uptake in 
the UK. My results suggest that the public have no general concept of adult immunisation, as they 
have for childhood immunisation. Instead, their beliefs and attitudes are vaccine-specific and in 
some cases age-specific. Participants classified influenza and tetanus, and to a lesser extent 
pneumonia, as severe diseases. Consistent with their disease appraisal, participants felt that the 
influenza, tetanus and pneumococcal vaccines were important. Understandably, few participants 
had heard of the hepatitis vaccines or knew about hepatitis, as both hepatitis A and B are 
uncommon in the UK. Participants generally associated influenza and pneumonia vaccines with older 
age, tetanus with adolescence and MMR with childhood. 
The perceived age segmentation and general lack of awareness of an adult immunisation schedule 
may be a reflection of the way adult immunisation policy in the UK has been communicated. 
Although a recent shift toward ‘life course vaccination’ (Gusmano and Michael, 2009) is a move in 
the right direction, unlike the CDC’s annually Recommended adult immunization schedule (Advisory 
Committee on Immunization Practices, 2013), the NHS provides an overall schedule from 2 to 70 
years old, which includes only three adult vaccines, all for over 65s: influenza, pneumococcal and the 
recently introduced shingles vaccine (NHS (1), 2014). The rest of the recommended adult vaccines 
fall into the “Vaccines for special groups” and “Travel vaccines” categories detailed in additional 
documents or webpages, which, in turn, include many sub-categories and at times somewhat 
ambiguous exceptions. A case in point is the tetanus booster recommendation, which  states: “A 
tetanus vaccination is usually recommended for anyone who: has not been vaccinated before, has 
not been fully vaccinated, is travelling to a country with limited medical facilities, and whose last 
dose of the tetanus vaccine was more than 10 years ago”(NHS (3), 2014).  
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Participants’ knowledge about influenza and the influenza vaccine was reasonably accurate and 
generally acquired through mainstream media, mostly TV news, and healthcare professionals, 
whereas information about vaccine risks was usually found online and in some cases in social 
networking sites such as Facebook. These findings resonate with those from previous research 
evaluating the impact of different media on vaccination behaviour (Maurer, Uscher-Pines et al., 
2010) and suggest that mass vaccination campaigns are indeed improving knowledge and prompting 
uptake. They also indicate that confirmation bias (Nickerson, 1998) may be driving hesitant 
individuals to seek unofficial sources that provide information at odds with scientific evidence and 
against vaccination – which confirms their own reluctance.  Knowledge about tetanus was less 
specific, but most participants were aware of the severity of the disease.  
Key vaccination drivers for influenza were the perceived risk of the disease, commonly assessed in 
the literature as a combination of perceived disease susceptibility, severity and likelihood (Brewer, 
Chapman et al., 2007), and a GP recommendation. In contrast, perceived lack of susceptibility to 
influenza, concerns around the vaccine side-effects and partial effectiveness were the main barriers 
to vaccination. These findings are comparable to those reported in Chapters 2 and 3 and in previous 
studies assessing social and psychological underpinnings of vaccination (Chapman and Coups, 1999; 
Kohlhammer, 2007; Ward and Draper, 2008; Wheelock, Thomson et al., 2013). Whilst the drivers of 
tetanus vaccination were analogous to those of influenza vaccination, the barriers were somewhat 
different and mostly related to lack of awareness, consistent with previous research (Johnson, Nichol 
et al., 2008; Böhmer, Walter et al., 2011), and variable vaccination practices. There is some 
indication that preventive vaccination is initiated by the vaccinee, while injury-led vaccination is 
instigated by healthcare professionals. 
I found that social influences played an important role in vaccination behaviour, sometimes 
trumping participants’ factual knowledge. Regular influenza vaccinators were more prone to 
consider the advice of relatives and peers and have positive attitudes toward healthcare 
professionals than those who were not vaccinated.  Furthermore, vaccinators reported that 
receiving regular reminders from their GPs about the influenza vaccine triggered vaccination uptake, 
which suggests that such reminders were indeed falling on fertile ground. This resonates with a vast 
body of literature which shows that a recommendation from a healthcare professional and routine 
reminders significantly influence vaccination uptake (Thomas, Russell et al., 2010). Conversely, 
participants who showed a lack of trust toward healthcare professionals or had a relative or friend 
who had reported a negative experience with the vaccine, were more likely to refuse vaccination or 
ignore their GP’s recommendation. Preventive tetanus vaccinators also displayed favourable 
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opinions toward doctors. However, some participants also felt healthcare professionals were 
hesitant when asked for advice on whether or not to receive a booster, which is another indication 
that the current tetanus vaccination policy in the UK may lead to inconsistent or inappropriate 
practice (Savage, Nash et al., 2007).   
In line with previous research reporting tetanus over-vaccination in A&E (Savage, Nash et al., 2007), 
participants generally associated tetanus boosters with the treatment of injuries as opposed to the 
prevention of tetanus. However, some also felt that “keeping up-to-date” with tetanus vaccination 
(every 10 years) was important. My findings suggest that a convoluted tetanus immunisation policy 
may not only underpin the routine administration of tetanus boosters in UK A&E departments, but 
also GP practices. Excess vaccination may be further exacerbated by the recently added ‘Adult 
Immunisation Program’ section of the Green Book (the official and most up-to-date source of 
information on immunisation for healthcare professionals in the UK), which features tetanus 
vaccination for adults prominently, above the influenza and pneumococcal vaccines (PHE (2), 2013). 
Worryingly, my results indicate that tetanus boosters may often be administered after an injury to 
prevent a possible infection. However, current guidelines state that the recommended course of 
action is administering intravenous human tetanus immunoglobulin, as the tetanus vaccine may not 
boost immunity in time to provide adequate protection (PHE (5), 2013). 
Attitudes toward childhood vaccines were often discordant with views on the adult versions of the 
same vaccines, further supporting the notion that people’s perceptions are disease, vaccine and age 
specific. Whilst participants were accepting of children being immunised against tetanus, they were 
largely unsupportive of paediatric influenza vaccination, consistent with parental concerns reported 
in previous studies (Ramet, Weil-Olivier et al., 2007).  Although some attitudes may be 
unsubstantiated (e.g. “children’s immune system should be built naturally”), others, such as the lack 
of perceived need for paediatric influenza vaccines, may be explained by the comparatively low child 
mortality attributed to this disease (CDC (2), 2014).  
4.4.1 Limitations of this study 
Although interviews were conducted in an open and non-judgmental manner and efforts were made 
to minimise availability and social desirability biases, it is possible that some participants may at 
times have felt compelled to give what they perceived to be rational or desirable answers. 
Furthermore, it is likely that recall bias may have influenced some of the participants’ recollections 
about past experiences, particularly those around tetanus boosters.    
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Of similar importance, the composition and size of my sample, although balanced and appropriate 
for a qualitative study (Pope and Mays, 2006), may have an effect on the generalisability of my 
results. Promisingly, the achieved theme saturation is a good indication of sample adequacy. Yet, 
experimental and quantitative study designs should be used to further test my findings.   
4.4.2 Summary and implications for further research 
This study found that the uptake of both influenza and tetanus vaccines is largely driven by people’s 
risk perception of these diseases. For influenza, this appears to be mediated by trust in healthcare 
professionals and the perceived risks of the vaccine, insofar as the latter do not outweigh the 
perceived risks of influenza. The tetanus vaccine is largely viewed as sufficiently tested and safe, 
whereas the changing composition of the influenza vaccine is a cause of uncertainty and distrust.  
The broader implications for policy and practice of this and the following studies will be addressed in 
the main discussion of the thesis (Chapter 8). Of immediate relevance to the next chapter, in order 
to gain an in-depth understanding of vaccination decision-making processes, it is necessary to 
uncover the internal and external influences and triggers that lead people to vaccinate or remain 
unimmunised over time. I report on the development and testing of a new approach to elicit these 
aspects in Chapter 5.  
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5 Journey to vaccination: a qualitative exploration 
of the factors influencing adult vaccination 
behaviour over time 
5.1   Introduction 
Making decisions about our own health in general, and vaccinations in particular, can be a difficult 
task. Typically, it involves navigating an often intricate healthcare system, discussing the issue with a 
healthcare professional, researching the internet, consulting family members and peers, and trying 
to make sense of a vast amount information, which is likely to be incomplete and conflicting 
(Hunink, 2001).  
A key challenge in health decision-making processes is weighing up the benefits of an intervention 
versus its potential harm. In the case of vaccination, this process can be particularly complex as it 
often entails the assessment of several disease-related variables including severity, likelihood of 
catching the pathogen and susceptibility to it, as well as vaccine attributes such as effectiveness, 
side-effects and safety, among others (Serpell and Green, 2006). Furthermore, the benefits and 
drawbacks of vaccines are normally conveyed in statistical terms, a language that has proven to be 
difficult to grasp for most people. For example, results from an experimental study showed that 16% 
to 20% of highly educated participants answered incorrectly relatively simple questions about risk 
magnitudes (e.g., which represents the larger risk: 1%, 5%, or 10%?) (Lipkus, Samsa et al., 2001). 
Therefore, it is conceivable that a significantly larger proportion of less educated individuals, who 
constitute a majority of the population, are likely to misunderstand this type of data. 
As described in Chapter 1, people rely on a limited number of heuristics when assessing risk, which 
reduce the complexity of calculating probabilities and predicting outcomes to simpler mental 
operations (Meehl, 1954; Simon, 1957; Kahneman and Tversky, 1973). By its very nature, the use of 
heuristics can be efficient and accurate in some occasions, but it can also lead to cognitive errors and 
flawed decision making when used in circumstances that require thorough logical analysis 
(Kahneman, Slovic et al., 1982). Furthermore, individuals’ judgement is often influenced by their 
context and personal or family experiences, whether these are conscious or not (De Martino, 
Kumaran et al., 2006). Health decisions in general, and vaccination decisions in particular, can also 
be significantly influenced by patients’ trust in healthcare professionals and the latter’s ability to 
communicate risk effectively (Alaszewski and Horlick-Jones, 2003). 
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As noted in Chapter 4, although some qualitative studies have explored aspects of influenza 
vaccination decisions in the UK (Telford and Rogers, 2003; Evans, Prout et al., 2007; Kwong, Pang et 
al., 2010), thus far, little research has investigated how participants’ own context, experiences and 
risk assessment approaches influence their vaccination decision-making process over time.  
5.1.1 Study aims 
The overarching aim of this study was to gain a deeper understanding of the socio-psychological 
factors influencing the uptake of influenza and tetanus vaccines in the UK, by exploring how people’s 
context and experiences shape their beliefs, attitudes and behaviour toward these vaccines. A 
secondary objective was to develop more effective methods to elicit such data. Specifically, I aimed 
to: i) elicit the wider constellation of socio-psychological factors likely to influence adult vaccination 
decisions over time; ii) explore how health services and immunisation communications impact 
vaccination behaviour; iii) evaluate differences and commonalities between vaccines; and iv) assess 
whether vaccination decisions are driven by scientific facts or heuristics.  
5.1 Methods 
The methods of this study are described fully in Chapter 4. I detail below the conceptual framework 
and development of the “journey to vaccination” approach, as well as the procedures and analyses 
specific to this approach.   
5.1.1 Conceptual framework 
This research sits well within the constructivist (or interpretivist) paradigm, which is concerned with 
people’s experiences from the perspective of those who live them, and whereby the researcher and 
participant “jointly create findings from their interactive dialogue and interpretation” (Ponterotto, 
2005). From an epistemological point of view, however, my position draws from both constructivism 
and positivism, in that I recognise there is a degree of bias introduced by the researcher’s experience 
when creating knowledge, but the researcher endeavours to be objective and to elicit the 
participant’s experience in an unprejudiced manner (Sciarra, 1999).  
The methodology of this study rests on two theoretical approaches: heuristics and biases, specifically 
the availability heuristic (Tversky and Kahneman, 1973), and the customer journey mapping 
(Shostack, 1984; Bitner, 1992; Kingman-Brundage, 1992). These approaches are described in detail in 
Chapter 1. 
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5.1.2 Development and testing of a new approach: journey to vaccination  
Most qualitative studies in the field of vaccination decision-making have elicited barriers and 
enablers to vaccination using traditional methodological approaches such as explicit enquiry (e.g. 
why did you vaccinate?) and indiscriminate use of probes, often within a focus group setting. A key 
shortcoming of these approaches is that the influence of individuals’ personal circumstances and 
past experiences on vaccination decisions over time is seldom explored. Thus, researchers may fail 
to notice participants’ tendency to fall back on readily available information and report post-
decisional rationalisations of their behaviours rather than actual drivers.  
In an effort to address these shortcomings, a new qualitative approach called “journey to 
vaccination” was developed in collaboration with Ipsos MORI. Anchored on the two complementary 
lines of thought described above and nested within the qualitative research tradition, the journey to 
vaccination is a visual exercise in which the interviewer and the participant jointly build a timeline 
that captures salient events that led the participant to get or not to get vaccinated. The exercise 
starts with a participant’s latest influenza or tetanus vaccination experience as an adult; it then 
extends backwards to the participant’s first memory of such experience. The participant is asked to 
describe these events, which in turn allows the interviewer to indirectly elicit a range of factors that 
affected positively or negatively the decision to get vaccinated. Importantly, this exercise enables 
the participant to produce a personal historical narrative, through which vaccination decisions are 
discussed as a continuum and not in isolation from each other or from other important health, or 
lifestyle-related decisions.  
The journey to vaccination approach was designed to comprehensively capture psychological but 
also social influences on vaccination decisions, and to better understand the interplay between 
these influences and health services and immunisation communications. Participants were, 
therefore, asked to recall key actors who were involved in the vaccination process (e.g. their family 
or GP) and how they influenced the process. Emotional aspects of the decision making were also 
explored and taken into account.  
The journey to vaccination section of my interviews lasted approximately 20 minutes. Two versions 
were used: one for vaccinated and one for non-vaccinated participants (see Appendices 8 and 9). 
Key interview questions included: 1) How would you describe to a friend how you came to have (or 
not to have) the vaccination? What things happened that meant you ended up getting vaccinated?; 
2) What would you say happened at that point that triggered that change? And why was that 
important? 3) How did you know where to go for the vaccination? How did you book an 
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appointment and fit it into your plans? What other things were competing for your time?; 4) Before 
you were vaccinated, do you remember any times when you thought about or started the process 
toward being vaccinated but didn’t end up getting vaccinated? (only for vaccinated); 5) Of all of 
those things, which would you say was the most important thing that led to you not getting 
vaccinated? And the second most important thing? And the third? (only for non-vaccinated) 
5.1.3 Data Analysis 
As reported in Chapter 4, the recorded interviews were professionally transcribed verbatim and 
checked for accuracy by Ipsos MORI. To ensure reliability of coding and interpretation, all the 
transcripts were analysed by myself and 50% of the transcripts were double-coded independently by 
Dr Anam Parand (Pope, Ziebland et al., 2000). Differences were resolved through dialogue until 
consensus was reached. The data was analysed using an ideographic strategy – investigating 
individuals in personal, in-depth detail to achieve a unique understanding of them (Allport, 1962; 
Barlow and Nock, 2009).  
Based on the customer journey mapping approach described in Chapter 1, previous evidence on 
vaccination behaviour (Chapters 2 and 3) and aspects emerging from the data analysis, an initial 
linear coding framework was proposed. This was comprised of three stages and a number of 
touchpoints through which the individual interacts with immunisation services: 1) pre-vaccination 
period (appointment with a healthcare professional, information – websites, news, vaccination 
campaigns – and reminders from healthcare professionals); 2) the vaccination experience itself 
(location, consultation experience and vaccination experience); and 3) a post-vaccination experience 
(vaccine quality – e.g. side-effects, effectiveness – and post-vaccination advice or information from 
healthcare professionals and other official sources) (Dunn and Davis, 2002; Shaw and Ivens, 2002; 
Wheelock, Thomson et al., 2013).  
An important component of a journey to vaccination is a cue to action or trigger, which consists of 
an internal or external stimulus (e.g. salient health related experiences, advice from a relative) that 
prompts individuals to vaccinate or not to vaccinate, as proposed by the Health Belief Model 
(Rosenstock, Strecher et al., 1988). Existing evidence suggests that vaccination triggers may usually 
take place during the pre-vaccination stage and could sometimes overlap with vaccination 
touchpoints (Wheelock, Thomson et al., 2013). For example, a vaccination reminder letter from the 
general practitioner would be both a trigger and a touchpoint, if participants explicitly mention that 
the letter prompted them to vaccinate. All triggers were coded under the relevant vaccination stage 
and touchpoint, when applicable. 
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The journey to vaccination section of the transcripts was analysed alongside the hand drawn 
journeys. A journey to vaccination or non-vaccination for influenza and one for tetanus were 
produced for each participant. Differences and commonalities emerging from these data were 
identified and synthesised, and typical journeys proposed. 
5.2 Results 
The characteristics of the sample are described in the previous chapter. Briefly, participants were 
classified as regular (N=8), intermittent (N=5) and unvaccinated (N=7) for influenza; and preventive 
(N=4), injury-led (n=9), mixed (N=3) and unvaccinated (N=4) for tetanus. Findings from this study are 
reported using this classification. 
Although each journey to vaccination or non-vaccination was unique, I found important sub-group 
commonalities in the reported triggers and touch-points and the order in which these took place 
(see Figure 5.1).  
5.2.1 Influenza vaccination journeys 
Most regular influenza vaccinators had their first vaccine following a consultation with their GP, 
where they had been diagnosed with a chronic health condition (e.g. diabetes), and all were eligible 
for a free vaccine. The majority reported receiving a routine GP reminder to get the influenza 
vaccine before the beginning of the influenza season and felt their relationship with their GP was 
generally positive. Except for one participant who vaccinated to protect a vulnerable family member, 
all regular influenza vaccinators also recalled feeling vulnerable to the disease at the time of 
vaccination. 
“I just know, and I can always [tell]. It's literally when it just starts getting cold and the hot 
weather stops and then it's colder weather... My chest starts getting worse and stuff like 
that, so I just go and get it done and then I'll ask if I'm due for one… I don't really like 
needles and someone said I'm quite nervous and everything, but it's just a load off your 
mind and I don't really have to think of it that much, because it's once a year.” (P16) 
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Tetanus vaccination 
Influenza vaccination 
“[Tetanus is] not really 
common or anything like that, 
so I wouldn't really see the 
need. Plus, other than my 
asthma, I do have quite a good 
immune system.” (P16) 
“I was chatting to the nurse… 
you get talking about what you 
do: ‘well, it's about time you 
had a tetanus booster'. I've 
had tetanus jabs for as long as I 
can remember, from my 
footballing days.” (P17) 
“I was bitten by a dog… I went 
to A&E and they asked: ‘when 
did you last have a tetanus?' I 
really couldn't remember so 
they said: 'if you want we'll 
give you another tetanus just 
to make sure’.” (P3) 
“Well, [tetanus] is quite a 
frightening thing to have… I 
always knew it was quite bad 
because my mother was very 
hot on making sure you had 
tetanus jabs and things.” (P14) 
 
“I feel well now; why should I 
have an anti-flu jab and then it 
might not make me seriously ill 
but it might make me feel 
under the weather and I don’t 
want to feel like that.” (P14) 
“[I would do] Anything to make 
my life better, anything… Flu 
and diseases wreak havoc with 
my epilepsy.” (P5) 
“As a student I had the flu… I 
kept sort of having flu jabs 
after that, but then I kind of 
forgot and I was more 
interested in the children's 
health.” (P7) 
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Figure 5.1 Journeys to vaccination 
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Some regular vaccinators noted the vaccine was not “100% effective” and mentioned they had also 
experienced influenza-like symptoms after vaccinating, but they felt the alternative (i.e. catching 
influenza) was worse. 
“Yes, because I guess the people that you have to trust, because it's their field, would say, 
'Well, you've been unlucky first of all and who knows how bad it would've been if you'd 
not had the jab to lessen the effects of [influenza].” (P17) 
Similarly, intermittent vaccinators reported getting their first influenza vaccine after being diagnosed 
with a chronic illness, after experiencing a severe bout of influenza-like illness or to protect a 
vulnerable relative. Most also felt vulnerable due to their underlying condition or their recent 
influenza experience. Yet, they did not recall receiving a GP reminder. When asked about how they 
felt during the seasons they had not vaccinated, most mentioned they had not felt particularly 
vulnerable to influenza, thus vaccination had not been a priority or need.  
“Then I think I've probably got rather blasé… You're brought up sharp when you have had 
something like cancer, you think 'crikey, yes' your own mortality and all that, and then 
slowly, although it is always there, but slowly you regain some of your nonchalance about 
things.” (P18) 
A perceived lack of susceptibility to influenza was common among those who had not vaccinated, 
particularly if they did not belong to a high-risk group. Unvaccinated participants who were eligible 
for an influenza vaccine received regular vaccination reminders from their GP, but had ignored them, 
and some expressed negative feelings toward healthcare professionals. 
“It's a practice, and every time I go I see somebody different and they're all the same GPs. 
Pen in hand ready to write you a prescription, rather than…they don't have time to 
perhaps really discuss if you have a problem.” (P9) 
A third of those who had not vaccinated recalled a traumatic health-related experience during 
childhood, including painful vaccination, allergy to (injected) penicillin or frequent tonsillitis (that 
required penicillin injections), which had left them fearful of needles.  
“Somehow I feel children need to be more protected than adults, because they don't have 
a say in really what happens to them. Adults can refuse, and the children go with their 
parents not knowing what's going to happen, that they're going to have a needle stuck in 
them and it's going to hurt, and they could be ill. Yes, I have [had a bad experience with 
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injections]. Throughout my life I've had a lot of allergies, and so I had to have lots of 
injections as an older child, not a young child. I used to go to somebody who was not very 
gentle and just did a lot of stabbing with the needle, so yes” (P9) 
Yet, peers or media reports about the side-effects of the influenza vaccine (mainly influenza-like 
symptoms) or its partial efficacy were the most salient concerns among unvaccinated participants. 
“Yes, I've also heard various people have been ill after having the injection. I think it's 
meant to give you a bit of flu for you to build up antibodies or something… I thought, well, 
I feel well now; why should I have an anti-flu jab and then it might not make me seriously 
ill but it might make me feel under the weather and I don't want to feel like that.” (P14) 
Influenza vaccinators’ decision-making was generally driven by facts, whereas the vaccination 
behaviour of intermittent and unvaccinated participants was based on a combination of logic and 
heuristic reasoning. The latter was employed when evaluating the benefits of the vaccine versus its 
costs – which were generally magnified and supported by anecdotal evidence. 
5.2.2 Tetanus vaccination journeys 
Participants who reported having tetanus boosters preventively felt susceptible to tetanus due to a 
chronic illness such as diabetes, or felt likely to get it due to life-style choices such as travel or 
gardening. They also reported feelings of fear toward the disease triggered by memories of their 
mothers’ warnings about tetanus during childhood.  
“I remember years ago, I think my brother fell over, I don't know if he banged his head or 
something and he cut himself, and I remember them saying he had to have a tetanus… I 
just always remember my mum saying 'You've got to have a tetanus now, you haven't had 
a tetanus since you were little, and you need your tetanus'.” (P19) 
Similarly, those who had a booster after an injury mentioned they had gone to A&E and accepted it 
for fear of contracting a life-threatening disease. Most also recalled their mother’s warnings during 
childhood about the dangers of contracting tetanus. Conversations with peers or advice from 
relatives to get a tetanus booster was also mentioned by injury-led vaccinators as important 
vaccination triggers. 
Yes, yes, because some of us sometimes would have to be using massive hammers and we 
were knocking down walls and stuff like that, and sometimes something would come and 
it would cut and then I'd think, yes, this cut here could be a tetanus cut. So, we would joke 
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and we'd say, 'Oh, you’ve got a cut. Hope you had the jab. You’ve probably got tetanus 
but that’s fine'…” (P15) 
Unvaccinated participants were either not aware of adult boosters or reported that they had not 
had tetanus-prone injury that required vaccination. Only one participant mentioned that tetanus 
was uncommon, so vaccinating was unnecessary. None of the participants reported concerns about 
the boosters’ safety or efficacy. 
“As I say, I always thought of it as something when, you know, if the dog bit you, well, 
'Ooh, you need to go for a tetanus injection'. I hadn't ever thought of it really in terms of 
preventative.” (P18) 
Decisions around tetanus vaccination were generally based on logic, insofar as they were aligned 
with what participants perceived to be healthcare professionals’ position. However, in some cases, 
childhood memories triggered a strong protective response which may have not been proportionate 
with participants’ actual risk.  
5.3 Discussion 
This study explored the social and psychological factors underpinning adult vaccination uptake over 
time, alongside participants’ experience of health and immunisation services.  It also gauged 
differences and similarities of vaccination journeys across vaccines and vaccination status, and 
assessed whether vaccination decisions were made using logic, heuristics or a combination of both. 
The journey to vaccination methodology allowed me to narrow down on the most important triggers 
to vaccination and non-vaccination, and to uncover new ones. I found that participants’ perceived 
susceptibility to influenza and perceived susceptibility to and severity of tetanus were key triggers to 
vaccination. These two factors formed an “emotional prism” through which the vaccines’ costs and 
benefits were assessed. Those who felt vulnerable to influenza, for example, although still able to 
recognise the vaccine’s side-effects and partial efficacy, were more likely to receive the influenza 
vaccine than those who did not feel vulnerable. The latter, on the contrary, were more prone to 
focus on the vaccine costs than its benefits.  
A striking psychological finding of this study is that previous experiences related to injections, 
particularly during childhood, had both a positive and a negative influence on vaccination uptake. 
One-third of influenza unvaccinated participants reported having had a traumatic experience with 
vaccines, injections or medication in the past, which they stated had influenced their decision to not 
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vaccinate against influenza. This resonates with previous research which showed that painful 
neonatal experiences such as circumcision or Heel Stick Capillary Blood sampling in neonates can 
magnify the experience of pain later in life (Chamberlain, 1989; Taddio, Katz et al., 1997). Similarly, 
some tetanus vaccinators recalled that the memory of their mother’s warnings about the danger of 
contracting tetanus in childhood had influenced their decision to have a tetanus booster. These 
findings suggest that pain (caused by needles) and fear (of contracting a severe disease) during 
childhood could become both a potent vaccination deterrent and enabler in adulthood, thus 
vaccination behaviour should be viewed as a continuum – from childhood to adulthood. More 
research in this area is needed.  
My results showed that tetanus vaccination was practically a non-decision; none of the participants 
had refused a booster. This may be explained by the combination of perceived susceptibility to and 
severity of the disease, particularly after an injury, and the widespread belief that tetanus boosters 
were stable in their composition and “tried and tested”, therefore safe.   
This research also shed light on the opportunity offered by healthcare touchpoints to harness 
vaccination triggers and defuse non-vaccination ones.  For influenza vaccination, a clear diagnosis of 
a relevant chronic illness and a subsequent vaccine recommendation from a healthcare professional, 
regular vaccination reminders and a positive consultation experience, resulted in regular 
vaccination. Conversely, those who had not vaccinated were more likely to have had a bad 
experience with vaccines or injections in childhood (during a consultation with a healthcare 
professional), were more prone to focus on negative information about the influenza vaccine and to 
ignore vaccination reminders. This suggests that, for some individuals, these three pre-vaccination 
touchpoints are ineffective at best and detrimental to vaccination uptake at worst.  
In the case of tetanus, healthcare touchpoints appeared to be less important than vaccination 
triggers. Although a recommendation from a healthcare professional and information from websites 
(e.g. NHS, pharmacies) were the most mentioned touchpoints among preventive vaccinators, feeling 
concerned and vulnerable during a visit to A&E was the most common vaccination trigger among 
injury-led vaccinators. For both vaccinator types, the memory of their mother’s warning about 
tetanus during childhood acted as a powerful immunisation trigger, often more effective than 
currently available information about the vaccine. This, again, indicates that memorable events 
during childhood can impact adult health behaviours in general and vaccination in particular. 
The findings suggest that while some decisions are based on medical advice and scientific 
information, vaccination behaviour is often influenced by heuristics. For example, as reported in 
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Chapter 4, most participants agreed that influenza is a severe disease and vaccinating against it is 
important, yet the majority were either intermittent or unvaccinated participants. As noted above, it 
is possible that the dissonance between participants’ beliefs and actions is mainly due to their 
perceived lack of susceptibility to the disease, but also their apprehension toward the vaccine. This is 
supported by previous quantitative evidence which found little or no association between perceived 
severity of influenza and vaccine uptake among healthy adults or those who do not feel susceptible 
to influenza (Weinstein, Kwitel et al., 2007). It is also consistent with findings from past research 
showing that people tend to perform cost-benefit analyses when assessing influenza vaccination 
(e.g. threat of influenza vs. threat of the influenza vaccine), which significantly affect behaviour 
(Chapman and Coups, 1999). In many cases, however, these perceptions were unfounded and may 
have driven participants to make decisions which were potentially detrimental to their health. 
5.3.1 Limitations of this study 
In line with the limitations discussed in Chapter 4, although qualitative explorations enable us to gain 
in-depth understanding of a particular issue, such data may not be representative of the target 
population. Thus, quantitative research is needed to evaluate whether my findings are generalisable.  
Furthermore, a new approach such as the journey to vaccination should be further tested across 
vaccinations and populations, and potentially other health behaviours, to assess its usefulness and 
possible applications. The journey to vaccination revealed the use of heuristic reasoning in 
vaccination decisions. However, in order to robustly evaluate the importance of specific heuristics in 
vaccination behaviour, an experimental design is required. 
Finally, although journey to vaccination is designed to facilitate data extraction by mapping out 
vaccination-related events in an open and comprehensive manner, some past memories may have 
not been readily accessible or easy to recall. Therefore, some facts, particularly those related to 
distant or inconsequential events, may have been imprecise or overlooked.   
5.3.2 Summary and implications for further research 
This study showed how specific stages and touchpoints of the vaccination journey can facilitate or 
hinder vaccination uptake. It also revealed the main internal and external triggers to vaccination and 
non-vaccination, many of which were aligned with service touchpoints.  
The journey to vaccination approach demonstrated that while some vaccination decision are based 
on logic and scientific knowledge, others circumvent facts. An interesting finding which deserves 
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further reconsideration is the importance of childhood experiences in adult vaccination decisions. 
These results have a number of implications for research and immunisation policy and practice, 
which will be discussed in the final chapter (Chapter 8).  
Drawing on the findings reported here and the previous chapters, I now move on to report the 
development and testing of instruments aiming to capture quantitatively the determinants of adult 
influenza and tetanus vaccination behaviour, and to predict uptake.  
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6 Determinants of influenza vaccination in the UK: 
a survey study 
6.1   Introduction 
As stated in Chapter 1, multilateral efforts to identify factors which affect confidence in vaccines 
have gathered pace (NVAC, 2013; LSHTM, 2014; Vaccines Europe, 2014; WHO (2), 2014). Such 
efforts stem from unquestionable evidence that the uptake of biomedical prevention approaches, 
specifically vaccination, not only depends upon availability and access, but is increasingly influenced 
by socio-psychological factors (Larson, Cooper et al., 2011; Wheelock, Thomson et al., 2013).  
Therefore, in order to improve vaccination coverage, immunisation programmes should be 
conceived as a combination of safe and efficacious biomedical products, effective communication 
strategies and behavioural interventions aimed at addressing the public’s concerns. This holistic 
approach, which has been successful in HIV prevention (UNAIDS, 2010), is particularly important 
when introducing novel vaccines for existing diseases and in response to the new epidemics (WHO, 
2005). 
Two essential features of effective communication and behaviour change strategies are: 1) the 
extent to which they align with the needs of the population they are aimed at; and 2) their ability to 
adapt when these needs change (Government Social Research Unit, 2008). Thus, the development of 
instruments which can reliably capture vaccination sentiment and its impact on vaccination uptake, 
and can be periodically deployed to track variations in perceptions, should be an integral part of the 
design and evaluation of immunisation programmes.  
Previous studies have attempted to develop such instruments, yet most have been concerned with 
testing health behaviour theories rather than the ability of the instrument to predict behaviour. 
Furthermore, feedback received from policy and industry forums as part of this ongoing project 
indicate that although there is interest in instruments which are predictive and insightful, too often 
these are lengthy, thus costly to roll-out on an annual basis, and difficult to translate into policy 
(Sevdalis and Wheelock, 2013; Wheelock and Sevdalis, 2013; Wheelock, Rigole et al., 2013; Rigole, 
Wheelock  et al., 2014). Consequently, the focus of this chapter is to identify the most predictive 
socio-psychological determinants of influenza vaccination and to propose a compact set of items 
which can be easily incorporated into national immunisation surveys. 
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Important lessons can be drawn from the wealth of data on the factors underpinning seasonal 
influenza vaccination, which I have synthesised in Chapters 2 and 3, but also from empirical findings 
reported in Chapters 4 and 5. First, influenza vaccination decisions are shaped by socio-psychological 
aspects such as social influence, influenza risk perceptions, the benefits and risk perceptions of the 
influenza vaccine, habit, general attitudes toward health and vaccines, awareness and knowledge, 
and altruism. Second, the wording of survey items matters, particularly those measuring risk 
perceptions.  For example, measures which are specific and concern the individual are generally 
better predictors of vaccination behaviour than generic ones. Third, there are a number of 
potentially relevant constructs from health behaviour models and theories which remain largely 
untested. A case in point is the Protection Motivation Theory (PMT), which postulates that a process 
of threat appraisal and a process of coping appraisal, in which the options of minimising a threat are 
evaluated, can lead to either adaptive or maladaptive coping (Rogers, 1975). Maladaptive coping 
mechanisms include avoidance, denial and fatalism, whereas active coping leads to protective 
behaviours (e.g. vaccination). These mechanisms are yet to be tested in the context of influenza 
vaccination. Additionally, Chapters 4 and 5 showed that childhood experiences may influence adult 
vaccination behaviour, a novel finding which deserves further testing.  
6.1.1 Study aims 
Drawing on findings from Chapters 2-5, the primary aim of this study is to develop and test a tool to 
identify the determinants of influenza vaccination in the UK and to predict vaccination behaviour. 
Secondary objectives are: i) to assess whether socio-psychological factors are better predictors of 
influenza vaccination than population characteristics and practical barriers; ii) to test whether 
generic items, which could predict the uptake of multiple vaccines, are equally effective at predicting 
influenza vaccination as influenza-specific items; and iii) to propose a compact set of socio-
psychological items which can be easily incorporated into national immunisation surveys.  
6.2 Methods 
The instrument described in this chapter was tested alongside a comparable instrument developed 
to capture the determinants of adult tetanus vaccination, the results of which are discussed in the 
following chapter. Thus, this section describes the methods employed in the design and testing of 
the overall survey-tool. This study was approved by the Imperial College Research Ethics Committee 
(see Appendix 3). All participants provided consent after being informed about the nature of the 
study and anonymity of their responses (see Appendix 10). 
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6.2.1 Sampling and recruitment strategies 
A nationally representative adult sample was sought, using stratified random sampling (Groves, 
Fowler Jr et al., 2009). This sampling strategy involves dividing a population into a number of strata. 
Each stratum is comprised by a random sample of individuals who share specific attributes, which is 
proportional to the overall population. Interlocking quotas based on gender, age and socioeconomic 
status were set (ONS (1), 2014; ONS (2), 2014).  In addition, to ensure national representativeness, 
regional, settlement type (rural / urban) and ethnicity non-interlocking quotas were put in place 
(ONS, 2012; ONS (1), 2013; ONS (1), 2014).  
Sample size calculations were based on the intended objective of assessing associations between 
self-reported vaccination uptake and participants’ demographic, socio-economic, health-related and 
socio-psychological characteristics. The minimum sample size to test the null hypothesis of no 
significant correlation between dependent and independent variables was calculated using G*Power 
(Faul, Erdfelder et al., 2009) given the most conservative assumption that the correlation coefficient 
between the variables in the population is in the region of 0.1 (a “low” effect size). A bi-directional 
test with 95% significance level reached a standard 80% power level at a minimum sample of N = 
782 subjects (Cohen, 1998). 
Online and telephonic surveys were employed. Self-completion online surveys were sent to an 
online market research panel and random-digit dialling was used to recruit the subset of participants 
who were interviewed telephonically (12% of the sample). The telephone-based survey was identical 
to the online survey but included instructions to moderators to aid the completion and ensure 
consistency. Telephone interviews were administered to a proportion of the 65+ age category and 
those falling into the D/E socio-economic groups, since these two populations are less represented 
on online panels and have more limited access to or are less familiarised with internet-based 
applications (Duffy, Smith et al., 2005; Callegaro, Baker et al., 2014).   
6.2.2 Procedure 
Double Helix (DH), a market research company, was responsible for programming the online survey 
and conducting the interviews.  Before the piloting stage, we collectively tested the online survey to 
ensure it was usable, logic, correctly worded and appropriately formatted.  
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6.2.2.1 Pilot 
Face-to-face pilot interviews were conducted with seven purposively selected members of the 
general public to test the survey’s face and content validity (i.e. it appears relevant to participants 
and it covers all important aspects of the vaccination decision making process, respectively), 
acceptability and ease of completion. Interviews lasted 45 minutes and were conducted by a trained 
DH researcher. A live broadcast of the interviews was transmitted to other members of the team, 
including myself, viewing from an adjoining room and interviews were audio recorded.  All members 
of the team were able to view the participant’s screen as the survey was being completed (See 
figure 6.1).   
Participants were asked to answer the online self-completion survey noting down any questions that 
were unclear or confusing.  Upon completion of the survey, participants were asked questions 
related to the ease of completion, language and format of the survey.  Questions which were unclear 
or generated hesitation (self-reported or observed) were reviewed with the participant to 
understand the cause of the difficulty.  Following the initial face-to-face pilots, the study team 
conducted a thorough review of the study materials and reached a consensus regarding minor 
amendments and finessing of the instrument.  Three additional interviews were conducted over the 
telephone with the aid of a screen sharing platform.  Findings from the telephone pilots confirmed 
the results from the face-to-face pilot interviews with few additional changes.  
 
 
 
Figure 6.1 Indicative image of interviewing facilities used for survey piloting 
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Overall, the pilots showed that the survey was easy to fill out and to understand, and the majority of 
the questions were clear. Most of the refinements to the study materials were related to wording 
and programming changes.  Questions were also re-ordered and grouped into themes to facilitate 
the timely completion of the survey.   
6.2.2.2 Fieldwork and quality assurance 
Responses to telephonic interviews were entered into a computer-assisted telephone interviewing 
system (CATI) in order to reduce inputting errors. Telephone interviews were longer in duration (~40 
min) than online versions (~20 min) and participants were able to pause mid-way through and 
complete it at a later time if they were unable to do so in one session. Furthermore, to reduce 
cognitive effort and improve the interview flow, telephone participants were asked to draw a scale 
from 0-10 and focus on it when stating their level of agreement or disagreement with the relevant 
survey items.  
This study employed a quota system to ensure that the composition of the final sample was similar 
to that of the general adult population. Therefore, if a particular quota was full, some participants 
became non-eligible, despite opening the email and completing the screener.  The benchmark for 
adequate response rates used by market research companies for this kind of sampling strategy is 
based on the number of participants who drop out before completing the survey.  For the online 
survey, 16 stopped doing the survey once they had passed the screener and for the telephone 
interviews 10 were incomplete. These small numbers indicate a good response rate.  
As an additional quality control measure, the data was monitored throughout the fieldwork and 
participants who classified as ‘speeders’ and ‘flat-liners’ were removed and replaced, as their 
responses are likely to be unreliable.  From the initial launch, the average time for survey completion 
was 16 minutes.  A ‘speeder’ was defined as a participant who completed the survey in half of the 
average time (i.e., in under eight minutes).  Flat-liners were those who completed the survey in 
under 10 minutes (i.e., half of the optimum survey length of 20 minutes) and also gave 
homogeneous responses (i.e., entered the same code throughout a particular section or throughout 
the survey).  Two members of the study team (DH) reviewed flat-liner data and came to a consensus 
before agreeing to keep or remove these participants. 
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6.2.3 Instrument 
In order to meet the aims of this study, I developed an instrument which sought to achieve a 
number of psychometric properties (Anastasi and Urbina, 1997; Rust and Golombok, 1999). The 
properties sought and the steps to attain them are described below. 
Face validity is the perceive adequacy and relevance of an instrument. As described above, this 
property was achieved during the pilot phase by eliciting participants’ views regarding the clarity, 
appropriateness and importance of the included items, and finessing the instrument as a result.  
Internal consistency is a measure of reliability used to evaluate the degree to which different survey 
items that measure the same construct produce similar results. This property was attained by 
including a number of items which are conceptually associated with key broader constructs that 
predict influenza and tetanus vaccination. The attainment of this property was tested by calculating 
Cronbach’s alpha coefficients for each of the assessed scales. 
Content validity is the extent to which an instrument captures every single domain of interest. This 
property was achieved by identifying the array of drivers and barriers to influenza vaccination 
through a narrative review (Chapter 2), a systematic review and meta-analysis (Chapter 3), 
qualitative research (Chapters 4 and 5), this study’s pilot and expert advice from Sanofi Pasteur 
(Marketing, Advocacy, Influenza and Tetanus Divisions), and DH. I selected socio-psychological 
constructs (and items) which had consistently predicted influenza and, to a lesser extent, tetanus 
vaccination in adults (only two articles meeting the eligibility criteria were identified), based on the 
above sources and relevant theories of health behaviour specified in Chapter 1, notably the Health 
Belief Model (HBM) and the Protection Motivation Theory (PMT). Additional constructs from health 
behaviour theories and risk communication research, which had scarcely or never been tested in the 
context of vaccination, were also included (see blocks 7 and 8 of Table 6.1).  Demographic, socio-
economic and health-related characteristics which had previously been associated with influenza 
vaccination behaviour were prioritised.  
Predictive validity is the extent to which an instrument predicts a given outcome, in this case, 
influenza and tetanus vaccination behaviour. This was attained by including items which have 
consistently predicted influenza, and to a lesser extent, tetanus vaccination behaviour in adults, as 
well as well as testing new items which may be significantly associated with this health behaviour. 
This property was tested by conducting hierarchical logistic regression analyses and calculating the 
extent to which the resulting model was able to discriminate the vaccination status of participants.  
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Table 6.1. Source of selected variables 
Explanatory variables Source 
1. Demographic, socio-economic and health variables 
 (1) Age  
(Chapman and Coups, 1999; Kohlhammer, 2007; 
Ward and Draper, 2008)  
(14) Eligible health condition* 
(120) Private health insurance 
(2) Gender  
(11) Marital status 
(10) Income bands 
(119) Level of education 
(5) Setting 
(3) Ethnicity 
2. Practical barriers to influenza vaccination 
 (73) Vaccine access  
Chapters 2 and 4 / (Chapman and Coups, 1999; 
Kohlhammer, 2007)  
(73) Time to vaccinate 
(73) Vaccine affordability 
3. Social influence  
(69) GP thinks I should vaccinate Chapters 2-4 / (Zimmerman, Santibanez et al., 
2003)  
 
(70) Relatives think I should vaccinate 
(75) Peer experienced vaccine adverse reaction  
4. Influenza perceptions 
 (43) Perceived knowledge of influenza (Kohlhammer, 2007) 
(59) Vulnerability to influenza 
Chapters 2-5 / (Brewer, Chapman et al., 2007; 
Weinstein, Kwitel et al., 2007)  
(52) Susceptibility to influenza 
(62) Likelihood of influenza  
(63) Likelihood of influenza (2) 
(44) Frequency of influenza episodes  
(49) Severity of influenza 
(56) Severity of influenza bed days 
(55) Fear of influenza 
(72) Worry of transmitting influenza (Chapman and Coups, 2006)  
(53) Worry of missing out on important activities or events Chapters 2 and 4 / (Shahrabani and Benzion, 
2010) 
0.526 
(51) Fear of transmitting influenza (vulnerable relative) Chapters 4 and 5 / (Chapman and Coups, 2006)  
(61) Perceived control (Wallston, Wallston et al., 1987)  
(54) Coping – influenza 
(Carver, 1997) 
(50) Maladaptive coping – influenza 
5. Influenza vaccine perceptions 
(64) Perceived knowledge of vaccine (informed decisions) Chapter 2 / (Robinson and Thomson, 2001; 
Kohlhammer, 2007)  
  
(71) Do not know much about the vaccine (trust advice)   
(57) Vaccine effectiveness 
Chapters 2-5 / (Chapman and Coups, 1999; 
Kohlhammer, 2007; Ward and Draper, 2008; 
Wheelock, Thomson et al., 2013)  
(58) The vaccine reduces severity of influenza 
(82) The contents of the vaccine can be dangerous 
(76) Vaccinating yearly can be dangerous 
(81) The vaccine could transmit influenza 
(79) The vaccine is painful 
(77) I am allergic to the vaccine 
(80) Fear of vaccine 
(83) Self-efficacy – influenza vaccination (Bandura, 2006) 
(74) Anticipated regret of not vaccinating (Chapman and Coups, 2006) 
6. Trust and disposition toward vaccination and vaccination stakeholders 
(36) Vaccination importance 
Chapter 2 (28) Vaccination favourability 
(38) Vaccination part of healthy life-style 
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Explanatory variables Source 
(26) Trust GP (scale) Chapter 4 / (Safran, Kosinski et al., 1998) 
(33) Trust in the NHS 
Chapter 4 / (Telford and Rogers, 2003; Black and 
Rappuoli, 2010; Gilles, Bangerter et al., 2011; 
Larson, Cooper et al., 2011) 
(30) Trust in vaccination  
(32) Trust in vaccine manufacturers 
(29) Trust in medications 
(31) Trust in alternative medicine 
(65) Trust in influenza vaccine information - NHS 
(66) Trust in influenza vaccine information - mass media 
(67) Trust in influenza vaccine information - social media 
(68) Trust in influenza vaccine information - GP 
(39) Importance of paediatric influenza vaccine Chapter 4 
7. General perceptions and psychological constructs 
(34) Understand how vaccination helps 
(Kohlhammer, 2007)  
(35) Does not understand how vaccination works 
(37) Autonomy of vaccination decisions (Ende, Kazis et al., 1989) 
(13) Perceived health Chapter 4 / (Evans and Watson, 2003) 
(18) Optimism 
(Scheier, Carver et al., 1994) 
(20) Pessimism 
(19) Self-efficacy (Bandura, 2006) 
(21) Risk-taking (Dohmen, Falk et al., 2011)  
(22) Information seeking 
(Miller, Brody et al., 1988)  
(23) Information avoidance 
(24) Shared decision-making – relatives (Elwyn, Edwards et al., 2000; Robinson and 
Thomson, 2001) 
 
(25) Shared decision-making – GP 
8. Previous  vaccine  and health-related experiences 
(41) Bad experience with vaccines (child) 
Chapter 5 
(41) Scary health experience (child) 
(41) Bad experience with HCP (child) 
(41) Positive experience with healthcare (child) 
(42) Bad experience with vaccines (adult) 
(42) Scary health experience (adult) 
(42) Bad experience with HCP (adult) 
42) Positive experience with healthcare (adult) 
In brackets is the number of the question corresponding to each explanatory variable (see Appendix 11). 
*Includes being pregnant or breastfeeding. 
The survey comprised a total of 120 items: 19 demographic, socio-economic and health-related 
items, 26 socio-psychological general items, 42 socio-psychological items about influenza and the 
influenza vaccine, and 33 socio-psychological items about tetanus and the tetanus vaccine (see the 
full survey in Appendix 11). In an effort to reduce the number of variables included in the model (a 
minimum of 10 participants per item (Field, 2013)), some items added by Sanofi Pasteur were 
excluded from this thesis (see Appendix 11), as they were untested variations of items which were 
included in the analyses. All survey-items were left in the survey for reference.  
I used 11-points likert scales (0-10) for the majority of socio-psychological items, as these are 
recognised for their reliability and ease of completion (Saris and Gallhofer, 2007), and multiple-
choice items and alternate-choice items when appropriate. In sections where thematic hierarchy 
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(e.g. from specific to general) was not important, items were rotated to minimise response bias due 
to item ordering. Some items were routed depending upon participants’ vaccination status. For 
example, only those who had received an influenza or tetanus vaccine in the past were asked about 
how they usually remembered to get it. These items were not included in the model. 
6.2.4 Data analysis 
In order to enhance the usability, transparency and translational nature of the instrument, all 
analyses were conducted using single items rather than multi-item constructs or factors. Yet, given 
that blocks 3-6 were also overarching constructs comprised of more than three scale-items (see 
Table 6.1), Cronbach’s alpha tests were conducted to explore correlations between items and test 
the reliability of these constructs (Rust and Golombok, 1999; Eisinga, Grotenhuis et al., 2013). 
Fisher's Exact test was used to evaluate differences between the final sample and the general 
population (p < 0.05 was considered significant). Descriptive statistics, Pearson’s Chi-square 
(categorical variables) and t-tests (interval or continuous variables) were computed to gauge the 
relationships between each of the assessed variables and vaccination behaviour (p < 0.05 was 
considered significant). The outcome measure was having received an influenza vaccine in the last 6 
months (latest influenza season).  
Since the outcome measure was categorical, logistic regression analysis was conducted to uncover 
the predictors of influenza vaccination. Logistic regression does not make many of the key 
assumptions of linear regression. Some assumptions, however, still apply. These are: 1) the 
dependent variable is dichotomous; 2) the categories are mutually exclusive and exhaustive, that is, 
a case can only be in one group and every case must be a member of one of the groups; 3) the 
model should be fitted correctly, thus overfitting or underfitting should be avoided; 4) the model 
should have little or no multicollinearity; and 5) sample sizes are large; a minimum of 10 cases per 
predictor (Hosmer Jr and Lemeshow, 2004; Field, 2013).  
Although stepwise regression is widely used in logistic regression, in recent years, the purposeful 
selection of variables has been favoured over deterministic model-building methods. This is because 
the latter rely on automatic selection of variables based upon mathematical criteria, which can lead 
to overfitting or underfitting the model (Hosmer Jr and Lemeshow, 2004; Field, 2013). Therefore, to 
achieve a parsimonious model, that is, one that offers the simplest explanation to vaccination 
behaviour, I used a forced entry, hierarchical approach. The specific procedure employed is 
described below. 
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When predictors are correlated, as it is often the case, the order of variable entry can have an effect 
on the parameters calculated. Variables were, therefore, entered in “blocks” using a hierarchical 
approach based on previous evidence (Field, 2013) and my aim of assessing whether socio-
psychological factors are better predictors of influenza vaccination than population characteristics 
and practical barriers. Blocks of variables which had predicted vaccination uptake in the past were 
entered first and those which had seldom or not been explored before were entered last 
(Kohlhammer, 2007; Ward and Draper, 2008; Nagata, Hernandez-Ramos et al., 2013; Wheelock, 
Thomson et al., 2013). Priority was given to demographic, socio-economic and health-related 
variables, and practical vaccination barriers to evaluate the extent to which they contributed to 
explain the variance in vaccination behaviour before socio-psychological variables were 
incorporated. Consequently, eight blocks of explanatory variables were entered in the following 
order: 1) demographic, socio-economic and health-related variables; 2) practical barriers to 
influenza vaccination; 3) social influence; 4) influenza perceptions; 5) influenza vaccine perceptions; 
6) trust and disposition toward vaccination and vaccination stakeholders; 7) general perceptions and 
constructs; 8) previous vaccine and health-related experiences.  
Two goodness-of-fit tests were used to assess the overall model and each of the 8 models (blocks): 
chi-square and Nagelkerke R². If the chi-square of any given model was not significant (p>0.05), that 
is, the contribution of such model over the previous one was statistically negligible, its variables 
were systematically excluded one at a time, starting from those which were not significant, and 
regressions rerun until significance was attained (Field, 2013). Non-significant variables from models 
with a significant chi-square (p<0.05) were also excluded one at a time and regressions were rerun. If 
the predictability of the overall model decreased by more than 1%, the excluded variable was added 
back. This process continued until all of the important variables appeared to be included in the 
model. I then added back all the excluded variables to identify those which may not have been 
significant by themselves, but could be important in the presence of other variables (Hosmer Jr and 
Lemeshow, 2004). 
An overall model with a Nagelkerke R² a value close to 1, which indicates optimal predictability, was 
sought. Odds ratios for the hierarchical logistic (logit) model, together with the standard errors, 
significance levels and confidence intervals, as well as the predictidibility of the model, are 
presented (p < 0.1 was considered significant). Thorough checks to ensure the robustness of the 
model were conducted, including variance inflation factor (VIF) to assess collinearity, standardised 
residuals to detect and evaluate outliers and Cook’s distance to identify influential cases. All analyses 
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were conducted by myself using IBM SPSS Statistics 22. Regression analyses were also carried out by 
expert statisticians (Kerry O'Neill, solutions-2) who validated the results reported in this chapter. 
6.2.4.1 Variable coding 
For bivariate and logistic regression analyses the variables age, eligible health condition (including 
pregnant or breastfeeding women), marital status, level of education and ethnicity were 
dichotomised, both to aid interpretation and ensure there was a fair number of subjects in each cell 
for validity (a minimum of five per cell) (Greenland, 1989).  
For logistic regression analysis, 11 variables with “I do not know” responses were also recoded as 
dummy variables in order to maximise the number of observations, as follows:  values expressing 
agreement with a given statement (6-10) were coded as 1 = “yes” and the rest (0-5 and “I do not 
know”) were coded as 0 = “other than yes” (see recoded variables in Table 6.3).  
6.3 Results 
6.3.1 Participants 
Participants were surveyed in March 2014. The online survey was completed by 791 participants and 
100 participants were interviewed via the telephone. Recruitment flow diagrams for the online and 
telephone samples are presented in Figures 6.2 and 6.3, respectively.  
Response rates were calculated by dividing the total number of surveys completed by the number of 
opened emails or interviews attempted minus the number of ineligible individuals (surveys 
completed / opened emails or interviews attempted – ineligible individuals) (American Association 
for Public Opinion Research, 2008). Online response rates were 20%, in line with average rates for 
internet-based surveys (Nulty, 2008), and telephone response rates were 9%.  Telephonic interviews 
targeted older people and those belonging to D/E socio-economic strata, two populations with 
particularly low response rates (Sheldon, Graham et al., 2007). 
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Figure 6.2 Online sample recruitment flow diagram 
 
 
 
 
 
 
 
 
 
Figure 6.3 Telephone sample recruitment flow diagram 
 
 
807 completed screener 
16 did not complete the survey  
 
53,656 email invitations sent 
42 emails that bounced back  
9,925 opened emails 
706 surveys included in sample 
791 surveys completed 
9,118 did not complete screener 
5,909 stopped due to full quota 
2,902 stopped voluntarily 
299 did not provide consent 
8 were not eligible 
  
 
85 were excluded 
35 due to speeding 
10 due to flat-lining 
40 were practicing HCWs 
 
9,927 random telephone numbers 
703 unusable 
675 not working 
28 fax 
9,224 working residential telephone 
numbers 
100 interviews completed 
1,472 did not pass screener 
466 were not eligible 
1,006 refusals 
 
7,641 unscreened 
7619 no contact 
22 language barrier 
1,583 interviews attempted 
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The initial sampling strategy included healthcare professionals for the purpose of the wider research 
programme of which this study is a part. However, as noted in previous chapters, evidence suggests 
that their views and motivation to vaccinate may differ from those of the general public, thereby 
rendering them a different sample (Riphagen Dalhuisen, 2012). Therefore, descriptive statistics and 
t-tests were computed to explore whether the relationships between key socio-psychological factors  
(social influences, influenza and influenza vaccine perceptions) and the vaccination behaviour of this 
professional group were comparable to those of the rest of the sample or not. The analyses 
confirmed that, for a number of variables, the perceptions of vaccinated and unvaccinated 
healthcare professionals were not significantly different, unlike those of the general public (see 
Appendix 12). Further, I found that healthcare professionals were more motivated (or compelled) to 
vaccinate to protect others (32%) than the rest of the sample (19%). Consequently, healthcare 
professionals were excluded from the final sample. To minimise sample bias, pregnant or 
breastfeeding women were included, as they were only 1% of participants and exploratory 
regression analyses (with and without this sub-group) confirmed their inclusion did not significantly 
affect the results. 
The characteristics of the final sample (N = 806) were fairly representative of the UK population 
except for education: 9% of the study sample had no formal education and 24% had achieved A 
levels vs. 23% and 12%, respectively, in the general population (see Table 6.2). However, this 
difference did not warrant data weighting, which may augment sampling error (National Council on 
Public Polls, 2014), as this characteristic has seldom been associated with adult vaccination 
behaviour. Average influenza vaccination rate among ≥ 65s in the study sample was very close to the 
national coverage for that group (75% vs. 74%). Statistics for influenza vaccination coverage for the 
18-64 age brackets are not publically available in the UK. A formal request for these data was 
submitted (and followed up) to Public Health England (Begum, Personal communication, April 24, 
2014), but there was no reply. 
Table 6.2 Participant characteristics (N = 806) 
Characteristic Categories Sample Population 
Gender Women 52% 51% 
Age ≤65 years of age 77% 77% 
≥65 years of age 23% 23% 
Ethnicity White British or Irish 88% 87% 
 Other ethnic background 11% 13% 
 Prefer not to say 1% N/A 
Annual household 
income 
Below median 46% 48% 
Above median 46% 52% 
Prefer not to say  9% N/A 
    
115 
 
Characteristic Categories Sample Population 
Marital status Living as a couple 55% 58% 
 Not living as a couple 45% 42% 
Education No education 9% 23%*¥ 
Other degree 3% 9% 
GCSE 27% 29% 
A-level 24% 12%* 
University degree 38% 27% 
Ever been diagnosed 
with any of the 
following conditions 
Diabetes 7% 6% 
A chronic lung condition  9% 8-10% 
A chronic kidney condition 2% 4% 
A chronic heart condition 3% 2% 
A condition which causes a weakened immune system 2% 1% 
Cancer 5% 2% 
A chronic neurological condition 2% 2% 
Private health insurance  Yes 14% 11% 
Region North East 4% 4% 
North West 11% 11% 
Yorkshire and the Humber 9% 8% 
East Midlands 7% 7% 
West Midlands 8% 9% 
East 10% 9% 
London 14% 13% 
South East 15% 14% 
South West 7% 8% 
Wales 5% 5% 
Scotland 9% 8% 
Northern Ireland 2% 3% 
Settlement type Urban  77% 81% 
Rural  23% 19% 
Influenza vaccination 
status 
< 65 years of age who received influenza vaccine 27% Unavailable 
≥ 65 years of age who received influenza vaccine 75% 73% 
 
Population estimates for gender and age (ONS (1), 2014), prevalence of chronic conditions (HSCIC, 2014), ethnicity 
(ONS, 2012), region (ONS (1), 2014), settlement type (ONS (1), 2013), income (ONS (2), 2014), marital status (ONS 
(4), 2014), education (ONS (3), 2014), private health insurance (Private Health UK, 2012) and influenza vaccination 
(PHE (1), 2014). Percentages may not total 100 because of rounding. *The sample was significantly different from 
the population (p < 0.05). ¥Census data on qualifications include 16 and 17 year olds. 
 
6.3.2 Descriptive, bivariate and reliability analyses 
I also enquired about vaccination triggers and vaccination venue to test the findings from Chapters 4 
and 5. As illustrated in Figure 6.4 and consistent with previous findings, the most important 
vaccination triggers were a recommendation from a GP or midwife (38%), followed by adverts in 
pharmacies or GP practices (15%) and remembering to vaccinate without being prompted (15%). 
Being reminded to vaccinate by relatives, the news, at work or when feeling vulnerable were all 
equally important (8%), but significantly less frequent than the former triggers. As shown in Figure 
6.5, the majority of participants vaccinate at their GP practice (79%), yet a sizeable 21% receive their 
influenza vaccine elsewhere. 
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Note: participants were allowed to choose more than one trigger.  
Figure 6.4 Influenza vaccination triggers (N =442) 
 
 
 
Figure 6.5 Influenza vaccination venue (N =442) 
Three additional vaccination drivers from previous chapters were also explored here. The first was 
“altruism”, which was evaluated by asking vaccinators whether they had mainly vaccinated against 
influenza to protect others. Almost a third of participants strongly disagreed (29%), 17% disagreed, 
19% neither agreed nor disagreed, 16% agreed and 19% strongly agreed. Other items measuring 
altruistic behaviours (see items 72 and 51 in Table 6.1) among both vaccinated and unvaccinated 
participants were also tested in bivariate analysis and multiple regression.  
The second driver was the importance of flu-like symptoms for those who had vaccinated in the 
past. When asked if they had felt strong flu-like symptoms after vaccinating, 36% of participants who 
had vaccinated once or twice in the past strongly disagreed, 18% disagreed, 11% neither agreed nor 
38%
15%
15%
8%
8%
8%
7%
1%
GP or midwife
Pharmacy or GP adverts
I remember on my own
Relatives
News
Work
When feeling vulnerable
I do not have it anymore
79%
7%
5%
2%
2% 1%
4%
GP
Work
Pharmacy
Supermarket or shopping centre
At a hospital
University
Other
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disagreed, 20% agreed and 15% strongly agreed. In contrast, 47% of participants who vaccinated 
regularly strongly disagreed, 21% disagreed, 7% neither agreed nor disagreed, 16% agreed and 10% 
strongly agreed. The third was whether those who had vaccinated in the past had become habitual 
vaccinators. Although nearly half of the sample reported they vaccinated every year (45%), the 
majority had either vaccinated once or twice (40%) or vaccinated almost every year (15%).  
I chose having received an influenza vaccine in the last 6 months (latest influenza season) as the 
outcome variable for both bivariate and regression analyses, since it yielded similar results to the 
alternative four-points variable exploring vaccination frequency. Chi-square and t-tests’ results 
showed that most of the responses of vaccinated and unvaccinated participants were significantly 
different (p < 0.001 - 0.05), except for the following variables: gender, marital status, income, 
education, knowing someone who experienced a vaccine adverse reaction, maladaptive coping 
(influenza), being allergic to the vaccine, trusting alternative medicine and information about the 
influenza vaccine from social media sources, not understanding how vaccination works, optimism, 
pessimism, risk-taking, information avoidance, shared decision-making (relatives), having had a bad 
experience with healthcare professionals as a child, positive experiences with healthcare as a child, a 
bad experience with vaccines or healthcare professionals in adulthood and having had positive 
experiences with healthcare as an adult (Table 6.3). 
Those who had received an influenza vaccine were more concerned about the risks of influenza and 
less concerned about the risks of the vaccine (p < 0.001 - 0.05), and were also more trusting of 
vaccination in general and vaccine manufacturers and providers than unvaccinated participants (p < 
0.001). Similarly, vaccinated participants reported having a better understanding of vaccination in 
general (p < 0.001), were more likely to agree that vaccination is a personal choice (p < 0.05), felt 
unhealthier (p < 0.001), were more information seeking (p < 0.001) and more prone to let their GPs 
make decisions about their health than unvaccinated ones (p < 0.001). Finally, unvaccinated 
participants were more likely to have had a bad vaccine or injection-related experience as a child (p 
< 0.05), and less likely to have had a scary health-related experience in childhood and adulthood (p < 
0.001) than vaccinated participants. 
As shown in Table 6.4, the assessed scales showed very good internal reliability (α = 0.80 - 0.90) 
(Cortina, 1993; Kline, 1999), when excluding poorly correlated items (Corrected Item-Total 
Correlation below 0.30) (Field, 2013). 
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Table 6.3          Determinants of influenza vaccination by vaccination status 
Explanatory variables Min Max Vaccinated Unvaccinated SE 95% C.I. t/X2 df 
1. Demographic, socio-economic and health 
variables 
  Total/yes M SD SE Total/yes M SD SE   Lower Upper     
Age (dummy: 1 = ≥65) 0 1 302/134 - - - 504/45 - - - - - - 137.308‡ 1 
Eligible health condition (dummy: 1 = yes) 0 1 302/141 - - - 504/42 - - - - - - 166.871‡ 1 
Private health insurance (dummy: 1 = yes) 0 1 302/52 - - - 504/57 - - - - - - 5.638* 1 
Gender (dummy: 1 = female) 0 1 302/147 - - - 504/266 - - - - - - 1.272 1 
Marital status (dummy: 1 = in a partnership) 0 1 300/177 - - - 501/270 - - - - - - 1.985 1 
Income bands (1 = ≤£10,000 - 8 = ≥£70,000) 1 8 274 2.97 1.760 0.106 472 3.19 1.853 0.086 0.139 -0.055 0.490 1.568 734 
Level of education (dummy: 1 = university degree) 0 1 292/103 - - - 492/198 - - - - - - 1.914 1 
Setting (1 = urban) 0 1 302/218 - - - 504/402 - - - - - - 6.107* 1 
Ethnicity (1 = white) 0 1 302/278 - - - 497/435 - - - - - - 4.010* 1 
2. Practical barriers to influenza vaccination                               
Vaccine access (dummy: 1 = yes) 0 1 302/281 - - - 504/371 - - - - - - 46.151‡ 1 
Time to vaccinate (dummy: 1 = yes) 0 1 302/270 - - - 504/360 - - - - - - 35.750‡ 1 
Vaccine affordability (dummy = yes) 0 1 302/169 - - - 504/192 - - - - - - 26.117‡ 1 
3. Social influence                               
GP thinks I should vaccinate¥ 0 10 271 8.86 1.943 0.118 370 3.38 3.307 0.182 0.217 -5.906 -5.054 -25.261‡ 546.171 
Relatives think I should vaccinate¥ 0 10 255 7.52 2.691 0.169 390 2.80 3.005 0.152 0.227 -5.161 -4.269 -20.767‡ 583.611 
Peer experienced vaccine adverse reaction ¥ 0 10 242 3.06 3.430 0.220 406 3.06 3.368 0.167 0.275 -0.542 0.540 -0.004 646 
4. Influenza perceptions                               
Perceived knowledge of influenza 1 4 302 3.06 0.747 0.043 504 2.87 0.772 0.034 -0.189 -0.298 -0.080 -3.408‡ 804 
Frequency of influenza episodes  1 4 302 2.19 0.671 0.039 504 1.99 0.681 0.031 -0.201 -0.300 -0.102 -3.987‡ 766 
Vulnerability to influenza 0 10 302 7.22 2.6893 0.155 504 3.10 2.5019 0.111 -4.112 -4.480 -3.744 -21.956‡ 804 
Likelihood of influenza  0 10 302 5.66 2.707 0.156 504 2.31 2.480 0.110 -3.348 -3.715 -2.981 -17.921‡ 804 
Likelihood of influenza (2) 1 5 268 3.31 0.856 0.052 457 2.40 0.691 0.032 0.061 -1.036 -0.794 -14.889‡ 469.667 
Susceptibility to influenza 0 10 302 5.28 3.162 0.182 504 3.36 2.805 0.125 -1.924 -2.358 -1.491 -8.719‡ 575.290 
Severity of influenza 0 10 302 7.90 2.396 0.138 504 6.06 2.552 0.114 -1.836 -2.187 -1.485 -10.273‡ 665.451 
Severity of influenza (bed days) 1 6 302 3.14 1.216 0.070 504 2.83 1.227 0.055 -0.311 -0.486 -0.136 -3.496‡ 804 
Fear of influenza 0 10 302 4.87 3.200 0.184 504 3.14 2.696 0.120 -1.732 -2.164 -1.300 -7.879‡ 551.800 
Fear of transmitting influenza (vulnerable relative) 0 10 302 7.14 2.790 0.161 504 6.06 3.008 0.134 -1.083 -1.493 -0.672 -5.179‡ 671.369 
Worry of transmitting influenza  0 10 302 6.64 2.900 0.167 504 4.70 2.920 0.130 -1.937 -2.353 -1.521 -9.140‡ 804 
Worry of missing out on important activities or events 0 10 302 5.11 3.190 0.184 504 4.49 2.925 0.130 -0.220 -1.059 -0.194 -2.844† 804 
Coping - influenza 0 10 302 7.61 2.579 0.148 504 4.12 2.986 0.133 -3.492 -3.883 -3.100 -17.522‡ 706.107 
Maladaptive coping - influenza 0 10 302 4.84 3.192 0.184 504 5.10 2.889 0.129 0.258 -0.182 0.699 1.151 584.681 
Perceived control (over influenza) 0 10 302 3.21 2.703 0.156 504 5.68 2.595 0.116 2.472 2.095 2.849 12.886‡ 804 
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Explanatory variables Min Max Vaccinated Unvaccinated SE 95% C.I. t / χ² df 
5. Influenza vaccine perceptions     Total Mean SD SE Total Mean SD SE   Lower Upper     
Perceived knowledge of vaccine (informed decisions)¥ 0 10 301 8.26 2.033 0.117 502 6.44 2.611 0.117 -1.826 -2.151 -1.502 -11.050‡ 748.411 
Do not know much about the vaccine (trust advice)¥ 0 10 295 6.47 3.100 0.180 431 5.21 2.682 0.129 -1.262 -1.698 -0.826 -5.687‡ 570.099 
Vaccine effectiveness 0 10 302 7.50 2.194 0.126 504 5.24 2.768 0.123 -2.257 -2.603 -1.910 -12.786‡ 743.903 
The vaccine reduces severity of influenza 0 10 302 7.78 2.248 0.129 504 5.85 2.662 0.119 -1.934 -2.279 -1.590 -11.021‡ 716.570 
The vaccine is painful¥ 0 10 299 2.38 2.958 0.171 364 3.06 2.899 0.152 0.228 0.231 1.128 2.977† 661 
I am allergic to the vaccine¥ 0 10 294 1.17 2.424 0.141 332 1.35 2.319 0.127 0.176 -0.197 0.548 0.927 624 
The vaccine could transmit influenza 0 10 302 2.80 3.090 0.178 504 4.18 3.019 0.135 1.377 0.941 1.812 6.210‡ 804 
Vaccine contents could be dangerous 0 10 302 2.41 2.758 0.159 504 3.42 2.992 0.133 1.008 0.601 1.415 4.863‡ 674.428 
Vaccinating yearly can be dangerous 0 10 302 2.46 2.905 0.167 504 3.30 2.970 0.132 0.839 0.419 1.260 3.915‡ 804 
Fear of vaccine 0 10 302 1.74 2.811 0.162 504 2.15 2.755 0.123 0.407 0.010 0.804 2.015* 804 
Self-efficacy – influenza vaccination 0 10 302 9.05 1.803 0.104 504 7.16 2.880 0.128 -1.890 -2.214 -1.566 -11.449‡ 802.472 
Anticipated regret of not vaccinating 0 10 302 8.52 2.176 0.125 504 3.94 3.027 0.135 -4.582 -4.943 -4.221 -24.901‡ 777.860 
6. Trust and disposition toward vaccination and stakeholders              
Vaccination part of healthy life-style 0 10 302 8.24 1.870 0.108 504 6.77 2.393 0.107 -1.468 -1.765 -1.170 -9.688‡ 749.593 
Vaccination importance 0 10 302 8.66 1.650 0.095 504 6.71 2.587 0.115 -1.950 -2.243 -1.657 -13.058‡ 800.933 
Vaccination favourability 0 10 302 8.92 1.363 0.078 504 7.64 2.262 0.101 -1.285 -1.536 -1.034 -10.062‡ 803.971 
Trust in vaccination 0 10 302 8.35 1.588 0.091 504 7.18 2.298 0.102 -1.168 -1.438 -0.899 -8.517‡ 787.921 
Trust in medications 0 10 302 7.82 1.791 0.103 504 7.04 2.142 0.095 -0.771 -1.047 -0.495 -5.489‡ 720.991 
Trust in alternative medicine 0 10 302 4.74 2.554 0.147 504 4.69 2.529 0.113 -0.043 -0.405 0.320 -0.231 804 
Trust in vaccine manufacturers 0 10 302 6.71 2.187 0.126 504 5.58 2.513 0.112 -1.127 -1.458 -0.796 -6.691‡ 702.585 
Trust in the NHS 0 10 302 7.71 1.954 0.112 504 6.86 2.156 0.096 -0.849 -1.146 -0.551 -5.599‡ 804 
Trust GP (scale) 0 7 302 4.68 1.742 0.100 504 3.99 1.538 0.069 -0.687 -0.925 -0.448 -5.655‡ 572.957 
Trust in influenza vaccine information - NHS¥ 0 10 292 8.57 1.715 0.100 468 6.73 2.445 0.113 0.151 -2.129 -1.535 -12.122‡ 747.744 
Trust in influenza vaccine information - GP¥ 0 10 295 8.79 1.661 0.097 464 7.16 2.356 0.109 0.146 -1.915 -1.342 -11.152‡ 749.036 
Trust in influenza vaccine information - mass media¥ 0 10 271 6.17 2.794 0.170 457 4.87 2.608 0.122 0.205 -1.703 -0.896 -6.328‡ 726 
Trust in influenza vaccine information - social media¥ 0 10 224 3.53 3.124 0.209 409 3.05 2.576 0.127 0.244 -0.958 0.003 -6.218 536.282 
Importance of paediatric influenza vaccine 0 10 302 7.63 2.304 0.133 504 5.91 2.910 0.130 -1.720 -2.084 -1.356 -9.274‡ 744.416 
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Explanatory variables Min Max Vaccinated Unvaccinated SE 95% C.I. t / χ² df 
7. General perceptions and psychological constructs   Total/yes Mean SD SE Total/yes Mean SD SE   Lower Upper     
Perceived health 0 10 302 6.45 2.1341 0.123 504 7.15 1.7352 0.077 0.691 0.421 0.962 5.014‡ 804 
Understand how vaccination helps 0 10 302 8.20 1.878 0.108 504 7.41 2.265 0.101 -0.792 -1.082 -0.502 -5.355‡ 724.846 
Does not understand how vaccination works 0 10 302 3.63 3.069 0.177 504 3.56 2.854 0.127 -0.068 -0.496 0.359 -0.314 597.831 
Autonomy of vaccination decisions 0 10 302 8.09 2.3195 0.133 504 7.61 2.3023 0.103 -0.486 -0.815 -0.156 -2.890 804 
Optimism 0 10 302 5.89 2.360 0.136 504 5.58 2.225 0.099 -0.311 -0.636 0.014 -1.875 804 
Pessimism 0 10 302 4.80 2.823 0.162 504 4.77 2.537 0.113 -0.029 -0.417 0.360 -0.146 581.222 
Self-efficacy 0 10 302 6.60 2.216 0.128 504 6.54 2.029 0.090 -0.056 -0.356 0.244 -0.368 804 
Risk-taking 0 10 302 5.00 2.432 0.140 504 5.24 2.294 0.102 0.242 -0.093 0.577 1.418 804 
Information seeking 0 10 302 7.15 2.311 0.133 504 6.53 2.324 0.104 -0.614 -0.945 -0.283 -3.638‡ 804 
Information avoidance 0 10 302 4.27 2.831 0.163 504 4.24 2.415 0.108 -0.029 -0.412 0.355 -0.147 557.225 
Shared decision-making – relatives 0 10 302 4.31 3.077 0.177 504 3.95 2.819 0.126 -0.358 -0.784 0.069 -1.647 590.508 
Shared decision-making – GP 1 5 302 2.85 0.908 0.052 504 3.21 1.000 0.045 0.357 0.223 0.492 5.203‡ 681.888 
8. Previous  vaccine and health-related experiences (dummy: 1 = yes) 
  
  
  
                        
Bad experience with vaccines (child) 0 1 302/22 - - - 504/63 - - - - - - 5.445* 1 
Scary health experience (child) 0 1 302/58 - - - 504/45 - - - - - - 17.893‡ 1 
Bad experience with HCP (child) 0 1 302/32 - - - 504/38 - - - - - - 2.224 1 
Positive experience with healthcare (child) 0 1 302/240 - - - 504/405 - - - - - - 0.093 1 
Bad experience with vaccines (adult) 0 1 302/25 - - - 504/41 - - - - - - 0.005 1 
Scary health experience (adult) 0 1 302/61 - - - 504/50 - - - - - - 16.799‡ 1 
Bad experience with HCP (adult) 0 1 302/41 - - - 504/77 - - - - - - 0.438 1 
Positive experience with healthcare (adult) 0 1 302/247 - - - 504/396 - - - - - - 1.211 1 
 
SD = standard deviation; SE = standard error; df = degrees of freedom; df with decimals are adjusted to correct for the violation of the assumption of equal variances (Levene's Test for 
Equality of Variances was statistically significant). p-values were obtained using Chi-square tests (χ²) for categorical variables and Independent t-tests (t) for interval or continuous 
variables. *p < 0.05; †p < 0.01; ‡p < 0.001.  ¥Variables with “I do not know” responses which were dichotomised for regression analysis. 
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6.4 Reliability analysis of socio-psychological scales 
Explanatory variables* Cronbach α Corrected Item-Total Correlation 
3. Social influence     
GP thinks I should vaccinate 0.80 0.653 
Relatives think I should vaccinate  0.653 
Peer experienced vaccine adverse reaction   < .30 
4. Influenza perceptions     
Vulnerability to influenza 0.80 0.733 
Likelihood of influenza   0.665 
Fear of influenza  0.615 
Susceptibility to influenza  0.553 
Worry of transmitting influenza   0.542 
Coping - influenza  0.532 
Likelihood of influenza (2)  0.526 
Severity of influenza  0.438 
Fear of transmitting influenza (vulnerable relative)  0.407 
Worry of missing out on important activities or events  0.374 
Perceived control (over influenza)*  0.326 
Frequency of influenza episodes  < .30 
Severity of influenza (bed days)   
Perceived knowledge of influenza   
Maladaptive coping – influenza*   
5. Influenza vaccine perceptions     
Vaccine contents could be dangerous* 0.80 0.614 
The vaccine could transmit influenza*  0.552 
Fear of vaccine*  0.546 
The vaccine is painful*  0.542 
I am allergic to the vaccine*  0.537 
Vaccinating yearly can be dangerous*  0.514 
The vaccine reduces severity of influenza  0.423 
Vaccine effectiveness  0.416 
Perceived knowledge of vaccine (informed decisions)  0.342 
Self-efficacy – influenza vaccination  0.321 
Anticipated regret of not vaccinating  0.300 
Do not know much about the vaccine (trust advice)  < .30 
6. Trust and disposition toward vaccination and stakeholders   
Trust in vaccination 0.90 0.820 
Vaccination part of healthy life-style  0.771 
Vaccination importance  0.758 
Vaccination favourability  0.744 
Trust in influenza vaccine information - NHS  0.735 
Trust in influenza vaccine information - GP  0.698 
Trust in vaccine manufacturers  0.686 
Trust in medications  0.666 
Importance of paediatric influenza vaccine  0.612 
Trust in the NHS  0.622 
Trust in influenza vaccine information - mass media  0.425 
Trust GP (scale)  0.381 
Trust in influenza vaccine information - social media  < .30 
Trust in alternative medicine   
   
Continuous scales were used for reliability analyses. “I do not know” responses were coded as missing. 
*items that were reverse-scored to perform reliability analyses. 
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6.3.3 Regression analysis 
A logistic regression analysis was conducted to uncover the determinants of influenza vaccination. 
All variables in Table 6.3 were included. Table 6.5 shows the associations between influenza 
vaccination and the assessed variables. From the eight blocks of variables entered only six 
significantly contributed to the model. None of the variables in block 2 (practical barriers) and block 
6 (trust and disposition toward vaccination and stakeholders) significantly contributed to the model.  
The beginning model 0 (null model), which evaluates the model with only the constant in the 
equation, showed that it was 63% accurate in predicting vaccination behaviour. This is based on the 
distribution of the outcome measure (63% did not vaccinate) and equivalent to the accuracy of 
random guessing. The first model (M1) comprised socio-demographic and health-related variables 
and classified 79% of the cases correctly, an improvement in predictability of 16% compared to 
model 0. Although M1 was significant χ² (3) = 255.645, p<0.001, Nagelkerke R² was only 0.372, which 
indicates that the model fits the data moderately and is able to explain only 37% of the variance. 
Models M2 to M6 contained socio-psychological variables which significantly contributed to explain 
the variance in vaccination behaviour. The final model (M6) comprised 16 variables and correctly 
classified 91% of the cases, 94% of unvaccinated participants and 86% of vaccinated ones. The model 
was significant χ² (20) = 702.369, p<0.001 and Nagelkerke R² was 0.796, which indicates that the 
model is a very good fit of the data and can explain approximately 80% of the variance in behaviour. 
None of the excluded predictors became significant when these were reincorporated into the model. 
Collinearity diagnostics showed that only one item (trust in vaccination) had a VIF above 5 (5.44), 
(Bowerman and O'Connell, 1990), as it was highly correlated with three other items (vaccination part 
of healthy life-style, vaccination importance and vaccination favourability). This item was, therefore, 
excluded from the regression analyses. Standardised residuals were examined to identify outliers. 
Less than 5% of the cases had standardised residuals above 2 and no more than 1% had absolute 
values higher than 3, thus there was no need to eliminate or transform cases (Field, 2013). Cook’s 
distance statistics were evaluated to identify cases exerting excessive influence on the model. No 
values were higher than 1, which indicate there is not cause for concern (Cook and Weisberg, 1982). 
The final model showed that older people (p < 0.05), those who reported having one or more of the 
assessed eligible health conditions (p < 0.001) and were living in a partnership (p < 0.05) were more 
likely to have received an influenza vaccine during the 2013/2014 influenza season.  
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Table 6.5 Logit regression determinants of influenza vaccination (N = 801) 
 M1 M2 M3 
Independent variables OR SE 95% C.I. OR SE 95% C.I. OR SE 95% C.I. 
Age 6.517‡ 0.215 4.280 9.923 3.612‡ 0.253 2.199 5.933 3.978‡ 0.325 2.102 7.527 
Eligible health condition  8.667‡ 0.214 5.701 13.176 4.276‡ 0.248 2.629 6.954 4.181‡ 0.312 2.267 7.711 
Marital status  1.738† 0.181 1.218 2.481 1.726** 0.217 1.129 2.639 2.152† 0.260 1.292 3.584 
GP thinks I should vaccinate     8.414‡ 0.232 5.340 13.257 4.142‡ 0.287 2.361 7.268 
Relatives think I should vaccinate     3.041‡ 0.232 1.932 4.788 1.564 0.289 0.888 2.757 
Likelihood of influenza         1.166† 0.055 1.047 1.298 
Vulnerability  –  influenza         1.246‡ 0.058 1.112 1.396 
Severity influenza  – bed days         1.245** 0.103 1.018 1.523 
Coping - influenza         1.259‡ 0.049 1.143 1.385 
Perceived control over influenza         0.739‡ 0.050 0.670 0.815 
Vaccine contents – dangerous             
Anticipated regret  – influenza             
Self-efficacy – influenza vaccine             
Shared decision-making  –  GP             
Scary vaccine experience  –  child             
Scary health experience  –  child             
Predicted unvaccinated   85%    86%    92%  
Predicted vaccinated   69%    79%    83%  
Total predicted behaviour   79%    84%    89%  
Chi-square   255.645    204.545    168.037  
Nagelkerke R²   0.372    0.596    0.741  
          
 M3 M4 M5 
Independent variables OR SE 95% C.I. OR SE 95% C.I. OR SE 95% C.I. 
Age 2.462† 0.352 1.234 4.912 2.492† 0.361 1.228 5.057 2.502** 0.373 1.205 5.197 
Eligible health condition  3.826‡ 0.342 1.958 7.476 3.952‡ 0.349 1.995 7.829 3.780‡ 0.362 1.858 7.689 
Marital status  2.143† 0.282 1.232 3.727 1.946** 0.287 1.109 3.415 1.940** 0.291 1.097 3.432 
GP thinks I should vaccinate 3.201‡ 0.317 1.720 5.959 3.115‡ 0.322 1.657 5.858 3.122‡ 0.329 1.639 5.948 
Relatives think I should vaccinate 1.716* 0.319 0.919 3.204 1.580 0.327 0.833 2.996 1.532 0.332 0.798 2.939 
Likelihood of influenza 1.279‡ 0.065 1.125 1.453 1.256‡ 0.066 1.103 1.429 1.277‡ 0.068 1.117 1.460 
Vulnerability  –  influenza 1.113* 0.066 0.978 1.266 1.111 0.067 0.975 1.266 1.102 0.068 0.964 1.260 
Severity influenza  – bed days 1.236* 0.110 0.997 1.533 1.240* 0.113 0.995 1.547 1.281** 0.115 1.023 1.604 
Coping - influenza 1.228‡ 0.052 1.108 1.360 1.252‡ 0.054 1.126 1.391 1.245‡ 0.055 1.117 1.387 
Perceived control over influenza 0.797‡ 0.055 0.715 0.888 0.795‡ 0.056 0.712 0.887 0.791‡ 0.057 0.707 0.885 
Vaccine contents – dangerous 0.843‡ 0.050 0.765 0.930 0.840‡ 0.052 0.759 0.929 0.840‡ 0.054 0.755 0.934 
Anticipated regret  – influenza 1.238‡ 0.052 1.119 1.370 1.256‡ 0.053 1.133 1.393 1.259‡ 0.054 1.132 1.399 
Self-efficacy – influenza vaccine 1.261‡ 0.067 1.105 1.439 1.258‡ 0.069 1.098 1.441 1.272‡ 0.072 1.105 1.465 
Shared decision-making  –  GP     0.632‡ 0.143 0.478 0.836 0.634† 0.146 0.476 0.845 
Scary vaccine experience  –  child         0.322** 0.483 0.125 0.829 
Scary health experience  –  child         2.911† 0.417 1.284 6.596 
Predicted unvaccinated   93%    94%    94%  
Predicted vaccinated   84%    86%    86%  
Total predicted behaviour   90%    91%    91%  
Chi-square   53.380    10.825    9.937  
Nagelkerke R²   0.781    0.789    0.796  
 
OR = odds ratio; SE = standard error; CI = confidence interval; OR = odds ratio; SE = standard error; CI = 
confidence interval; *p < 0.1; **p < 0.05; †p < 0.01; ‡p < 0.001. 
Note: the change in model fit as indicated by chi-square tests for each block of variables (M1-M6) was 
significant for all blocks (p < 0.05). 
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The model also indicated that when controlling for participant characteristics, socio-psychological 
variables predict 12% of influenza vaccination behaviour. Specifically, those who reported that their 
GP (p < 0.001) thinks they need to get vaccinated against influenza, who felt they were more likely to 
catch influenza (p < 0.001), who believed they would spend more days in bed if they catch influenza 
(p < 0.05), who reported influenza-specific coping behaviour (p < 0.001), who perceived they were 
less likely to avoid influenza without a vaccine (p < 0.001), who were less worried about the contents 
of the vaccine (p < 0.001), who reported anticipated regret of not vaccinating (p < 0.001), who 
reported higher vaccine-specific self-efficacy (p < 0.001), who were more likely to let GPs make 
decisions about their health (p < 0.01), had not had a bad experience with vaccines or injections as a 
child (p < 0.05) and who had had a scary health-related experience as a child (p < 0.01), were more 
likely to report having been vaccinated in the same time period. Influence from relatives and 
perceived vulnerability to influenza were not significant, but were retained as they contributed to 
the model. 
6.4 Discussion 
This chapter aimed to identify the determinants of adult influenza vaccination in the UK, and to 
predict influenza vaccination behaviour. This research ultimately sought to propose a set of highly 
predictive items to be used in national immunisation surveys or other immunisation tools aimed at 
improving influenza vaccination uptake. Although responses from vaccinated and unvaccinated 
individuals were significantly different for most variables in bivariate analyses, only 14 items 
predicted vaccination uptake in multiple regression analysis.   
The model that best fitted the data was comprised of 16 items which captured key socio-
demographic, health and socio-psychological factors associated with influenza vaccination. It 
predicted 91% of self-reported vaccination behaviour overall and correctly identified 94% of 
unvaccinated and 86% of vaccinated participants. The results from this study support findings from 
previous studies and add new insights to the evidence-base. 
Socio-demographic and health variables explained 37% of the variance in vaccination behaviour. As 
expected, older participants, those who reported having an eligible health condition and living with a 
partner were more likely to receive an influenza vaccine.  Previous research, mostly from the US, has 
consistently found that age and health status predict influenza vaccination, yet it is less conclusive 
regarding marital and socio-economic status, private insurance and education (Chapman and Coups, 
1999; Xakellis, 2005; Winston, Wortley et al., 2006; Kohlhammer, 2007; Ward and Draper, 2008).  
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To my knowledge, this is the first study showing that marital status predicts influenza vaccination 
uptake in the UK. Higher vaccination rates among participants living with a partner may be explained 
by people’s tendency to protect their significant other or encouragement from partners to get 
vaccinated, yet more evidence is needed to substantiate this assertion.  
The lack of association between influenza vaccination, private insurance, income and education may 
be explained by the UK healthcare system, which, unlike in the US, provides universal access and 
free of charge vaccination for those at higher risk. Consistently, practical barriers such as lack of 
access, time and affordability were not significantly associated with influenza vaccination. Although 
ethnicity was not associated with vaccination in multiple regression analysis, bivariate analyses 
suggest that populations from ethnic minorities may be less likely to vaccinate against influenza. 
Thus far, there is no published evidence of differences in influenza vaccination uptake across 
minority populations in the UK. However, ethnic disparities in human papillomavirus vaccination in 
England may be indicative of a similar trend across other vaccines (Roberts, Brabin et al., 2011). This 
potential health inequality warrants further research among these populations using adequately 
powered samples. 
Socio-psychological factors explained most of the variance in vaccination behaviour (43%). 
Encouragingly, unlike socio-demographic and health determinants, these factors can be modified. 
Further, socio-psychological factors are likely to be more pivotal and discriminant within high risk 
groups, as age may be less predictive of vaccination among over 65s and health status may be less 
important among younger people with eligible health conditions. Understanding and monitoring the 
socio-psychological determinants of vaccination is, therefore, essential to develop behaviour change 
interventions and targeted communication strategies, particularly among those at higher risk.  
In line with previous research, this study confirmed that GPs’ opinion significantly influence 
vaccination behaviour (Kohlhammer, 2007; Ward and Draper, 2008; Wheelock, Thomson et al., 
2013). Consistent with this finding, most of those who vaccinated reported that they were prompted 
to do so by their GP, adverts in GP practices or pharmacies, which further support the relevance of 
GP-led vaccination communications. Yet, I should note that this study’s sample included younger 
individuals who are not eligible to get vaccinated at a GP practice and have probably not received a 
GP recommendation to vaccinate; hence, the variable “GP thinks I should vaccinate” may be less 
discriminant among high-risk groups. Interestingly, almost half of those who had vaccinated in the 
past did not develop the vaccination “habit” reported in previous studies (Wheelock, Thomson, et 
al., 2013), which suggests that this construct may not be as important to vaccination behaviour as 
triggers such as a GP reminder. 
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My results compare well with those from previous studies showing that those who feel at greater 
risk of contracting influenza are more likely to vaccinate (Brewer, Chapman et al., 2007; 
Kohlhammer, 2007; Ward and Draper, 2008; Wheelock, Thomson et al., 2013). Interestingly, 
perceived severity of influenza was only significant when measured as a number of days in bed, 
rather than degree of seriousness. This resonates with previous evidence and findings from Chapter 
3, which show that perceived disease severity, usually measured as disease seriousness, is not as 
strongly correlated with vaccination as perceived likelihood of and susceptibility to the disease 
(Brewer, Chapman et al., 2007). It is, therefore, recommendable to use more realistic measures 
based on common experiences to capture and communicate perceived severity. When evaluated 
concurrently with perceived likelihood and severity of influenza, perceived vulnerability to influenza 
was not significant. Again, this echoes previous research which suggests that perceived likelihood of 
and vulnerability or susceptibility to influenza may be viewed by participants as interchangeable 
concepts (Brewer, Chapman et al., 2007).  In multiple regression analysis, however, perceived 
likelihood was a better predictor of influenza vaccination uptake; thus, its inclusion in future surveys 
should be encouraged.  
Anticipated regret if not vaccinated and perceived vaccine-specific self-efficacy, two important 
constructs which have seldom been explored in the context of influenza vaccination, also predicted 
uptake (Chapman and Coups, 2006; Liao, Cowling et al., 2011). Given that an individual’s perceived 
ability to engage in a particular behaviour may depend upon psychological but also contextual 
factors (Strecher VJ, DeVellis BM et al., 1986), a clearer understanding of the factors underpinning 
vaccine-specific self-efficacy is needed.  
Coping, a novel concept in immunisation research, but widely used to evaluate how people manage 
difficult circumstances or health conditions (Penley, Tomaka et al., 2002), too was a vaccination 
predictor. This indicates that actively protecting oneself against influenza is normally associated with 
vaccination as opposed to other prevention strategies (e.g. washing hands, avoiding crowds).  
In contrast, participants who felt more able to avoid influenza despite not being vaccinated and 
those who were more inclined to make health decisions independently from their GP, were less 
likely to vaccinate against influenza. These findings indicate that perceived control of the disease and 
health decision-making styles and preferences can affect influenza vaccine uptake and, therefore, 
should inform future immunisation interventions. To my knowledge, this is the first study exploring 
the association between these two dimensions and influenza vaccination.  
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Concerns around the vaccine’s contents were significantly more prevalent in unvaccinated 
participants and the only negative vaccine perception predicting vaccination behaviour. As shown in 
Table 6.4, this concern was closely related with the perception that the vaccine can cause influenza, 
but was a better predictor of vaccination uptake. These findings resonate with those of previous 
studies and Chapters 2 and 3 (Chapman and Coups, 1999; Kohlhammer, 2007; Wheelock, Thomson 
et al., 2013), and suggest that the current strategies to assuage the public’s concerns regarding the 
safety of the influenza vaccine have a limited effect. Furthermore, I found that those who seldom 
vaccinated were more likely to report having experienced strong influenza-like symptoms after 
vaccination. This may partly explain why they discontinued vaccination.  
A striking qualitative finding reported in Chapter 5 held true when tested quantitatively in this 
chapter.  People who had had a bad experience with vaccines or injections in childhood were less 
likely to receive the influenza vaccine in adulthood. As previously discussed, traumatic experiences 
can linger through to adulthood and significantly influence our health decisions. This is further 
confirmed by the finding that those who reported having a scary health-related experience in 
childhood were more likely to vaccinate, which, again, may be explained by a lasting perception of 
vulnerability triggered by a childhood event that results in enhanced preventive behaviours. 
Alternatively, this health-related event in childhood may have had a real impact on individuals’ 
health throughout their lives. To the best of my knowledge, this is the first quantitative study that 
has linked adult vaccination behaviour with childhood experiences.  
Lessons can also be drawn from constructs which did not predict vaccination. Vaccine effectiveness, 
for example, which has been previously highlighted as a key vaccination determinant, was found to 
be less relevant than other apprehensions around vaccines. Another behaviour which did not predict 
vaccination in the present study, but was associated with influenza vaccination uptake in a recent 
study, is altruism (Shim, Chapman et al., 2012). This study, however, was conducted among 
university employees, most of whom do not belong to a high-risk group, thus their motivation may 
be more related to both their and their students’ class attendance than their own risk. Further, one 
of the two items used to measure altruism (‘If you were to receive the influenza shot this Autumn, 
how worried would you be about infecting people at work with the influenza?’) was rather complex 
and may have confused participants. The present study suggests that although people may indeed 
worry about infecting others, altruistic behaviour does not predict influenza vaccination in the 
general population, and supports the supremacy of self-interest in influenza vaccination decisions.  
Likewise, general perceptions and personal characteristics, most of which have not been previously 
tested in the context of adult vaccination, were not linked to vaccination status in bivariate analyses, 
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except for information seeking, which was found to be significantly higher in vaccinators. This 
characteristic, however, did not predict vaccination in multiple regression analysis. Similarly, trust in 
vaccination and key vaccination stakeholders does not appear to predict influenza vaccination, over 
and above influenza and vaccine-specific perceptions. Trust in the information provided by GPs 
about the influenza vaccine, for example, was not as predictive as a GP recommendation. This 
indicates that the contents and delivery of the recommendation may be less important than the 
recommendation itself.  
Although the HBM (Rosenstock, 1966) and the PMT (Maddux and Rogers, 1983) have many 
commonalities, this study shows that the latter may better explain influenza vaccination behaviour. 
As described in Chapter 1, the PMT proposes that information sources (verbal persuasion, 
observational learning, personality variables, prior experience, etc.) initiate cognitive activity, which 
leads to protection motivation and later to health protective behaviour. Since intention to vaccinate 
is highly correlated with vaccination, for the purpose of this research I omitted the protection 
motivation component of the model.  
In this study, the importance of information sources was reflected by the influence of GPs and 
relatives, health decision-making preferences, and previous childhood experiences on vaccination 
behaviour. The PMT also postulates that a process of threat appraisal (perceived severity of and 
vulnerability to the threat, and fear) and a process of coping appraisal (perceived self-efficacy, 
perceived response effectiveness and perceived response cost), in which the options of minimising a 
threat are evaluated, can lead to either adaptive coping (protection motivation) or maladaptive 
coping (response that may lead to health risk – e.g. avoidance). My results also support this notion, 
yet some of the components differ. Severity and likelihood of influenza predicted vaccination 
behaviour whereas vulnerability and fear were not important components of the threat appraisal 
process. Similarly, perceived self-efficacy, coping behaviour, anticipated regret of not vaccinating 
and concerns around the contents of the vaccine were predictive components of coping appraisal, 
yet vaccine effectiveness was not relevant, thus its relevance deserves further consideration. Finally, 
perceived control of influenza, a maladaptive response, was negatively associated with vaccination.  
Encouragingly, the employed instrument showed good face, content and predictive validity. The 
assessed constructs also showed good internal consistency, an indication that the included items 
reliably measured the intended construct. Items which did not correlate well with other items were 
either measuring knowledge (“frequency of influenza episodes”, “severity of influenza (bed days)”, 
“perceived knowledge of influenza”) or had not been tested before as part of their assigned 
construct (“Do not know much about the vaccine, but trust advice”, “maladaptive coping – 
129 
 
influenza”, “peer-experienced adverse reactions”, “trust in influenza vaccine information - social 
media” and “trust in alternative medicine”). The latter were both poorly correlated with their 
construct and the outcome measure, as supported by results from bivariate analyses, which show 
that responses from vaccinated and unvaccinated participants were not significantly different for 
these items. The exclusion of these four items from future surveys measuring influenza vaccination 
should be considered. 
6.4.1 Limitations of this study 
In common with most studies in this field, for feasibility, influenza vaccination was self-reported. 
Although self-reported behaviour may lead to inexact responses (Evans and Watson, 2003), previous 
research comparing the accuracy of self-reported influenza vaccination to medical records found 
that these are accurate in approximately 90% of the cases (Hutchison, 1988; Nichol, Korn et al., 
1990). Further, since some people vaccinate at work or alternative facilities such as pharmacies, it 
remains unclear whether medical records are more accurate than self-reports. 
A second limitation of this study was the use of trained participants from a market research panel. 
Despite efforts to exclude speeders and flat-liners, trained participants may not have been as 
committed to providing accurate answers as “fresh” ones (Toepoel, Das et al., 2008). Reassuringly, 
the results from this study were largely consistent with comparable findings from previous studies.  
A third limitation is the number of questions included in the survey. Lengthy survey tools may 
fatigue participants, thereby affecting the quality of the data. Pilot results, however, indicated that 
participants did not feel the survey was long or difficult to complete. 
A fourth limitation is the dichotomisation of 11 continuous variables (yes/other than yes), as it may 
lead to a reduction in the statistical power to detect an association between the variable and the 
outcome measure, increase the risk of a positive result being a false positive, and underestimate the 
extent of variation in outcome between groups, among other problems (Altman and Royston, 2006). 
Although dichotomisation is not recommendable, it was deemed acceptable due to the number of 
missing responses (“I do not know”), which in some cases reached 25% of the sample. Moreover, 
most of the affected variables were not statistically important, both when tested as continuous and 
dichotomised variables. The two items that were statistically significant (“My GP thinks I should 
vaccinate” and “My relatives think I should vaccinate”) lent themselves to be dichotomised, as those 
who may influence vaccination decisions would normally be either supportive or unsupportive of 
their patient or relative being vaccinated.  
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A fifth limitation is related to the psychometric properties of the employed instrument. Although it 
showed good face, content and predictive validity, as well as internal consistency, compromises 
were made which may have affected some of the instrument’s psychometric qualities. As stated at 
the beginning of this chapter, the present study was concerned with identifying the most predictive 
socio-psychological determinants of influenza vaccination. Face validity, content validity and 
predictive validity were, therefore, prioritised over internal consistency. Consequently, the final tool 
was comprehensive but heterogeneous, since some dimensions, such as practical barriers, were best 
measured using alternate-choice items (yes/no) rather than rating-scales. Moreover, some 
constructs, particularly novel ones, were comprised of two items due to survey-length restrictions – 
three or more items per construct are recommended (Rust and Golombok, 2009). Therefore, I was 
only able to conduct partial reliability analyses. Promisingly, analyses outside the scope of this thesis 
showed that most of the socio-psychological predictors reported in this study also predicted 
influenza vaccination in the US and France. This indicates that the proposed set of items reliably 
predicts influenza vaccination behaviour across different settings. 
An additional limitation is that the sample was somewhat more educated than the general 
population, which may affect the generalisability of the results. A related drawback is the use of a 
standard list of chronic illnesses as part the survey tool, which did not specify liver disease and 
morbid obesity. This omission may have had an effect on the magnitude of the association between 
health status and vaccination uptake.  
Lastly, and consistent with other retrospective cross-sectional studies, causation cannot be inferred 
(Weinstein, 2007). In other words, some of the assessed perceptions may have been generated or 
reinforced by individuals’ vaccination behaviour and not the other way around.  
6.4.2 Summary and implications for further research 
To my knowledge, this is one of few empirical studies using regression analysis to evaluate a wide-
ranging number of known and potential predictors of influenza vaccination behaviour. This chapter 
demonstrated that 16 survey-items can predict 91% of influenza vaccination behaviour overall and 
that social and psychological factors are at the heart of suboptimal influenza vaccination rates.  
The identified predictors can be used to forecast uptake and monitor vaccination sentiment. They 
also provide an opportunity to develop and evaluate targeted interventions aiming to assuage 
concerns and dispel misconceptions. Yet, the variables associated with influenza vaccination should 
be assessed across different time-points to further test their reliability. I will discuss the wider 
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implications of this study and areas for future research in the main discussion of the thesis (Chapter 
8). 
In the following chapter, I report the development and testing of an analogous instrument aimed at 
uncovering the determinants of tetanus vaccination in adults and predicting its uptake. 
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7 Determinants of tetanus vaccination in the UK: a 
survey study 
7.1   Introduction 
Tetanus boosters are, together with influenza vaccination, routinely administered to all adults. As 
stated in Chapter 1, in the UK, adult tetanus boosters are not included in ‘The complete routine 
immunisation schedule 2013/14’, yet it is recommended to those who are not fully immunised,  
those who are travelling to a country with limited medical facilities and pregnant women (NHS (3), 
2014).  Although there are no publicly available statistics on tetanus vaccination uptake in adults, a 
previous study suggested that the success of the tetanus vaccination programme in the UK may be 
partly due to over-vaccination, specifically in emergency departments (Savage, Nash et al., 2007). 
The same study also highlighted the lack of knowledge among healthcare professionals regarding 
changes in tetanus immunisation policy and current recommendations.   
Research on the determinants of tetanus vaccination in the general population is largely missing in 
the UK, but also elsewhere. The low incidence of tetanus and lack of controversy around the tetanus 
vaccine, possibly due to its proven effectiveness and limited side-effects, may partly explain this gap 
in the literature (Miller, 1999; PHE (5), 2013). Another reason may be that obtaining vaccination 
records or accurate self-reports could be challenging due to the recommended time-schedule of 
tetanus vaccination, usually every 10 years (PHE (5), 2013; CDC (2), 2015).  
Emerging evidence, however, indicates that tetanus boosters are often administered after an injury 
rather than preventively. A US study found that 74% of unvaccinated participants thought that 
vaccinating against tetanus was only necessary after an injury, whilst 51% reported that their doctor 
had not recommended it (Johnson, Nichol et al., 2008). Similarly, a study conducted in Germany 
found that tetanus vaccination coverage was insufficient, particularly among older people and ethnic 
minorities, and that 34% of those vaccinated had been immunised after an injury (Böhmer, Walter et 
al., 2011). Findings from Chapters 4 and 5 and the aforementioned UK study point in the same 
direction (Savage, Nash et al., 2007). This is a cause for concern, since vaccination may not boost 
immunity in time to provide the required protection (Porter, Perkin et al., 1992).  
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7.1.1 Study aims 
The primary aim of this study is to develop and test a tool to uncover the determinants of tetanus 
vaccination in the UK and to predict tetanus vaccination behaviour. Secondary objectives are: i) to 
evaluate the importance of socio-psychological factors in predicting tetanus vaccination; ii) to test 
whether generic items are equally effective at predicting tetanus vaccination as tetanus-specific 
items; and iii) to explore whether official immunisation recommendations are aligned with current 
vaccination practices. 
7.2 Methods 
The methods of this study are described in full in Chapter 6. The criteria used to design and test the 
instrument reported in this chapter and to attain its intended psychometric properties were 
analogous to those specified in the previous chapter. As there is little research on the socio-
psychological factors underpinning tetanus vaccination, constructs were chosen based on relevant 
evidence on both tetanus and influenza vaccination (see Table 7.1). The tetanus instrument was 
approved by the Imperial College Ethics Committee (see Appendix 3) and tested concurrently with 
the influenza instrument (Chapter 6) using the same sample of participants.  
7.2.1 Data analysis 
As reported in Chapter 6, analyses were conducted using single items and Cronbach’s alpha tests for 
blocks 3-6 were performed to explore correlations between items and test the reliability of the 
scales. Descriptive statistics, Pearson’s Chi-square (categorical variables) and t-tests (interval or 
continuous variables) were computed to explore the relationships between the assessed variables 
and self-reported tetanus vaccination behaviour (p < 0.05 was considered significant). The outcome 
measure was having received an adult tetanus booster (≥18 years old) in the past 10 years. Logistic 
regression analysis was conducted to uncover the predictors of tetanus vaccination (and validated by 
Kerry O'Neill, solutions-2). All analyses were performed by myself using IBM SPSS Statistics 22. 
Following the same hierarchical approach described in Chapter 6, variables were entered in blocks. 
Given that the available evidence on tetanus vaccines is limited (Johnson, Nichol et al., 2008; 
Böhmer, Walter et al., 2011) and that there is some overlap between the barriers and drivers of 
tetanus and influenza vaccination (Chapters 4 and 5), the order of variable entry was based on 
previous research on both tetanus and influenza vaccines (Kohlhammer, 2007; Ward and Draper, 
2008; Nagata, Hernandez-Ramos et al., 2013; Wheelock, Thomson et al., 2013), as well as my aim of 
assessing whether socio-psychological factors are better predictors of tetanus vaccination than 
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population characteristics and practical barriers. Thus, variables which had previously been 
associated with tetanus vaccination were entered first and those which could potentially predict it 
were entered last. Consequently, eight blocks of explanatory variables were entered in the following 
order: 1) demographic, socio-economic and health-related variables; 2) practical barriers to tetanus 
vaccination; 3) social influence; 4) tetanus perceptions; 5) tetanus vaccine perceptions; 6) trust and 
disposition toward vaccination and vaccination stakeholders; 7) general perceptions and constructs; 
8) previous vaccine and health-related experiences. The same data checks and procedures described 
in the previous chapter were replicated here. Odds Ratios for the hierarchical logistic (logit) model, 
standard errors, significance levels and confidence intervals, as well as the discriminating ability of 
the model, are presented (p < 0.1 was considered significant).  
Table 7.1 Source of selected variables 
Explanatory variables Source 
1. Demographic, socio-economic and health variables 
 (1) Age  
(Johnson, Nichol et al., 2008; Böhmer, Walter 
et al., 2011)  
(14) Eligible health condition (influenza)* 
(120) Private health insurance 
(2) Gender  
(11) Marital status 
(10) Income bands 
(119) Level of education 
(5) Setting 
(3) Ethnicity 
2. Practical barriers to tetanus vaccination 
 (109) Vaccine access  
(Johnson, Nichol et al., 2008) (109) Time to vaccinate 
(109) Vaccine affordability 
3. Social influence  
(106) GP thinks I should vaccinate 
Chapter 4 / (Johnson, Nichol et al., 2008; 
Böhmer, Walter et al., 2011) 
(107) Relatives think I should vaccinate 
(111) Peer experienced vaccine adverse reaction  
4. Tetanus perceptions 
 
(85) Perceived knowledge of tetanus 
(Johnson, Nichol et al., 2008; Böhmer, Walter 
et al., 2011) 
(97) Vulnerability to tetanus 
Chapters 4 and 5 / (Johnson, Nichol et al., 
2008)  
(93) Susceptibility to tetanus 
(99) Likelihood of tetanus  
(100) Likelihood of tetanus (2) 
(91) Severity of tetanus 
(95) Fear of tetanus 
(98) Perceived control over tetanus (Wallston, Wallston et al., 1987)  
(94) Coping – tetanus 
(Carver, 1997) 
(92) Maladaptive coping – tetanus 
5. Tetanus vaccine perceptions 
(101) Perceived knowledge of vaccine (informed decisions) (Johnson, Nichol et al., 2008; Böhmer, Walter 
et al., 2011) (108) Do not know much about the vaccine (trust advice) 
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Explanatory variables Source 
(96) Vaccine effectiveness 
Chapters 4 and 5 / (Johnson, Nichol et al., 
2008) 
(116) The contents of the vaccine can be dangerous 
(115) The vaccine could transmit tetanus 
(113) The vaccine is painful 
(112) I am allergic to the vaccine 
(114) Fear of vaccine 
117) Self-efficacy – tetanus vaccination (Bandura, 2006) 
(110) Anticipated Regret of not vaccinating (Chapman and Coups, 2006) 
6. Trust and disposition toward vaccination and vaccination 
stakeholders 
 
(36) Vaccination importance 
Chapter 2 (28) Vaccination favourability 
(38) Vaccination part of healthy life-style 
(26) Trust GP (scale) Chapter 4 / (Safran, Kosinski et al., 1998) 
(33) Trust in the NHS 
Chapter 4 / (Black and Rappuoli, 2010; Gilles, 
Bangerter et al., 2011; Larson, Cooper et al., 
2011) 
(30) Trust in vaccination  
(32) Trust in vaccine manufacturers 
(29) Trust in medications 
(31) Trust in alternative medicine 
(102) Trust in tetanus vaccine information - NHS 
(105) Trust in tetanus vaccine information - GP 
(103) Trust in tetanus vaccine information - mass media 
(104) Trust in tetanus vaccine information - social media 
(40) Importance of paediatric tetanus vaccine Chapter 4 
7. General perceptions and psychological constructs  
(34) Understand how vaccination helps 
(Kohlhammer, 2007)  
(35) Does not understand how vaccination works 
(37) Autonomy of vaccination decisions (Ende, Kazis et al., 1989) 
(13) Perceived health Chapter 4 / (Böhmer, Walter et al., 2011) 
(18) Optimism 
 (Scheier, Carver et al., 1994) 
(20) Pessimism 
(19) Self-efficacy (Bandura, 2006) 
(21) Risk-taking (Dohmen, Falk et al., 2011)  
(22) Information seeking 
(Miller, Brody et al., 1988)  
(23) Information avoidance 
(24) Shared decision-making - relatives (Elwyn, Edwards et al., 2000; Robinson and 
Thomson, 2001) 
  
(25) Shared decision-making – GP 
8. Previous  vaccine  and health-related experiences  
(41) Bad experience with vaccines (child) 
Chapter 4 & 5 
(41) Scary health experience (child) 
(41) Bad experience with HCP (child) 
(41) Positive experience with healthcare (child) 
(42) Bad experience with vaccines (adult) 
(42) Scary health experience (adult) 
(42) Bad experience with HCP (adult) 
(42) Positive experience with healthcare (adult) 
 
In brackets is the number of the question corresponding to each explanatory variable (see Appendix 11). 
*Although UK recommendations for tetanus vaccination do not specify particular health conditions, the 
variable “eligible health condition” used in the previous chapter was included in order to explore possible 
associations between having an underlying illness (e.g. diabetes) or being pregnant and tetanus vaccination.  
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7.4.2.1 Variable coding 
As in the previous chapter, for comparability and validity the variables age, eligible health condition 
(influenza), marital status, level of education and ethnicity were also dichotomised. Similarly, 11 
variables with “I do not know” responses were recoded as dichotomous or dummy variables to 
maximise the number of observations included in logistic regression analysis.  Values expressing 
agreement with a given statement (6-10) were coded as 1 = “yes” and the rest (0-5 and “I do not 
know”) were coded as 0 = “other than yes” (see recoded variables in Table 7.3).  
7.3 Results 
7.3.1 Participants 
Participants were surveyed in March 2014. The recruitment strategy and response rates are 
described in the previous chapter. The characteristics of the sample are analogous to those 
presented in Table 6.2 (Chapter 6). Almost half of the sample had not received a tetanus booster in 
the last 10 years (47%), 35% reported having been vaccinated in the same time-period and 18% were 
not able to recall whether or not they had vaccinated.  
7.3.2 Descriptive, bivariate and reliability analyses 
To test the qualitative findings presented in Chapters 4 and 5, tetanus vaccination triggers, setting 
and motivation were explored. As shown in Figure 7.1 and in line with qualitative findings, most 
participants vaccinated against tetanus because it was offered after an injury (31%), followed by 
remembering to vaccinate on their own (20%) and a GP recommendation (19). A minority vaccinated 
prompted by the news (11%), feeling vulnerable (10%), relatives (6%) or work (3%). Although most 
participants vaccinated at a GP practice (61%), an important minority received a tetanus booster at a 
hospital (32%). A small number of participants vaccinated at work, a walk-in clinic, a pharmacy or 
travel clinic (2% each) or other setting (1%) (Figure 7.2). The majority reported having been injured 
as the main motivation for seeking tetanus vaccination (31%), followed by travel (18%), a 
recommendation from a GP (15%) and feeling it was important to keep up to date with their 
boosters (12%), whereas a minority could not recall why they had vaccinated or selected “other 
reason” (8%), vaccinated because it was recommended by the NHS (7%), worked in construction 
(6%), had a eligible health condition (influenza) (2%) or wanted to protect others from acquiring 
pertussis (1%) (Figure 7.3).  
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Note: participants were allowed to choose more than one option 
 
Figure 7.1 Tetanus vaccination triggers (N = 379) 
 
 
 
Note: participants were allowed to choose more than one option 
 
Figure 7.2 Tetanus vaccination setting (N = 379) 
 
 
 
Note: participants were allowed to choose more than one option 
 
Figure 7.3 Tetanus vaccination motivation (N = 379) 
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A summary of the results from Chi-square and t-tests provided in Table 7.2, is provided next. Those 
who had a tetanus booster in the last 10 years were more likely to have a private insurance (p < 
0.05), higher income (p < 0.05) and a higher educational level (p < 0.05), and felt it was easier to 
access gain access to boosters and find time to vaccinate (p < 0.001) than those who had not.  
Vaccinated participants were also more likely than unvaccinated ones to report that their GP and 
relatives thought they should get a booster (p < 0.001), and to know someone who had experienced 
an adverse reaction after having a booster (p < 0.001). 
Those who had vaccinated felt more vulnerable to tetanus, likely to acquire it and fearful of it than 
unvaccinated participants (p < 0.001). Perceived severity of and susceptibility to tetanus were also 
higher, albeit marginally, in vaccinators (p < 0.05), as was their reported tetanus-specific coping 
behaviour (p < 0.001). Similarly, perceived knowledge of the tetanus vaccine and trust in vaccine-
related advice (p < 0.001), perceived vaccine effectiveness (p < 0.01), anticipated regret and vaccine-
specific self-efficacy (p < 0.001) were higher in vaccinated participants. Conversely, those who had 
not received a booster in the past 10 years were more likely to report higher perceived control over 
tetanus (p < 0.001) and were more concerned about the contents of the vaccine (p < 0.01). 
Further, vaccinated participants were more likely to trust vaccination in general, to be in favour of it 
and to feel that vaccination in general and paediatric tetanus vaccines are important (p < 0.001). 
They were also more prone to trust the NHS (p < 0.01), the information about the tetanus vaccine 
provided by the latter (p < 0.001) and to a lesser extent by GPs (p < 0.01). Equally, trust in vaccine 
manufacturers and medications was more prevalent in those who had vaccinated. 
Finally, good perceived health (p < 0.001), optimism (p < 0.05), self-efficacy (p < 0.01), risk-taking (p 
< 0.01), information seeking (p < 0.05) and shared decision-making with relatives (p < 0.01) were also 
more common in vaccinators. Those who had vaccinated were also more likely to let their GPs make 
decisions about their own health (p < 0.05). Previous vaccine and health experiences were not 
correlated with tetanus vaccination. 
The assessed scales showed good internal reliability (α = 0.70 - 0.90) (Cortina, 1993; Kline, 1999), 
when excluding poorly correlated items (Field, 2013), which accounted for nearly half of tetanus and 
tetanus vaccine related items (see Table 7.3)  
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Table 7.2          Determinants of tetanus vaccination by vaccination status 
Explanatory variables Min Max Vaccinated Unvaccinated SE 95% C.I. t/X2 df 
1. Demographic, socio-economic and health 
variables 
  Total/Yes M SD SE Total/Yes M SD SE   Lower Upper     
Age (dummy: 1 = ≥65) 0 1 280/67 - - - 379/87 - - - - - - 0.085 1 
Eligible health condition (influenza) (dummy: 1 = yes) 0 1 280/64 - - - 379/86 - - - - - - 0.003 1 
Private health insurance (dummy: 1 = yes) 0 1 280/52 - - - 379/44 - - - - - - 6.271* 1 
Gender (dummy: 1 = female) 0 1 280/137 - - - 379/207 - - - - - - 2.089 1 
Marital status (dummy: 1 = in a partnership) 0 1 278/163 - - - 378/208 - - - - - - 0.848 1 
Income bands (1 = ≤£10,000 - 8 = ≥£100,000) 1 8 257 3.30 1.879 0.117 353 2.98 1.735 0.092 0.147 -0.602 -0.023 -2.122* 604 
Level of education (dummy: 1 = university degree) 0 1 274/120 - - - 368/126 - - - - - - 6.069* 1 
Setting (dummy: 1 = urban) 0 1 280/212 - - - 379/291 - - - - - - 0.101 1 
Ethnicity (dummy: 1 = white) 0 1 280/249 - - - 376/334 - - - - - - 0.002 1 
2. Practical barriers to tetanus vaccination                
Vaccine access (dummy: 1 = yes) 0 1 280/224 - - - 379/227 - - - - - - 30.135‡ 1 
Time to vaccinate (dummy: 1 = yes) 0 1 280/222 - - - 379/247 - - - - - - 15.634‡ 1 
Vaccine affordability (dummy: 1 = yes) 0 1 280/139 - - - 379/162 - - - - - - 3.089 1 
3. Social influence                
GP thinks I should vaccinate¥ 0 10 188 5.56 3.478 0.254 195 3.04 3.193 0.229 0.341 -3.188 -1.847 -7.383‡ 381 
Relatives think I should vaccinate¥ 0 10 188 4.54 3.350 0.244 227 2.51 2.821 0.187 0.308 -2.637 -1.426 -6.600‡ 366.547 
Peer experienced vaccine adverse reaction¥ 0 10 201 3.04 3.252 0.229 254 2.10 2.754 0.173 0.287 -1.502 -0.373 -3.264‡ 391.693 
4. Tetanus perceptions                
Vulnerability to tetanus 0 10 280 5.60 2.909 0.174 379 3.95 2.518 0.129 0.217 -2.078 -1.227 -7.627‡ 549.168 
Likelihood of tetanus  0 10 280 3.74 2.840 0.170 379 2.77 2.356 0.121 0.208 -1.375 -0.556 -4.630‡ 533.175 
Likelihood of tetanus (2) 0 5 241 2.57 0.804 0.052 286 2.33 0.738 0.044 0.068 -0.373 -0.107 -3.541‡ 492.575 
Fear of tetanus 0 10 280 4.46 3.281 0.196 379 3.54 2.914 0.150 0.247 -1.407 -0.438 -3.739‡ 558.863 
Susceptibility to tetanus 0 10 280 4.53 3.078 0.184 379 4.07 2.693 0.138 0.230 -0.913 -0.009 -2.003* 553.156 
Coping – tetanus 0 10 280 5.10 3.219 0.192 379 2.99 2.701 0.139 0.237 -2.576 -1.645 -8.898‡ 537.415 
Severity of tetanus 0 10 280 6.89 2.978 0.178 379 6.41 3.045 0.156 0.238 -0.944 -0.010 -2.005* 657 
Perceived control (over tetanus) 0 10 280 4.42 2.821 0.169 379 5.18 2.434 0.125 0.210 0.355 1.179 3.654‡ 547.937 
Perceived knowledge of tetanus 1 4 280 3.34 0.901 0.054 379 3.29 0.830 0.043 0.069 -0.178 0.092 -0.624 572.528 
Maladaptive coping – tetanus 0 10 280 4.85 3.127 0.187 379 4.64 2.935 0.151 0.238 -0.676 0.258 -0.878 657 
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Explanatory variables Min Max Vaccinated Unvaccinated SE 95% C.I. t / χ² df 
5. Tetanus vaccine perceptions     Total Mean SD SE Total Mean SD SE   Lower Upper     
Vaccine contents could be dangerous 0 10 280 2.91 2.831 0.169 379 3.61 2.895 0.149 0.226 0.249 1.136 3.064† 657 
The vaccine could transmit tetanus 0 10 280 2.68 2.728 0.163 379 2.85 2.577 0.132 0.208 -0.233 0.585 0.847 657 
Fear of vaccine¥ 0 10 280 2.20 2.909 0.174 379 2.62 2.902 0.149 0.229 -0.028 0.870 1.839 657 
The vaccine is painful¥ 0 10 244 3.23 3.018 0.193 252 3.52 2.916 0.184 0.266 -0.237 0.810 1.074 494 
I am allergic to the vaccine¥ 0 10 235 1.40 2.498 0.163 234 1.63 2.448 0.160 0.228 -0.221 0.677 0.999 467 
Vaccine effectiveness 0 10 280 7.50 2.142 0.128 379 6.97 2.435 0.125 0.182 -0.889 -0.173 -2.909† 657 
Perceived knowledge of vaccine (informed decisions) 0 10 280 6.43 2.927 0.175 379 4.83 3.087 0.159 0.238 -2.074 -1.139 -6.749‡ 657 
Self-efficacy – tetanus vaccination 0 10 280 7.84 2.364 0.141 379 6.71 2.812 0.144 0.202 -1.532 -0.739 -5.621‡ 646.072 
Anticipated regret of not vaccinating 0 10 280 7.40 2.805 0.168 379 6.28 2.938 0.151 0.227 -1.563 -0.671 -4.917‡ 657 
Do not know much about the vaccine (trust advice)¥  0 10 254 7.07 2.464 0.155 281 6.31 2.615 0.156 0.220 -1.194 -0.329 -3.458‡ 533 
6. Trust and disposition toward vaccination and stakeholders            
Trust in vaccination 0 10 280 7.98 1.845 0.110 379 7.41 2.264 0.116 0.160 -0.879 -0.250 -3.521‡ 650.682 
Vaccination part of healthy life-style 0 10 280 7.81 1.985 0.119 379 7.09 2.428 0.125 0.152 -0.552 0.046 -1.661 657 
Vaccination importance 0 10 280 8.06 1.990 0.119 379 7.11 2.654 0.136 0.181 -1.302 -0.591 -5.230‡ 656.851 
Vaccination favourability 0 10 280 8.62 1.600 0.096 379 7.87 2.237 0.115 0.149 -1.038 -0.451 -4.980‡ 656.346 
Trust in tetanus vaccine information – NHS¥ 0 10 261 7.84 1.867 0.116 307 6.93 2.426 0.138 0.180 -1.258 -0.549 -5.010‡ 560.592 
Trust in tetanus vaccine information – GP¥ 0 10 263 8.11 1.844 0.114 309 7.63 2.380 0.135 0.177 -0.830 -0.136 -2.732† 565.175 
Trust in vaccine manufacturers 0 10 280 6.44 2.304 0.138 379 5.82 2.555 0.131 0.190 -0.991 -0.244 -3.248‡ 631.568 
Trust in medications 0 10 280 7.62 1.752 0.105 379 7.23 2.176 0.112 0.153 -0.692 -0.090 -2.553† 652.170 
Importance of paediatric tetanus vaccine 0 10 280 8.57 1.671 0.100 379 8.02 2.272 0.117 0.154 -0.849 -0.246 -3.566‡ 656.989 
Trust in the NHS 0 10 280 7.46 1.858 0.111 379 7.04 2.286 0.117 0.162 -0.732 -0.098 -2.567* 650.989 
Trust in tetanus vaccine information - mass media¥ 0 10 239 5.38 2.778 0.180 288 5.08 2.694 0.159 0.239 -0.774 0.165 -1.273 525 
Trust GP (scale) 0 7 280 4.31 1.624 0.097 379 4.24 1.724 0.089 0.133 -0.328 0.192 -0.513 657 
Trust in tetanus vaccine information - social media¥ 0 10 224 3.51 2.977 0.199 269 3.08 2.686 0.164 0.258 -0.933 0.079 -1.658 454.217 
Trust in alternative medicine 0 10 280 4.92 2.597 0.155 379 4.72 2.485 0.128 0.200 -0.587 0.197 -0.976 657 
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Explanatory variables Min Max Vaccinated Unvaccinated SE 95% C.I. t / χ² df 
7. General perceptions and psychological constructs 
 
  Total/Yes M SD SE Total/Yes M SD SE   Lower Upper   
Understand how vaccination helps 0 10 280 7.96 1.973 0.118 379 7.66 2.250 0.116 0.165 -0.631 0.017 -1.861 638.013 
Does not understand how vaccination works 0 10 280 3.50 2.992 0.179 379 3.66 3.002 0.154 0.236 -0.301 0.627 0.691 657 
Autonomy of vaccination decisions 0 10 280 7.78 2.377 0.142 379 7.95 2.179 0.112 0.179 -0.173 0.528 0.994 657 
Perceived health 0 10 280 7.10 1.932 0.115 379 6.85 1.935 0.099 0.172 -1.054 -0.378 -4.158‡ 650.287 
Optimism 0 10 280 6.02 2.423 0.145 379 5.62 2.203 0.113 0.181 -0.754 -0.043 -2.201* 657 
Pessimism 0 10 280 4.79 2.841 0.170 379 4.74 2.598 0.133 0.216 -0.466 0.382 -0.193 569.845 
Self-efficacy 0 10 280 6.98 2.048 0.122 379 6.46 2.118 0.109 0.165 -0.837 -0.191 -3.124† 657 
Risk-taking 0 10 280 5.53 2.369 0.142 379 4.98 2.337 0.120 0.185 -0.917 -0.190 -2.987† 657 
Information seeking 0 10 280 7.08 2.207 0.132 379 6.71 2.369 0.122 0.181 -0.729 -0.016 -2.053* 657 
Information avoidance 0 10 280 4.22 2.698 0.161 379 4.22 2.558 0.131 0.206 -0.405 0.405 0.001 657 
Shared decision-making –  relatives 0 10 280 4.48 2.946 0.176 379 3.86 3.008 0.155 0.235 -1.081 -0.158 -2.635† 657 
Shared decision-making – GP 1 5 280 2.96 0.940 0.056 379 3.13 1.008 0.052 0.077 0.022 0.325 2.252* 657 
8. Previous  vaccine and health-related experiences (dummy: 1 = yes)             
Bad experience vaccines –  child  0 1 280/24 - - - 379/40 - - - - - - 0.722 1 
Scary health experience –  child 0 1 280/35 - - - 379/50 - - - - - - 0.069 1 
Bad experience HCP –  child 0 1 280/18 - - - 379/36 - - - - - - 2.018 1 
Positive experience healthcare – child 0 1 280/232 - - - 379/295 - - - - - - 2.534 1 
Bad experience vaccines – adult 0 1 280/23 - - - 379/34 - - - - - - 0.117 1 
Scary health experience – adult 0 1 280/43 - - - 379/46 - - - - - - 1.429 1 
Bad experience with HCP – adult 0 1 280/36 - - - 379/59 - - - - - - 0.959 1 
Positive experience healthcare – adult 0 1 280/227 - - - 379/299 - - - - - - 0.438 1 
 
SD = standard deviation; SE = standard error; df = degrees of freedom; df with decimals are adjusted to correct for the violation of the assumption of equal variances (Levene's Test 
for Equality of Variances was statistically significant). p-values were obtained using Chi-square tests (χ²) for categorical variables and Independent t-tests (t) for interval or 
continuous variables. *p < 0.05; †p < 0.01; ‡p < 0.001. ¥Variables with “I do not know” responses which were dichotomised for regression analysis. 
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7.3 Reliability analysis of socio-psychological scales 
Explanatory variables α Corrected Item-Total Correlation 
3. Social influence     
GP thinks I should vaccinate 0.80 0.653 
Relatives think I should vaccinate  0.653 
Peer experienced vaccine adverse reaction   < .30 
4. Tetanus perceptions     
Vulnerability to tetanus 0.80 0.642 
Likelihood of tetanus   0.595 
Fear of tetanus  0.549 
Coping - tetanus   0.511 
Susceptibility to tetanus  0.447 
Likelihood of tetanus (2)  0.376 
Severity of tetanus  < .30 
Perceived control (over tetanus)   
Perceived knowledge of tetanus   
Maladaptive coping - tetanus   
5. Tetanus vaccine perceptions     
Vaccine contents could be dangerous 0.70 0.580 
Fear of vaccine   0.561 
The vaccine could transmit tetanus  0.561 
The vaccine is painful  0.554 
I am allergic to the vaccine  0.426 
Vaccine effectiveness  < .30 
Self-efficacy – tetanus vaccination    
Perceived knowledge of vaccine (informed decisions)   
Anticipated regret of not vaccinating   
Do not know much about the vaccine, but trust advice    
6. Trust and disposition toward vaccination and stakeholders   
Trust in vaccination 0.90 0.828 
Vaccination part of healthy life-style  0.756 
Vaccination favourability  0.733 
Vaccination importance  0.732 
Trust in medications  0.690 
Trust in vaccine manufacturers  0.668 
Importance of paediatric tetanus vaccine  0.666 
Trust in tetanus vaccine information - NHS  0.639 
Trust in the NHS  0.606 
Trust in tetanus vaccine information – GP  0.595 
Trust GP (scale)  0.384 
Trust in tetanus vaccine information - mass media  0.331 
Trust in tetanus vaccine information - social media  < .30 
Trust in alternative medicine   
   
Continuous scales were used for reliability analyses. “I do not know” responses were coded as missing. 
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7.3.3 Regression analysis 
A logistic regression analysis was conducted to uncover the determinants of tetanus vaccination. All 
variables in Table 7.2 were included. Table 7.4 shows the associations between tetanus vaccination 
and the assessed variables. From the eight blocks of variables entered, only five blocks significantly 
contributed to the model (blocks 1-5) and only 10 variables were retained in the final model. None 
of the variables in blocks 6 (trust and disposition toward vaccination and stakeholders), 7 (general 
perceptions and psychological constructs) and 8 (previous vaccine and health-related experiences) 
significantly contributed to the model. 
The beginning model 0 (null model), showed that it was 57% accurate in predicting vaccination 
behaviour. The first model (M1) comprised participant characteristics and classified 59% of the cases 
correctly, an improvement in predictability of 2% compared to model 0. Although M1 was significant 
χ² (2) = 11.415, p<0.003, Nagelkerke R² was only 0.024, which indicates that the model is a poor fit of 
the data and able to explain less than 3% of the variance in behaviour. The second model (M2) 
comprised practical barriers and classified 62% of the cases correctly. The model was significant χ² 
(3) = 42.139, p<0.001, yet Nagelkerke R² was 0.085, representing a modest improvement compared 
to M1. Models 3 to 5 contained socio-psychological variables which significantly contributed to 
explain the variance in vaccination behaviour. The final model, M5, correctly classified 72% of the 
cases, 81% of unvaccinated participants and 59% of vaccinated ones. The model was significant χ² 
(10) = 165.426, p<0.001 and Nagelkerke R² was 0.305, which suggests that the model fits the data 
moderately well. None of the excluded predictors became significant when these were 
reincorporated into the model. 
Collinearity diagnostics showed that the item ‘trust in vaccination’ also had a VIF above 5 (6.02) 
(Bowerman and O'Connell, 1990), therefore, it was excluded from the regression analyses. 
Standardised residuals were examined to identify outliers. Less than 5% of the cases had 
standardised residuals above 2 and no more than 1% had absolute values higher than 3, thus there 
was no need to eliminate or transform cases. Cook’s distance statistics were lower than 1 (Cook and 
Weisberg, 1982), hence, all cases were retained.  
The final model showed that those who had private insurance and higher education (p < 0.1), those 
who felt it was easy to get to a vaccination site (p < 0.05), reported that their GP thought they should 
vaccinate against tetanus (p < 0.001), felt more vulnerable to tetanus (p < 0.01), reported tetanus 
coping behaviour (p < 0.001) and vaccine-specific self-efficacy (p < 0.05), and did not know much 
about tetanus but trusted the advice they had received (p < 0.05), were more likely to have had a 
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tetanus booster in the past 10 years.  Conversely, participants who felt more able to avoid tetanus 
without the vaccine (p < 0.05) and were more concerned about its contents (p < 0.001) were less 
likely to have received an adult tetanus booster.   
Table 7.4 Logit regression determinants of tetanus vaccination (N = 642) 
 M1 M2 M3 
Independent variables OR SE 95% C.I. OR SE 95% C.I. OR SE 95% C.I. 
Private health insurance  1.692** 0.228 1.083 2.643 1.711** 0.234 1.081 2.707 1.532* 0.241 0.955 2.457 
Education 1.443** 0.165 1.043 1.995 1.482** 0.170 1.063 2.068 1.512** 0.176 1.071 2.135 
Vaccine access      2.694‡ 0.185 1.877 3.869 2.729‡ 0.193 1.871 3.981 
GP thinks I should vaccinate         4.033‡ 0.216 2.642 6.157 
Vulnerability - tetanus             
Coping - tetanus              
Perceived control over tetanus             
Vaccine contents - dangerous             
Self-efficacy - tetanus vaccination             
Do not know much (trust advice)             
Predicted unvaccinated     89%       77%        87%   
Predicted vaccinated   19%    41%    35%  
Total predicted behaviour   59%    62%    65%  
Chi-square  11.415  30.724  45.279 
Nagelkerke R²     0.024      0.085 
  
  
   0.171 
  
  
         
 M4 M5   
Independent variables OR SE 95% C.I. OR SE 95% C.I. 
Private health insurance  1.464 0.252 0.894 2.396 1.617* 0.255 0.982 2.663 
Education 1.464** 0.184 1.020 2.101 1.408* 0.189 0.972 2.038 
Vaccine access  2.360‡ 0.199 1.598 3.485 1.673** 0.215 1.097 2.551 
GP thinks I should vaccinate 2.392‡ 0.242 1.488 3.844 2.349‡ 0.254 1.427 3.866 
Vulnerability - tetanus 1.105† 0.037 1.027 1.189 1.103† 0.039 1.023 1.190 
Coping - tetanus  1.161‡ 0.033 1.088 1.240 1.162‡ 0.034 1.086 1.243 
Perceived control over tetanus 0.897† 0.037 0.834 0.964 0.914** 0.038 0.848 0.985 
Vaccine contents - dangerous     0.889‡ 0.036 0.829 0.954 
Self-efficacy - tetanus vaccination     1.090** 0.038 1.012 1.175 
Do not know much (trust advice)     1.607** 0.194 1.098 2.352 
Predicted unvaccinated   82%    81%  
Predicted vaccinated   57%    59%  
Total predicted behaviour   71%    72%  
Chi-square  53.953  24.055 
Nagelkerke R²  0.265   0.305  
 
OR = odds ratio; SE = standard error; CI = confidence interval; *p < 0.1; **p < 
0.05; †p < 0.01; ‡p < 0.001. 
Note: the change in model fit as indicated by chi-square tests for each block of 
variables (M1-M5) was significant for all blocks (p < 0.05). 
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7.4 Discussion 
This study aimed to uncover the determinants of adult tetanus vaccination in the UK and to predict 
tetanus vaccination behaviour. The model that best fitted the data retained 10 items, all of which 
were significantly associated with vaccination uptake. Socio-economic factors explained only 2% of 
the variance in vaccination behaviour, perceived access barriers explained 6% and socio-
psychological factors explained 22% of vaccination behaviour. The final model predicted 72% of 
tetanus vaccination behaviour status overall, correctly identifying 81% of unvaccinated and 59% of 
vaccinated participants. To my knowledge, this is the first study evaluating and modelling the socio-
psychological predictors of adult tetanus vaccination in the UK and elsewhere.  
Results showed that only two socio-economic factors predicted tetanus vaccination, albeit weakly: 
education and private health insurance. Those who had a higher education degree were more likely 
to vaccinate. As previously discussed, the UK vaccination programme against tetanus is difficult to 
grasp and not widely advertised (NHS (3), 2014). It is, therefore, plausible that those who are more 
educated are also more able to access and understand adult booster recommendations. Participants 
who had private health insurance were also more likely to have had a tetanus booster. This may be 
because private health insurers actively advertise and offer travel vaccines (BUPA, 2015; AXA, 2015), 
which is further supported by the finding that an important self-reported motivation to vaccinate 
against tetanus is travel. 
Consistent with the above findings, perceived ease of access, tetanus coping behaviour and vaccine-
specific self-efficacy also predicted tetanus vaccination, further suggesting that personal 
resourcefulness and motivation may significantly influence tetanus vaccination uptake. Alternatively, 
these predictors may reflect a degree of confidence characteristic of those who have received a 
vaccine that is not consistently recommended, which vaccination-naïve individuals may not yet 
possess.  
This study also demonstrated that GPs significantly influence tetanus vaccination uptake and, 
consequently, most people receive a booster at a GP practice. However, my findings revealed that 
both the main indication and motivation to vaccinate was having had an injury. As hypothesised, 
these results suggest that tetanus vaccination in the UK is often used therapeutically rather than 
preventively, in both acute and primary care (Savage, Nash et al., 2007). 
Perceived vulnerability to tetanus was the only disease risk perception that predicted uptake. 
Interestingly, tetanus severity was not an important concern, yet it would not be unreasonable to 
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assume that participants who reported they would feel very vulnerable if they contracted tetanus 
could also have had in mind the potential seriousness of the disease. Understandably, tetanus 
likelihood did not predict vaccination. Participants’ low perceived risk of infection is consistent with 
tetanus incidence in the UK (HPA, 2014) and the low profile of this disease in official communication 
outlets. Low perceived likelihood of acquiring tetanus is also consistent with participants’ perceived 
control over the disease, a belief which was negatively associated with tetanus vaccination. 
Similarly, only one vaccine-related risk perception (concerns around the vaccine contents) was 
negatively associated with the uptake of tetanus boosters. Lack of concern around tetanus boosters 
is not surprising, as this vaccine has a good safety and efficacy profile (Miller, 1999; PHE (5), 2013), 
and has been successfully administered to infants, adolescents and adults for several decades (PHE 
(1), 2013). This notion is also supported by the propensity of vaccinators to trust a booster 
recommendation despite not knowing much about the vaccine.  
The results from this study are largely comparable with analogous findings from emerging research. 
A US study exploring the reasons for not having been vaccinated against tetanus, found that 74% of 
participants thought they only needed a vaccine when injured, 60% mentioned they did not need 
one because they were healthy, whereas others reported that either their doctor had not 
recommended it (51%), they did not know when to get it (37%) or they did not visit their doctor 
regularly (30%) (Johnson, 2008). Concerns about side-effects (22%), needles (20%), lack of insurance 
coverage (17%) or affordability (13%), and lack of effectiveness of the vaccine (13%) were mentioned 
by a minority of participants. Although this study only reported descriptive statistics and focused on 
unvaccinated participants, its findings resonate with those presented here; notably, the widespread 
belief that tetanus vaccines are administered after an injury, the lack of information and tetanus 
vaccine’s recommendation during medical consultations and fewer concerns around the vaccine. 
A large study conducted in Germany, where tetanus vaccines are also included in the adult routine 
vaccination schedule, found that higher socio-economic status, having statutory health insurance 
and receiving advice from a GP predicted vaccination uptake in multiple regression analysis, 
whereas, perceived general health, having an underlying chronic illness and feeling sufficiently 
informed about the risks of vaccination were not significant (Böhmer, Walter et al., 2011). However, 
this study also showed that gender (male), age (≤60) and living in less populated areas also predicted 
vaccination, whilst having private health insurance was non-significant. The differences between 
these findings and those reported here may be due to the size of the sample (over 20,000 people), 
which enables the detection of relatively small variances, but also to country-specific vaccination 
policies. Notably, in Germany, tetanus boosters are routinely recommended every 10 years and free 
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for all. Further, 90% of Germans are covered by the statutory health insurance, whilst those who 
have private insurance have to pay for the tetanus vaccine out-of-pocket, which may explain why 
having the latter did not predict vaccination (National Association of Statutory Health Insurance 
Funds, 2015). 
As stated in the previous chapter, lessons can be drawn from constructs which did not predict 
tetanus vaccination. First, this study suggests that structural barriers, such as access, as well as other 
related confounders which were not measured, may be more relevant to tetanus vaccination than 
disease or vaccine-specific perceptions. This is supported by the finding that those who vaccinated 
‘did not know much about the vaccine but trusted the advice they had been given’, and resonates 
with results from Chapter 4, which showed that tetanus vaccination appears to be a ‘non-decision’. 
It is indeed plausible that most people will readily accept to be vaccinated against tetanus due to 
their perceived threat of the disease, which may be heightened after an injury, and the safety and 
efficacy of the vaccine. The overriding effect of an imminent threat may also explain the lack of 
association between previous vaccine and health related experiences and tetanus vaccination. 
Although general constructs were not significant in multiple regression analysis, patterns of 
associations observed in bivariate analyses are worth mentioning. For example, tetanus vaccinators 
were generally more trusting of vaccination and vaccination stakeholders, yet there was no 
difference between vaccinated and unvaccinated participants regarding trust in GPs and tetanus 
information from mass and social media sources. This further confirms the lack of controversy 
around the vaccine, but also suggests that tetanus boosters are not exempt from general mistrust 
toward vaccines, vaccine manufacturers and providers.  
Consistent with findings from Chapter 6, the Protection Motivation Theory (Maddux and Rogers, 
1983) could also be useful in explaining tetanus vaccination behaviour, albeit preliminarily. This is 
because, as discussed above, the limited predictability of the model suggests the presence of 
endogenous variables which remain uncovered.  Sources of information (GP influence and trust in 
the received advice), threat appraisal (vulnerability to tetanus) and coping appraisal (perceived self-
efficacy, coping behaviour, concerns about vaccine contents and lack of access) predicted 
vaccination. The maladaptive coping behaviour “perceived control of influenza” was also negatively 
associated with vaccination.  
Unlike the instrument reported in the previous chapter, the survey evaluated here showed good 
face validity, but only moderate content and predictive validity. This is mainly due to the lack of 
evidence on tetanus vaccination behaviour, which often left me with more questions than answers. 
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However, the assessed constructs showed good internal consistency, in other words, they measured 
what they intended to measure. Moreover, several items which did not correlate well with other 
items were analogous to those reported in the previous chapter. These were perceived knowledge 
of tetanus and perceived knowledge of the vaccine both in relation with being capable of making 
informed decisions and trusting the received advice, maladaptive coping (tetanus), peer-experienced 
adverse reactions (vaccine), trust in tetanus vaccine information from social media and trust in 
alternative medicine. Bivariate analyses show that responses from vaccinated and unvaccinated 
participants were not significantly different for perceived knowledge of tetanus, maladaptive coping 
(tetanus), peer-experienced adverse reactions (vaccine), trust in tetanus vaccine information from 
social media and trust in alternative medicine. Thus, the exclusion of these four items from future 
surveys measuring tetanus vaccination should be considered. Puzzlingly, perceived tetanus severity, 
perceived control over tetanus, perceived vaccine effectiveness, self-efficacy and anticipated regret 
of not vaccinating were also poorly correlated with their respective constructs. Further research 
exploring the underlying latent constructs of tetanus vaccination behaviour is warranted. 
The present study indicates that over a third of adults have received a booster in the past 10 years, a 
sizeable number when taking into consideration that adult tetanus boosters are not routinely 
recommended in the UK.  For example, in the US, where tetanus boosters are routinely 
recommended, only 53% of over 65s and 64% in the 18-49 age bracket had received a booster in the 
same period of time (Williams WW, Lu P-J et al., 2014). Further, results show that a GP 
recommendation is the most important predictor of tetanus vaccination, yet around a third of 
vaccinators received a booster in acute healthcare settings as a result of an injury. In line with results 
from Chapters 4 and 5 and previous research (Savage, Nash et al., 2007), these findings suggest that 
people may be both over and under-vaccinated, depending upon whether or not they travel or have 
been injured (or both), and support the need for a simpler and standardised tetanus vaccination 
policy.  
7.4.1 Limitations of this study 
This study shares the methodological limitations discussed in the previous chapter. Additionally, the 
quality of the data may have been affected by recall bias, as some participants might not accurately 
remember events that occurred five or 10 years ago. Moreover, participants who had not vaccinated 
in the last 10 years were classified as “unvaccinated”, yet they may have still vaccinated in the past. 
Thus, it is possible that the magnitude of the effect of certain predictors (e.g. risk perceptions) may 
be even larger. Importantly, most of the employed socio-psychological measures were designed to 
capture current beliefs and perceptions. Given the potential time-lag between vaccination and 
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survey completion, it is possible that the factors driving tetanus vaccination decisions in a state of 
arousal (i.e. after an injury) may differ from those reported when cognitive processes are less 
influenced by emotion (Abelson, 1963). 
Lastly, I should note that the included variables accounted for a limited proportion of the variance in 
behaviour. Further testing is necessary to identify other predictors which could improve the 
predictive validity and reliability of the survey or to confirm the limited predictability of tetanus 
boosters in the examined policy context and elsewhere. However, as reported in the previous 
chapter, analyses using data from the US and France showed that most of the socio-psychological 
factors predicting tetanus vaccination in the UK, also predicted uptake in these countries. This 
demonstrates that the set of items identified here also predicts tetanus vaccination behaviour across 
different high-income settings. 
7.4.2 Summary and implications for further research 
This is the first study, to my knowledge, investigating the determinants of tetanus vaccination 
among the UK adult general population. This chapter showed that 10 survey items can predict 72% 
of tetanus vaccination behaviour. These items can be used to monitor the adequacy of the 
administration of tetanus boosters and address inconsistencies between policy and practice.   
An important proportion of the variance in vaccination behaviour, however, could not be explained 
by the variables evaluated in the survey. Thus, further research is required into the determinants of 
tetanus vaccination in adults. Additionally, the predictive validity and reliability of the variables 
which were associated with tetanus vaccination should be assessed across different time-points and 
settings.  
In the next and final chapter of my thesis, I will summarise my findings and discuss how the results 
from this study compare to those described in Chapter 6. I will also discuss the strengths and 
limitations of my work, propose areas for future research and consider the wider implications of my 
research for immunisation policy and practice. 
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8 General discussion 
Improving adult vaccination rates remains an important public health challenge. Recent efforts to 
understand the causes of inadequate vaccination uptake have shed light on the importance of socio-
psychological factors in vaccination decisions. These factors, however, are not robustly monitored 
nor used as a basis for effective service delivery and communication strategies.  
Building upon the existing knowledge-base, this programme of research set out to improve our 
understanding of the factors that drive or hinder adult influenza and tetanus vaccination in the UK, 
and to develop better instruments to capture them. Following an introductory section to set the 
context for my thesis (Chapter 1), the specific objectives (Section 1.6) were achieved through two 
reviews of the literature (Chapters 2 and 3) and four empirical studies: two qualitative explorations 
(Chapters 4 and 5) and two large survey studies (Chapters 6 and 7).  In this final section, I summarise 
the findings of my research under each of the four research aims outlined in Chapter 1, discuss its 
limitations, propose areas for further research and consider the implications of my work for 
immunisation policy. The chapter ends with concluding remarks. 
8.1   Summary of findings 
I began by conducting a narrative review in order to gain a general understanding of the socio-
psychological factors underpinning influenza vaccination in high-income countries, and to identify 
the most reported reasons for accepting or refraining from influenza vaccination (Chapter 2). This 
study showed that social influence, perceived disease and vaccine-related factors, habit, general 
attitudes toward health and vaccines, awareness and consideration, and to a lesser extent, practical 
barriers and motivators, and altruism, were frequently associated with influenza vaccination uptake. 
The review also revealed that published research on the socio-psychological determinants of 
influenza vaccination has proliferated in the US, but remains limited in the UK and other developed 
countries.   
Based on the findings from Chapter 2, in Chapter 3, I conducted a systematic review and meta-
analysis of four dimensions which have consistently predicted influenza vaccination behaviour: 
influenza risk perception, influenza vaccine risk perception, perceived vaccine effectiveness and 
reported physician recommendation. I originally intended to include reports on tetanus vaccination, 
but none of the three articles retrieved met the review’s inclusion criteria. The aim of this study was 
twofold: first, to better understand the effects of these dimensions on vaccination by focusing on 
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studies using similar measures and second, to evaluate the quality of such measures in order to 
inform my empirical research. My findings confirmed the hypothesised associations between the 
assessed dimensions and vaccination behaviour, and offered new insights into the importance of 
certain vaccine risk perceptions, notably post-vaccination influenza-like symptoms and unspecific 
side-effects. The review and meta-analysis also revealed that the existing evidence is highly 
heterogeneous, and highlighted the importance of using standardised and specific measures to 
attain a more accurate understanding of the magnitude of the relationships between vaccination 
behaviour and its determinants.  
Drawing on the findings from Chapters 2 and 3, in Chapter 4 I explored in depth the social and 
psychological factors that drive or hinder adult vaccination in the UK, specifically influenza and 
tetanus, and evaluated whether these factors were comparable between vaccines or vaccine-
specific.  This research showed that the uptake of influenza and tetanus vaccines was largely driven 
by people’s risk perception of influenza and tetanus (e.g. likelihood of contagion), respectively, and 
that a recommendation from a trusted healthcare professional influenced vaccination acceptance, 
particularly influenza. It also revealed that perceptions are largely age, disease and vaccine specific. 
For example, I found that attitudes toward childhood vaccines were often discordant with views on 
the adult versions of the same vaccines. Further, the tetanus vaccine was viewed as sufficiently 
tested and safe, whereas the changing composition of the influenza vaccine caused uncertainty and 
distrust.  
This study confirmed the importance of using specific measures to evaluate the public’s perceptions 
about diseases and vaccines. It also indicated that tetanus vaccination, which is not routinely 
recommended in the UK, is commonly administered and readily accepted, particularly after an 
injury, thereby suggesting that both acute and primary care healthcare professionals may not always 
be following current tetanus vaccination guidelines. 
To better understand vaccination decision-making processes and how these are shaped over time, 
together with market research experts from Ipsos MORI, I developed and tested a novel approach 
called journey to vaccination.  This approach allows the researcher and the participant to jointly 
build a timeline that captures salient events which led the participant to get or not to get vaccinated. 
It is designed to capture both psychological and social influences on vaccination decisions over time. 
Journey to vaccination also enabled me to assess the differences and similarities of vaccination 
journeys across vaccines and vaccination status, to narrow down on the most important vaccination 
and non-vaccination stages, touchpoints and triggers, and to evaluate whether vaccination decisions 
are driven by facts or intuition, or a combination of both.  
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This study showed that disease risk perceptions formed an “emotional prism” through which the 
vaccines’ costs and benefits were assessed; if a disease was deemed harmful, participants were 
inclined to minimise the drawbacks of the associated vaccine. A novel finding was that some 
childhood experiences influenced adult vaccination decisions. For example, a traumatic vaccine or 
needle-related event in childhood led to vaccination avoidance or refusal in adulthood, whereas 
mothers’ warnings about the dangers of tetanus in early age triggered tetanus vaccination uptake.     
My research also illustrated the role of specific healthcare touchpoints and triggers in vaccination 
uptake. For example, being diagnosed with an eligible health condition and receiving a vaccine 
recommendation from a healthcare professional, followed by regular vaccination reminders and a 
positive consultation experience, resulted in regular influenza vaccination, but only if these were 
accompanied by feelings of vulnerability (triggers). Similarly, both preventive and injury-led tetanus 
vaccination took place after accessing relevant NHS information (website) or receiving a 
recommendation from a healthcare professional, yet injury-led vaccination was often coupled with 
feeling concerned and vulnerable.  
Lastly, my findings indicated that while some decisions are based on scientific fact, vaccination 
behaviour is often driven by heuristics. A case in point is refusing to be vaccinated due to a perceived 
lack of susceptibility to influenza or unsubstantiated concerns about the vaccine’s safety. 
Drawing on the above findings, in Chapters 6 and 7 I reported the development and testing of two 
instruments designed to capture the determinants of influenza and tetanus vaccination in adults and 
to predict vaccination behaviour.  
Findings from Chapter 6 showed that it is possible to attain a compact set of variables which can 
highly predict influenza vaccination uptake (91% accuracy). This study confirmed my hypothesis that 
socio-psychological factors account for most of the variance in vaccination behaviour, over and 
above demographic, socio-economic, and health-related factors. It showed that social influences, 
and both disease and vaccine-related risk perceptions remain important determinants of influenza 
vaccination uptake. Additionally, I found that anticipated regret and self-efficacy, two psychological 
constructs seldom explored in the context of vaccination, predicted vaccination. Lastly, this study 
uncovered five novel psychological predictors of influenza vaccination: coping behaviour, perceived 
control over influenza, health decision-making preferences, scary experiences with vaccines or 
injections and scary health-related experiences during childhood. 
Findings from Chapter 7 showed a similar albeit less complete picture. Although, the final model was 
72% accurate in predicting vaccination behaviour, it fitted the data only moderately. Consistent with 
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findings from Chapter 6, socio-psychological variables also predicted the majority of the variance in 
tetanus vaccination behaviour. These results are promising, particularly when taking into 
consideration the lack of evidence on tetanus vaccination behaviour. However, further work is 
needed to uncover other predictors that may explain the variance in behaviour which the model 
could not account for.  
The studies reported in Chapters 6 and 7 demonstrated that socio-psychological factors are the most 
important determinants of vaccination behaviour. They also showed that while some socio-
psychological predictors are vaccine-specific, a considerable number of them are comparable across 
vaccines. For instance, five of the seven socio-psychological predictors of tetanus vaccination also 
predicted influenza vaccination: a GP recommendation, disease-specific coping behaviour, perceived 
control over the disease, concerns about the contents of the vaccine and vaccine-specific self-
efficacy. This suggests that while some of the factors influencing vaccination depend upon the 
particular characteristics of a given disease or vaccine (e.g. the severity of influenza), others may be 
deep-rooted in people’s belief system (e.g. “vaccines are dangerous”) or are an integral aspect of 
their personality (e.g. overconfidence), and hence span across vaccines. 
8.2 Strengths and limitations of the research 
This thesis has drawn upon a combination of methodologies, including two reviews of the literature 
and a meta-analysis, qualitative methods for depth and quantitative methods to gauge aspects of 
interest. Specific methodological issues of each study have been discussed in the respective 
chapters. Here I present the methodological strengths and limitations that are both substantive and 
relevant across multiple studies within this thesis.  
8.2.1 Existing evidence  
This thesis was built upon a methodologically disparate body of evidence in the case of influenza, 
and a very limited evidence-base in the case of tetanus. One of the most important gaps in the 
literature is that studies evaluating the link between socio-psychological factors and vaccination 
using multiple regression analysis are few and far between. Therefore, the extent to which a variable 
predicts vaccination in relation to other important variables is often unknown. The articles that do 
report these sort of analyses usually include a limited number of predictors (Chapman and Coups, 
1999; Weinstein, Kwitel et al., 2007; Irving, Donahue et al., 2009; Liao, Wong, et al., 2013), which can 
result in omitted variable bias, whereby the model compensates for the missing variables by over or 
underestimating the effect of the included variables.  
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Further, many studies focus on testing health behaviour models, which is indeed important from a 
theoretical perspective. Yet, few studies aim to predict behaviour, which is equally important, both 
for theory and practice. Studies which have aimed to predict behaviour, however, frequently include 
proxies of vaccination uptake such as past vaccination or intention to vaccinate as predictors, 
thereby artificially boosting the predictability of their model without necessarily explaining real-
world behaviours (Gené, Espínola et al., 1992; Chapman and Coups, 1999; Nexøe, Kragstrup et al., 
1999).  
Another methodological shortcoming is that a majority of studies use inappropriate measures (e.g. 
general perceived risk rather than individual’s own perceived risk) and small convenience samples, 
which calls into question the generalisability of their findings (Brewer, Chapman et al., 2007).  
My research has aimed to address these gaps by using a mixed-methods approach, employing 
appropriate measures, using a sample representative of the population of interest (UK adult 
population) and building multivariate models to explain and predict vaccination behaviour. However, 
my work is not without its limitations. These are described below. 
8.2.2 Study design and sample composition 
My empirical studies were cross-sectional and retrospective in their design. This has important 
implications with regards to the collected data. First, cross-sectional designs are restrictive to the 
point in time in which the data is collected. However, the journey to vaccination reported in Chapter 
5 provided an in-depth account of participants’ vaccination experience overtime, which partially 
remedied this limitation. Secondly, causality could not be demonstrated. Therefore, it is possible 
that some of the assessed socio-psychological factors may have taken root after vaccination (i.e. “I 
vaccinated, therefore the vaccine must be effective”). Time allowing, the directionality of key 
associations would have been examined using experimental designs. Lastly, the accuracy of 
participants’ reports about their perceptions and experience of tetanus vaccination may have been 
compromised due to the time lag between vaccination and interview and survey completion. 
The sample size of the qualitative studies reported in Chapters 4 and 5 was small (N =20) and 
purposive, albeit appropriate for research of this nature (Pope and Mays, 2006). Hence, findings may 
not be generalisable. Encouragingly, key results from my qualitative explorations (Chapters 4 and 5), 
both novel and previously reported, held true when tested quantitatively (Chapters 6 and 7). For 
example, a traumatic experience with vaccines or injections in childhood predicted adult influenza 
vaccination. This emphasises the importance of using in-depth methods of enquiry to better 
understand preventive behaviour and uncover important issues which need addressing.  
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Finally, since the quantitative studies aimed to examine the socio-psychological determinants of 
both influenza and tetanus vaccination, a sample which was representative of the UK adult 
population was considered an acceptable compromise. This is because it provided coverage data for 
tetanus vaccination, which was not publically available at the time of the submission of this thesis. 
However, focusing on populations at higher risk of developing influenza-related complications may 
have provided more relevant and actionable insights.  
8.2.3 Outcome measures 
Both my qualitative and quantitative studies relied heavily on self-report. Although using an 
objective outcome measure may have been preferable, this was not possible due to resource and 
time constraints, but also feasibility. In the case of influenza vaccination, for example, one in five 
vaccinated participants did not usually vaccinate at their GP practice. Therefore, their medical 
records would probably be incomplete. Discrepancies between actual and recorded tetanus 
vaccination are likely to be even more important, as only 61% of participants who vaccinated 
reported having received a tetanus booster at a GP practice. Encouragingly, self-reported 
vaccination has proven to be fairly accurate. US studies comparing self-reported to actual influenza 
vaccination found that self-reports matched medical records in approximately 90% of the cases 
(Hutchison, 1988; Nichol, Korn et al., 1990). These findings suggest that, in the absence of integrated 
vaccination records, the use of self-report may be a methodological strength rather than a 
limitation. 
8.2.4 Multi-partnered approach 
As stated in the beginning of this thesis, my research was undertaken in partnership with Sanofi 
Pasteur and two international market research companies: Ipsos MORI and Double Helix. Each 
partner brought different skills, which, in my opinion, enriched both the research process and 
outcomes.  
As with any collaboration, this joint endeavour was not without challenges. Although the design, 
data collection, analysis and write-up of the research was my responsibility, the other partners, 
particularly Sanofi Pasteur, were involved in each stage of the research and often challenged my 
ideas and assumptions. While frustrating at first, the majority of the times this had a positive effect 
on my command of the literature and the quality of the research. Moreover, managing a complex 
project and the expectations and needs of a diverse team provided me with valuable experience, 
which will undoubtedly prove useful in the future. 
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8.3 Further directions for the research 
Future research should endeavour to address the limitations of my work, but also to build upon it in 
a number of different directions. These are discussed below. 
8.3.1 Using cross-theoretical approaches 
Instead of adhering to a particular health behaviour theory, which may have restricted my findings, 
the design and analysis of my studies were underpinned by a number of theoretical approaches 
which were either well validated within influenza vaccination behaviour research or were considered 
relevant to a specific research aim. The overall aim of this thesis, however, was to identify the socio-
psychological determinants of influenza and tetanus vaccination, and predict vaccination behaviour. 
Therefore, my focus was on developing more effective in-depth forms of enquiry and testing 
relevant constructs rather than model testing.  
Among the employed theoretical approaches, however, I found Roger’s Protection Motivation 
Theory (Rogers, 1975; Maddux and Rogers, 1983) a useful lens to analyse vaccination behaviour. It is 
a model that allows the mapping out of information sources, personality variables and cognitive 
mediating processes, and their interplay, which hinder or lead to health protective behaviour. The 
PMT has been used to predict and understand other health behaviours such as sexual risk 
behaviours, alcohol abuse and dental hygiene (Milne, Sheeran et al., 2000). Puzzlingly, aside from 
the research reported here, no application of this model to vaccination has been published since it 
was first conceived. This may be explained by the similarities between the PMT and the Health Belief 
Model (Rosenstock, 1966), and the fact that the latter offers a simpler approach which may be easier 
to use and communicate (Prentice-Dunn and Rogers, 1986). The PMT, however, enables a more 
comprehensive understanding of the factors underlying preventive behaviours. Further testing of 
this model within the context of vaccination should be encouraged.  
Future studies borrowing constructs from the HBM and PMT to explain influenza vaccination 
behaviour, but also other protective behaviours, should also consider incorporating perceived 
likelihood of a health threat, perceived control of the threat and anticipated regret of not 
performing the assessed protective behaviour (e.g. vaccination) as part of threat appraisal or disease 
risk perception constructs. Research testing these and other novel factors, such as traumatic 
childhood experiences, across different vaccines and populations is needed to ascertain their 
generalisability. For example, my findings show that those who had had a negative experience with 
vaccines or injections during childhood were less likely to vaccinate against influenza, but not against 
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tetanus. A mixed-methods study could investigate whether this link is specific to influenza 
vaccination in the UK or whether it is replicable across other vaccines (e.g. HPV, hepatitis, etc.) and 
countries, and the reasons why. 
Similarly, heuristics and biases (Meehl, 1954; Simon, 1957; Kahneman and Tversky, 1973) and 
customer journey mapping (Shostack, 1984; Bitner, 1992; Kingman-Brundage, 1992), the two 
theoretical approaches underpinning journey to vaccination, allowed me to uncover the importance 
of recent and past emotionally charged experiences on vaccination decisions, and to identify the 
points within the vaccination pathway or journey which require attention. Journey to vaccination, 
however, requires further exploration to ascertain its value across different contexts and health 
behaviours. 
8.3.2 Measuring and predicting vaccination behaviour 
Due to the methodological heterogeneity and quality of the existing evidence, it would be unwise to 
provide conclusive recommendations regarding measures and study design based on findings from 
Chapters 2 and 3. However, some important lessons can be drawn from previous research and 
Chapters 6 and 7.  
First, measures concerning the individual (e.g. influenza can make me seriously ill) are more likely to 
represent participants’ own perceptions and circumstances, hence these should be prioritised over 
general measures (e.g. influenza is a serious disease).  
Secondly, vaccine and disease-specific measures are more predictive of vaccination behaviour than 
generic measures [e.g. vaccine-specific self-efficacy (I can get an influenza vaccine if I choose to) vs. 
generic self-efficacy (I am confident I can achieve anything I set my mind on)]. Thus, their use should 
be encouraged.  
Thirdly, in order to uncover the true importance of the factors influencing vaccination and to predict 
this preventive behaviour, multiple regression analysis and, when possible, evidence-based 
hierarchical approaches should be employed.   
Fourthly, dichotomising scales when analysing data should be avoided, as this strategy may inflate 
results. Lastly, in order to truly understand and predict vaccination behaviour, and reliably monitor 
changes over time, researchers should endeavour to employ tools comprised of all the constructs 
(and items) which have consistently predicted uptake. 
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Importantly, findings from clinical trials testing long-lasting universal influenza vaccines, capable of 
attacking a part of the virus that changes little from year to year, have invigorated the field (Gilbert, 
2013). I anticipate that once such a product becomes available, some of the predictors revealed in 
this thesis may no longer be relevant and new ones could emerge. Exploratory research evaluating 
changes in perceptions toward novel influenza vaccines should be encouraged. 
8.3.3 Evaluating the validity and reliability of the employed research instruments in other 
contexts 
As stated in Chapter 1, this thesis is part of a large-scale multinational programme of research aimed 
at developing instruments to explain and predict vaccination uptake in different contexts. The 
qualitative studies reported here were replicated in five additional countries:  the US, France, Brazil, 
India and China. Preliminary analyses of the qualitative data-set indicate that although there are 
similarities between countries, key drivers and barriers of adult vaccination are context-specific, and 
there are important differences between developing and developed settings. Due to resource 
constraints, the survey-tool was originally tested in the UK, the US and France. Encouragingly, 
although initial analyses also show country-specific differences, the predictability of the tools and 
the determinants of vaccination are largely comparable across these three settings. Given these 
promising results, additional funding was approved to test the influenza instrument in Mexico 
(2014/2015) and China (2015/2016).  
Based on these preliminary results, for certain countries the proposed instruments may require the 
addition of new items which capture specific practical barriers, religious beliefs or cultural traits. 
Therefore, future research exploring whether the findings from this thesis hold true in other 
contexts and across vaccines, and to what extent, is warranted.  
8.3.4 Employing experimental and interventional study designs to test the findings 
This thesis was concerned with understanding and predicting adult vaccination behaviour in the UK. 
The next step is to design and test cost-effective interventions to change behaviour. I propose two 
directions for future research in this area. First, since correlations cannot be interpreted as causal 
effects (i.e. it is not known whether a particular perception caused the vaccination behaviour or vice 
versa), experimental designs should be considered to explore whether specific modifying predictors, 
typically in isolation, can lead to a change of behaviour. Experiments could investigate, for example, 
whether vaccine-specific self-efficacy or coping behaviours lead to vaccination or vice versa.  
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Developing interventions using well-designed behavioural randomised controlled trials (RCTs) should 
also be encouraged. This is because RCTs enable effective control of sources of bias (blinding) and 
unknown confounders (randomisation), thereby enhancing the degree of confidence in the results. 
My findings indicate that future interventions could evaluate the effect of tailored risk 
communications (according to age and health status) and different recommendation approaches on 
vaccination uptake. For instance, emerging evidence on how doctors initiate a paediatric vaccine 
recommendation showed that parents are more likely to resist the advice if the doctor uses a 
participatory (e.g. “What do you want to do about shots?”) rather than a presumptive initiation 
approach (e.g. “Well, we have to do some shots”) (Opel, Heritage et al., 2013). Future research could 
test the replicability of these findings on adult vaccination and further explore the role of health 
decision-making preferences on doctor-patient communication about vaccines.   
Interventions around tetanus vaccination should focus on addressing the gap between national 
recommendations and practice. Developing clearer immunisation policies and guidelines, and 
ensuring these are adequately implemented, should be prioritised. 
8.4 Wider implications of my research 
Despite the limitations of this body of work, I believe my findings have a number of implications for 
research, immunisation policy and practice. I discuss these below. 
8.4.1 Exploring wider transferability 
The wider usability of my research has started to become apparent. In addition to the roll-out of the 
influenza vaccine instrument (Chapter 6) in Mexico and China, my supervisor and I have been asked 
by Sanofi MSD (a sister company of Sanofi Pasteur) to be involved in the development of a similar 
tool to identify the determinants of the uptake of the newly introduced Herpes Zoster or shingles 
vaccine in the UK.  We are, of course, testing key findings from the present research. Sanofi MSD 
became aware of my research through a publication reporting findings from Chapter 2, a positive 
indication of the relevance of this work. I was also approached by a US research group interested in 
using the journey to vaccination (Chapter 5) as part of a longitudinal qualitative study exploring the 
drivers and barriers of the human papilloma virus vaccine. Lastly, US and UK senior scientists 
conducting HIV pre-exposure prophylaxis (PrEP) trials have asked me to provide advice on the 
development of instruments to uncover the determinants and predict the uptake of this novel 
preventive approach.  
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8.4.2 Improving surveillance 
Although efforts to understand and address vaccine hesitancy and its determinants are gathering 
pace (NVAC, 2013; WHO (2), 2014), thus far, socio-psychological factors are not routinely monitored 
at a national level. An exception is the US, which, for the past two decades, has recorded the main 
reason why Medicare beneficiaries (public health insurance program for ≥65s and younger people 
with certain disabilities or chronic illness) have not vaccinated for each vaccination they have not 
received (CDC, 2004). Yet, as highlighted in this thesis, this sort of explicit and one-sided enquiry, 
although easier to undertake, can lead to erroneous conclusions. Governments’ lack of 
understanding of the socio-psychological factors underpinning vaccination may partly explain why 
influenza vaccination rates have remained stubbornly below the minimum 75% coverage 
recommended by the WHO and the Council of the European Union (56th World Health Assembly, 
2003; Council of the European Union, 2009), particularly in younger high-risk groups. 
I argue that national strategies to sustain and increase vaccination uptake should be built upon an 
evidence-based understanding of the beliefs and attitudes of the public and healthcare professionals 
toward vaccination, and should include longitudinal evaluation of their impact, as others too have 
proposed (Cairns G, MacDonald L et al., 2012). As noted in Chapter 1, failure to recognise the 
importance of these aspects in vaccination decisions, and to act upon it, have great health-damaging 
potential, particularly after the emergence of novel virus strains or vaccination scares (Wakefield, 
Murch et al., 1998; Bone, Guthmann et al., 2010).  
Through an evidence-based, mixed-methods approach, this thesis has demonstrated that socio-
psychological factors are not only important predictors of vaccination uptake, but they explain most 
of the variance in vaccination behaviour. My research also showed that it is possible to build 
predictive and insightful models with a relatively small number of variables, some of which were 
comparable across vaccines, thereby making data collection and analysis simpler and cheaper (see 
Box 8.1).  
As a first step, national immunisation surveys and policy evaluation tools should include the 
vaccination predictors reported in this thesis, and make additions or adjustments over time 
depending upon resource availability and fluctuations in vaccination sentiment. A second and 
equally important step is to engage in a multi-level dialogue, from the GP practice to national 
campaigns, aimed at addressing people’s concerns or misconceptions around vaccines, and in turn, 
preventing morbidity and mortality. 
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Box 8.1            Predictors of influenza and tetanus vaccination  
   
Vaccination predictors Influenza Tetanus 
Age   
Eligible health condition    
Private health insurance    
Marital status    
Education   
Vaccine access    
GP thinks I should vaccinate   
Likelihood of catching the disease   
Vulnerability  to the disease   
Severity of the disease (bed days)   
Disease-specific coping behaviour   
Perceived control over the disease   
Not knowing much about the vaccine but trusting advice    
Vaccine contents – dangerous   
Anticipated regret of not vaccinating   
Vaccine-specific self-efficacy   
Shared decision-making  –  GP   
Scary vaccine experience  –  child   
Scary health experience  –  child   
 
8.4.3 Tailoring risk communications and improving the consultation experience 
8.4.2.2 Evidence-based risk communications 
An important body of knowledge has demonstrated that communicating risks effectively is a 
challenging endeavour, particularly in an era of hyper-connectivity and readily available information. 
This is because the way we make decisions depends upon our ability to understand the risk and 
benefits of a given option, how we feel about a particular information source, our awareness of the 
limitations of our knowledge, the extent to which our interpretation of information is influenced by 
emotional factors, among other aspects (Berry, 2004).  This is consistent with findings from Chapter 
5, which showed that vaccination decisions are often driven by heuristics rather than rational 
thinking, possibly due to both cognitive ability and affective factors. For example, most unvaccinated 
interviewees did not feel at risk of catching influenza or developing complications, regardless of their 
current health status, and some were deterred from protecting themselves against influenza due to 
an unrelated traumatic experience during childhood.  
Consequently, risk communications at a national (i.e. mass campaigns) and local level (i.e. 
consultation) aiming to address prevalent beliefs and attitudes toward vaccination should not only 
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present facts in a way that takes into account our cognitive limitations, but should also harness the 
power of emotional appeals. Importantly, risk communicators ought to adopt evidence-based 
approaches which have proven effective, such as providing population data alongside real-life 
stories, using data on absolute risk rather than relative risk, presenting information in pictographs 
which are less cognitively demanding, etc. (Berry, 2004; Visschers VH, Meertens RM et al., 2009). 
Based on my findings, I provide below recommendations for developing and delivering more 
effective communications about influenza and tetanus, and their corresponding vaccines. 
8.4.2.3 Bridging the gap between the perceived and actual risks of influenza 
As demonstrated throughout this thesis, risk perceptions about both influenza and tetanus are often 
misaligned with the real risks posed by these diseases. In the case of influenza, I argue that risk 
communications ought to evolve from generic messages about its severity, such as those used in 
Public Health England’s campaigns (NHS, 2015), toward tailored messages which take into 
consideration the needs and characteristics of different at-risk populations. For example, influenza-
related complications in young diabetics may differ from those prevalent among individuals 
undergoing cancer treatment or elderly people. Therefore, specific messages will allow individuals 
and their families to better identify risks that are relevant to their condition and, in turn, may 
compel them to take preventive measures (Brewer and Hallman, 2006). A possible conduit for these 
communications is the tried and tested system of vaccination reminders. Reminders have been 
effective in increasing vaccination rates in primary care practices in the UK and elsewhere, yet their 
utilisation remains insufficient, particularly for younger eligible patients (Thomas, Russell et al., 
2010; Dexter, Teare et al., 2012).  
Tailored messages could also be delivered in combination with general communications based 
around key vaccination determinants (Chapter 6). For example, a national campaign could focus on 
the likelihood of catching influenza, its severity (number of bed-days, morbidity and mortality for 
different at-risk populations), the limited effectiveness of avoidance strategies (e.g. taking vitamins, 
or evading crowds) and potential feelings of regret for not having vaccinated. 
In line with the above implications, and as discussed in Chapter 6, decision-making styles should be 
taken into consideration when designing immunisation communications; while those who are more 
prone to delegate health decisions to their GP may not require additional information, some risk 
communication efforts are likely to be better spent on those who prefer to make decisions about 
their heath independently. Further, with increased information availability and discerning capability, 
strategies to engage with information-seeking individuals that take into account the prevalence of 
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heuristic judgement in vaccination decisions, should be a priority. One such strategy could be the 
provision of internet-based information about the influenza risks vs. the vaccine risks using well-
established framing tactics (Halpern, Blackman et al., 1989; Gurm & Litaker, 2000); for example, 
employing a negative frame to present the risks of contracting influenza (e.g. 20% of people (or 1 in 
5) contract influenza every year) and a positive frame for risks associated with the vaccine (e.g. 
999.999.999 out of 1,000,000 people will only present mild symptoms such as soreness and redness 
in the arm after getting the vaccine).    
8.4.2.4 Employing a combination of trusted and effective information channels  
Trust in the NHS and widespread use of its information resources should be harnessed to support 
the delivery of tailored vaccination messages in the UK, alongside a more extensive use of social 
media channels. These messages could be reinforced during consultations or vaccination-related 
correspondence.  
My research also showed that mass media is an important source of information about diseases and 
vaccines, particularly influenza (Chapters 4 and 6). Thus, as suggested by May (May, 2005), in order 
to avoid sensationalism or misrepresentation of the truth, the scientific and public health 
community should recognise the importance of educating science reporters and presenting facts in a 
manner that will be understood and remembered by the intended audiences. 
Although mass-media campaigns and official information outlets are important, the existing 
evidence-base and findings from this thesis show that the role of primary care healthcare 
professionals is pivotal in sustaining vaccination rates. Vaccine-hesitant parents, for example, report 
that reassurance and information from their child’s doctor is the main reason behind their decision 
to vaccinate their child (Gust, Darling et al., 2008). More generally, studies have demonstrated that 
patient-doctor interactions and health outcomes improve when patients are regarded as experts of 
their own condition and are given a voice to express their fears, preferences and expectations 
(Stewart, 1995). However, in a context of reduced public spending GPs and nursing staff have limited 
time and resources to address specific concerns. Given that vaccination is one of the most successful 
and cost-effective public health interventions (WHO, UNICEF et al., 2009), increased investment in 
the provision of training, adequate communication materials and decision aids to enhance patient-
doctor communication are urgently needed and much deserved.  
Efforts to develop more effective and cost-effective communications could also benefit from 
synergistic strategies to deliver vaccination messages. For example, the importance of vaccination 
could be communicated as part of a wider health plan tailored around specific health conditions. 
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Since very few people appear to be familiar with the adult immunisation schedule, as described in 
Chapter 4, a key aspect of such communications should be introducing the concept of life course 
vaccination in the public’s mind (Gusmano and Michael, 2009). 
8.4.2.5 Addressing vaccine risk perceptions 
Concerns about vaccines remain a significant challenge for immunisation programmes. Yet, 
communication campaigns seldom address prevailing vaccine risk perceptions such as the belief that 
the vaccine causes influenza.  People’s anxieties around vaccine safety, both regarding its 
infectiousness and toxicity, ought to be addressed explicitly through clearer communication from 
trusted sources (e.g. NHS, GPs) about what to expect after being immunised, as these perceptions 
question the very purpose of influenza vaccination and can seriously thwart immunisation efforts.  
My research has demonstrated that although some vaccine risk perceptions are more pervasive than 
others, there is value in unpacking and addressing specific concerns deterring individuals from 
vaccinating (i.e. is it fear of pain? influenza-like symptoms? Or vaccine contents?). This could be 
achieved using short screening tools before or during the consultation and engaging in relevant 
dialogue to tackle specific issues.  
Given the lasting effect of negative past experiences with needles, support to help GPs to make all 
childhood encounters with injections as easy as possible may be a good investment in the success of 
vaccination programs in the future. Furthermore, the epidemiological and societal impact of the 
newly introduced paediatric influenza vaccine should be monitored closely, as it can affect future 
adult vaccination rates.  Aversion to needles in adults should be elicited and talked about openly and 
in an unprejudiced manner, also as part of the consultation or a vaccination reminder, but it could 
also be incorporated into mass communication strategies.  
Although vaccine effectiveness was not a predictor of vaccination uptake, it was associated with 
vaccination in bivariate analyses and has been linked to vaccination acceptance in previous studies. 
Therefore, it is advisable that the advantages of newer vaccines, such as quadrivalent influenza 
vaccines that provide broader coverage, are emphasised at local and national levels. It should also 
be stressed that although vaccination may not always prevent influenza due to the potential 
mismatch between the vaccine and circulating virus strains, it can reduce the risk of more serious 
outcomes. 
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8.4.3.1 Improving tetanus vaccination policy, communications and training  
My thesis revealed that approximately 30% of the UK population has received an adult booster, a 
sizeable figure for a vaccine which is not currently included in the UK routine adult immunisation 
schedule. Moreover, around 30% of vaccinators received a booster after an injury. Tetanus 
vaccination appears to be recommended by GPs and emergency doctors alike to protect individuals 
from acquiring the disease after a potentially risky injury. However, as discussed in Chapter 7, 
vaccination may not boost immunity in time to prevent infection (Porter, Perkin et al., 1992). 
Instead, Public Health England recommends a course of tetanus immunoglobulin (PHE (5), 2013). A 
clearer adult tetanus immunisation policy should be considered, alongside an effective 
dissemination plan for healthcare professionals – as current national tetanus immunisation 
guidelines appear not to be followed in practice. Additionally, the vertical integration of vaccination 
records is advisable, particularly when immunisation is taking place in both tertiary and primary care 
settings. 
My findings also showed that, unlike influenza vaccination, tetanus vaccination is readily accepted 
once it has been recommended by a healthcare professional. This is because of the potential 
seriousness of the disease, but also the perceived efficacy and safety of the vaccine. Further, in some 
cases, vaccination is actively requested by individuals who feel they may be at risk of acquiring 
tetanus. A simpler, standardised tetanus immunisation policy (e.g. one adult booster for all adults) 
may lead to better informed vaccination decisions, help to minimise under and over-vaccination and 
reduce unnecessary A&E visits.  
8.4.4 Learning from well-accepted vaccines 
Efforts to develop a universal influenza vaccine, which could see the implementation of a long-
lasting and more efficacious product in the next decade (Gilbert, 2013), can draw valuable lessons 
from tetanus vaccination. This is because the characteristics and schedule of such product may 
resemble those of tetanus boosters. On one hand, concerns around effectiveness and side-effects 
are likely to lessen due to a more stable (and tested) vaccine composition, which may in turn 
increase uptake. On the other hand, monitoring coverage, keeping records and developing a 
reminder system for long-lasting vaccines may prove challenging. If and when the universal influenza 
vaccine becomes available, these potential barriers should be considered in cost-effectiveness 
analyses and implementation research. 
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8.4.5 Translating research into practice 
A key goal of this multidisciplinary collaboration was to propose barometer-style monitoring tools 
which can be used by academics, policy-makers and industry to track vaccination sentiment and 
predict uptake. Results from this research were presented to the CEO of Sanofi Pasteur (November 
2014) and disseminated to its affiliates worldwide. A second output currently under development is 
an influenza vaccine simulator, which seeks to translate findings from Chapter 6, as well as those 
from France and the US, into an interactive and user-friendly internet-based tool (see simulator draft 
in Appendix 13). The simulator will enable vaccination stakeholders to modify predictors and 
visualise in real-time the consequent changes in vaccination rates. This tool aims to improve 
knowledge and facilitate immunisation policy prioritisation, and could also be used by clinicians to 
understand and predict patients’ vaccination behaviour. 
8.5 Concluding remarks 
The studies within this thesis collectively improve our understanding of the importance of socio-
psychological factors on adult vaccination behaviour, specifically influenza and tetanus. My research 
has shown that using an evidence-based systematic approach, it is possible to explain and predict 
vaccination behaviour. Importantly, my findings have demonstrated that socio-psychological factors 
are more predictive of adult vaccination behaviour than other factors. This sole finding warrants 
their inclusion in all aspect of immunisation policy. 
Although my research is not without its limitations, I believe it has a number of implications for 
policy and practice, and ultimately for improving public health. Monitoring public sentiment by 
including socio-psychological variables in national immunisation surveys could enable decision-
makers and practitioners to improve their understanding about vaccination behaviour, predict 
uptake, develop better communication strategies and more effective interventions, and evaluate 
immunisation policies. These efforts could, in turn, improve at best or sustain at worst current 
vaccination rates. Due to the high mobility of European citizens, a concerted multi-national strategy 
in this direction could bring a huge return on investment. 
Lastly, on a personal level, carrying out this research as part of a multi-disciplinary team has been an 
invaluable experience, which has not only improved my knowledge, research and management skills, 
but has also strengthen ‘softer’ skills such as communication, cooperation and forbearance. I hope 
that beyond the academic and translational initiatives which have arisen from this work, my 
research can contribute to improve immunisation programmes and vaccination experience.  
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Appendix 1          Permission to republish 
 
On 2/3/14 3:04 AM, "Wheelock, Ana" <a.wheelock@imperial.ac.uk> wrote: 
 
Dear Scott, 
 
As promised, please find below a link to our article. I hope you'll find it useful! 
http://bmjopen.bmj.com/content/4/1/e004279.full.pdf+html 
 
All the best, 
 
Ana 
 
-----Original Message----- 
From: Scott Davis [mailto:sdavis@prophet.com] 
Sent: 23 August 2013 16:39 
To: Wheelock, Ana 
Cc: Michael Dunn; Amanda Nizzere 
Subject: Re: A request from Imperial College London 
 
Hi Ana - it would be our pleasure to grant you permission to use the Brand Touchpoint Wheel 
referenced below.  We would love to see a copy of the article when it is published. 
 
Best, 
 
Scott 
 
Scott M. Davis 
Chief Growth Officer, Prophet 
Tel: (312) 878-4934 
Cell: (312) 296-7756 
Email: sdavis@prophet.com<mailto:sdavis@prophet.com> 
Visit our new blog, theinspiratory.com<http://theinspiratory.com> 
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www.prophet.com<http://www.prophet.com/> 
twitter.com/scottdavisshift 
 
From: "Wheelock, Ana" a.wheelock@imperial.ac.uk<mailto:a.wheelock@imperial.ac.uk 
Date: Tue, 20 Aug 2013 06:03:57 -0700 
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you be able to grant us permission to cite your work or would it be best to contact your publisher 
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Figure 1. The Brand Touchpoint Wheel. Source: Davis & Dunn (2003) 
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Ana Wheelock 
Researcher 
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Floor Imperial College London Medical School Building St Mary's Campus  
Norfolk Place London, W2 1PG 
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Appendix 2          Ethic approval qualitative studies (Chapters 4 and 5) 
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Appendix 3          Ethic approval survey studies (Chapters 6 and 7) 
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Appendix 4          Narrative review themes definition 
 
Social influence 
Change in vaccination behaviour in response to advice or pressure from a healthcare professional, a 
relative or peer.  
Perceived disease-related factors 
Perceived risks of influenza, including the likelihood of catching the disease, the perceived 
constitutional vulnerability to it and its perceived severity. 
Perceived vaccine-related factors 
Perceived harm of the influenza vaccine, including post-vaccination illness, pain and the safety (or 
lack thereof) of its contents.  
Habit  
Regular vaccination behaviour, which may occur consciously or unconsciously. 
General beliefs and perceptions toward health and vaccines 
Beliefs and perceptions about health behaviours or vaccines which affect influenza vaccination 
uptake, such as believing that preventing illness is important or that vaccines are harmful. 
Awareness and lack of consideration 
Awareness (or lack thereof) of being at risk of developing influenza-related complications or knowing 
when to vaccinate. Lack of consideration refers to not thinking about or not remembering to 
vaccinate. 
Practical barriers and motivators 
Real or perceived everyday obstacles and enablers of vaccination, such as not vaccinating due to lack 
of time or vaccinating because it was offered at work. 
Altruism 
Vaccinating or not vaccinating in order to protect others. 
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Appendix 5          Systematic review search terms 
No Search terms Hits 
1 ((adult$ or elderly or older or 65$ or chronic disease or chronic illness or patient$ or particip$ or 
employee$ or individual$ or coverage) adj5 (vaccin$ or immuni$ or booster$ or behavio$3 or 
psychosocial or determinant$ or predictor$ or factor$ or effect$ or decid$3 or decision$ or 
decision-making or (decision adj making) or belief$ or perception$ or preference$ or opinion$ or 
attitude$ or accept$7 or choice$ or reason$ or action$ or uptake or adherence or knowledge or 
understanding$ or trust or barrier$ or risk$)).ti,ab. 
 
2,039,695 
2 (Adult/ or Aged/ or Aging/ or At Risk Populations/ or Chronic Illness/ or Chronic Disease/) and 
(Behavior/ or Decision Theory/ or Decision Making/ or Preferences/ or Perception/ or Attitudes/ 
or Attitude/ or health belief/ or Awareness/ or Knowledge/ or Adult Attitudes/ or patient 
decision making/ or Patient Preference/ or Prevention/ or Health Behavior/ or Health Care 
Seeking Behavior/ or Trust/ or Risk/ or Risk Factors/ or Risk Perception/) 
 
833,207 
3 1 or 2 
 
2,664,371 
4 ((((influenza or flu or pneumococcal or diphtheria or pertussis or tetanus) adj5 (vaccin$ or 
immuni$ or booster$)) or Hib or Tdap or Td or TT) adj5 (behavio$3 or psychosocial or 
determinant$ or predictor$ or factor$ or effect$ or decid$3 or decision$ or decision-making or 
(decision adj making) or belief$ or perception$ or preference$ or opinion$ or attitude$ or 
accept$7 or choice$ or reason$ or action$ or uptake or adherence or knowledge or 
understanding$ or trust or barrier$ or risk$)).ti,ab. 
 
18,551 
5 (Influenza Vaccines/ or Pneumococcal Vaccines/ or Diphtheria-tetanus-pertussis vaccine.de. or 
Pertussis Vaccine/ or Pneumococcal/ or Tetanus toxoid.de.) and (Behavior/ or Decision Theory/ 
or Decision Making/ or Preferences/ or Perception/ or Attitudes/ or Attitude/ or health belief/ 
or Awareness/ or Knowledge/ or Adult Attitudes/ or patient decision making/ or Patient 
Preference/ or Prevention/ or Health Behavior/ or Health Care Seeking Behavior/ or Trust/ or 
Risk/ or Risk Factors/ or Risk Perception/) 
 
6,068 
6 4 or 5 
 
22,943 
7 3 and 6 
 
10,123 
8 (healthcare worker$ or HCW$ or doctor$ or general practitioner$ or GP$ or (medical adj3 
personnel) or (medical adj3 staff) or nurse$ or healthcare personnel or HCP or pregnan$ or 
mothers$1 or fathers$1 or parent$3 or guardian$ or family, or child$ or baby or babies or 
infant$1 or pre-school or toddler$1 or adolescent$ or HPV or human papilloma, or hepatitis A or 
hepatitis B or zoster or meningococcal or travel or measles or MMR).ti,ab. 
 
5,889,154 
9 7 not 8 
 
5,884 
10 limit 9 to abstracts 
 
5,279 
11 limit 10 to human 
 
4,891 
12 remove duplicates from 11 3,114 
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Appendix 6          Consent form – interviews 
 
Socio-psychological determinants of adult routine immunisation 
 
Investigator: Nick Sevdalis 
(Research Information Sheet must accompany this form) 
 
 
 
 
1. I confirm that I have read and understand the research 
information sheet for the above study and have had the 
opportunity to ask questions which have been answered fully. 
 
 
2. I understand that my participation is voluntary and I am free to 
withdraw at any time, without giving any reason, without my 
legal rights being affected. 
 
 
3. I understand that sections of my interview notes maybe looked 
at by responsible researchers from Imperial College and Ipsos 
MORI. I give permission to these individuals to access the 
information relating to this interview. 
 
 
4. I give consent for this interview to be recorded and later 
transcribed.  The transcript will then be de-identified for the 
purposes of analysis.  No personally identifiable information will 
be reported from this study.  Findings will be based on the 
collective contributions of participants, which may include 
anonymous representative quotes taken from the interviews. 
 
 
5.   I agree to take part in the above study. 
 
 
 
 
 
________________________         __________________________               ______________ 
         Name of Participant      Signature                                               Date                                    
                     
 
 
 
________________________         __________________________               ______________ 
       Name of Person taking consent                           Signature                                               Date 
 
 
 
  
Please initial box 
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Appendix 7          Research Information Sheet – interviews 
 
Socio-psychological determinants of adult routine immunisation 
 
Investigator: Nick Sevdalis 
(Research Consent Form must accompany this form) 
Invitation  
You are being invited to take part in a research study. Before you decide to take part, it is important 
for you to understand why the research is being done and what it will involve. Please take the time 
to read the following information carefully. 
What is the purpose of the study? 
When individuals are vaccinated, their immune system is strengthened to prevent them from getting 
a specific disease. This is a very effective way of protecting their health and that of their 
communities. However, not everyone who is eligible for vaccination gets vaccinated.  
The purpose of this study is to understand why some adults vaccinate and some do not, particularly 
for seasonal influenza (flu) vaccine and tetanus. This study will also form part of a PhD.   
Why have I been chosen? 
You have been chosen because of the vaccinations you have or have not had and your personal 
characteristics (for example, your age and gender).  
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form. If you decide to take part you 
are still free to withdraw at any time and without giving a reason.   
What will happen to me if I take part? 
If you decide to take part in the study you will be asked to answer the following: 
1. Questions about your personal characteristics 
2. Questions about your views on general health and adult vaccination 
What are the possible disadvantages and risks of taking part? 
There are few disadvantages of taking part because the research only involves an interview. It does 
not involve any use of a drug and is not trying to sell any kind of medication. Taking part in the study 
may involve some loss of privacy for you, in that your responses will be known to the interviewer 
carrying out the interview.  However, the information that you provide will be kept anonymous and 
confidential and only the research team will see it. The other disadvantage of taking part is the time 
this interview will take, which is 60 minutes or less. 
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What are the possible benefits of taking part? 
We will collect and analyse information about the reasons why people do or do not vaccinate. We 
hope the results of this study will be published in academic journals and used to inform national and 
international vaccination policy and communication strategies. We will also be giving you a gift as a 
thank you for taking part in the research. 
What if something goes wrong?  
We do not foresee anything going wrong. However, if there are any problems you are free to 
terminate your participation from the study at any time.  
Will my taking part in this study be kept confidential? 
Information that is collected about you during the course of this interview will be kept strictly 
confidential and will only be seen by Imperial College, icare and Ipsos researchers. Anything you say 
will be anonymous when reported. The data will be kept securely. 
What will happen to the results of the research study? 
The results of the research will be written up as a research report. It may be published in a research 
journal and presented at conferences. You will not be personally identifiable in any report or 
publication. 
Who is organising and funding the research? 
The study is funded by Sanofi Pasteur and designed and organised by Imperial College London and 
Ipsos. Ipsos is helping to design the research, recruiting participants to take part in it, conducting the 
interviews, and then analysing and reporting on the findings along with Imperial College London. 
Insurance and indemnity 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have grounds for a 
legal action.  Regardless of this, if you wish to complain, or have any concerns about any aspect of 
the way you have been treated during the course of this study then you should immediately inform 
the Investigator Nick Sevdalis (n.sevdalis@imperial.ac.uk).  If you are still not satisfied with the 
response, you can contact the Imperial AHSC Joint Research Office.  
Who has reviewed the study? 
The Imperial College Research Ethics Committee has approved this study.  
Contact for Further Information 
If you would like further information about this study please contact Ana Wheelock 
(a.wheelock@imperial.ac.uk).  
You will be given a copy of the research information sheet and a signed consent form to keep, if you 
wish.
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Appendix 8          Interview schedule vaccinators 
Section title Key questions and probes Interviewer prompts and probes Aims and objectives of 
section and notes 
Time: 
60 min 
 
A. Welcome and 
introduction 
 
 
 Thank participants for taking part. 
 
 Introduce yourself, Ipsos, Imperial College London 
and Sanofi Pasteur. 
 
 Explain the interview should last about 60 minutes.  
 
 Explain the purpose of the discussion: to explore 
what you think about health and vaccinations for 
adults, and why you did/didn’t get vaccinated. 
 
 Explain that there are no right or wrong answers. We 
just want to hear about their views and experiences. 
 
 Obtain permission to record discussion – we’ll be 
using all the transcripts in our analysis. 
 
 Reassure all responses anonymous. We will be 
passing on a transcript of the interview to the 
Imperial College research team to assist with their 
analysis, but these transcripts will not be passed on 
to any third party and no information that could 
identify them personally will be placed in the public 
domain. Ipsos MORI works in accordance with MRS 
guidelines and the Data Protection Act. 
 
 
IF THE PARTICIPANT ASKS HOW THE FINDINGS WILL 
BE USED, EXPLAIN THAT THE RESULTS WILL BE 
PUBLISHED IN ACADEMIC JOURNALS AND 
PRESENTED AT CONFERENCES, RELEVANT POLICY 
AND INDUSTRY MEETINGS.  
 
 Introduce the discussion 
 Set the participant at 
ease 
 Confidentiality issues 
and permission to record 
 
2 mins 
 
B. About you 
 
1. Please tell me a bit about yourself and your life, for 
example, what you spend your time doing and how 
you enjoy yourself. 
 
PROBES: 
 What things in your life really matter to you? 
 What sorts of things do you worry about? 
 
 Warm up the participant 
and set them at ease. 
 
5 mins 
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  NOTE TO INTERVIEWER: ALLOW SUFFICIENT  
TIME FOR THIS SECTION GIVEN THAT IT 
PROVIDES USEFUL CONTEXT FOR REASON 
FOR/AGAINST VACCINATIONS 
 
 Get an overview of their 
life and values. 
 Note the things that 
matter to them to assist 
with probing later. 
 This section provides 
context for the journey 
mapping. 
 
 
C. Influences 
 
1. Can you tell me how you find out what’s happening 
generally in the world?  
 
 
 
 
 
 
 
 
 
2. What sort of devices do you use to access the 
internet, if any?  
 
3. And who are the people whose opinion you value 
or who you discuss important issues with? 
 
 
PROBES: 
 What newspapers or magazines do you watch? 
 What radio stations do you listen to? 
 What sorts of TV programmes do you watch? 
 What sorts of things do you look at on the 
internet? Do you look at social media sites like 
Facebook or Twitter? Do you read news online? 
How about reading blogs? What other sorts of 
things do you do online? 
 Internet? From work/home/phone? 
 
 
 
 
 Family / friends / work colleagues EXTRA PROBES 
FOR OPINIONS VALUED: figures in the media 
/people in government 
 
 
 To understand what 
influences there are on 
people. 
 To understand where 
they get their 
information from. 
 These are the channels 
through which people’s 
knowledge about and 
attitudes toward 
vaccinations may be 
formed / influenced, but 
asked in an open way 
rather than focusing on 
vaccinations to build a 
wider understanding of 
the individual. 
 
 
3 mins 
 
D. Health and 
views about 
vaccination 
 
1. Can I ask how you feel your own health is? 
 
2. When you think about your health, what are all the 
things that come to mind? Anything else? 
 
IF PARTICIPANT DOES NOT MENTION VACCINATIONS, 
PROBE: 
 
PROBES FOR LIFESTYLE (HEALTHY EATING, 
EXERCISE, SMOKING, DRINKING ALCOHOL, 
MAINTAINING A HEALTHY WEIGHT), ADULT 
VACCINATIONS, TAKING VITAMINS, CHECK UPS 
WITH HEALTH PROFESSIONALS, HAND WASHING, 
ALTERNATIVE MEDICINES 
 
 
 To understand what 
health means to people. 
 This again provides 
context for how people 
view vaccinations and 
how perceptions of 
health interact with 
 
10 mins 
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3. And how about vaccinations, do vaccinations make 
you think about health? 
 
ASK ALL 
4. Do you do anything to keep healthy? What sorts of 
things? 
 
5. Have you seen a doctor or nurse in the last year 
about health issues? How regularly would you say 
you use health services? 
 
6. Which doctors or nurses do you particularly trust 
and listen to, if any? And why is that? Why is that 
important to you? 
 
7. Thinking now about vaccinations, what are all the 
things that come to mind when you think about 
vaccinations? 
 
8. Looking at these cards, which are all adult 
vaccinations for various diseases or conditions, please 
can you sort them into groups?  
 
 
HAND SORTING CARDS TO THE PARTICIPANT. IF THEY 
ASK, REASSURE THAT THERE ARE NO RIGHT OR 
WRONG ANSWERS, WE’RE JUST INTERESTED IN HOW 
THEY WOULD GROUP THEM. 
 
9. Why did you group the cards in that way, can you 
talk me through how you did it? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CARDS INCLUDE: VACCINE TO PREVENT INFLUENZA 
/ FLU, VACCINE TO PREVENT PNEUMONIA, 
VACCINE TO PREVENT HEPATITIS, VACCINE TO 
PREVENT TETANUS, VACCINE TO PREVENT 
MEASLES, MUMPS AND RUBELLA  
 
 
 
 
 
PROBES: 
 What makes this group of vaccinations different 
to the other groups? Why do you say that? 
 Which vaccinations are more or less important? 
 
 
knowledge about and 
attitudes toward 
vaccinations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 This exercise aims to 
understand how people 
group/segment the 
vaccinations. 
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E. The journey to 
vaccination 
 
 
SELECT INFLUENZA OR TETANUS VACCINATION 
 
1. I’d like to talk about vaccinations in more detail 
now. Thinking back to the last time you were 
vaccinated for INSERT VACCINATION 
 
WHEN SELECT TETANUS VACCINE, EXPLAIN This is the 
adult booster vaccination (for preventing Tetanus, 
and possibly other diseases such as Diphtheria or 
whooping cough), building on the vaccination you had 
as a child.  
 
 
 
 
 
 
 
 
 
2. How would you describe to a friend how you came 
to have the vaccination? What things happened that 
meant you ended up getting vaccinated? 
 
INTERVIEWER TO DRAW JOURNEY ON FLIP CHART 
 
3. And why was that important to you?  
 
PROBE ON IMPORTANCE AND LADDER TO 
UNDERSTAND CORE UNDERLYING REASONS 
 
CLARIFY IF PARTICIPANT HAS BEEN VACCINATED 
PREVIOUSLY. IF SO, PROBE FULLY AROUND THE FIRST 
TIME THEY WERE VACCINATED AND THE PERIOD IN 
BETWEEN THE FIRST AND LAST VACCINE (I.E. 
THOUGHTS, REASONS AND DECISIONS) 
USEFUL PROBES FOR SPONTANEOUS MENTIONS 
(SEE ADDITIONAL SHEET) – NOTE TO INTERVIEWER, 
ONLY USE THESE TO FOLLOW UP ON WHAT THE 
PARTICIPANT SAYS. DO NOT USE THEM TO PROMPT 
THE PARTICIPANT TO TALK ABOUT SOMETHING 
THEY HAVE NOT MENTIONED. FOR REFERENCE, THE 
PROBES LISTED INCLUDE: 
 
A. RECOMMENDATION BY HEALTHCARE 
PROFESSIONAL 
B. RECOMMENDATION BY FAMILY/FRIENDS 
C. VULNERABLE TO DISEASE/BEING HIGH RISK 
D. VACCINE EFFECTIVENESS 
E. BELIEF THAT INFLUENZA / TETANUS HAS A 
SEVERE IMPACT 
F. PREVENTION IS IMPORTANT / VACCINATION IS 
WORTHWHILE 
G. DOES NOT WANT TO INFECT OTHER PEOPLE 
H. HISTORY OF PREVIOUS VACCINATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 To build the journey the 
participant went through 
to get vaccinated. 
 
 NOTE TO INTERVIEWER: 
it is essential that you 
‘ladder’ throughout this 
section of the interview, 
to get to the core reason 
and distinguish System 1 
/ System 2 thinking. 
Keep tracing the journey 
backwards until you get 
to the start point. 
 
 
 
 
 
 
 To gain a full 
understanding of 
people’s reasons and 
decisions surrounding 
vaccination over the 
complete time period. 
 
 Aim of this part is to 
understand the triggers 
for each pivot point: 
what made a difference? 
 
 
 
 
 
20 mins 
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INTERVIEWER AND PARTICIPANT TO REVIEW JOURNEY 
ON FLIPCHART ONCE  COMPLETED  
 
4. What would you say happened at that point that 
triggered that change? And why was that important? 
 
5. Of all of those things, which would you say was the 
most important thing that led to you getting 
vaccinated? And the second most important thing? 
And the third? 
 
6. How did you know where to go for the vaccination? 
How did you book an appointment and fit it into your 
plans? What other things were competing for your 
time? 
 
7. Where did you get vaccinated? How far away from 
your home is that? How long does it take you to get 
there and how did you get there? How much does it 
cost to make that journey? What other things were 
competing for your money at that time? What other 
sorts of things do you go to that clinic for?  
 
IF IT IS A TOWN OR VILLAGE A LONG DISTANCE FROM 
THE PARTICIPANT’S HOME 
 
8. What other sorts of things do you go to that town 
or village for? What sorts of things? What other 
things can you do or get in that [INSERT PLACE]? 
 
PLEASE NOTE THAT THIS SHOULD HAVE BEEN 
COVERED IN THE JOURNEY MAPPING – IF IT HASN’T 
BEEN COVERED YOU MUST ASK THIS QUESTION. 
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9. Before you were vaccinated, do you remember any 
times when you thought about or started the process 
toward being vaccinated but didn’t end up getting 
vaccinated?  
PROBE FOR INFLUENCES: INTERNAL, FAMILY, 
FRIENDS, MEDIA, ETC. 
 
 
 
 
F. The journey to 
vaccination 
 
ONLY FOR 
PARTICIPANTS WHO 
HAVE BOTH 
VACCINATIONS 
 
 
ONLY ASK IF PARTICIPANT HAS HAD BOTH 
VACCINATIONS 
 
1. How do you think this journey applies to INSERT 
OTHER VACCINATION? 
 
WHEN SELECT TETANUS VACCINE, EXPLAIN This is the 
adult booster vaccination (for preventing Tetanus, 
and possibly other diseases such as Diphtheria or 
whooping cough), building on the vaccination you had 
as a child.  
 
IF JOURNEY IS VERY DIFFERENT, MAP OUT JOURNEY 
FOR SECOND VACCINATION AS WELL 
 
IF PARTICIPANT HAS NOT ALREADY TALKED ABOUT 
PREVIOUS HISTORY OF VACCINATIONS 
2. Were you able to bring your vaccinations card with 
you? What other vaccinations have you had in the 
last year or so? And what about in the last five years? 
 
 
USEFUL PROBES: 
 What is the same about it? 
 What is different?  
 Why do you think that is? 
 And why is that important? 
 
  
5 mins 
 
G. Barriers to 
vaccination 
 
ONLY FOR 
PARTICIPANTS WHO 
HAVE ONLY HAD 
ONE OF THE 
VACCINATIONS 
 
ONLY FOR PARTICIPANTS WHO HAVE HAD ONE OF THE 
VACCINATIONS BUT NOT THE OTHER 
 
REFER TO MAP FOR THE VACCINATION THEY HAVE 
HAD 
1. What would you say is different about the INSERT 
VACCINATION THEY HAVEN’T HAD that means you 
haven’t been vaccinated for it? Which points in this 
 
USEFUL PROBES FOR SPONTANEOUS MENTIONS 
(SEE ADDITIONAL SHEET) – NOTE TO INTERVIEWER, 
ONLY USE THESE TO FOLLOW UP ON WHAT THE 
PARTICIPANT SAYS. DO NOT USE THEM TO PROMPT 
THE PARTICIPANT TO TALK ABOUT SOMETHING 
THEY HAVE NOT MENTIONED. FOR REFERENCE, THE 
PROBES LISTED INCLUDE: 
 
  
5 mins 
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 journey still apply? Which points don’t apply? And 
why was that less important to you? Where did you 
hear about that? Are there other things that should 
be on the map? Why is that important? 
 
PROBE ON IMPORTANCE AND LADDER TO 
UNDERSTAND CORE UNDERLYING REASONS 
 
2. Of all of those things, which would you say was the 
most important thing that led to you not getting 
vaccinated? And the second most important thing? 
And the third? 
 
3. What do you think the difference is between 
INSERT VACCINATION and INSERT VACCINATION? 
Why do you think you had one but not the other? And 
why is that important to you?   
 
4. Do you remember any times when you thought 
about or started the process toward being vaccinated 
for INSERT VACCINE but didn’t end up getting 
vaccinated?  
 
IF PARTICIPANT HAS NOT ALREADY TALKED ABOUT 
PREVIOUS HISTORY OF VACCINATIONS 
5. Were you able to bring your vaccinations card with 
you? What other vaccinations have you had in the 
last year or so? And what about in the last five years? 
 
A. RECOMMENDATION BY HEALTHCARE 
PROFESSIONAL 
B. VULNERABLE TO DISEASE/BEING HIGH RISK 
C. VACCINE EFFECTIVENESS 
D. CONCERN ABOUT SIDE EFFECTS 
E. CAUSES OTHER ILLNESS / WORSENS OTHER 
CONDITIONS / CAUSES THE DISEASE 
F. WEREN’T AWARE THEY NEEDED IT 
G. ACCESS TO VACCINATIONS – TOO FAR AWAY 
H. ACCESS TO VACCINATIONS – VACCINE 
SHORTAGE 
I. ACCESS TO VACCINATIONS – FINANCIAL 
PROBLEMS/ COST  
J. NEVER CONSIDERED VACCINATION FOR THAT 
VACCINE  
K. DIDN’T GET AROUND TO IT / PROCRASTINATED / 
FORGOT 
 
 
 
 
 
 
H. Children’s 
vaccinations  
 
 
1. In general, do you think people should vaccinate 
their children against tetanus? Why/why not? 
 
2. And do you think people should vaccinate their 
children against influenza? Why/why not? 
 
 
PROBE FOR WHETHER PEOPLE THINK ABOUT 
ADULT AND CHILD VACCINATIONS DIFFERENTLY 
 
To understand people’s 
views on childhood 
vaccinations 
 
2 mins 
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I. Awareness of 
vaccinations and 
diseases 
 
ASK ALL 
PARTICIPANTS 
 
 
 
 
ASK ALL PARTICIPANTS 
1. How much would you say you know about 
influenza, or flu? How serious or life-threatening do 
you think the disease is? In general, how likely do you 
think you are to catch the disease? PROBE FOR 
REASONS WHY 
 
2. How much would you say you know about the 
vaccine for influenza? Do you happen to know how 
often it’s recommended that you have it, or who it’s 
recommended for? 
 
3. And how much would you say you know about 
tetanus? How serious or life-threatening do you think 
the disease is? In general, how likely do you think you 
are to catch the disease? PROBE FOR REASONS WHY 
 
4. And how much would you say you know about the 
vaccine for tetanus? Do you happen to know how 
often it’s recommended that you have it, or who it’s 
recommended for? 
 
 
 
 
 
Further context about how 
people view the 
vaccinations and diseases 
 
 
 
3 mins 
 
J. Survey items & 
demographics 
 
 
INTERVIEWER REFER TO QUANTITATIVE 
QUESTIONNAIRE SHEET AND ASK THE QUESTIONS ON 
IT 
 
 
PLEASE RECORD ANSWERS CAREFULLY 
 
 5 mins 
 
K. Conclusion 
 
1. Is there anything else you would like to add? 
THANK AND CLOSE 
 
  
Round up discussion and 
chance for any final 
observations. 
 
Any 
remain-
ning 
time. 
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Appendix 9          Interview schedule unvaccinated participants 
Section title Key questions and probes Interviewer prompts and probes Aims and objectives of 
section and notes 
Time: 
60 min 
 
A. Welcome and 
introduction 
 
 
 Thank participants for taking part. 
 
 Introduce yourself, Ipsos, Imperial College London 
and Sanofi Pasteur. 
 
 Explain the interview should last about 60 minutes.  
 
 Explain the purpose of the discussion: to explore 
what you think about health and vaccinations for 
adults, and why you did/didn’t get vaccinated. 
 
 Explain that there are no right or wrong answers. We 
just want to hear about their views and experiences. 
 
 Obtain permission to record discussion – we’ll be 
using all the transcripts in our analysis. 
 
 Reassure all responses anonymous. We will be 
passing on a transcript of the interview to the 
Imperial College research team to assist with their 
analysis, but these transcripts will not be passed on 
to any third party and no information that could 
identify them personally will be placed in the public 
domain. Ipsos MORI works in accordance with MRS 
guidelines and the Data Protection Act. 
 
 
IF THE PARTICIPANT ASKS HOW THE FINDINGS WILL 
BE USED, EXPLAIN THAT THE RESULTS WILL BE 
PUBLISHED IN ACADEMIC JOURNALS AND 
PRESENTED AT CONFERENCES, RELEVANT POLICY 
AND INDUSTRY MEETINGS.  
 
 Introduce the discussion 
 Set the participant at 
ease 
 Confidentiality issues 
and permission to record 
 
2 mins 
 
B. About you 
 
1. Please tell me a bit about yourself and your life, for 
example, what you spend your time doing and how 
you enjoy yourself. 
 
PROBES: 
 What things in your life really matter to you? 
 What sorts of things do you worry about? 
 
 Warm up the participant 
and set them at ease. 
 
5 mins 
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  NOTE TO INTERVIEWER: ALLOW SUFFICIENT  
TIME FOR THIS SECTION GIVEN THAT IT 
PROVIDES USEFUL CONTEXT FOR REASON 
FOR/AGAINST VACCINATIONS 
 
 Get an overview of their 
life and values. 
 Note the things that 
matter to them to assist 
with probing later. 
 This section provides 
context for the journey 
mapping. 
 
 
C. Influences 
 
1. Can you tell me how you find out what’s happening 
generally in the world?  
 
 
 
 
 
 
 
 
 
2. What sort of devices do you use to access the 
internet, if any?  
 
3. And who are the people whose opinion you value 
or who you discuss important issues with? 
 
 
PROBES: 
 What newspapers or magazines do you watch? 
 What radio stations do you listen to? 
 What sorts of TV programmes do you watch? 
 What sorts of things do you look at on the 
internet? Do you look at social media sites like 
Facebook or Twitter? Do you read news online? 
How about reading blogs? What other sorts of 
things do you do online? 
 Internet? From work/home/phone? 
 
 
 
 
 Family / friends / work colleagues EXTRA PROBES 
FOR OPINIONS VALUED: figures in the media 
/people in government 
 
 
 To understand what 
influences there are on 
people. 
 To understand where 
they get their 
information from. 
 These are the channels 
through which people’s 
knowledge about and 
attitudes toward 
vaccinations may be 
formed / influenced, but 
asked in an open way 
rather than focusing on 
vaccinations to build a 
wider understanding of 
the individual. 
 
 
3 mins 
 
D. Health and 
views about 
vaccination 
 
1. Can I ask how you feel your own health is? 
 
2. When you think about your health, what are all the 
things that come to mind? Anything else? 
 
IF PARTICIPANT DOES NOT MENTION VACCINATIONS, 
PROBE: 
 
PROBES FOR LIFESTYLE (HEALTHY EATING, 
EXERCISE, SMOKING, DRINKING ALCOHOL, 
MAINTAINING A HEALTHY WEIGHT), ADULT 
VACCINATIONS, TAKING VITAMINS, CHECK UPS 
WITH HEALTH PROFESSIONALS, HAND WASHING, 
ALTERNATIVE MEDICINES 
 
 
 To understand what 
health means to people. 
 This again provides 
context for how people 
view vaccinations and 
how perceptions of 
health interact with 
 
10 mins 
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3. And how about vaccinations, do vaccinations make 
you think about health? 
 
ASK ALL 
4. Do you do anything to keep healthy? What sorts of 
things? 
 
5. Have you seen a doctor or nurse in the last year 
about health issues? How regularly would you say 
you use health services? 
 
6. Which doctors or nurses do you particularly trust 
and listen to, if any? And why is that? Why is that 
important to you? 
 
7. Thinking now about vaccinations, what are all the 
things that come to mind when you think about 
vaccinations? 
 
8. Looking at these cards, which are all adult 
vaccinations for various diseases or conditions, please 
can you sort them into groups?  
 
 
HAND SORTING CARDS TO THE PARTICIPANT. IF THEY 
ASK, REASSURE THAT THERE ARE NO RIGHT OR 
WRONG ANSWERS, WE’RE JUST INTERESTED IN HOW 
THEY WOULD GROUP THEM. 
 
9. Why did you group the cards in that way, can you 
talk me through how you did it? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CARDS INCLUDE: VACCINE TO PREVENT INFLUENZA 
/ FLU, VACCINE TO PREVENT PNEUMONIA, 
VACCINE TO PREVENT HEPATITIS, VACCINE TO 
PREVENT TETANUS, VACCINE TO PREVENT 
MEASLES, MUMPS AND RUBELLA  
 
 
 
 
 
PROBES: 
 What makes this group of vaccinations different 
to the other groups? Why do you say that? 
 Which vaccinations are more or less important? 
 
 
knowledge about and 
attitudes toward 
vaccinations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 This exercise aims to 
understand how people 
group/segment the 
vaccinations. 
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E. The journey to 
non-vaccination 
 
1. How would you describe to a friend how you ended 
up not having the vaccination? What things happened 
that meant you ended up not getting vaccinated? 
 
INTERVIEWER TO DRAW JOURNEY ON FLIP CHART 
 
2. And why was that / wasn’t that important to you?  
 
3. Can you take me back before that? What led you 
to…? 
 
ASK ITERATIVELY UNTIL YOU GET BACK TO THE 
BEGINNING OF THE ‘JOURNEY’. FOR EACH STAGE, 
PROBE ON IMPORTANCE AND LADDER TO 
UNDERSTAND CORE UNDERLYING REASONS 
 
INTERVIEWER AND PARTICIPANT TO REVIEW JOURNEY 
ON FLIPCHART ONCE  COMPLETED  
 
4. What would you say happened at that point that 
triggered that change? And why was that important? 
 
5. Of all of those things, which would you say was the 
most important thing that led to you not getting 
vaccinated? And the second most important thing? 
And the third? 
 
6. How do you think this journey applies to INSERT 
OTHER VACCINATION? 
 
IF JOURNEY IS VERY DIFFERENT, MAP OUT JOURNEY 
FOR SECOND VACCINATION AS WELL 
 
IF PARTICIPANT HAS NOT ALREADY TALKED ABOUT 
PREVIOUS HISTORY OF VACCINATIONS 
 
USEFUL PROBES FOR SPONTANEOUS MENTIONS 
(SEE ADDITIONAL SHEET) – NOTE TO INTERVIEWER, 
ONLY USE THESE TO FOLLOW UP ON WHAT THE 
PARTICIPANT SAYS. DO NOT USE THEM TO PROMPT 
THE PARTICIPANT TO TALK ABOUT SOMETHING 
THEY HAVE NOT MENTIONED. FOR REFERENCE, THE 
PROBES LISTED INCLUDE: 
 
A. RECOMMENDATION BY HEALTHCARE 
PROFESSIONAL  
B. VULNERABLE TO DISEASE/BEING HIGH 
RISK 
C. VACCINE EFFECTIVENESS 
D. CONCERN ABOUT SIDE EFFECTS 
E. CAUSES OTHER ILLNESS / WORSENS 
OTHER CONDITIONS / CAUSES THE 
DISEASE 
F. WEREN’T AWARE THEY NEEDED IT 
G. ACCESS TO VACCINATIONS – TOO FAR 
AWAY 
H. ACCESS TO VACCINATIONS – VACCINE 
SHORTAGE 
I. ACCESS TO VACCINATIONS – FINANCIAL 
PROBLEMS/ COST 
J. NEVER CONSIDERED VACCINATION FOR 
THAT VACCINE 
K. DIDN’T GET AROUND TO IT / 
PROCRASTINATED / FORGOT 
 
PROBE FOR INFLUENCES: INTERNAL, FAMILY, 
FRIENDS, MEDIA ETC 
 
 
 
 
 To understand why 
people weren’t 
vaccinated 
 
 Where in the journey did 
people fall out? And why 
was that? 
 
 Laddering again very 
important to get back to 
the underlying value and 
distinguish System 1 / 
System 2 thinking 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 mins 
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7. Were you able to bring your vaccinations card with 
you? What other vaccinations have you had in the 
last year or so? And what about in the last five years? 
 
 
USEFUL PROBES: 
 What is the same about it? 
 What is different?  
 Why do you think that is? 
 And why is that important? 
 
 
 
 
 
 
 
 
F. Children’s 
vaccinations  
 
 
1. In general, do you think people should vaccinate 
their children against tetanus? Why/why not? 
 
2. And do you think people should vaccinate their 
children against influenza? Why/why not? 
 
 
PROBE FOR WHETHER PEOPLE THINK ABOUT 
ADULT AND CHILD VACCINATIONS DIFFERENTLY 
 
To understand people’s 
views on childhood 
vaccinations 
 
2 mins 
 
G. Awareness of 
vaccinations and 
diseases 
 
ASK ALL 
PARTICIPANTS 
 
ASK ALL PARTICIPANTS 
1. How much would you say you know about 
influenza, or flu? How serious or life-threatening do 
you think the disease is? In general, how likely do you 
think you are to catch the disease? PROBE FOR 
REASONS WHY 
 
2. How much would you say you know about the 
vaccine for influenza? Do you happen to know how 
often it’s recommended that you have it, or who it’s 
recommended for? 
 
3. And how much would you say you know about 
tetanus? How serious or life-threatening do you think 
the disease is? In general, how likely do you think you 
are to catch the disease? PROBE FOR REASONS WHY 
 
4. And how much would you say you know about the 
vaccine for tetanus? Do you happen to know how 
often it’s recommended that you have it, or who it’s 
recommended for? 
 
 
 
 
Further context about how 
people view the 
vaccinations and diseases 
 
 
 
3 mins 
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H. Survey items & 
demographics 
 
 
INTERVIEWER REFER TO QUANTITATIVE 
QUESTIONNAIRE SHEET AND ASK THE QUESTIONS ON 
IT 
 
 
PLEASE RECORD ANSWERS CAREFULLY 
 
 5 mins 
 
I. Conclusion 
 
1. Is there anything else you would like to add? 
THANK AND CLOSE 
 
  
Round up discussion and 
chance for any final 
observations. 
 
Any 
remain-
ning 
time. 
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Appendix 10          Invitation to participate – survey 
FOR TELEPHONE INTERVIEWS THIS INFORMATION WILL BE READ OUT; FOR THOSE PARTICIPATING 
ONLINE THIS WILL APPEAR IN THE INTRODUCTORY SCREEN. 
Introduction  
Dear participant,       
This is an invitation to participate in a research study conducted by Imperial College London and 
Double Helix Development. Your participation depends upon the completion of a few questions to 
determine your eligibility for this survey. If you are eligible, you will be asked to state whether you 
agree or disagree with a series of individual statements and to provide some additional background 
information about yourself. The entire survey should take approximately 20 minutes to complete.  
Before you decide to take part, it is important for you to understand why the research is being 
carried out and what it will involve. Please take the time to read the following information carefully. 
What is the purpose of the study? 
The purpose of this study is to understand why some adults vaccinate and some do not, particularly 
for seasonal influenza (flu) and tetanus. The information you provide will contribute to our 
understanding of the psychology of how people make decisions in relation to vaccination. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you opt to take part you are still free to 
withdraw at any time should you decide to do so and without giving a reason.   
What are the possible risks and disadvantages of taking part? 
We do not anticipate any risks or disadvantages resulting from taking part in this study, because the 
research only involves completion of a survey. It does not involve any drugs/vaccines and it is not 
trying to sell or advocate any kind of medication. All the information that you provide will be kept 
anonymous and confidential and only the research team will see it. Some of the questions in this 
survey may be of a personal nature, please be assured that these are important questions and that 
they are in no way meant to make you feel uncomfortable.   
What are the possible benefits of taking part? 
You may enjoy thinking about your own opinions on vaccination. We hope the results of this study 
will help understand better how people like you make vaccination decisions. The results will be 
published in scientific journals and used to inform national and international vaccination policy and 
communication strategies. 
Will my taking part in this study be kept confidential? 
Information that is collected about you during the course of this survey will be kept strictly 
confidential and will only be seen by Imperial College and Double Helix Development researchers. 
Anything you say will be anonymous when reported. Once collected, your answers will form part of a 
larger database from which only group data will be analysed and reported. The data will be kept 
securely. 
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Who is organising and funding the research? 
The study is funded by Sanofi Pasteur and designed and organised by Imperial College London and 
Double Helix Development. 
Complaints: 
If you wish to complain or have concerns about any aspect of this study, then you should 
immediately inform the Investigator, Dr Nick Sevdalis (n.sevdalis@imperial.ac.uk). If you are still not 
satisfied with the response, you can contact the Imperial AHSC Joint Research Office 
(jrco@imperial.ac.uk)  
Who has reviewed the study? 
The Imperial College Research Ethics Committee and the American Institutes for Research have 
reviewed and approved this study.  
Contact for Further Information 
A summary of the results will be available toward the end of the 2014. If you are interested in 
receiving this information, please contact Ana Wheelock (a.wheelock@imperial.ac.uk).    
 
Thank you for your time and consideration.      
Please tick the following statements to indicate your consent to participate in this study: 
I am over the age of 18.  
I have read the information on this page and understand what my participation will involve.  
I understand that I have the right to withdraw from the survey without giving a reason at any 
time during completion without my legal rights being affected.  
I consent to the processing of my responses by responsible researchers from Imperial College 
and Double Helix Development. I give permission to these individuals to access the information 
relating to this survey.  
I understand that my information will be treated as strictly confidential and handled in 
accordance with the provisions of the Data Protection Act 1998. No personally identifiable 
information will be reported from this study.  Findings will be based on the collective contributions 
of participants. 
I agree to take part in the above study. 
 
 
 
  
217 
 
NEW SCREEN 
ADVERSE EVENTS REPORTING: 
You are about to enter a survey.  We are now being asked to pass on to our client details of adverse 
events and / or product complaints that are raised during the course of such surveys.  Although this 
is an on-line market research interview and how you respond will, of course, be treated in 
confidence, should you raise an adverse event and / or product complaint, we will need to report 
this, even if it has already been reported by you directly to the company or the regulatory 
authorities using the MHRA’s ‘Yellow Card’ system.  In such a situation you will be contacted to ask 
whether or not you are willing to waive the confidentiality given to you under the market research 
codes of conduct specifically in relation to that adverse event and / or product complaint.  
Everything else you contribute during the course of the interview will continue to remain 
confidential. 
Are you happy to proceed with the interview on this basis?  
 I would like to proceed and would like to keep my details confidential 
 I would like to proceed and give permission for my contact details to be passed on to the Drug 
Safety department of the company if an adverse event is mentioned by me during this activity. 
 I don’t want to proceed and would like to end the interview here [TERMINATE] 
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Appendix 11          Influenza and tetanus vaccination survey  
 
SCREENER 
First, we would like to ask you a few questions about yourself. 
1) What is your date of birth? 
IF UNDER 18 CLOSE 
*ACCEPTABLE RANGE TO BE APPROPRIATE FOR EACH MONTH 
 
 
2) What is your gender?  
SINGLE SELECT 
Female    ⃝ 
Male ⃝ 
 
3) Which of the following ethnic groups do you feel you belong to? 
SINGLE SELECT 
White British or Irish  ⃝ 
Asian or Asian British: Indian ⃝ 
Asian or Asian British: Pakistani ⃝ 
Asian or Asian British: Bangladeshi ⃝ 
Asian or Asian British: Chinese ⃝ 
Asian or Asian British: Other Asian ⃝ 
Black African ⃝ 
Black Caribbean ⃝ 
Mixed Race ⃝ 
Other 
 
⃝ 
Prefer not to say  ⃝ 
 
4) Please state or select the city, region and postcode you live in  
County Drop down 
Post code / zip code (first part only) Open ended 
 
 
Day (dd) Month (mm) Year (yyyy) 
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5) Which of the below best describes the location where you live? 
Major city / town with a population over 750,000 inhabitants  
(For example London, Manchester, Glasgow) - URBAN 
⃝ 
City / town with a population of 10,000-750,000 inhabitants  
(For example Sheffield, Bristol, Oxford, Edinburgh) - URBAN 
⃝ 
Town / village with a population less than 10,000 inhabitants - 
RURAL 
⃝ 
 
6) Are you currently employed? (Item included by Sanofi Pasteur) 
SINGLE SELECT 
Yes, full-time   ⃝ 
Yes, part-time ⃝ 
No ⃝ 
I am retired ⃝ 
 
7) Are you currently studying? (Item included by Sanofi Pasteur) 
SINGLE SELECT 
Yes, full-time   ⃝ 
Yes, part-time ⃝ 
No ⃝ 
 
8) Which of the following best describes the type of occupation (or previous occupation if retired) 
of the chief income earner in your household? (Item included by Sanofi Pasteur) 
SINGLE SELECT   
High managerial, administrative or professional – e.g. doctor, 
lawyer, company director (50+ people), judge, surgeon, school 
headmaster, etc. /A 
⃝ 
Intermediate managerial, administrative or professional – e.g. 
school teacher, office manager, junior doctor, bank manager, 
police inspector, accountant etc. /B 
⃝ 
Supervisor, clerical, junior managerial, administrative or 
professional – e.g., policeman, nurse, secretary, clerk, self-
employed (5+ people), etc. /C1 
⃝ 
Skilled manual worker – e.g. mechanic, plumber, electrician, 
lorry driver, train driver, etc. /C2 
⃝ 
Semi-skilled or unskilled manual worker – e.g, baggage handler, 
waiter, factory worker, receptionist, labourer, gardener, etc. /D 
⃝ 
Unemployed /E ⃝ 
Student /E ⃝ 
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9) In which of the following industries are you currently (or were you, if now retired) employed (or 
studying, if still in education)? (Item included by Sanofi Pasteur) 
Please select the answer which best applies to your current or previous employment 
SINGLE SELECT; ROTATE ORDER 
Forestry, fishing, hunting or agriculture ⃝ 
Mining ⃝ 
Utilities ⃝ 
Construction ⃝ 
Manufacturing ⃝ 
Wholesale trade ⃝ 
Retail trade ⃝ 
Transportation or warehousing ⃝ 
Information ⃝ 
Finance or insurance ⃝ 
Real estate or rental and leasing ⃝ 
Professional, scientific or technical services ⃝ 
Management of companies or enterprises ⃝ 
Admin, support, waste management, remediation services ⃝ 
Educational services ⃝ 
Healthcare or social assistance (regular contact with patients) ⃝ 
Healthcare or social assistance (no contact with patients) ⃝ 
Arts, entertainment or recreation ⃝ 
Accommodation or food services ⃝ 
Military / Armed Forces ⃝ 
Other services (except public administration) ⃝ 
Unclassified establishment ⃝ 
Other ⃝ 
 
10) What is your combined annual household income? 
SINGLE SELECT 
UK CODES  
Less than 10,000 ⃝ 
10,000 – 19,999 ⃝ 
20,000 - 29,999 ⃝ 
30,000 – 39,999 ⃝ 
40,000 – 49,999 ⃝ 
50,000 – 59,999 ⃝ 
60,000 – 69,999 ⃝ 
70,000 – 79,999 ⃝ 
80,000 – 89,999 ⃝ 
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11) Which of the following best describes your current situation?  
SINGLE SELECT 
Married / living with a partner  ⃝ 
Single ⃝ 
Widowed ⃝ 
Divorced or separated ⃝ 
Other ⃝ 
Prefer not to say ⃝ 
 
12) Do you currently live with any children or elderly relatives (aged 65 or over)? (Item included by 
Sanofi Pasteur) 
MULTIPLE SELECT 
Yes – Children aged 2 or under ⃝ 
Yes – Children aged 3-12 years ⃝ 
Yes – Children aged 13-17 years ⃝ 
Yes – Children aged 18 or over ⃝ 
Yes – Elderly relatives  ⃝ 
None of the above  ⃝ 
 
13) How would you personally rate your health, overall?  
Please give your answer on the scale below where 0 is very poor / unhealthy and 10 is very fit / 
healthy 
SINGLE SELECT 
Very poor 
/ 
Unhealthy 
0 
 
 
 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
5 
 
 
 
6 
 
 
 
7 
 
 
 
8 
 
 
 
9 
Very fit 
/ 
healthy 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
 
 
 
 
 
 
 
 
90,000 – 99,999 ⃝ 
100,000 or more ⃝ 
Prefer not to say  ⃝ 
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14) Have you ever been diagnosed with any of the following conditions?  
Please select all the conditions that apply  
MULTIPLE SELECT & ROTATE LIST APART FROM ‘NONE OF THE ABOVE’ 
Diabetes ⃝ 
High or low blood pressure ⃝ 
A chronic lung condition (such as asthma, Chronic Obstructive 
Pulmonary Disease (COPD)) 
⃝ 
A chronic kidney condition ⃝ 
A chronic inflammatory bowel condition (Crohn’s, ulcerative 
colitis etc. – IBS not included) 
⃝ 
A chronic heart condition (such as Heart failure) ⃝ 
A condition which causes a weakened immune system (such as 
HIV) 
⃝ 
Cancer ⃝ 
A chronic neurological condition (such as Parkinson’s disease) ⃝ 
None of the above ⃝ 
 
15) Have you received a flu vaccine (flu jab) in the past 6 months (this autumn / winter)?  
SINGLE SELECT 
Yes   ⃝ 
No ⃝ 
 
16) Have you received a tetanus containing adult booster in the last 10 years?  
SINGLE SELECT 
Yes   ⃝ 
No 
 
⃝ 
I do not know / remember ⃝ 
 
ONLY IF CODE 1 SELECTED IN Q16 
17) Which of the following tetanus containing adult booster vaccines have you received? (Item 
included by Sanofi Pasteur) 
MULTIPLE SELECT 
Tetanus – Diphtheria (Td) ⃝ 
Tetanus – Diphtheria – Pertussis (Tdap) ⃝ 
Tetanus- Diphtheria- Pertussis - Polio (Tdap/IPV)  ⃝ 
Tetanus-Diphtheria-Polio (Td/IVP)  ⃝ 
I do not know/ I do not remember ⃝ 
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GENERAL SOCIO-PSYCHOLOGICAL ITEMS  
Thank you for answering those initial questions.  Now, we would like to understand your attitudes to 
life in general.   
We are going to show you several statements about life in general.  Please give your level of 
agreement with each statement using the scales provided (where 0 = strongly disagree, & 10 = 
strongly agree) 
FOR TELEPHONE INTERVIEWS ONLY: I will be asking you to answer most questions using a 0-10 point 
scale.  To make answering these questions easier, please make a scale for yourself on a piece of 
paper.  I would like you to mark 11 ‘X’s on the paper and label each one with a number from 0 to 10.  
Below the X marked ‘0’ please write ‘strongly disagree’, and below the X marked ‘10’ please write 
‘Strongly agree’.  Throughout our conversation, when you answer questions, please refer to this 
scale to remind you what each of the numbers means.  I will also let you know which questions do 
not use the 0 to 10 rating scale.   
NEW SCREEN: ROTATE QUESTIONS 18-20 SHOWING THEM ON ONE SCREEN. 
18) In uncertain times I usually expect the best 
 
19) I am confident I can achieve anything I set my mind on  
 
20) If something can go wrong for me, it will  
SINGLE SELECT 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
NEW SCREEN 
Throughout this survey we will use a 0-10 point scale, but the scale answers may change from time 
to time (for example, rather than measuring level of agreement, we might want to measure 
willingness to do something, etc.), so please read through each question and answer option carefully 
before selecting your answer. 
21) How do you see yourself? Are you generally a person who is fully prepared to take risks or do 
you avoid taking risks?  
Please use the scale below to rate your willingness to take risks 
SINGLE SELECT; FOR TELEPHONE INTERVIEWS NOTE CHANGE IN SCALE 
Avoid 
risks 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Take 
risks 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
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NEW SCREEN: ROTATE QUESTIONS 22-24 SHOWING THEM ON ONE SCREEN. 
Now we will move on to some questions about how you think and feel about health related issues.  
22) I usually seek information about health issues that worry me 
 
23) I usually avoid thinking about health issues that worry me  
 
24) My parents / spouse / relatives / friends help me make decisions about my health  
SINGLE SELECT 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
NEW SCREEN: ROTATE QUESTIONS 25-26 BUT SHOWING THEM ON ONE SCREEN FOR TELEPHONE 
INTERVIEWS NOTE CHANGE IN ANSWER OPTIONS FOR THIS SET OF QUESTIONS 
25) How actively do you participate with your GP(s) in making decisions about health, generally? 
SINGLE SELECT 
My GP(s) always makes decisions for me ⃝ 
I like to know the options available but still let my GP(s) decide 
for me 
⃝ 
My GP(s) and I make decisions together ⃝ 
I make decisions for myself, after considering the advice of my 
GP(s)  
⃝ 
I always make my own decisions, independently of the advice of 
my GP(s)  
⃝ 
 
26) Which of the following statements best represents how much you trust your GP(s)? 
Please select all the answers that apply  
MULTIPLE SELECT 
I can tell my doctor (US and France) / GP(s) (UK) anything, even 
things that I might not tell anyone else 
⃝ 
My doctor (US and France) / GP(s) (UK) sometimes pretends to 
know things when he / she is not really sure 
⃝ 
I completely trust my doctor’s (US and France) / GP’s (UK) 
judgement about my medical care 
⃝ 
My doctor (US and France) / GP(s) (UK) cares more about cutting 
down costs than about doing what is needed for my health 
⃝ 
My doctor (US and France) / GP(s) (UK) would always tell me the 
truth about my health, even if there was bad news 
⃝ 
225 
 
My doctor cares as much as I do about my health ⃝ 
If a mistake was made in my treatment, my doctor would try to 
hide it from me 
⃝ 
 
NEW SCREEN  
27) In the space below, please write down the first three words that come to mind when you think 
of vaccination (Item included by Sanofi Pasteur) 
 
 
28) Thinking about vaccination in general, would you say you are personally…  
SINGLE SELECT 
Strongly 
against 
vaccination 
0 
 
 
 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
5 
 
 
 
6 
 
 
 
7 
 
 
 
8 
 
 
 
9 
Strongly in 
favour of 
vaccination 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
NEW SCREEN: PLEASE DO NOT ROTATE QUESTIONS 29-33, BUT SHOW THEM ON ONE SCREEN FOR 
TELEPHONE INTERVIEWS. NOTE CHANGE IN ANSWER OPTIONS FOR THIS SET OF QUESTIONS  
We are now going to show you several statements about vaccination in general. Please give your 
level of agreement with each statement using the scales provided (where 0 = strongly disagree & 
10= strongly agree) 
29) I generally trust medications 
 
30) I generally trust vaccination  
 
31) I generally trust alternative medicine  
 
32) I generally trust vaccine manufacturers or pharmaceutical companies  
 
33) I generally trust the NHS  
 
SINGLE SELECT 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
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NEW SCREEN: ROTATE QUESTIONS 34-40 SHOWING THEM ON ONE SCREEN  
34) I understand how vaccination helps my body fight infectious disease 
 
35) How vaccination works is a mystery to me  
 
36) I feel it is important that I get vaccinated  
 
37) The decision to get vaccinated is a personal choice  
 
38) Vaccination forms part of a healthy lifestyle  
 
39) I feel it is important that children get vaccinated against the flu 
 
40) I feel it is important that children get vaccinated against tetanus  
 
SINGLE SELECT 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
NEW SCREEN: DO NOT ROTATE QUESTIONS 41-42, BUT SHOWING THEM ON ONE SCREEN FOR 
TELEPHONE INTERVIEWS NOTE CHANGE IN ANSWER OPTIONS FOR THIS SET OF QUESTIONS 
41) Which of these statements best represents your past experiences as a child? 
Please select all the answers that apply  
MULTIPLE SELECT 
I had a bad experiences with vaccines or injections as a child ⃝ 
I had a scary health-related experiences as a child ⃝ 
I had a bad experiences with healthcare professionals as a child ⃝ 
I generally had positive experiences with my healthcare as a child  ⃝ 
 
42) Which of these statements best represents your past experiences as an adult? 
Please select all the answers that apply 
MULTIPLE SELECT 
I have had a bad experience with vaccines or injections as an 
adult 
⃝ 
I have had a scary health-related experiences as an adult ⃝ 
I have had a bad experiences with healthcare professionals as an 
adult 
⃝ 
I have generally had positive experiences with my healthcare as 
an adult 
⃝ 
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INFLUENZA AND INFLUENZA VACCINE SOCIO-PSYCHOLOGICAL ITEMS  
ROTATE ENTIRE ‘INFLUENZA’ AND ‘TETANUS’ SECTIONS ACROSS PARTICIPANTS 
NEW SCREEN; SHOW QUESTIONS 43-45 ON ONE SCREEN 
We would now like to understand your views and experiences of flu and the flu vaccine, commonly 
known as the ‘flu jab’.  As before we will show you a series of questions and statements and we 
would like you to select the answer(s) which best apply to you personally. 
Please be assured, there are no ‘right’ or ‘wrong’ answers! We are just interested in your personal 
views and experiences. 
43) Which of the following statements best represents your knowledge of flu?  
Please select the answer which best applies to you 
SINGLE SELECT 
I have heard of flu, but know nothing about it ⃝ 
I have a little knowledge about flu ⃝ 
I have some knowledge about flu ⃝ 
I know a lot about flu ⃝ 
 
44) How often do you have the flu? 
Please select the answer which best applies to you 
SINGLE SELECT 
I have never had the flu ⃝ 
I have had the flu once or twice ⃝ 
I have the flu almost every year ⃝ 
I have the flu every year ⃝ 
I do not know ⃝ 
 
45) How often do you have the flu jab? 
Please select the answer which best applies to you  
SINGLE SELECT 
I have never had the flu jab ⃝ 
I have had the flu jab once or twice ⃝ 
I have the flu jab almost every year ⃝ 
I have the flu jab every year ⃝ 
 
 
SKIP Q46 & 47 IF ‘I HAVE NEVER HAD THE FLU JAB’ WAS SELECTED AT Q45 (CODE 1) 
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46) Which of these statements best represents how you usually remember to get the flu jab? 
Please select all the answers that apply  
MULTIPLE SELECT 
I remember to have the flu jab on my own MUTUALLY EXCLUSIVE ⃝ 
I remember if I am feeling vulnerable to illness ⃝ 
I remember when I see it on the news (e.g. TV, newspapers, etc.) ⃝ 
I remember when I see adverts in pharmacies or my GP surgery ⃝ 
My doctor (US and FR) / GP (UK) reminds me or sends a reminder ⃝ 
My work place / employer reminds me or sends me a reminder ⃝ 
Relatives or close friends remind me ⃝ 
Other, please specify ⃝ 
 
47) Where do you normally have a flu jab? 
SINGLE SELECT 
At my doctor’s office (US and France) / GP’s surgery (UK) ⃝ 
At a pharmacy ⃝ 
At a supermarket or shopping centre / [mall (US SPECIFIC)] ⃝ 
At my place of work ⃝ 
At a university healthcare centre UK ⃝ 
At a hospital ⃝ 
Other, please specify ⃝ 
 
48) How likely are you to get the flu jab next winter? (Item included by Sanofi Pasteur) 
SINGLE SELECT 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
NEW SCREEN: ROTATE BETWEEN REMAINING SCREENS IN THE FLU SECTION 
Now we will move on to some questions and statements about your current knowledge and feelings 
toward flu & the flu jab.  Please give your level of agreement with each statement using the scales 
provided (where 0= strongly disagree, & 10= strongly agree).  
 
As before, there are no right or wrong answers! We are just interested in your personal views and 
experiences. 
ROTATE THESE QUESTIONS SHOWING THEM ON ONE SCREEN 
49) The flu could make me severely ill  
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50) I avoid thinking about what may happen if I get the flu 
 
51) If I got the flu, I would feel scared to pass it to a close relative who is currently very vulnerable 
to the flu  
 
52) If I got the flu, I would feel sicker than other people my age  
 
53) If I got the flu, I worry that I would miss out on important activities or events  
 
54) I’ve been taking action to try to protect myself against the flu  
 
55) I am scared of getting the flu [ANCHOR, ALWAYS SHOW AT THE BOTTOM]  
 
SINGLE SELECT 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
56) I believe that if I got the flu I would have to stay in bed for…  
Please select the most appropriate answer  
SINGLE SELECT 
0 days ⃝ 
1-2 days ⃝ 
3-4 days ⃝ 
5-6 days ⃝ 
1 week – 2 weeks ⃝ 
More than 2 weeks ⃝ 
 
 
NEW SCREEN: ROTATE QUESTIONS 57-63 SHOWING THESE AND 64 ON ONE SCREEN 
Please once again give your level of agreement with each statement using the scales provided 
(where 0= strongly disagree & 10= strongly agree) 
57) If I get a flu jab, I will be protected against the flu  
 
58) If I get a flu jab, it will reduce the severity of the flu  
 
59) With no flu jab, I would feel very vulnerable to the flu 
SKIP IF ‘I HAVE NEVER HAD THE FLU JAB’ WAS SELECTED AT 45 (CODE 1) 
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60) I get the flu jab mainly to protect others who are more vulnerable than me 
 
61) I am confident I can avoid getting the flu, even without the flu jab 
 
62) Without a flu jab, I am sure I would get the flu this winter  
SINGLE SELECT 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
63) If I don’t get a flu jab this autumn/winter, the chances of me getting flu are:  
SINGLE SELECT 
Zero ⃝ 
Small ⃝ 
Moderate ⃝ 
Significant  ⃝ 
Certain ⃝ 
I don’t know ⃝ 
 
NEW SCREEN: ROTATE QUESTIONS 64-72 SHOWING THESE AND 73 ON ONE SCREEN 
Please once again give your level of agreement with each statement using the scales provided 
(where 0= strongly disagree & 10= strongly agree) 
64) I feel I know enough about the flu jab to make an informed decision about whether to get 
vaccinated or not 
 
65) I trust the information provided by the NHS about the flu jab INCLUDE A ‘DON’T KNOW / NOT 
APPLICABLE’ OPTION 
 
66) I trust the information provided by news reports on TV & radio or newspapers about the flu 
jab INCLUDE A ‘DON’T KNOW / NOT APPLICABLE’ OPTION 
 
67) I trust information provided by blogs, Facebook or Twitter about the flu jab 
INCLUDE A ‘DON’T KNOW / NOT APPLICABLE’ OPTION 
 
68) I trust the information provided by my GP about the flu jab INCLUDE A ‘DON’T KNOW / NOT 
APPLICABLE’ OPTION 
 
69) My GP thinks I should get a flu jab INCLUDE A ‘DON’T KNOW / NOT APPLICABLE’ OPTION 
70) My relatives or close friends think that I should get a flu jab INCLUDE A ‘DON’T KNOW / NOT 
APPLICABLE’ OPTION 
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71) I do not know much about the flu jab but I trust the advice I have been given INCLUDE A 
‘DON’T KNOW / NOT APPLICABLE’ OPTION 
 
72) If I do not get the flu jab and I get the flu, passing the flu to other people would worry me 
because it would be my fault 
 
SINGLE SELECT 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
73) Which of the following statements apply to you?  
Please select all the answers that apply. If none of the answers apply, please select ‘none of the 
above’ 
MULTIPLE SELECT 
It is easy for me to get to a place where I can get the flu jab ⃝ 
I can make time to get the flu jab ⃝ 
If I had to pay for the flu vaccine, I think I could afford it ⃝ 
I have been informed about whether I should or could get the jab 
(Item included by Sanofi Pasteur) 
 
 
⃝ 
I am open to the idea of receiving the flu jab, in principle 
(Item included by Sanofi Pasteur) 
⃝ 
None of the above [EXCLUSIVE] ⃝ 
 
NEW SCREEN: ROTATE QUESTIONS 75-83 & 64 SHOWING THESE ON ONE SCREEN  
Please give your level of agreement with each statement using the scales provided (where 0= 
strongly disagree & 10= strongly agree) 
74) If I don’t get a flu jab and end up getting the flu this winter, I would regret not getting the jab 
 
75) A relative or close friend had a bad reaction after having a flu jab (e.g. fell ill or was in a lot of 
pain INCLUDE A ‘DON’T KNOW / NOT APPLICABLE’ OPTION 
 
76) I am worried that having the flu jab every year may be dangerous for me 
 
77) I am allergic to the flu jab INCLUDE A ‘DON’T KNOW’ OPTION 
SKIP IF ‘I HAVE NEVER HAD THE FLU JAB’ WAS SELECTED AT 45 (CODE 1): 
78) In the past, I have felt strong flu-like symptoms after getting a flu jab  
 
79) The flu jab is painful INCLUDE A ‘DON’T KNOW’ OPTION 
 
80) I am scared of getting a flu jab 
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81) The flu jab could give me the flu 
 
82) I am worried that some of the contents of the flu jab may be dangerous for me 
 
83) I am confident I can get a flu jab if I want one 
ASK ALL PARTICIPANTS WHO SELECTED CODE 2 (“NO”) AT Q15 
84) For which of the following reasons, if any, did you not get a flu jab this autumn / winter? (Item 
included by Sanofi Pasteur) 
Please select all the answers that apply. 
MULTIPLE SELECT & ROTATE ANSWERS 
I was unable to get to a place where I could get a flu jab this 
autumn / winter 
⃝ 
I was too busy to get a flu jab this autumn / winter ⃝ 
I couldn’t afford a flu jab this autumn / winter ⃝ 
I forgot to get a flu jab this autumn / winter ⃝ 
I am healthy, therefore I didn’t need a flu jab this autumn / 
winter 
⃝ 
My doctor didn’t recommend a flu jab to me this autumn / 
winter 
⃝ 
I was not eligible for a free flu jab this autumn / winter ⃝ 
I was worried about the contents (adjuvants) contained in this 
autumn / winter’s flu jab 
⃝ 
I have already had the flu this winter, so I did not need a flu jab ⃝ 
I was worried about the side effects of this autumn / winter’s flu 
jab  
⃝ 
Other please specify_______  ⃝ 
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ATTITUDES TOWARD AND USE OF THE TETANUS VACCINE  
ROTATE ENTIRE ‘FLU’ AND ‘TETANUS’ SECTIONS ACROSS PARTICIPANTS 
NEW SCREEN; SHOW QUESTION 85 ON ONE SCREEN 
In the next section we would like to ask you about tetanus and tetanus containing adult boosters, 
which can also protect against other diseases such as diphtheria and pertussis/whooping cough. 
These are commonly known as tetanus jabs. As before we will show you a series of questions and 
statements and we would like you to select the answer(s) which best apply to you personally. 
85) Which of the following statements best represents your knowledge of tetanus?  
SINGLE SELECT 
I have never heard of tetanus ⃝ 
I have heard of tetanus, but know nothing about it ⃝ 
I have a little knowledge about tetanus ⃝ 
I have some knowledge about tetanus ⃝ 
I know a lot about tetanus ⃝ 
 
NEW SCREEN; SHOW QUESTIONS 86 - 90 ON ONE SCREEN 
The next series of questions will focus on your views on the adult tetanus containing booster.  Please 
answer these questions carefully, but again, please be assured that there are no ‘right’ or ‘wrong’ 
answers! We are just interested in your personal views and experiences. 
86) Which of the following statements best represents your experience with a tetanus containing 
booster as an adult, that is from 18 years old onwards? 
Please select the best statement which is most appropriate for you 
SINGLE SELECT 
I have never heard of the adult tetanus containing booster ⃝ 
No one has ever offered me an adult tetanus containing booster ⃝ 
I have chosen not to have a tetanus containing booster ⃝ 
I have had a tetanus containing booster preventively, for 
example, in case I get injured 
⃝ 
I have had tetanus containing boosters preventively but also 
right after I have been injured 
⃝ 
I have only had tetanus containing boosters after I have been 
injured 
⃝ 
I do not remember ⃝ 
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SKIP Q87 – 90 IF PARTICIPANT HAS NOT HAD A TETANUS BOOSTER (CODES 1, 2, 3 OR 7) AT Q86 
87) How long ago did you have your last adult tetanus containing booster? (Item included by 
Sanofi Pasteur) 
Please write in how many years & months. If you cannot remember how long ago you had your last 
tetanus booster, please select ‘I don’t remember’ 
XX Years XX Months 
EXCLUSIVE CODE – “I don’t remember” 
88) Where have you had an adult tetanus containing booster? 
Please select all the answers that apply 
MULTIPLE SELECT 
At my GP’s surgery ⃝ 
At a hospital ⃝ 
At my place of work ⃝ 
Pharmacy / independent travel clinic ⃝ 
Emergency / Walk-in clinic ⃝ 
Other, please specify ⃝ 
 
89) Why have you had a tetanus containing booster? 
Please select all the answers that apply 
MULTIPLE SELECT; ROTATE ORDER OF ANSWER OPTIONS 
Because it is was recommended to me by my GP  ⃝ 
Because a tetanus containing booster is recommended by the 
health authorities  
⃝ 
Because it is important to keep up to date with my boosters ⃝ 
Because I was injured ⃝ 
Because I have a chronic condition which makes me more 
vulnerable to tetanus 
⃝ 
Because I have a chronic condition which makes me more 
vulnerable to whooping cough (pertussis)  
⃝ 
Because I want to protect a relative (for example a child or older 
relative) who is vulnerable to whooping cough (pertussis) 
⃝ 
Because I like gardening ⃝ 
Because I work in construction, agriculture, or other risky line of 
work 
⃝ 
Because of travel ⃝ 
Because I frequently come into contact with needles / sharps ⃝ 
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Because I am pregnant (ONLY SHOW IF CODE 1 WAS SELECTED @ 
Q2 I.E. FEMALE) 
⃝ 
Other, please specify ⃝ 
I don’t remember / I don’t know EXCLUSIVE ⃝ 
 
90) Which of the following statements best represents how you normally remember to get your 
tetanus containing booster?  
Please select all the answers that apply 
MULTIPLE SELECT; ROTATE ORDER OF ANSWER OPTIONS 
I remember to have the booster on my own MUTUALLY 
EXCLUSIVE 
⃝ 
My GP reminds me or sends a reminder ⃝ 
Relatives or close friends remind me to get a booster 
preventively 
⃝ 
My work place / employer reminds me or sends me a reminder ⃝ 
It is offered by my GP after I have been injured ⃝ 
Other, please specify ⃝ 
 
NEW SCREEN: ROTATE QUESTIONS 91-95 & 104 SHOWING THEM ON ONE SCREEN; ROTATE 
BETWEEN REMAINING SCREENS IN THE TETANUS SECTION 
Now we will move on to some questions about your current knowledge and feelings toward tetanus 
containing boosters.  For these questions we will ask you to answer based on the same 0-10 point 
scale used earlier. As before, there are no right or wrong answers. We are just interested in your 
personal views and experiences. 
91) Tetanus could make me severely ill 
 
92) I avoid thinking about what may happen if I get tetanus 
 
93) If I got tetanus, I would feel sicker than other people my age 
 
94) I’ve been taking action to try to protect myself against tetanus 
 
95) I am scared of getting tetanus [ANCHOR, ALWAYS SHOW AT THE BOTTOM] 
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SINGLE SELECT 
 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
Please give your level of agreement with each statement using the scales provided (where 0= 
strongly disagree & 10= strongly agree)  
NEW SCREEN: ROTATE QUESTIONS 96-99 & SHOW THESE & 110 ON ONE SCREEN  
96) If I get a tetanus containing booster, I will be protected against tetanus  
 
97) With no tetanus containing booster, I would feel very vulnerable to tetanus 
  
98) I am confident I can avoid getting tetanus, even without the tetanus containing booster 
 
99) Without a tetanus containing booster, I am sure I would get tetanus  
SINGLE SELECT 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
100) If I don’t get a tetanus containing booster, the chances of me getting tetanus are:  
SINGLE SELECT 
Zero ⃝ 
Small ⃝ 
Moderate ⃝ 
Significant  ⃝ 
Certain ⃝ 
I don’t know ⃝ 
 
 
NEW SCREEN: ROTATE QUESTIONS 101-108 SHOWING THESE ON ONE SCREEN 
Please once again give your level of agreement with each statement using the scales provided 
(where 0= strongly disagree & 10= strongly agree) 
101) I feel I know enough about the tetanus containing booster to make an informed decision 
about whether to get vaccinated or not 
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102) I trust the information provided by the NHS about the tetanus containing booster INCLUDE A 
‘DON’T KNOW / NOT APPLICABLE’ OPTION 
 
103) I trust the information provided by news reports on TV & radio or newspapers about the 
tetanus containing booster INCLUDE A ‘DON’T KNOW / NOT APPLICABLE’ OPTION 
 
104) I trust information provided by blogs, Facebook or Twitter about the tetanus containing 
booster INCLUDE A ‘DON’T KNOW / NOT APPLICABLE’ OPTION 
 
105) I trust the information provided by my GP about the tetanus containing booster INCLUDE A 
‘DON’T KNOW / NOT APPLICABLE’ OPTION 
 
106) My GP thinks I should get a tetanus containing booster INCLUDE A ‘DON’T KNOW / NOT 
APPLICABLE’ OPTION 
 
107) My relatives or close friends think that I should get a tetanus containing booster INCLUDE A 
‘DON’T KNOW / NOT APPLICABLE’ OPTION 
 
108) I do not know much about the tetanus containing booster but I trust the advice I have been 
given INCLUDE A ‘DON’T KNOW / NOT APPLICABLE’ OPTION 
 
SINGLE SELECT 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
109) Which of the following statements apply to you?  
Please select all the answers that apply. If none of the answers apply, please select ‘none of the 
above’ 
MULTIPLE SELECT 
It is easy for me to get to a place where I can get a tetanus 
containing booster 
⃝ 
I can make time to get a tetanus containing booster ⃝ 
If I had to pay for a tetanus containing booster, I think I could 
afford it 
⃝ 
I have been informed about whether I should or could get a 
tetanus containing booster (Item included by Sanofi Pasteur) 
⃝ 
I am open to the idea of receiving a tetanus containing booster, 
in principle (Item included by Sanofi Pasteur) 
⃝ 
None of the above [EXCLUSIVE] ⃝ 
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Please give your level of agreement with each statement using the scales provided (where 0= 
strongly disagree & 10= strongly agree) 
NEW SCREEN: ROTATE QUESTIONS 110-117 SHOWING THESE ON ONE SCREEN  
110) If I don’t get a tetanus containing booster and end up getting the tetanus, I would regret not 
getting the booster 
 
111) A relative or close friend had a bad reaction after having a tetanus containing booster (e.g. 
fell ill or was in a lot of pain INCLUDE A ‘DON’T KNOW / NOT APPLICABLE’ OPTION 
 
112) I am allergic to tetanus containing boosters INCLUDE A ‘DON’T KNOW’ OPTION 
 
113) Tetanus containing boosters are painful INCLUDE A ‘DON’T KNOW’ OPTION 
 
114) I am scared of getting a tetanus booster 
 
115) The tetanus containing booster could give me tetanus 
 
116) I am worried that some of the contents of the tetanus containing booster may be dangerous 
for me 
 
117) I am confident I can get a tetanus containing booster if I want one 
 
SINGLE SELECT 
Strongly 
disagree 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
Strongly 
agree 
10 
⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
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DETAILED DEMOGRAPHICS  
In this final section we will ask you a few more questions about yourself.   
We would like to reassure you that all the information that you provide will be kept confidential and 
only the research team will see it. 
ASK FEMALES (CODE 1 @ Q2) ONLY 
118) Are you pregnant or breastfeeding?  
SINGLE SELECT 
Yes   ⃝ 
No ⃝ 
 
119) What is the highest level of education you have completed?  
SINGLE SELECT 
GCSE (UK) / High school (US) / Brevet (FR) ⃝ 
A-level (UK Only) / Baccalauréat (FR) / or equivalent ⃝ 
University Diploma ⃝ 
BSc/BA Degree ⃝ 
Masters Degree ⃝ 
Doctoral Degree ⃝ 
Professional Degree (e.g., JD, MD) ⃝ 
Other degree ⃝ 
None of the above ⃝ 
 
120) Do you have private health insurance?  
SINGLE SELECT 
Yes   ⃝ 
No ⃝ 
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Appendix 12          Selected determinants of influenza vaccination by vaccination status – healthcare professionals 
   
Explanatory variables Min Max Vaccinated Unvaccinated SE 95% C.I. t / χ² df p-value 
3. Social influence     Total Mean SD SE Total Mean SD SE   Lower Upper       
GP thinks I should vaccinate 0 10 27 4.93 4.763 0.917 14 9.71 1.139 0.304 0.966 -6.757 -2.819 -4.958 31.288 0.000 
Relatives think I should vaccinate 0 10 27 4.19 4.421 0.851 14 7.79 2.860 0.764 1.144 -5.918 -1.283 -3.148 36.867 0.003 
Peer experienced vaccine adverse reaction  0 10 27 4.70 4.103 0.790 14 5.71 4.795 1.281 1.431 -3.905 1.884 -0.706 39 0.484 
4. Influenza perceptions                 
Perceived knowledge of influenza 1 4 27 3.22 0.698 0.134 14 3.00 0.679 0.182 0.228 -0.239 0.683 0.975 39 0.335* 
Frequency of influenza episodes  1 4 27 2.26 0.859 0.165 14 1.64 0.497 0.133 0.250 0.112 1.121 2.470 39 0.018 
Vulnerability to influenza 0 10 27 2.22 2.375 0.457 14 6.86 2.931 0.783 0.848 -6.350 -2.920 -5.468 39 0.000 
Likelihood of influenza  0 10 27 1.89 1.968 0.379 14 5.07 3.125 0.835 0.796 -4.792 -1.573 -4.000 39 0.000 
Likelihood of influenza (2) 1 5 27 3.04 1.315 0.253 14 3.21 0.699 0.187 0.378 -0.941 0.587 -0.469 39 0.642* 
Susceptibility to influenza 0 10 27 3.33 2.961 0.570 14 4.50 3.032 0.810 0.983 -3.155 0.822 -1.187 39 0.243* 
Severity of influenza 0 10 27 6.11 1.908 0.367 14 6.93 3.245 0.867 0.803 -2.441 0.806 -1.019 39 0.315* 
Severity of influenza (bed days) 1 6 27 2.67 1.209 0.233 14 3.14 1.406 0.376 0.421 -1.328 0.375 -1.131 39 0.265* 
Fear of influenza 0 10 27 2.70 2.743 0.528 14 5.00 3.762 1.005 1.028 -4.375 -0.218 -2.235 39 0.031 
Fear of transmitting influenza (vulnerable relative) 0 10 27 6.00 2.935 0.565 14 8.43 1.651 0.441 0.849 -4.147 -0.710 -2.859 39 0.007 
Worry of transmitting influenza  0 10 27 4.11 2.979 0.573 14 7.07 2.269 0.606 0.910 -4.800 -1.120 -3.254 39 0.002 
Worry of missing out on important activities or events 0 10 27 4.04 3.107 0.598 14 5.50 3.132 0.837 1.026 -3.538 0.612 -1.426 39 0.162* 
Coping - influenza 0 10 27 4.93 2.921 0.562 14 8.29 2.199 0.588 0.890 -5.160 -1.560 -3.776 39 0.001 
Maladaptive coping - influenza 0 10 27 4.26 2.683 0.516 14 4.14 2.316 0.619 0.845 -1.593 1.826 0.138 39 0.891 
Perceived control (over influenza) 0 10 27 5.74 2.625 0.505 14 2.93 2.495 0.667 0.851 1.092 4.533 3.306 39 0.002 
241 
 
 
 
SD = standard deviation; SE = standard error; df = degrees of freedom; df with decimals are adjusted to correct for the violation of the assumption of equal variances (Levene's Test for 
Equality of Variances was statistically significant). p-values were obtained using Chi-square tests (χ²) for categorical variables and Independent t-tests (t) for interval or continuous variables. 
*Variables that were significant in the final sample (excluding HCPs). ¥Variables that were not significant in the final sample.   
 
 
 
 
 
 
 
 
Explanatory variables Min Max Vaccinated Unvaccinated SE 95% C.I. t / χ² df p-value 
5. Influenza vaccine perceptions     Total Mean SD SE Total Mean SD SE   Lower Upper       
Perceived knowledge of vaccine (informed decisions) 0 10 27 6.85 2.248 0.433 14 7.29 2.946 0.787 0.824 -2.101 1.233 -0.526 39 0.602* 
Do not know much about the vaccine (trust advice)  0 10 27 6.59 3.308 0.637 14 5.64 3.365 0.899 1.096 -1.267 3.166 0.867 39 0.391* 
Vaccine effectiveness 0 10 27 5.26 2.521 0.485 14 7.29 1.590 0.425 0.742 -3.528 -0.525 -2.731 39 0.009 
The vaccine reduces severity of influenza 0 10 27 6.07 2.433 0.468 14 7.93 1.685 0.450 0.728 -3.328 -0.381 -2.546 39 0.015 
The vaccine is painful 0 10 27 4.11 4.423 0.851 14 3.36 3.734 0.998 1.385 -2.048 3.556 0.544 39 0.589* 
I am allergic to the vaccine 0 10 27 4.22 4.799 0.923 14 1.43 3.106 0.830 1.242 0.277 5.310 2.250 36.859 0.031¥ 
The vaccine could transmit influenza 0 10 27 3.78 3.004 0.578 14 2.21 2.547 0.681 0.942 -0.342 3.469 1.660 39 0.105* 
Vaccine contents could be dangerous 0 10 27 3.44 3.332 0.641 14 1.64 1.906 0.509 0.819 0.144 3.459 2.200 38.504 0.034 
Vaccinating yearly can be dangerous 0 10 27 2.93 3.316 0.638 14 2.43 2.441 0.652 0.912 -1.357 2.351 0.545 34.152 0.589* 
Fear of vaccine 0 10 27 1.67 2.557 0.492 14 1.29 2.335 0.624 0.818 -1.275 2.036 0.465 39 0.644* 
Self-efficacy – influenza vaccination 0 10 27 7.37 3.176 0.611 14 9.07 1.730 0.462 0.767 -3.252 -0.150 -2.219 38.835 0.032 
Anticipated regret of not vaccinating 0 10 27 3.11 2.979 0.573 14 7.29 3.361 0.898 1.025 -6.247 -2.102 -4.074 39 0.000 
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Appendix 13          Draft of the influenza simulator tool  
 
 
